

DRIVING DRIVING DRIVING DRIVING DRIVING SUSTAINED SUSTAI

ANNUAL REPORT 2017-18

CONTENTS

COMPANY OVERVIEW

- 2 Introducing Aurobindo Pharma Limited
- 6 Geographical Presence
- 8 Year in Review
- 10 Financial Highlights
- 12 Vice-Chairman's Review
- 14 Managing Director's Message
- 16 Business Model
- 18 Operating Landscape
- 20 Strategic Priorities
- 22 Pursuit of Sustained Excellence
- 24 Quality is Sacrosanct
- 29 Scaling the Growth Curve is Exhilarating
- 32 Reinforcing a Culture of Ownership
- 36 Robust Risk Governance
- 38 Environment, Health and Safety
- 40 Shaping Holistic Community Well-being
- 42 Board of Directors

STATUTORY REPORTS

- 44 Notice
- 53 Board's Report
- 63 Management Discussion and Analysis
- 73 Management of Risks
- 80 Business Responsibility Report
- 124 Report on Corporate Governance

FINANCIAL STATEMENTS

- 137 Standalone Financial Statements
- 199 Consolidated Financial Statements



For further information, log on to **www.aurobindo.com**



Introducing Aurobindo Pharma Limited

For more information, see **page 2**



Year in Review For more information, see page 8

Key highlights of 2017-18

Total Revenue (₹ in million)

164,998 ^{● 9.3%}

EPS (7) 41.36 EBITDA (₹ in million)

37,885 [●] 10.3%

Market Cap (₹ in million)

326,800

PAT (₹ in million)

24,232 ◆ 5.3%

(as on 31 March 2018) Growth over 2016-17

Driving sustained excellence

For over three decades, we have steadily built an institution through our sustained pursuit of excellence.

Excellence is an operative word at Aurobindo Pharma. It has many facets. It is reflected in the quality products we manufacture across complex and critical therapeutic areas.

It is demonstrated through our focus on Research and Development (R&D) and the investments that we plan to accomplish our long-term growth objectives. Excellence is also vindicated in the way we nurture our talent pool and future leadership; and drive our sustainability initiatives.

We are making lasting contributions to human health and well-being through the intervention of science; and creating value for stakeholders through care and integrity.

We are bringing excellence in all that we do diligently and sustainably.

INTRODUCING AUROBINDO PHARMA LIMITED

Delivering sustainable growth

Aurobindo is a leading global pharmaceutical company, producing generic formulations and Active Pharmaceutical Ingredients (APIs).

At Aurobindo, our three decades of expertise was sharpened by our intense focus on productivity, operational efficiency and commitment to highest quality standards. Our robust product portfolio spans over seven major therapeutic areas, including antibiotics, antiretrovirals (ARVs), cardiovascular (CVS), central nervous systems (CNS), gastroenterologicals, anti-diabetics and antiallergics, supported by an outstanding R&D capability.

Strengthened by several large manufacturing facilities, approved by the USFDA, UK MHRA, MCC-SA, EMA and ANVISA Brazil for both APIs and formulation, Aurobindo markets its products and solutions across 150+ countries; with growing penetration in the US and Europe.

Our in-house scientific talent pool strengthens our intellectual capital and helps us to commercialize cost-effective, quality generic finished dosages. Our competitive advantage is the broad portfolio of diversified dosage forms, including Rx and OTC oral solids and liquids, injectables, ophthalmics, specialty products and controlled substances. The focus is on complex molecules, differentiated technology platforms and specialty products.

Our mission

Aurobindo's mission is to become the most valued pharmaceutical partner to the world pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.



Auro Values



Business Care

- Operational excellence •
- Stakeholder orientation •
- Quality and innovation •



People Care

- Fairness, humility and • respect for individuals
- Teamwork •
- Applied learning



Organization Care

- Accountability •
- Integrity •
- Achievement

INTRODUCING AUROBINDO PHARMA LIMITED Global Business Overview Formulations

US



- Ranked 5th prescription supplier according to the IQVIA total prescriptions dispensed for the 12 months ending April 2018
- Caters to the geography through subsidiaries: Aurobindo Pharma USA, Auro Life, AuroMedics, AuroHealth and Natrol
- Differentiated pipeline with new launches, including injectables, ophthalmics, specialty products and controlled substances
- Expanded presence in dietary supplement business through Natrol
- Manufacturing and R&D presence, including controlled substances

Europe



- Among the top 15* generics companies by sales
- Operations in nine countries with full-fledged pharmacy, hospital and tender sales infrastructure
- Focus markets comprise France, Germany, the Netherlands, Spain, the UK, Portugal and Italy
- Reinforce position through new product launches and extension to select markets of Eastern Europe
- Manufacturing plant at Portugal provides a strategic advantage
- 250+ products under development
- Batch Test and Release facility in Malta for oral and sterile dosages
- * As per market reports

Growth Markets



- Market our products through subsidiaries and local distributors
- Focus on major markets: Canada, Brazil and South Africa
- Expansion into select markets of Asia Pacific, Africa and the Middle East

Revenue (₹ in million)



Revenue (₹ in million)



Revenue (* in million) 8,971

6%

ARVs




- Focus on global tenders; availability across 125 countries
- Maintain competitiveness through development of new products
- Received USFDA approval for Dolutegravir and its triple drug combination product under President's Emergency Plan for AIDS Relief (PEPFAR) program

Revenue (₹ in million)



APIs



- Cost-effective with vertical integration of around 70% of API requirement being sourced internally
- One of the leading suppliers of APIs from India – serves as a source for various generics and branded drugs
- Strong regulatory capability with 227 US DMF filings as on 31 March 2018

29,622



Company Overview

Statutory Reports

Financial Statements


Portfolio mix (31 March 2018)

-		
Therapy	ANDAs	Addressable Market Size (\$ Bn)*
Anti Diabetic	15	6.3
ARV*	42	7.0
CNS	90	24.6
Controlled Substances	16	1.7
CVS	76	24.5
Gastroenterological	30	4.1
Ophthalmics	11	0.5
Others	142	15.5
Penem	2	0.5
Respiratory	11	0.7
Oncology & Hormones	13	3.0
SSP & Cephalosporins	30	0.8
Total	478	89.2

* As per IQVIA MAT March 2018

GEOGRAPHICAL PRESENCE Growing global footprint

USA	Portugal	Myanmar
India	Italy	Canada
France	Romania	Mexico
Germany	Belgium	Colombia
Netherlands	Ukraine	Brazil
Spain	South Africa	Japan
UK	East Africa	





Largest generic company by sales globally[#]



Largest listed Indian pharmaceutical company by revenues*



Largest generic company by Rx dispensed in the US**



Employees



Global revenues in FY2017-18

19,000+ \$2.6 Bn



150+ Markets in which we are present 25

Manufacturing facilities globally

26+ Bn Diverse dosage forms manufactured

Diverse dosage forms manufactured in FY2017-18

Source: Evaluate Pharma;

*as per FY2017-18 revenues

** Source: IQVIA National Prescription Audit, 12 months ending Apr 2018;

YEAR IN REVIEW

Each quarter takes us forward



FY2017-18

- Filed 21 ANDAs with USFDA, including 11 in oral and 10 in injectable
- Received final approval for 2 ANDAs and tentative approval for 3 ANDAs
- Launched 8 products, including 2 injectables in the US
- Transferred manufacturing of 3 products from Europe to India
- First company to launch Sevelamer Carbonate tablets in the US market



FY2017-18

- Filed 13 ANDAs with USFDA, including 9 in oral and 4 in injectable
- Received final approval for 17 ANDAs, including 16 orals and one injectable; tentative approval for 3 ANDAs
- Launched 15 products, including 3 injectables in the US
- Agile Pharma B.V., Netherlands, a whollyowned step-down subsidiary of the Company, successfully completed the acquisition of Generis Farmaceutica S.A.
- Transferred the manufacture of 2 products from Europe to India
- New Betalactum injectable manufacturing facility i.e. Unit XVI has been commissioned during the guarter
- First company to launch Sevelamer Carbonate oral suspension in the US market









FY2017-18

- Filed 11 ANDAs with USFDA, including 2 injectables
- Received final approval for 10 ANDAs
- Launched 7 products, including one injectable in the US
- Transferred manufacturing of 5 products from Europe to India

 $\mathbf{3}$

FY2017-18

quarter

• Filed 2 ANDAs with USFDA

from Europe to India

• Received final approval for 20 ANDAs and tentative approval for 2 ANDAs

• Launched 8 products in the US during the

• Transferred manufacturing of 4 products




Annual Report 2017-18 9


FINANCIAL HIGHLIGHTS

Delivering robust financials


Revenues



Revenue Mix




EBITDA



EBITDA Margin

(%)





*Includes higher sales from limited competition product

Financial Statements


Net Debt / EBITDA

Net Debt / Equity





Net Profit



vice-chairman's review Driving holistic excellence

"If there is one thing that makes me confident about the future, it is the passion of our people to deliver, despite challenges; and this passion shapes our culture of excellence."

K. Nithyananda Reddy Vice Chairman I am delighted to report that our strategy to drive holistic excellence has translated into encouraging business momentum in a year that presented its fair share of challenges. Despite hardships, we performed satisfactorily in catering to critical patient needs across geographies.

MACRO LANDSCAPE

The global economy saw definite signs of recovery in 2017, and the major markets of our operations reflected this growth trend. According to IMF, the US economy grew by 2.3% vis-à-vis 1.6% in 2016. The Indian economy too registered robust growth as the GDP grew by 6.7% in FY2017-18.

Demand growth and renewed investments across geographies have helped economies record encouraging progress. However, the global pharmaceutical sector encountered hurdles caused by buyer consolidation in the US, and improved pace of USFDA approvals has resulted in rising pricing pressures and increasing competition.

Despite international headwinds, we retained our growth momentum and continued to further reinforce our financial strength. With launches in the US market and improving market presence in Europe and other Growth Markets, we continued to progress and deliver encouraging results.

PERFORMANCE REVIEW

We achieved a 9.3% revenue growth over the previous year at ₹164,998 million, at the consolidated level. The Company's diversified geographical presence and product portfolio made all the difference in a challenging and competitive market.

EBITDA for the year stood at ₹37,885 million and reflected an impressive 10.3% growth. We saw improvement in the EBITDA margin, as it stood at 23.0%, compared to 22.8% in the previous year.

Profit after tax (PAT) was at ₹24,232 million, higher by 5.3% over 2016-17. Earnings per Share for the year were healthy at ₹41.36.

TRANSFORMATION IN OUR DNA

We believe, transformation in response to market requirements, industry dynamics,

and regulatory demands is the only reliable roadmap to sustainable growth.

We have strengthened our manufacturing facilities and adopted top-notch technologies to stay ahead of the curve in a competitive market scenario. To elevate our manufacturing capabilities, we have successfully commissioned Betalactum injectables manufacturing facility (Unit XVI) at Jadcherla in Telangana; and the creation of Unit X for an USFDA compliant oral manufacturing facility at Naidupet, Andhra Pradesh, is on track.

We strengthened our manufacturing processes through operational training and further enhanced the integrated process systems such as quality management system by automating the complaint management process to facilitate timely and effective handling of complaints and also implemented a real-time data management system called PRISM. As part of continuous improvement, the Laboratory Information Management System (LIMS) is now being upgraded to fully automated electronic platform for improved transparency and efficiency and an initiative was taken to implement Continued Process Verification through automated electronic system to ensure that processes are in a constant state of control, thus ensuring product quality.

INNOVATION ALL THE WAY

Our priority is to grow our product portfolio and drive our R&D efforts to create solutions for growing healthcare threats. In this context, it is relevant to mention that we continue to ramp up our pipeline of products.

We are investing extensively in our R&D efforts towards creating high-value complex products and drug delivery systems. We are making steady progress in the realms of oncology and hormones including steroids, penems, vaccines, biosimilars, peptides, dermatology and respiratory. We remain optimistic that the growth in these categories will amass for the business, while also helping us fulfil our objective to create affordable medicines for unmet medical needs. During the year, we continued to focus on promoting education, sanitation, healthcare, rural development and sports in the communities where we operate. Our objective is to work as an agent of empowerment from the grassroots.

FUTURE GROWTH PROSPECTS

Global healthcare spending is estimated to increase at an annual rate of 4.1% during 2017-2021 (as per 2018 Global healthcare outlook: The evolution of smart healthcare by Deloitte). This coupled with more acceleration in the global economy will ensure steady growth in healthcare expenditure. We remain optimistic about our growth across geographies; and aim to further de-risk our business by extending our product portfolio.

CULTURE OF EXCELLENCE

If there is one thing that makes me confident about the future, it is the passion of our people to deliver, despite challenges; and this passion shapes our culture of excellence. We are also constantly enriching our culture and bringing on board new talent pool to grow the business sustainably.

We believe in the importance of thinking ahead and be proactive to remain at the vanguard of opportunities; and we will continue to follow this strategy diligently in the coming years.

Before I conclude, I must thank all our stakeholders for encouraging us to seek excellence in every facet of the business.

K. Nithyananda Reddy

Vice Chairman

MANAGING DIRECTOR'S MESSAGE

Execution brilliance shows the way



"Quality is of utmost importance to us; and every member of the team ensures that we remain at the top of the quality and compliance curve."

N. Govindarajan Managing Director

Dear Stakeholders,

I am pleased to share that we reported encouraging progress and better efficiencies across all our functions during FY2017-18. Most importantly, this progress was achieved against a backdrop of a volatile global pharma landscape, characterized by price erosions and intense competition.

In the last fiscal, we continued our efforts on strengthening the compliance and quality aspects of our business. Our dedicated efforts and integrity continue to enable us to create sustainable value for all stakeholders.

GROWTH ACROSS GEOGRAPHIES

Even as players in the global pharma sector experienced pricing pressures owing to customer consolidation in the US, uncertainty around BREXIT and faster pace of approval by the USFDA, we reinforced our market presence by key launches and investments in inorganic growth opportunities. Aurobindo is well-known globally for its execution capabilities and resilience against temporary headwinds; and it has lived up to its reputation and sustained its momentum. We ramped up volumes, improved efficiencies, optimized costs and strengthened supply chain and logistics. I am happy to state that despite the challenges, our US business has remained resilient; and continued to be a top contributor to our overall revenues. Our US formulations business contributed 45% to the overall formulations revenue during the year. The revenue generated from the US business grew to ₹74,421 million in FY2017-18 vis-à-vis ₹68,272 million in FY2016-17, an increase of 9% year-on-year.

We launched 38 products, including 6 injectables in the US market during the year under review. In FY2017-18, we received approvals for 49 ANDAs and filed a total of 47 ANDAs. With our increasing product pipeline, we believe we can further strengthen our market position in mid-to-long term; and set the course for our future growth prospects.

We commissioned a fully automated distribution center in East Windsor, NJ, during the year under review which facilitates enhanced storage of various dosage forms including orals, injectables and OTC products and spans across 567,000 sq ft. with a capacity of 20,000 pallet locations.

We have commissioned our new Betalactum injectables manufacturing facility (Unit XVI) at Jadcherla during the year, which will improve the injectable volumes for the US, EU and Growth Markets. Unit XV, the dedicated manufacturing facility for the Europe market has seen significant improvement in volumes.

In Europe, we registered an encouraging 32.9% growth, to reach ₹43,544 million revenue compared to ₹32,771 million in the previous year. We aim to improve our market presence in Italy, Spain, Portugal and France and foray into unexplored geographies like Poland and the Czech Republic.

We have successfully completed the acquisition of Generis Farmaceutica S.A., through our wholly-owned subsidiary Agile Pharma B.V. It has a wide portfolio of products with major share in the therapeutic areas of cardiovascular (CVS), central nervous system (CNS), anti-infectives and genito-urinary system ailments. Generis is one of the most prominent pharmaceutical brands in Portugal; and the acquisition will establish Aurobindo as the leading generics group in that country.

Our antiretroviral (ARV) product segment and Growth Markets presence were further strengthened with the launch of key products and selective geographical expansion. In our ARV segment in particular, we received the USFDA approval for Dolutegravir triple drug combination (TLD) product under the PEPFAR program; this will improve our patient outreach to around 5 million.

CONSISTENT EXECUTION

Aurobindo pioneered the execution of endto-end activities in the pharma value chain. Our continuous holistic efforts to optimize and rationalize the operations gives us the strength to face headwinds very efficiently. Team Aurobindo is well-focused on bringing the best out of available resources, which directly impacts our operational and financial outcomes.

The excellence in execution paved path for the Company to successfully register growth across the key markets. The execution excellence also resulted in diversifying our product portfolio, thereby minimizing the risk of product concentration. Aurobindo successfully executed the turnaround strategies of acquired business in Europe, which resulted in much healthier margins from that region.

QUALITY COUNTS

Quality is of utmost importance to us; and every member of the team ensures that we remain at the top of the quality and compliance curve. Hence, when our US-based subsidiary, AuroMedics Pharma LLC, was appraised for the presence of particulate matter in few of the products distributed in the US market, we initiated a voluntary recall of these products. Aurobindo has adopted a holistic life cycle approach to mitigate the particulate matter issues thereby ensuring patients receive highquality injectables in terms of product quality and safety.

We managed the task by fast-tracking our response time and immediate notifications were sent out to consumers. distributors and retailers about the recall. We, at Aurobindo, remain committed to ensuring high-quality of our products: and have strengthened the quality culture over the years, by being steadfast about our adherence to robust Standard Operating Procedures (SOPs). Aurobindo has invested in capability building to embrace a culture of quality for sustainable compliance. Employees are continuously trained on various quality aspects such as Effective Investigation and Authoring skills and Computerized Systems Compliance for understanding.

NEW INITIATIVES

The development across our new initiatives has been on track. In the fiscal gone by, for our oncology and hormonal products we filed 11 ANDAs with the USFDA. We have launched our first penem injectable in the US in the year, and in the process of launching one more penem injectable in the US and Europe.

We are happy to report that the production of exhibit batches for our upcoming dermatology and biosimilar products is on track. We are in the process of filing 5-6 ANDAs in dermatology for the US market. We are expecting to start the Phase-I clinical trials for our first biosimilar in FY2018-19.

The rapid pace at which our new initiatives are moving across the development and regulatory approval stages, we are confident of their successful commercialization in the foreseeable future. We strongly believe that, these products will ensure long-term growth of the Company and significant value creation for all our stakeholders.

NURTURING PEOPLE AND ENVIRONMENT

Our broad sustainability agenda encompasses our strategy about our people, community and the environment. In the preceding fiscal, we expanded our training and development program to bring more people into this ambit. We have further aligned each function of our operations with stringent quality needs.

As a fast-growing enterprise, we are conscious of the impact our business can have on the environment and the communities we work with. Hence, we continue to implement a strategic EHS and CSR framework to ensure holistic growth and environment sustainability.

Our execution brilliance across all aspects of the business has enabled us to grow and create value sustainably. We will continue to be an execution-focused Company, because at the end of the day sustained excellence is the outcome of steadfast execution.

I am grateful to all members of the Aurobindo family and the entire stakeholder fraternity for putting your faith in our vision and strategy.

N. Govindarajan Managing Director

BUSINESS MODEL

How we create value sustainably

STRATEGIC FOCUS AREAS

- Strengthen and diversify portfolio
- Build robust R&D and manufacturing capability and capacity in India and the US
- Create a fully-automated distribution center and an integrated supply chain and marketing structure

KEY RELATIONSHIPS



KEY INPUTS

Shareholders' equity	Manufacturing sites
Debt	R&D centers
Cash flow	Communities
Employees	

OUR STRENGTHS

Scale, diversity and leadership

Large manufacturing facilities inspected and approved by the USFDA, EMA, and other regulators

Dedicated, cutting-edge global R&D centers for diverse technology platforms and APIs

Unwavering commitment to bring access to highquality, low-cost generics to patients globally

Large talent pool with exceptional caliber and commitment

OUR KEY THERAPY AREAS

Antibiotics

Antiretrovirals (ARVs)

Cardiovascular (CVS)

Central nervous systems (CNS)


Gastroenterologicals

Anti-diabetics

Anti-allergics

OUR MARKETS





Financial Statements

OUR VALUE CHAIN





Research and Development







Sales and marketing

OUTCOMES

Returns

Returns for our equity holders and debt providers

Assets

Cash to re-invest in our assets and our people

Product efficacy

Products that help patients across the globe live better lives

Opportunity

Employment, training and development opportunities for all our employees, regardless of gender, race or age

A strong culture

An engaged workforce that enhances the communities they operate in



Growth of the

economy

The Company pays taxes on the economic value generated. Further, the Government collects taxes on goods sold and services provided. Most importantly, our operations yield one of the best net Forex inwards impacting the economy positively.

OPERATING LANDSCAPE

Major socio-economic trends

As a significant global player in the pharmaceutical landscape, we are increasing the complexity and diversity of our portfolio to treat more patients and win across global markets. However, regulatory and pricing pressures continue to shape the way the industry operates and creates value for all stakeholders.

Global economic growth and burgeoning population

The global economy grew by 3.8% in 2017. As per the IMF, the year reported the broadest synchronized growth across the world since 2010 and the growth pattern is expected to improve in 2018.

Additionally, the global population is increasing at a rapid pace. Thus, growing life expectancy with expected rise in per capita income will be the key growth driver for the pharmaceutical industry.

Global **population growth** (in billion)



[Source: United Nations' World Population Prospects]

Prevalence of lifestyle diseases

The proliferation of lifestyle diseases is likely to be a major concern in both developed and emerging economies. Obesity, cardiovascular diseases, hypertension and diabetes are persistent and will challenge public healthcare delivery systems to meet the growing demand for drugs and treatments.

592 million people to have **diabetes** by 2035



[Source: International Diabetes Federation (IDF)]

Ageing societies

Ageing societies are expected to drive the resources being diverted to social and health spending. Ageingrelated illnesses, such as cancer and dementia, will increasingly dominate health research agendas. Increasing life expectancy may trigger increased consumption of medical services and pharmaceuticals.

Population ageing will remain a long-term growth driver in Western Europe and Japan as well as in countries such as Argentina, Thailand, and China.

16% of the world's
population will be 65+
years by 2050



[Source: United Nations' World Population Ageing Report]

Science and technology

Innovation is critical to addressing the world's unmet medical needs. The delivery of new medicines will rely on a deeper understanding of diseases and the use of new technology and approaches.

Technological advances are helping the pharma industry to look at growth opportunities that help design and test novel products

~27% of the global pharma market to be **biologics** by 2020



[Source: Global pharma looks to India: Prospects for growth by PwC]

Globalization

Globalization will continue to facilitate the wide dissemination of knowledge, technologies and new business practices. It will progressively lead to more international initiatives to deepen the impact of public health programs. This necessitates further international co-operation in research and direct it towards global threats.

In 2015, **the World Health Organization (WHO)** endorsed a global action plan to tackle Antimicrobial Resistance (AMR)

100+ companies and

associations signed Industry Declaration on AMR at the World Economic Forum in Davos in 2016

Pricing scenario

Healthcare services are highly regulated by governments, insurers and other private payers. Hence, pricing and reimbursement remain challenging in many markets.

Pharma companies are now working hard to mitigate pricing pressures by diversifying into diverse geographies and complex products, promising high margins.

\$345–375 billion growth estimated from Pharmerging markets by 2022



[Source: IQVIA Market Prognosis, October 2017].

STRATEGIC PRIORITIES

Roadmap for sustained excellence

Strategic Priorities	Objectives	Outcomes Achieved
Focus on innovative science in key therapy areas	Work across small molecules and biologics, including immunotherapies and protein engineering, as well as build efficiency across a wide array of drug delivery systems	 Identified 79 oncology and hormonal products for development and filed 13 ANDAs with the USFDA Received approval from the USFDA and launched the first penem injectable successfully Commissioned the cell culture manufacturing facility Received tentative approval from the USFDA for Dolutegravir triple combination product (Tenofovir, Lamivudine and Dolutegravir tablets) under PEPFAR program
Elevate our R&D capabilities	Invest to acquire top-notch technologies and strengthen early-stage pipeline globally	 R&D centers on Specialty Products and Biosimilars inaugurated R&D spend at ₹6,665 million, 4% of revenues Filed 47 ANDAs, including 16 injectables Received final approval for 49 ANDAs, including 7 injectables Launched 38 products, including 6 injectables in the US
Focus on organic and inorganic growth	 Collaborate/ acquire strategically to broaden and accelerate the development of products Improve manufacturing capabilities Reach relevant markets globally 	 Agile Pharma B.V., Netherlands, a wholly-owned step- down subsidiary of the Company has successfully completed the acquisition of Generis Farmaceutica S.A. Transferred manufacturing activities of 83 products from Europe to India Successfully commissioned Betalactum injectables manufacturing at Unit XVI Building an USFDA-compliant oral manufacturing facility at Naidupet, Andhra Pradesh at Unit X Setting up a small non-Betalactum injectable manufacturing facility in the US US Formulations grew 9% year-on-year and contributed for 45% revenues EU Formulations grew 32.9% and accounted for 22% of revenue
	2000	1200

Strategic Priorities	Objectives	Outcomes Achieved
Ensure compliance to quality standards	Ensure consistent quality excellence; and comply with the evolving regulatory scenario	 Manufacturing facilities approved by the USFDA, UK MHRA, MCC-SA, ANVISA Brazil and EMA
Sustain market leadership; and a robust financial position	Maintain a strong balance sheet to fund growth ambitions	 12th largest generic company by sales globally* 2nd largest listed Indian pharmaceutical company by revenues (in FY2017-18) Revenue from operations at ₹164,998 million, a 9.3% year-on-year growth EBITDA margin continued to expand Basic and diluted EPS is ₹41.36 per share
Drive a people- focused culture	Ensure effective organization, leadership, talent management and recruitment	 5,578 employees with length of service of over five years 4,973 employees received training and development during FY2017-18

Pursuit of sustained excellence is an exciting voyage towards new harbors of opportunity.

SUSTAINED EXCELLENCE HAS MANY FACETS



We remain committed to deliver affordable and innovative solutions for unmet medical needs globally. Our commitment enables us to drive sustained excellence by manufacturing quality products, reaching new growth milestones and nurturing a culture of integrity. By creating high-quality products, and making them accessible to those who need them, we are helping shape a healthier world. We are passionately and thoughtfully translating science into lasting contributions to human health through the manufacture of **quality products**. Our intervention in key therapeutic areas and high-end manufacturing capabilities help us achieve financial and operational stability.

We have steadily grown the **scale and scope of our business** from a very modest beginning to emerge among the largest generic companies by sales globally. This is a collective achievement of our formidable talent pool. Our credo is to acquire and share knowledge and **nurture go-getters**, who can take the organization to the next level.

FACETS OF SUSTAINED EXCELLENCE

(1) Quality is sacrosanct

Aurobindo's growing market presence has been built on the foundation of high-quality products. Our core business philosophy is to manufacture quality products that are both accessible and affordable. With our brand promise of building capabilities that comply with regulatory standards, we remain committed to our patients and partners.

We are continuously upgrading our facilities and aligning them to match international standards.

Our collaboration with key global partners has enabled us to enrich our portfolio and provide critical healthcare solutions to those in need.

We believe, quality commitment cannot be sustainable, unless it is supported

by robust R&D and manufacturing capabilities.

RESEARCH AND DEVELOPMENT

During FY2017-18, we invested around ₹6,665 million, which is 4% of total revenues. Our R&D efforts have been focused on strengthening the product portfolio. During the year under review, we launched 38 products, including

six injectables in the US. In addition, approvals were received for 49 ANDAs, including seven injectables.

To ensure the continuous development of our product pipeline, we submitted a total of 47 ANDAs filings, including 16 injectables.

Unit-wise ANDA filings as on 31 March 2018

Site	Details	Final Approval	Tentative Approval*	Under Review	Tota
Unit III	Oral Formulations	108	11	7	126
Unit IV	Injectables & Ophthalmics	50	2	38	90
Unit VIB	Cephalosphorins Oral	11			11
Unit VII (SEZ)	Oral Formulations	117	21	22	160
Unit X	Oral Formulations			25	25
Unit XII	Penicillin Oral & Injectables	19		1	20
Aurolife USA	Oral Formulations	17		10	27
AuroNext	Penem Injectables	1		1	2
Eugia	Oral & Injectable Formulations			13	13
Others	Oral Formulations	4			4
Total		327	34	117	478
Total		327	34	117	4

*includes 11 ANDA approved under PEPFAR

25

FACETS OF SUSTAINED EXCELLENCE



QUALITY IS SACROSANCT

IMPROVING PRODUCTION CAPACITY

During FY2017-18, we commissioned the Unit XVI, the Betalactum injectable facility and started exporting to the US market. Our fully automated distribution center in New Jersey was commissioned during the year. The facility will enhance the storage of oral dosage forms, injectables and OTC products; and has a capacity of 20,000 pallet locations. The unit is equipped to ensure that the quality of our products is sustained at every stage of the distribution value chain. As a successful addition to our portfolio, we completed the acquisition of Generis Farmaceutica S.A. in Portugal through our wholly-owned subsidiary Agile Pharma B.V., Netherlands. With an investment of ₹9,690 million, the acquisition will add to the production capacity with 1.2 billion tablets or capsules annually.

Sustained excellence for the future



Fully-automated distribution center

Unit X

The Company is building a USFDAcompliant oral manufacturing facility at Naidupet, Andhra Pradesh; and the facility will be commissioned during the current fiscal. The facility has been inspected by the USFDA and EMA.

US Injectable facility

The Company is in the process of setting up a non-Betalactum injectable manufacturing facility in the US in line with its diversification strategy.



FACETS OF SUSTAINED EXCELLENCE

2 Scaling the growth curve is exhilarating

We began our journey as an API manufacturing company, gradually moving into production of formulations. Today, our product portfolio spans seven major therapeutic/product areas, including antibiotics, ARVs, CVS, CNS, gastroenterologicals, anti-diabetics and anti-allergics.

FACETS OF SUSTAINED EXCELLENCE



SCALING THE GROWTH CURVE IS EXHILARATING

Over the years, we have focused on augmenting our capabilities to create novel solutions that help provide patients across the world a healthier life.

We are diversifying into new product segments such as biosimilars, specialty injectables, oncology, peptides, respiratory, topicals, vaccines and penems.

We have identified 79 oncology and hormonal products for development. We are cognizant of the capabilities needed to fulfil this objective, as oncology products are a highly specialized class of products and are difficult to produce. We have already filed 13 ANDAs with the USFDA as on 31 March 2018, and our manufacturing facility was inspected by the USFDA and EMA.

We also successfully received approval from the USFDA and launched our first penem injectable during the year.

One of our other achievements was receiving tentative approval from the USFDA for Dolutegravir triple combination product (Tenofovir, Lamivudine and Dolutegravir tablets) under President's Emergency Plan for AIDS Relief (PEPFAR) program. We have developed the process of manufacturing 14 peptides and two more molecules are in the process of development. Till FY2017-18, we filed four DMFs to US regulatory authorities and plan to file three more DMFs in the next fiscal.


Through steady investment and strategic acquisitions, we have reinforced our R&D capabilities to pursue our long-term growth objectives. We have the expertise and resources to focus on more complex and differentiated products across a range of therapeutic categories, dosage forms and delivery systems.



Projected Future Growth in FY 2018-19

Unit IV facility

Our cell culture manufacturing facility was commissioned, and our first set of biosimilar exhibit batches will be completed. We also intend to commence Phase I clinical trials for our lead molecule, Bevacizumab. Among our topical products under the dermatology portfolio, exhibit batches of 17 products will be ready and we intend to file 5 ANDAs.



Annual Report 2017-18 31

FACETS OF SUSTAINED EXCELLENCE

3 Reinforcing a culture of ownership

Our culture is shaped by the passion and perseverance of our people. Our culture aligns every member of the team to our core values. Our HR initiatives focus on three key aspects: **people, process** and **performance**.

Total employees 19,000+

Inter-band elevation 17-20%

Our HR strategies focus on realizing the business sustenance and growth envisioned by the management through building a strong talent pipeline that is geared to instill accountability and integrity towards processes and functions.

Given the dynamic regulatory environment that the pharma industry is witnessing, it is essential to build human capacities that can take on challenges; and help the Company achieve sustained growth.

One of the most important achievements for us has been the mapping of leadership competencies and identification of people in terms of succession planning for leadership until 2022. Leadership competency is very critical; and our leaders demonstrate characteristics such as ownership, people leadership, strategic thinking, pursuit of innovation and an execution drive.

We have undertaken several steps to ensure overall growth and development of employees across every level, with an improved focus on inter-band promotions.

FACETS OF SUSTAINED EXCELLENCE



REINFORCING A CULTURE OF OWNERSHIP

1. NALANDA

Nalanda was launched with a vision towards business excellence through leadership and functional competency development; and to provide impetus to develop second-line managers for all critical functions. The components of the courses are customized to the APL Competency Framework and are curated with content from esteemed professors from leading universities such as Wharton, Insead, London School of Business, Harvard University and Kellogg School of Management to, name a few.

The strategic e-learning initiative that commenced last year with the objective of scaling leadership competencies in line with the organization's robust business growth completed the first season in March 2018.

2. QUALITY MARSHAL PROGRAM (QMP)

QMP is a key initiative to strengthen the Culture of Quality through continuous cascade and reinforcement of Quality Behaviours and adherence to SOPs at the shop-floor through the trained and qualified resource pool of Quality Marshals. The Quality Marshals have worked arduously towards strengthening our quality culture by developing confidence and communication among shop-floor employees towards increasing audit interface capabilities and continuously addressing quality risks in our processes through structured learning partnerships.

By, 2020 we aim to have around 400+ Quality Marshals across all formulation units in the organization.

3. HR OUTREACH & ENGAGEMENT

At Aurobindo, we are committed to extend learning to not only the employee, but also the employee's family. We create a positive wholeman approach through our various HR Outreach & Engagement programs like Saksham, Career Orientation Program, Prathiba and Aurobindo Appreciation Day.

4. KAIZEN

We, at Aurobindo, have adopted Kaizen in the work culture to focus on continual improvement. This requires unit-level involvement to map KPIs and drive efficiencies.

5. SKILL-BUILDING & DEVELOPMENT PROGRAMS

Aligning the HR function with the business strategy is one of our primary objectives, in view of this various skillbuilding and development programs are designed and implemented which includes preparation of skill matrix for all operators, initiating project on Talent Critical Equipment Repository and organizing OEMs from Gansons, Tofflon and FETTE for technical training programs.

Kaizen deals with four aspects:



Daily Kaizen

Focused on identifying daily KPIs and strict adherence to those KPIs



Project Kaizen

Encompasses KPIs that need to be put into action to improve processes and improve productivity





Support Kaizen

Ensures that the key enablers such as the support systems within an organizational structure and the governance mechanism follow certain goals to ensure process stability



Leaders Kaizen

Ensures that the top management is empowered and supported to build efficient capabilities

FACETS OF SUSTAINED EXCELLENCE

(4) Robust risk governance

Principal Risks	Context	Mitigation Strategy	Movement
Economic & geopolitical risks	Economic and political instability arising from changes in foreign policies and political leadership in countries, where the Company has business presence	 Continue to expand towards untapped Growth Markets Focus on growing each product segment and improve presence across existing markets 	
Competition risks	Aurobindo's products face consistent competition globally with multiple pharma players	 Manufacture products at competitive costs Ensure timely launch of new products Enhance manufacturing capabilities to ensure sufficient levels of production 	
Regulatory and compliance risks	An evolving regulatory landscape can pose challenges at an enterprise level	 Experienced and skilled staff adept in handling complex chemistry and filing processes Stringent quality systems and control policies to ensure adherence to compliance standards A robust 'statutory compliance system/ solution' to ensure compliance with all applicable laws Strong commitment towards creating and providing a safe working environment for all its employees and other stakeholders 	

Principal Risks	Context	Mitigation Strategy	Movement
Financial Controls	Our majority expenses and investments are primarily in Indian currency. However, revenues are spread out across various international currencies. Therefore, our net expenses and any future investment or other income may be vulnerable to fluctuations in exchange rates.	 Established robust currency hedging strategy to safeguard ourselves Ensured reduction in borrowing costs with proper negotiation with banks Defined credit policy for all customers Consistent monitoring of daily fund requirements 	
Intellectual Property	R&D initiatives are susceptible to significant risks. For example, specific product candidates are never approved; projects may even get abandoned, for various reasons	 Established a strong team of experts and thought leaders in the R&D team Monitored our progress on specific product candidates in R&D 	
Environment, Health and Safety and Sustainability	Any shortcoming in compliance with Company policies on maintaining EHS and Sustainability standards can jeopardize the brand salience	 Enhanced focus and regulatory activity on environmental issues Going an extra mile and thinking beyond regulatory compliance Stringent controls and governance framework, enabling compliance 	
People risks	Lack of quality human resource may impact our growth targets and sustainability	 Identify and develop talent with potential Implement tools to train individuals on a periodic basis Sharpen and strengthen quality compliance across the organization Initiated Social Accountability Certification process (SA 8000 series) to sustain our commitment towards fair people management 	
Aisk exposure increased	Risk exposure decreased	Risk exposure remains the same	

Financial Statements

Annual Report 2017-18

FACETS OF SUSTAINED EXCELLENCE

5 Environment, Health and Safety

We believe our EHS initiatives are part of our sustainability initiatives. We provide relevant information, training and support to all our employees to increase their awareness of the hazards and risks that are associated with our operations.

Financial Statements

In FY2017-18, like previous years, we recorded sustained and satisfactory environment operations across our API and formulation units. Major API manufacturing units in Telangana state demonstrated compliance to Zero Liquid Discharge. We established 30 MW captive solar power plant project at Varisam, Srikakulam District, Andhra Pradesh. The plant is fully functional and helps reduce carbon footprint. Aurobindo has initiated SA 8000 accreditation process for two formulations manufacturing units and aims for certification in 2018.

LIQUID DISCHARGE

We conform to all regulations for disposal of wastewater to Common Effluent Treatment Plants (CETPs) or marine discharge across our formulation units and API facilities. We developed new initiatives for treatment of wastewater using advanced technologies like membrane bio-reactors that complement our expansion projects in some of our API manufacturing locations.

SOLID WASTE MANAGEMENT

We continue to follow the standardized practice of disposing organic wastes in which they are sent to cement units for reuse as auxiliary fuel in kilns. We use Treatment, Storage and Disposal Facilities (TSDF) to manage our inorganic and miscellaneous solid wastes. We also commenced new initiatives for additional control measures on fugitive emissions at waste treatment facilities at some of our API units. These initiatives include providing hoods on wastewater storage tanks, arrangement of additional scrubbers and so on. Additionally, our API units are equipped with monitoring instruments for continuous assessments of fugitive emissions in the premises.

During FY 2017-18, we started vermi-composting of garden and kitchen waste in one of our API manufacturing units. The pilot project was highly successful and going forward, we will implement it across our other units.

ENVIRONMENTAL SUSTENANCE

We have installed, online continuous emissions monitoring systems across our manufacturing units. These are connected to the central and concerned state pollution control boards according to norms. We completed our public consultation process for expansion of Aurobindo Unit XI.

Now, we are gearing up for the submission of Environmental Impact Assessment (EIA) report to the Ministry of Environment and Forests & Climate Change (MoEF & CC). During FY 2017-18, our various customers conducted environment assessments functions across our API and DP formulations units.

We also worked towards enriching our environment with the following programs:

- ~1 lakh square meters of area brought under green cover
- 7,000 trees and 2,000 shrubs planted across manufacturing locations
- Collaborated with Governments to develop environmental awareness initiatives like Vanamahostavam by the Government of India, Vanam–Manam by Government of Andhra Pradesh; and Telangana Ku Haritha Haram by the Government of Telangana

SAFETY FIRST

In our drive to improve safety culture, to change behavior and thought process, behavior-based safety programs are being implemented. Software modelling and quantitative risk assessment tools like PHAST software is being used to identify hazards, and mitigate risks from bulks flammable material storage.

We initiated safety pep-talks before every shift on hazards in activities and necessary precautions to be taken in case of a mishap. We also conduct Hazard and Operability Study (HAZOP) and risk analysis for all new products.

Historical events including injuries and other incidents were analyzed and actions have been initiated to address the common root causes. We have also put in place a training matrix for contract workers based on their activities and special training modules have been implemented for production heads for managing and leading safety.

- Safety training person-hours increased from 0.54% in last year to 0.59% during this year.
- Sprinkler systems being put up as an additional layer of safety for bulk solvent storage yards
- Safety tests were conducted for all new chemicals
- Activity based risk assessments conducted three to four years earlier were re-visited and updated during the year

ANTI-MICROBIAL RESISTANCE (AMR) – A GLOBAL THREAT

Since 2015, there has been an intense focus by the international media on policy-level discussions over anti-microbial resistance (AMR). This has also raised concerns over pharmaceutical industry in India and Hyderabad in particular. Aurobindo recognizes that AMR is a serious global concern that needs to be handled through a comprehensive and multi-pronged strategy.

The Antimicrobial Resistance Benchmark is a first independent, detailed benchmarking of how pharmaceutical companies are halting the rise of drug resistance by Access to Medicine Foundation, an independent non-profit organization based in the Netherlands through collaboration with experts and specialists working across the spectrum of organizations trying to curb antimicrobial resistance.

The Access to Medicine Foundation approached Aurobindo, while describing the purpose of the benchmark, its process and the framework of the benchmark, in May 2017 with a request to take part in the initiative. Aurobindo has collaborated in the benchmarking exercise. The Antimicrobial Resistance Benchmark 2018 was published in January, 2018. The proposed 2020 AMR Benchmark will have more indicators with participation of 30 companies. We are engaging ourselves for the forthcoming 2020 AMR Benchmark as well.

FACETS OF SUSTAINED EXCELLENCE

6 Shaping holistic community well-being









Our commitment towards sustained excellence also includes our citizenship efforts to benefit the communities we work with. We operate through charitable donations, volunteering and by building a responsible business that abides by an essential set of social and environmental policies.

We collaborate with community groups to support public policies that promote economic and societal development, while respecting local cultures.

Aurobindo's CSR charter covers the following intervention areas:

- Promoting education
- Supporting preventive healthcare
- Eradicating hunger, poverty and malnutrition
- Making available safe drinking water
- Encouraging environment sustainability

- Sustaining ecological balance and conservation of natural resources
- Encouraging rural sports
- Setting up old-age homes

As part of our societal commitment, we support neighborhoods with educational aids for school children, construction of toilets and provision of safe drinking water. The primary focus is to promote education, encourage good health, provide drinking water and support sanitation.



BOARD OF DIRECTORS



Mr. K. RAGUNATHAN Non-Executive Chairman, Independent Director

Chartered Accountant

He is a CA by profession and a leading management consultant. He has over three decades of experience in consulting services.



Mr. K. NITHYANANDA REDDY Vice Chairman, Whole-time Director, a promoter of the Company

Postgraduate in Science from Venkateswara University

He has been associated with the Company from its initial days. He is wellversed with the manufacturing technology and supervises the overall affairs of the Company.



Mr. N. GOVINDARAJAN Managing Director

B.E. (Mechanical) from Annamalai University

He has more than 25 years of experience across a variety of domains such as active ingredients, CRAMS, finished dosages & biotechnology.



Dr. M. SIVAKUMARAN Whole-time Director

Postgraduate in Science from University of Madras and PhD in Organic Chemistry from Jadavpur University

He has more than four decades of experience in the pharmaceutical industry and is responsible for the technological evolution of the Company. He looks after research and development, new product development and total quality management.



Mr. M. MADAN MOHAN REDDY Whole-time Director

Postgraduate in Science (Organic Chemistry) from Bhopal University

He has held top managerial positions in leading pharmaceutical companies. He commands over 25 years of valuable experience in the pharmaceutical industry. He looks after formulations manufacturing of the Company.



Mr. P. SARATH CHANDRA REDDY Whole-time Director

Graduate in Business Administration

He is a second-generation entrepreneur, experienced in general management and has expertise in project executions, IT, procurement and other aspects of the business.

Financial Statements



Mr. P.V. RAMPRASAD REDDY Non-executive Director, Promoter

Postgraduate in Commerce from Venkateswara University

Prior to promoting Aurobindo in 1986, he held management positions in various pharmaceutical companies. In 2008, the widely read World Pharmaceutical Frontiers, named him among the top 35 most influential people in the pharmaceutical industry.



Mr. M. SITARAMA MURTY Non-executive, Independent Director

Postgraduate in Electronics from Andhra University

He is a professionally qualified banker and has over three decades of experience in the industry with various important positions in nationalized banks. He retired as the Managing Director & CEO of State Bank of Mysore, in 2003.

His specialized areas of interest are international banking, foreign exchange, money markets, funds management, credit management, rural development, computerization, commercial law and systems.



Dr. (Mrs.) AVNIT BIMAL SINGH Non-executive, Independent Director

M.B.B.S. degree from RNT Medical College, Udaipur and Postgraduate in obstetrics & gynecology from Rajasthan University

She is a medical practitioner and a senior obstetrician/gynecologist based in Hyderabad.



Mrs. SAVITA MAHAJAN Non-executive, Independent Director

MBA, IIM Ahmedabad.

Mrs. Savita Mahajan, is the former Deputy Dean of the Indian School of Business (ISB). She was associated with the ISB for 14 years, since its inception in 2001, and was responsible for building its second campus at Mohali, Punjab, as its CEO. She has also carried out consulting and training assignments for corporations and development organizations, including GE Capital, the Planning Commission, the World Bank, and the Tibetan Government in exile of His Holiness, the Dalai Lama. Chief Financial Officer Mr. SANTHANAM SUBRAMANIAN

Company Secretary Mr. B. ADI REDDY

Statutory Auditors M/s. BSR & Associates LLP Chartered Accountants Salarpuria Knowledge City Orwell, 6th Floor, Unit-3

Orwell, 6th Floor, Unit-3 Sy No. 83/1, Plot No. 2, Raidurg Hyderabad - 500 081

Registrars & Transfer Agents M/s. Karvy Computershare Private Limited

Karvy Selenium, Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 Phone : +91 40 6716 2222 Fax : +91 40 2300 1153 E-mail : einward.ris@karvy.com

Bankers

Andhra Bank Canara Bank DBS Bank Limited HDFC Bank Limited ICICI Bank Limited Standard Chartered Bank State Bank of India

Corporate website:

www.aurobindo.com

CIN: L24239TG1986PLC015190



Aurobindo Pharma Limited

(CIN - L24239TG1986PLC015190)

Regd.Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500 038 Tel No. +91 40 23736370, Fax No. +91 40 23747340 E-mail: info@aurobindo.com; Website : www.aurobindo.com

NOTICE is hereby given that the 31st Annual General Meeting of the Members of Aurobindo Pharma Limited will be held on **Thursday, the 30th day of August, 2018 at 3.00 p.m. at Kaveri Ball Room, Hotel Trident, Hi-tech City, Near Cyber Towers, Madhapur, Hyderabad 500 081** to transact the following business:

ORDINARY BUSINESS

- To receive, consider and adopt the Audited Standalone Balance Sheet as at March 31, 2018, Statement of Profit and Loss for the financial year ended on March 31, 2018, Cash Flow Statement for the financial year ended March 31, 2018 and reports of Directors and Auditors thereon.
- 2) To receive, consider and adopt the Audited Consolidated Balance Sheet as at March 31, 2018, Statement of Profit and Loss for the financial year ended on March 31, 2018, Cash Flow Statement for the financial year ended March 31, 2018 and report of Auditors thereon.
- 3) To confirm the first interim dividend of ₹1.50 and second interim dividend of ₹1.00 in aggregate ₹2.50 per equity share of ₹1/each, as dividend for the financial year 2017-18.
- To appoint a Director in place of Mr. K.Nithyananda Reddy (DIN: 01284195) who retires by rotation at this Annual General Meeting and being eligible, seeks re-appointment.
- To appoint a Director in place of Mr. M.Madan Mohan Reddy (DIN: 01284266) who retires by rotation at this Annual General Meeting and being eligible, seeks re-appointment.

SPECIAL BUSINESS

6) To appoint Mrs. Savita Mahajan (DIN: 06492679) as an Independent Director and in this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 read with Schedule IV and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), Mrs. Savita Mahajan (DIN: 06492679), who was appointed as an Additional Director of the Company by the Board of Directors with effect from December 16, 2017, pursuant to the provisions of Section 161(1) of the Companies Act, 2013 and the Articles of Association of the Company and whose term of office expires at this Annual General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Companies Act, 2013 from a member proposing her candidature for the office of Director, be and is hereby appointed as an Independent Director of the Company to hold office for 2 (two) years up to December 15, 2019, not liable to retire by rotation."

7) To re-appoint Mr. K.Nithyananda Reddy (DIN: 01284195) as Whole-time Director designated as Vice Chairman and in this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and subject to such other consents/approvals as may be required, Mr. K.Nithyananda Reddy (DIN: 01284195) be and is hereby re-appointed as Whole-time Director of the Company designated as Vice Chairman for a period of three years with effect from June 1, 2018, whose term of office shall be liable to determination by retirement of directors by rotation at a remuneration and perquisites as detailed below with liberty to the Board of Directors to alter and vary the terms and conditions of the said re-appointment and / or remuneration as it may deem fit and as may be acceptable to Mr.K.Nithyananda Reddy, subject to the same not exceeding the limits specified under Schedule V to the Companies Act, 2013 or any statutory modification(s) or reenactment thereof."

а	Salary	₹650,000 per month			
b	House Rent Allowance	₹433,333 per month			
С	Medical Reimbursement	i) Reimbursement of medical expenses incurred for self and family subject to a ceiling of one month's salary in a year or 3 months' salary over a period of 3 year			
		ii) Mediclaim insurance as per rules of the Company.			
d	Leave Travel Concession	For self & family once in a year as per the rules of the Company			
е	Personal Accident Insurance	Premium not exceeding ₹25,000 per annum			
f	Club Fees	Fees of clubs subject to a maximum of two clubs. This will not include admission and			
		life membership fee.			
g	Provident fund, superannuation benef	fits and gratuity as per the rules of the Company subject to the ceilings as per the			
	guidelines for managerial remuneratio	n in force from time to time.			
h	Provision of Company's car with drive	r.			
i	Provision of free telephone at residence	ce.			
j	Encashment of leave as per the rules	of the Company			
j	Encashment of leave as per the rules	of the Company			

8) To re-appoint Mr. N.Govindarajan (DIN: 00050482) as Managing Director and in this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and subject to such other consents/approvals as may be required, Mr. N.Govindarajan (DIN: 00050482) be and is hereby re-appointed as Managing Director of the Company for a period of three years with effect from June 1, 2018, whose term of office shall not be liable to determination by retirement of directors by rotation, at a remuneration and perquisites as detailed below with liberty to the Board of Directors to alter and vary the terms and conditions of the said re-appointment and / or remuneration as it may deem fit and as may be acceptable to Mr. N.Govindarajan, subject to the same not exceeding the limits specified under Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof."

а	Salary	₹1,935,940 per month
b	House Rent Allowance	₹1,290,626 per month
С	Medical Reimbursement	i) Reimbursement of medical expenses incurred for self and family subject to a ceiling
		of one month's salary in a year or 3 months' salary over a period of 3 years.
		ii) Mediclaim insurance as per rules of the Company.
d	Leave Travel Concession	For self & family once in a year as per the rules of the Company
е	Other Allowances	₹1,281,200 per annum
f	Provident fund, superannuation benef	its and gratuity as per the rules of the Company subject to the ceilings as per the
	guidelines for managerial remuneratio	n in force from time to time.
g	Provision of Company's car with drive	r.
h	Encashment of leave as per the rules	of the Company

"RESOLVED FURTHER THAT in addition to the above salary and perquisites, commission will also be payable up to 1% of the net profits of the Company calculated in the manner referred in Section 198 of the Companies Act, 2013 subject to a ceiling of ₹100 million for each financial year, as may be decided by the Board of Directors of the Company, subject to the overall remuneration payable to Mr.N.Govindarajan, Managing Director of the Company not exceeding the limits specified under Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof."

9) To re-appoint Dr.M.Sivakumaran (DIN: 01284320) as Whole-time Director and in this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and subject to such other consents/approvals as may be required, Dr.M.Sivakumaran (DIN: 01284320) be and is hereby re-appointed as Whole-time Director of the Company for a period of three years with effect from June 1, 2018, whose term of office shall be liable to determination by retirement of directors by rotation at a remuneration and perquisites as detailed below with liberty to the Board of Directors to alter and vary the terms and conditions of the said re-appointment and / or remuneration as it may deem fit and as may be acceptable to Dr.M.Sivakumaran, subject to the same not exceeding the limits specified under Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof."

а	Salary	₹650,000 per month			
b	House Rent Allowance	₹433,333 per month			
С	Medical Reimbursement	 Reimbursement of medical expenses incurred for self and family subject to a ceiling of one month's salary in a year or 3 months' salary over a period of 3 years. 			
		ii) Mediclaim insurance as per rules of the Company.			
d	Leave Travel Concession	For self & family once in a year as per the rules of the Company			
е	Personal Accident Insurance	Premium not exceeding ₹25,000 per annum			
f	Club Fees	Fees of clubs subject to a maximum of two clubs. This will not include admission			
		and life membership fee.			
g	Provident fund, superannuation benef	its and gratuity as per the rules of the Company subject to the ceilings as per the			
-	guidelines for managerial remuneratio	n in force from time to time.			
h	Provision of Company's car with drive	r.			
i	Provision of free telephone at residence	De.			
i	Encashment of leave as per the rules	of the Company			

10) To re-appoint Mr.M.Madan Mohan Reddy (DIN: 01284266) as Whole-time Director and in this regard to consider and, if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and subject to such other consents/approvals as may be required, Mr.M.Madan Mohan Reddy (DIN: 01284266) be and is hereby re-appointed as Whole-time Director of the Company for a period of three years with effect from June 1, 2018, whose term of office shall be liable to determination by retirement of directors by rotation at a remuneration and perquisites as detailed below with liberty to the Board of Directors to alter and vary the terms and conditions of the said re-appointment and / or remuneration as it may deem fit and as may be acceptable to Mr.M.Madan Mohan Reddy, subject to the same not exceeding the limits specified under Schedule V to the Companies Act, 2013 or any statutory modification(s) or re-enactment thereof."

а	Salary	₹1,150,000 per month			
b	House Rent Allowance	₹766,666 per month			
C	Medical Reimbursement	 Reimbursement of medical expenses incurred for self and family subject to a ceiling of one month's salary in a year or 3 months' salary over a period of 3 year 			
		ii) Mediclaim insurance as per rules of the Company.			
d	Leave Travel Concession	For self & family once in a year as per the rules of the Company			
е	Personal Accident Insurance	Premium not exceeding ₹25,000 per annum			
f	Club Fees	Fees of clubs subject to a maximum of two clubs. This will not include admission and			
		life membership fee.			
g	Provident fund, superannuation bene	fits and gratuity as per the rules of the Company subject to the ceilings as per the			
	guidelines for managerial remuneration	n in force from time to time.			
h	Provision of Company's car with drive	er.			
i	Provision of free telephone at residen	се.			
i	Encashment of leave as per the rules	of the Company			

By Order of the Board

Place: Hyderabad Date: 28 May 2018 B. Adi Reddy Company Secretary Notes

- 1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMESELF/ HERSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. A person can act as proxy on behalf of Members up to and not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company. Further, a Member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as proxy for any other person or Member. In order to become valid, the proxy forms should be deposited at the Registered Office of the Company not less than 48 hours before the time fixed for holding the meeting. The proxy form is enclosed.
- A Statement pursuant to Section 102 of the Companies Act, 2013 with respect to the Special Business set out in the Notice is annexed hereto and forms part of the Notice.
- Relevant documents referred to in the accompanying Notice and the statement are open for inspection by the Members at the Registered Office of the Company on all working days during business hours up to the date of the meeting of the Company and also be kept at the venue during the AGM.
- 4. The Register of Members and Share Transfer Books of the Company will remain closed from August 24, 2018 to August 30, 2018 (both days inclusive).

- The Board of Directors of the Company has declared first interim dividend @ 150% i.e., ₹1.50 per share of ₹1 each and second interim dividend @ 100% i.e. ₹1.00 per share of ₹1 each for the financial year 2017-18 and the same was paid on November 30, 2017 and February 28, 2018 respectively.
- 6. During the financial year 2017-18, the final unpaid/unclaimed dividend for the year 2009-10 and the interim unpaid / unclaimed dividend for the year 2010-11 were transferred to the Investor Education and Protection Fund (IEPF). The Company has uploaded the details of the unpaid and unclaimed dividend amounts of the previous years' on the website of the Company (www.aurobindo.com) and also on the website of Ministry of Corporate Affairs. The unpaid/unclaimed final dividend for the year 2010-11 will be transferred to the Investor Education and Protection Fund of the Central Government on the due date. Also shares pertaining to unclaimed dividend for the year 2009-10 and the interim unpaid /unclaimed dividend for the year 2010-11 were also transferred to IEPF as per the prescribed Rules.

Members may note that shares as well as unclaimed dividends transferred to IEPF authority can be claimed back from them. Concerned Members/ Investors are advised to visit the weblink http://iepf.gov.in/IEPFA/refund.html or contact Karvy for lodging claim for refund of shares and / or dividend from the IEPF Authority.

Financial year	Dividend	Declaration Date	Due Date
2010-11	Final Dividend	July 29, 2011	September 2, 2018
2011-12	Dividend	August 7, 2012	September 12, 2019
2012-13	Interim Dividend	February 7, 2013	March 14, 2020
2012-13	Final Dividend	August 7, 2013	September 11, 2020
2013-14	Interim Dividend	November 7, 2013	December 12, 2020
2013-14	2nd Interim Dividend	May 30, 2014	July 4, 2021
2014-15	Interim Dividend	August 7, 2014	September 11, 2021
2014-15	2nd Interim Dividend	February 4, 2015	March 11, 2022
2014-15	3rd Interim Dividend	May 28, 2015	July 2, 2022
2015-16	Interim Dividend	August 12, 2015	September 16, 2022
2015-16	2nd Interim Dividend	November 6, 2015	December 11, 2022
2015-16	3rd Interim Dividend	February 9, 2016	March 16, 2023
2015-16	4th Interim Dividend	May 30, 2016	July 5, 2023
2016-17	Interim Dividend	November 14, 2016	December 20, 2023
2016-17	2nd Interim Dividend	May 29, 2017	July 3, 2024
2017-18	Interim Dividend	November 9, 2017	December 14, 2024
2017-18	2nd Interim Dividend	February 7, 2018	March 14, 2025

Due dates for transfer of Final unclaimed/unpaid dividends for the financial year 2010-11 and thereafter to IEPF:

- Members holding shares in physical form are requested to notify immediately any change in their address to the Company's Registrar and Transfer Agents, M/s. Karvy Computershare Private Limited. Members holding shares in electronic form may intimate any such changes to their respective Depository Participants (DPs).
- 8. To avoid loss of dividend warrants in transit and undue delay in respect of receipt of dividend warrants, the Company has provided a facility to the Members for remittance of dividend through the National Electronic Clearing System (NECS), Real Time Gross Settlement (RTGS)/ National Electronic Fund Transfer (NEFT). For this purpose, the details such as, name of the bank, name of the branch, 9- digit code number appearing on the MICR band of the cheque supplied by the bank, account type, account number etc. are to be furnished to your DP if the shares are in electronic form or to the Registrar & Transfer Agents, if they are held in physical mode.
- 9. The Annual Report for the financial year 2017-18 is being sent by electronic mode only to the Members whose Email addresses are registered with the Company/Depository Participant(s) for communication purpose unless any Member has requested for a hard copy of the same. For Members who have not registered their Email addresses, physical copies of the Annual Report for the financial year 2017-18 are being sent by the permitted mode. For Members who have not registered their e-mail addresses so far are requested to register their e-mail address for receiving all communication including Annual Report, Notices, Circulars, etc., from the Company electronically.
- In terms of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and as per the requirements of the Securities and Exchange Board of India (Listing Obligations and Disclosure)

Requirements) Regulations, 2015, the Company is providing the facility to its Members holding shares in physical or dematerialized form as on the cut-off date, i.e August 23, 2018, to exercise their right to vote by electronic means (e-voting) on any or all of the agenda items specified in the accompanying Notice of Annual General Meeting. Details of the process and manner of E-voting along with the User ID and Password are being sent separately to all the Members along with the Notice.

- 11. Members may also note that the Notice of the 31st Annual General Meeting and the Annual Report for the financial year 2017-18 will be available on the Company's website www.aurobindo.com. The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours on working days. Members who require communication in physical form in addition to e-communication, or have any other queries, may write to us at ig@aurobindo.com.
- 12. Brief resume of Directors who have been proposed to be appointed/re-appointed, nature of their expertise in specific functional areas, names of companies in which they hold directorships and membership/chairmanships of Board Committees and shareholding in the Company as stipulated under Regulation 36 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by ICSI are forming part of the Notice and is appended to the Notice.
- 13 The requirement of ratification of appointment of Statutory Auditors at every Annual General Meeting is done away by the Ministry of Corporate Affairs. Accordingly, no resolution is proposed for ratification of appointment of Statutory Auditors at this Annual General Meeting.

Financial Statements

Statement pursuant to Section 102(1) of the Companies Act, 2013

Item 6

The Board of Directors appointed Mrs. Savita Mahajan as an Additional Director categorized as Independent Director of the Company with effect from December 16, 2017, and accordingly, she holds office up to the ensuing Annual General Meeting of the Company. In terms of Sections 149 and 152 and the Rules made there under read with Schedule IV of the Companies Act, 2013, the Board of Directors have reviewed the declaration made by Mrs. Savita Mahajan that she meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013. The Board is of the view that the association of Mrs. Savita Mahajan would benefit the Company given the knowledge and experience of Mrs. Savita Mahajan. The Board is of the opinion that she fulfills the conditions specified in the Companies Act, 2013 and the Rules made thereunder and is independent of the management. Based on the recommendation of the Nomination and Remuneration/Compensation Committee, it is proposed to appoint Mrs. Savita Mahajan as an Independent Director of the Company as per the provisions of the Companies Act, 2013.

The Company has received a notice in writing under the provisions of Section 160 of the Companies Act, 2013 from a Member proposing the candidature of Mrs. Savita Mahajan for the office of Independent Director.

The Resolution seeks the approval of the Members for appointment of Mrs. Savita Mahajan as an Independent Director of the Company up to December 15, 2019 pursuant to Section 149 and other applicable provisions of the Companies Act, 2013 and the Rules made there under. She is not liable to retire by rotation.

The terms and conditions of appointment shall be open for inspection by Members at the Registered Office during business hours on all working days and will also be kept open at the venue during the AGM.

She does not hold any shares in the Company.

Additional information in respect of Mrs. Savita Mahajan pursuant to Listing Regulation 2015 and Secretarial Standard on General Meetings is appended to the AGM Notice.

No Director, Key Managerial Personnel or their relatives, except Mrs. Savita Mahajan, to whom the Resolution relates, is interested or concerned in the Resolution.

The Board recommends the Ordinary Resolution set forth in Item 6 for approval of the Members.

Item 7

Mr. K.Nithyananda Reddy was re-appointed as Whole-time Director designated as Vice Chairman of the Company with effect from June 1, 2015 for a period of 3 years which was approved at the 28th Annual General Meeting of the Company held on August 27, 2015. Mr. K.Nithyananda Reddy is one of the promoters of the Company. The Board considering the significant contribution made by him in the growth and development of the Company and based on the recommendation of Nomination and Remuneration/ Compensation Committee, re-appointed Mr. K.Nithyananda Reddy as Whole-time Director designated as Vice Chairman of the Company with effect from June 1, 2018 for a period of three years, subject to the approval of shareholders at the general meeting.

The terms of reappointment of Mr. K.Nithyananda Reddy and remuneration payable to him are as set out in Item No.7 of the Notice. Presently Mr.K.Nithyananda Reddy is drawing a remuneration of ₹13 million p.a. and other perquisites.

Additional information in respect of Mr. K. Nithyananda Reddy pursuant to Listing Regulations 2015 and Secretarial Standard on General Meetings is appended to the Notice.

No Director, Key Managerial Personnel or their relatives, except Mr. K.Nithyananda Reddy to whom the resolution relates and his relative Mr.P.Sarath Chandra Reddy, Whole-time Director, are interested or concerned in the Resolution.

The Board recommends the Ordinary Resolution set forth in Item 7 for approval of the Members.

Item 8

Mr. N. Govindarajan was re-appointed as Managing Director of the Company with effect from June 1, 2015 for a period of 3 years which was approved at the 28th Annual General Meeting of the Company held on August 27, 2015. The Board, considering the significant contribution made by him in the growth and development of the Company and based on the recommendation of the Nomination and Remuneration/Compensation Committee, re-appointed Mr. N. Govindarajan as Managing Director of the Company with effect from June 1, 2018 for a further period of three years, subject to the approval of Members at the general meeting.

The terms of reappointment of Mr. N. Govindarajan and remuneration payable to him are as set out in Item 8 of the Notice. Presently, he is drawing remuneration of ₹38.72 million per annum, allowances of ₹1.28 million per annum and other perquisites and also being paid a commission up to 1% of the net profits of the Company calculated in the manner referred in Section 198 of the Companies Act, 2013 subject to a ceiling of ₹100 million for each financial year.

Additional information in respect of Mr. N. Govindarajan pursuant to Listing Regulations 2015 and Secretarial Standard on General Meetings is appended to the Notice.

No Director, Key Managerial Personnel or their relatives, except Mr. N. Govindarajan, to whom the resolution relates, is interested or concerned in the Resolution. The Board recommends the Ordinary Resolution set forth in Item 8 for approval of the Members.

Item 9

Dr. M.Sivakumaran was re-appointed as Whole-time Director of the Company with effect from June 1, 2015 for a period of 3 years which was approved at the 28th Annual General Meeting of the Company held on August 27, 2015. The Board considering the significant contribution made by Dr. M.Sivakumaran in the growth and development of the Company and based on the recommendation of Nomination and Remuneration/ Compensation Committee, re-appointed Dr. M.Sivakumaran as Whole-time Director of the Company with effect from June 1, 2018 for a period of three years, subject to the approval of shareholders at the general meeting.

Dr. M.Sivakumaran is responsible for the technological evolution of the Company. He looks after research and development, new product development and total quality management. Considering his long association with the Company and the pivotal role being played on the technical front, the Board justifies the proposal of his re-appointment.

The terms of reappointment of Dr. M.Sivakumaran and remuneration payable to him are as set out in Item No.9 of the Notice. Presently Dr. M.Sivakumaran is drawing a remuneration of ₹13 million p.a. and other perquisites.

Additional information in respect of Dr. M. Sivakumaran pursuant to Listing Regulations 2015 and Secretarial Standard on General Meetings is appended to the Notice.

No Director, Key Managerial Personnel or their relatives, except Dr. M.Sivakumaran, to whom the resolution relates, is interested or concerned in the Resolution.

The Board recommends the Special Resolution set forth in Item 9 for approval of the Members.

Item 10

Mr. M.Madan Mohan Reddy was re-appointed as Whole-time Director of the Company with effect from June 1, 2015 for a period of 3 years which was approved at the 25th Annual General Meeting of the Company held on August 27, 2015. The Board considering the significant contribution made by him in the growth and development of the Company and based on the recommendation of Nomination and Remuneration/ Compensation Committee, re-appointed Mr. M.Madan Mohan Reddy as Whole-time Director of the Company with effect from June 1, 2018 for a period of three years, subject to the approval of shareholders at the general meeting.

The terms of reappointment of Mr. M.Madan Mohan Reddy and remuneration payable to him are as set out in Item No.10 of the Notice. Presently Mr.M.Madan Mohan Reddy is drawing a remuneration of ₹23 million p.a. and other perquisites.

Additional information in respect of Mr. M. Madan Mohan Reddy pursuant to Listing Regulations 2015 and Secretarial Standard on General Meetings is appended to the Notice.

No Director, Key Managerial Personnel or their relatives, except Mr. M.Madan Mohan Reddy, to whom the resolution relates, is interested or concerned in the Resolution.

The Board recommends the Ordinary Resolution set forth in Item 10 for approval of the Members.

By Order of the Board

Place: Hyderabad Date: 28 May 2018 B. Adi Reddy Company Secretary Details of the Directors proposed to be appointed/re-appointed at the AGM scheduled to be held on Thursday, August 30, 2018 as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Secretarial Standard on General Meetings are as given below:

Particulars	Mrs.Savita Mahajan	Mr.K.Nithyananda Reddy	Mr.N.Govindarajan	Dr.M. Sivakumaran	Mr.M.Madan Mohan Reddy
Age	59	60	50	75	58
Qualification	Degree in Economics and MBA from IIM Ahmedabad	Postgraduate in Science	BE (Mechanical)	Postgraduate in Science and PhD	Postgraduate in Science
Experience (including expertise in specific functional area)/ Brief Resume	inception in 2001, and was responsible for building its second campus at Mohali, Punjab, as its CEO. She holds a degree in Economics from Delhi University and did her MBA from the Indian Institute of Management, Ahmedabad, in 1981. Since then, she worked in several Indian organizations, including Maruti Udyog Limited, Bharat Technologies, Karvy Consultants, and Intergraph India, in diverse industry sectors, including automobiles, engineering, financial services and software. Her professional interests include Strategic Management, Institutional Values, Leadership and Organizational Change. She has also carried out consulting and training assignments for corporations and development organizations, including GE Capital, the Planning Commission, the World Bank, and the Tibetan Government in exile of His Holiness, the Dalai Lama. Mrs. Savita Mahajan was featured in Business Today's 2013 list of "30 Most Powerful Women" in Indian Business.	He has been associated with the Company from the initial days as a promoter, and is well versed with manufacturing technologies, systems, processes and controls.	He has more than 25 years of experience across a variety of domains such as active pharmaceutical ingredients, CRAMS, finished dosages & biotechnology. Mr.N.Govindarajan is overseeing active pharmaceutical ingredients operations and CRAMS development business of the Company and also dietary supplements.	He has about 43 years of experience in the pharmaceutical industry. He is responsible for the technological evolution of the Company. Dr.M.Sivakumaran looks after research and development, generic product development and total quality management.	He held top managerial positions in leading pharmaceutical companies. He commands 28 years of experience in the pharmaceutical industry.
Terms and Conditions of Appointment / Reappointment	As per the resolution at item no. 6 of the Notice convening Annual General Meeting on August 30, 2018 read with explanatory statement thereto, Mrs. Savita Mahajan is proposed to be appointed as an Independent Director of the Company for a period of two years i.e. from 16 December 2017 to 15 December 2019	As per the resolution at item no. 7 of the Notice convening Annual General Meeting on August 30, 2018 read with explanatory statement thereto, Mr.K.Nithyananda Reddy is proposed to be re-appointed	As per the resolution at item no. 8 of the Notice convening Annual General Meeting on August 30, 2018 read with explanatory statement thereto, Mr.N.Govindarajan is proposed to	As per the resolution at item No. 9 of the Notice convening Annual General Meeting on August 30, 2018 read with explanatory statement thereto, Dr.M. Sivakumaran is proposed to	As per the resolution at item No. 10 of the Notice convening Annual General Meeting on August 30, 2018 read with explanatory statement thereto, Mr.M. Madam Mohan Reddy is proposed to be re-
	thereto, Mrs. Savita Mahajan is proposed to be appointed as an Independent Director of the Company for a period of two	30, 2018 read with explanatory statement thereto, Mr.K.Nithyananda	Meeting on August 30, 2018 read with explanatory statement thereto,	Meeting on August 30, 2018 read with explanatory statement thereto,	30, 20 with e staten Mr.M. Moha

Particulars	Mrs.Savita Mahajan	Mr.K.Nithyananda Reddy	Mr.N.Govindarajan	Dr.M. Sivakumaran	Mr.M.Madan Mohan Reddy
Remuneration last drawn (including sitting fees, if any)	₹0.10 Million	₹15.12 Million	₹146.27 Million	₹15.12 Million	₹26.74 Million
Remuneration proposed to be paid	No remuneration other than sitting fee for attending board/ committee meetings.	As per resolution at item No.7 of the notice convening this meeting read with explanatory statement thereto	As per resolution at item No.8 of the Notice convening this meeting read with explanatory statement thereto	As per resolution at item No.9 of the notice convening this meeting read with explanatory statement thereto	As per resolution at item No.10 of the notice convening this meeting read with explanatory statement thereto
Date of first appointment on the Board	December 16, 2017	December 26, 1986	May 29, 2012	March 30 1992	September 18, 2006
Shareholding in the Company as on March 31, 2018	Nil	25,359,572 equity shares	Nil	14,491,360 equity shares	2,010 equity shares
Relationship with other Directors/ Key Managerial Personnel	Not related to any Director /Key Managerial Personnel	He is related to Mr.P.Sarath Chandra Reddy, Whole-time Director of the Company.	Not related to any Director / Key Managerial Personnel	Not related to any Director / Key Managerial Personnel	Not related to any Director / Key Managerial Personnel
Number of meetings of the Board attended during the year	Nil	4	5	5	5
Directorships of other Boards as on March 31, 2018	Orient Green Power Company Limited	APL Healthcare Limited, APL Research Centre Limited, Auro Peptides Limited, AuroZymes Limited, Auronext Pharma Private Limited, Silicon Life Sciences Private Limited, Hyacinths Pharma Private Limited, Auro Pharma India Private Limited, Raidurgam Developers Limited and Patancheru Envirotech Limited.	Nil	APL Research Centre Limited, APL Healthcare Limited, Curepro Parentarals Limted, Auro Peptides Limited, AuroZymes Limited Tergene Biotech Private Limited	Eugia Pharma Specialities Limited, Curepro Parenterals Limited, APL Research Centre Limited, AuroZymes Limited, Pravesha Industries Private Limited, SGD Pharma Ltd., Crest Cellulose Private Limited, Oremsi Plastics Private Limited and Pharmaceuticals Export Promotion Council of India.
Membership / Chairmanship of Committees of other Boards as on March 31, 2018	Nil	Auro Peptides Ltd. Audit Committee- Member Nomination & Remuneration Committee-Member CSR Committee- Chairman	Nil	Nil	Nil

BOARD'S REPORT

Dear Members,

Your Directors are pleased to present the 31st Annual Report of the Company together with the audited accounts for the financial year ended 31 March 2018.

FINANCIAL HIGHLIGHTS

Standalone financials		₹ Million
	2017-18	2016-17
Revenue from operations	103,031.5	97,812.1
EBITDA	26,700.0	23,740.0
Depreciation	3,548.3	2,861.7
Finance cost	528.9	451.6
Profit before Tax	23,429.4	21,785.7
Provision for Tax	5,301.7	4,718.1
Net Profit after tax	18,127.7	17,067.6
Other Comprehensive Income/	-21.8	-56.1
(expense)		
Total Comprehensive income for	18,105.9	17,011.5
the period		

DIVIDEND

Your Company has paid first interim dividend of 150% i.e. ₹1.50 per equity share of ₹1/- and second interim dividend of 100% i.e ₹1/- per equity share of ₹1/-. The total dividend for the financial year 2017-18 comes to 250% i.e. ₹2.50 per equity share of ₹1/- against 250% i.e. ₹2.50 per equity share of ₹1/- paid in the previous year.

Pursuant to Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, top five hundred listed entities based on market capitalization are required to formulate a Dividend Distribution Policy. The Board has approved and adopted the Dividend Distribution Policy and the same is available on the Company's website viz. www.aurobindo.com.

PERFORMANCE REVIEW

Your Company continued to strengthen its position across global markets during the year. It delivered yet another year of consistent and profitable growth; and fortified its manufacturing and research capabilities.

Your Company continued to build a robust pipeline of products for the future and invested in elevating operational efficiencies to improve the quality of products. The holistic wellbeing of employees also remained a priority. During the reporting period, there was a sustained focus to augment the strengths of your Company and sharpen competitive advantages with a view towards long term value creation.

On a standalone basis, your Company revenues registered a growth of 5.3% reaching ₹103,032 million in FY 2017-18, compared to ₹97,812 million. EBITDA stood at ₹26,700 million, an increase of 12.5% over FY2016-17. EBITDA margins increased by ~160 bps to 25.9% during the year and profit before tax for the year at standalone level was ₹23,429 million, a 7.5% growth over the preceding year. Your Company's net profit was at ₹18,128 million, a growth of 6.2% over ₹17,068 million reported in FY2016-17. The diluted earnings per share stood at ₹30.94 compared to ₹29.16 in FY2016-17.

On a consolidated basis the performance for the FY2017-18 is, revenues increased to ₹164,998 million from ₹150,899 million in the previous year, at 9.3% growth. The formulations business registered a revenue growth of 12.4% and improved to ₹135,332 million from ₹120,454 million in the previous year. The API business sales stood at ₹29,622 million from ₹30,421 million in the corresponding previous period. EBITDA margins expanded by ~20 bps to 23.0% vis-à-vis 22.8% in 2016-17. EBITDA was ₹37,885 million, witnessed a 10.3% growth over the corresponding previous period. Net profit grew by 5.3% to ₹24,232 million. The growth in net profit was impacted by a one-time expense related to a tax charge.

The diluted earnings per share stood at ₹41.36 compared to ₹39.33 in 2016-17. The healthy growth in revenues and profits were driven by new product launches across markets, improvement in market share of existing products, enhanced productivity and cost optimizations.

In the US, the Tax Cuts and Jobs Act of 2017 was approved and enacted into a law on December 22, 2017. This resulted in reduction of federal corporate tax from 35% to 21%. As a result, the Company re-evaluated its U.S. deferred tax assets and liabilities, and recognized a one-time charge of ₹664 million.

As on 31 March 2018, the Company filed 478 ANDAs on a cumulative basis. Of the total count, 327 have final approvals and 34 have tentative approvals, including 11 ANDAs which are tentatively approved under the US President's Emergency Plan for AIDS Relief (PEPFAR) and the balance 117 ANDAs are under review.

Your Company witnessed growth across the key geographies in the formulations segment. The US business reported 9% growth to ₹74,421 million and contributed 45% to total revenues. The growth in revenues was driven by new product launches, including complex products, coupled with an increase in the market share of existing products. Your Company witnessed growth, despite pricing pressures in the orals segment. The pricing pressure in orals segment was led by an increase in competition with the improved pace of USFDA approvals and customer consolidation.

Your Company registered a robust 32.9% growth in revenue from the Europe formulations business, reaching to ₹43,544 million in FY2017-18 over the previous year revenue of ₹32,771 million. Aurobindo continues to work towards improving synergies between the acquired businesses of Actavis and Generis, and the Company's existing ground presence in several markets. During the year under review, the EBITDA margins in the European region touched double digit. **Financial Statements**

The improvement in revenue and profitability happened on the back of transferring manufacturing base for products to India, continued streamlining of business structures, integrating and optimizing the information flow to improve decision-making and control; and new product launches, including Day-1 launches. As on 31 March 2018, the Company has transferred the manufacturing activities of 83 products from Europe to India.

Your Company's formulations sales in Growth Markets including Brazil, Canada, Columbia and South Africa grew by 18.7% to ₹8,971 million vis-à-vis ₹7,556 million reported in 2016-17. This segment remains a key market for Aurobindo and renewed efforts are made to position your Company's products as one of the preferred suppliers in the existing and new geographies.

The ARV formulations business was negatively impacted during the year and posted sales of ₹8,396 million vis-à-vis ₹11,854 million. The decline in sales was due to incremental pricing pressure in one of the key molecules and delay in some country specific tenders. During the year, the Company received tentative approval from USFDA for Dolutegravir triple combination product (Tenofovir, Lamivudine and Dolutegravir tablets) under the PEPFAR program, which enables your Company to launch the product in PEPFAR markets. Your Company is the second pharma enterprise to receive the USFDA approval for this drug.

OUTLOOK

Your Company will continue to invest in building a diversified product portfolio and improve its market share in the existing product basket. Quality and regulatory compliance will continue to be the cornerstone of your Company's overall operations. As the demand for critical therapies continue to rise, your Company continues to develop differentiated and new drug delivery systems in these therapies and contribute to improve the lives of patients globally.

In the coming years, the organization's key priorities will comprise: building a robust pipeline of complex molecules and setting up state-of-the art manufacturing facilities for select therapies that meet high compliance standards; minimizing wastage and maximizing the recycling of materials; reducing the risk in operations; enhancing community wellbeing and being a preferred partner to all stakeholders.

Despite shifting industry trends, your Company's strong balance sheet and robust operations have helped it stay on track of its growth plans. Your Company's product portfolio and pipeline has significant potential for sustainable volume growth. Research and Development (R&D) initiative has been undertaken on difficult-to-manufacture and differentiated products, with possible low competitive pressure. Work is currently in progress for development of differentiated molecules, both for oral and injectable products. FY2018-19 promises to be a year with many milestones across a differentiated product basket. Aurobindo is optimistic of the sustained value that will be created through the planned new initiatives. In the last fiscal, your Company made considerable development across the upcoming product categories and the same is encapsulated in R&D section.

To manufacture a growing product pipeline, your Company initiated significant improvements in capacities to bolster volumes:

- Unit XVI: The Company has successfully commissioned Betalactum injectables manufacturing facility at Jadcherla, Telengana in FY2017-18, which will improve the injectable volumes for the US, EU and Growth Markets.
- Unit X: The Company is building an USFDA compliant oral manufacturing facility at Naidupet, Andhra Pradesh; and the facility will be commissioned during FY2018-19. It has been inspected by USFDA and EMA.
- Injectable facility in US: The Company is in the process of setting up a non-Betalactum injectable manufacturing facility in the US, which is in line with the diversification strategy.

For a sustainable future growth and to spread the geographical risk, Aurobindo has been steadily expanding its European footprint since 2006, via acquisitions across several key markets and organically building a diversified product basket. The acquisition of Generis, referred to earlier, builds upon an already successful growth strategy.

Your Company's products have the potential to improve the lives of millions of patients across the globe.

RESEARCH & DEVELOPMENT

Your Company's new product development initiatives ranges from conventional orals to injectable products to more complex and advanced dosage forms. In the last fiscal, the R&D efforts led to filing ANDAs of complex and niche products including oral and sterile drug products

Oncology and Hormones

Eugia's product portfolio comprises of 79 products that are prescribed for Oncology, Hormone & Immuno-suppressant indications. The Oncology product portfolio is diverse and are approved for treating cancers (involving 16 different indications), either in single or in combination with other drugs. The Hormonal products that are being developed by Eugia are approved prescribed for indications involving, Pre-term birth, birth control, Amenorrhea & Hypergonadism.

Oncology products are a highly specialized class of products and are difficult to produce due to their toxic characteristics and the need for specialized preparation and handling. Of the 71 oncology products which have been shortlisted, 55 products are already in the development phase. We have filed 7 ANDAs as on 31 March, 2018, in the Oncology Segment. In hormones segment, a total of eight products have been identified for development and the Company has already filed six ANDAs. The Company has also planned to develop and manufacture the Oncology and Hormone products for distribution in Europe markets. With a plan to de-risk the portfolio and improve market share, the Company aims to file these products across Canada and other key emerging markets in future. The facility is designed to cater to ~20% of the global volume demand for the products that are part of Eugia's portfolio.

The manufacturing facility at Eugia comprises of the Oral solid dosage forms (Tablets & Capsules) and Injectables (Wet vials, dry vials & pre-filled syringes) and was inspected twice by the USFDA in FY2017-18. The facility has also been inspected by EMA in FY2017-18 and has been approved without any observations.

In FY2017-18, the Company filed 11 ANDAs with the USFDA and Exhibit batches for 25 products were completed.

In FY2018-19, it is estimated that Exhibit batches for 20-24 products will be completed and 15-18 ANDA's will be filed in US market.

The Company has received its first ANDA approval (product name: Capecitabine) in the first quarter of FY2018-19.

According to IQVIA, global spending on cancer therapies and supportive care drugs now exceeds \$133 billion. The U.S. is the biggest contributor to this trend with spends accounting for 46% of global spending. The global market for oncology therapeutic medicines is estimated to reach \$200 billion by 2022, averaging 10–13% growth over the next five years, with the U.S. market reaching as much as \$100 billion by 2022, averaging 12–15% growth. The global market size of the products under development is \$45 billion.

Biologics

The Company started working on biosimilars a couple of years ago. In February 2017, Aurobindo acquired five molecules from TL Biopharmaceuticals. Your Company is currently developing nine more products and the pipeline spans across oncology, rheumatology and ophthalmology. The global market size of these products is around \$ 45 billion.

To build this segment into an important future growth driver, your Company has invested in a state-of-the-art manufacturing facility with 1,40,000 square feet comprising of mammalian cell culture, microbial fermentation, quality control, fill and finish sections. This facility has been commissioned and the exhibit batches will be completed in FY2018-19. With a total R&D employee strength of 75 people for biologics division, the Company will start Phase I clinical trials for its lead molecule i.e. Bevacizumab – a biosimilar to Avastin® in FY2018-19. Apart from Bevacizumab, the Company has also started doing animal toxic studies on an ophthalmic product which will be ready for Phase III trials in FY2019-20.

Peptides

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The Company has invested in developing a state-of-the-art peptide development laboratory and four manufacturing suites for its commercial production. Till date, Auro Peptides have developed the process for manufacturing 14 peptides; and two more molecules are in the process of development.

The unit has already filed four DMFs with US regulatory authorities and is planning to file an additional 3 DMFs in FY2018-19. Presently, Auro Peptides is supplying material for formulation development and the execution of its validation batches. These peptide APIs are being utilized for the development of three liposomal injectable products and seven injectable products. The addressable market size of these products is about \$ 12.2 billion

Biocatalysis

Aurobindo invents, identifies and produces biocatalysts through fermentation processes which are subsequently developed into scalable biocatalytic solutions. This reduces the usage of chemicals within the processes during pharmaceutical manufacturing, saving costs whilst benefiting from this green technology. The high technical base and core competence of Aurobindo has made it easier to initiate the entry in to enzyme production.

The Company has a highly qualified dedicated team of over 30 professionals, with an on-going technology development program which has built a library of over 7,000+ biocatalysts across 15 classes of enzymes. Supplementing the initial R&D molecular and microbiology facilities, your Company has invested in state-of-the-art fermentation development equipment which encompasses twelve 20 litre automated fermentation vessels, with associated downstream processing including: homogenization, tangential flow filtration and resin purification. A number of biocatalytic projects and processes have been identified utilizing internally developed technology, and these are now progressing through process validation. This development work is supported by the 1KL pilot facility leading to the 10KL enzyme production facility.

Penems

Penem products are manufactured at the Company's Auronext manufacturing facility at Bhiwadi, Rajasthan. The total capacity of the unit is ~ 1.0 million vials per month. The facility was re-inspected in February 2018 and received Establishment Inspection Report (EIR).

The Company has filed two ANDAs with USFDA and received approvals for both the products. The approval for Meropenem was received in March 2017 and the same was launched in US in April 2017. In the month of June 2018, an approval was received for Ertapenem injection and is in the process of launching in US. The market size of these products put together is around \$ 480 million for the 12 months ending 31 March 2018. In Europe, the Company already launched Meropenem injection (with a market size which is over \$ 200 million) and expects to launch Ertapenem in FY2018-19

Dermatology

Topicals

The Company has currently identified 38 products for development and started working on 23 products. The market size of these products is \$5 billion.

The identified products have presence across various dosages including Ointment (7 nos), Cream (14 nos), Gel (12 nos) and Solution (5 nos) in the pipeline. Of the 38 products under development, around 24 products need clinical trials or BE studies which are planned to kick-start in Jan 2019.

In FY2017-18, the Company has produced exhibit batches for two products and is planning to execute exhibit batches for another 17 products in FY2018-19. APL, North Carolina site, is expected to be ready for manufacturing these products in August 2018. The Company filed the first ANDA in the first quarter of FY2018-19; and is planning to file another five ANDAs by the end of this fiscal.

Transdermal

Currently, the Company's pipeline includes five patches under development. The addressable global market size of these products is around \$ 2.8 billion. The clinical studies for these products had started in June 2018 and the first ANDA for patches will be filed in November 2019. APL, North Carolina site is planned for manufacturing these products; and the capacity will be ready by October 2018.

Respiratory

Inhalers

Your Company has been working towards creating a diverse portfolio of products with different drug delivery systems. With the respiratory portfolio, the Company now has six inhaler products under development; of which four products are likely to come up for exhibit batches during FY2018-19. The market size of these products under development is \$ 7.5 billion.

The pilot pharmacokinetics analysis will start during April 2019 for one of the key products; and the Company expects to file its first ANDA during the first quarter of 2020. These products will be manufactured from APL, North Carolina, which will be commissioned in October 2018 for exhibit batch production. This facility will be equipped with a capacity to handle 10 to 15 million units with eight head filling machines and a 500L vessel.

Nasals

The Company has a strong pipeline of nasals with five products under development, of which two products already had exhibit batches in FY 18; and another two products are expected to have exhibit batches during FY2018-19. The market size of these products is \$ 0.5 billion. The Company expects to file two ANDAs in FY2018-19 and the remaining will be filed in FY2019-20. These products are manufactured in Unit X; and the unit has a current monthly capacity to produce 1.4 million units.

Depot Injections

Your Company is currently developing four depot injections, which have a combined addressable market size of \$ 3.6 billion. These products are ready for scaling-up and waiting for manufacturing capabilities to be commissioned.

Vaccines

The need for improved public health and medicines to protect infants is fast becoming a global priority. In view of this reality, your Company was focused on development of the pneumococcal conjugate vaccine (PCV), and the development was completed in FY2017-18. The global market size of the product is \$ 6 billion.

The Company has received the approval to conduct Phase I clinical trials from the Drug Controller General of India (DCGI) in April 2018; and has initiated the trials in May 2018 and completed the same in June 2018. The Company will be submitting the report to DGCI by August 2018 and Phase 2 clinical trials are expected to commence in the third quarter of FY2018-19.

All the clinical trials are expected to be completed by 2020; and the Company expects to be ready for taking part in the upcoming government tender during 2021. Your Company is setting up a manufacturing facility in Hyderabad with an annual capacity of 100 million doses.

ENVIRONMENT, HEALTH & SAFETY

Your Company's EHS imperatives are part of its broader sustainability journey. These initiatives focus on reducing the environment footprint, help enhance wellbeing of employees and set high safety standards for employees, contractors and visitors. While several steps have been taken to enhance these standards and raise awareness across the organization, Team Aurobindo believes that it is an area with no finish line; and more needs to be done to remain ahead of the curve in this dynamic industry.

Few initiatives taken during the year comprise of

Environment

In FY2017-18, the Company continued to ensure that environmental norms were abided by all its API and Formulation units. API manufacturing units in Telangana state demonstrated compliance to Zero Liquid Discharge norms.

The Formulations Units and other API units have conformed to the regulations for disposal of wastewater to Common Effluent Treatment Plants (CETPs) or marine discharge. New initiatives for treatment of wastewater using advanced technologies, viz., membrane bio-reactors, supplementing the infrastructure required in line with expansion projects have been started for some of the API manufacturing facilities.

Standardized practices for disposal of organic wastes to cement units for reuse as auxiliary fuel in cement kilns continues. While inorganic and miscellaneous solid wastes are being disposed to treatment, storage and disposal facilities (TSDF). New initiatives for additional control measures on fugitive emissions at waste treatment facilities at some of the API initiatives like providing hoods on waste water storage tanks, arrangement of additional scrubbers, among others have been started. The API units are equipped with monitoring instruments for continuous assessments of fugitive emissions in the premises.

Vermi-composting of garden and kitchen waste was attempted in one of the API manufacturing units on a pilot basis that proved to be highly successful. This initiative will be taken forward to other units in the future.

The Company has installed, online continuous emissions monitoring systems across manufacturing units. These are connected to the Central and concerned State Pollution Control Boards as per norms. Public consultation process for expansion of Aurobindo Unit XI is completed and is gearing up for the submission of Environmental Impact Assessment (EIA) report to the Ministry of Environments and Forests & Climate Change (MoEF & CC). Environment assessments across API and DP formulations units by Aurobindo's customers in FY2017-18 concluded on a highly satisfactory note.

Safety

To maintain a safe working environment, safety pep-talks were initiated before every shift, on hazards in activities and necessary precautions to be taken in case of a mishap. As an important process inclusion, hazard and operability study (HAZOP) and risk analysis were conducted for all new products.

Historical events including injuries and other incidents were analysed and actions have been initiated to address the common root causes. The Company has created a training matrix for contract workers, based on their initiatives and special training modules have been implemented for production heads for managing and leading the safety agenda.

HUMAN RESOURCES

Your Company's ability to respond to new challenges and opportunities depends on effective leadership, knowledge, expertise and new ideas shared at all levels. Therefore, Aurobindo recognizes human capital as the most important element to drive its progress. Hence, your Company has devised initiatives that enable training and development of employees across levels and enables their professional and personal growth.

Your Company's human resources management framework is aligned to the business goals and drives key decisions on business processes and introduction of new technology. The HR interventions of the Company focuses on skilling the existing workforce and empowering them to step beyond their defined roles. Emphasis is laid on ensuring that every colleague is well informed with the Standard Operating Procedures on quality and compliance. Shop floor executives are continuously trained and groomed in the area of compliance, supported adequately to raise their competence, confidence and anytime readiness. Employees at the shop floor undergo classroom training, on-thejob training and assessments. Over 8,000 person days of training was conducted for them during the year under review.

Nalanda, the online learning program, helps employees to choose from a range of strategic leadership courses in partnership with CROSS knowledge. Launched with a vision towards business excellence through leadership and functional competency development, 271 employees were trained under the program in FY2017-18. Nalanda training is exclusively for junior, middle and senior management.

Employees covered under Technical, Safety & Quality Trainings in addition to mandatory cGMP Trainings (FML + API) is above 1,000 during the year. Several employees underwent multiple, need-based programs. Aurobindo Training and Development Centre (ATDC) developed 464 talented professionals, who can be leaders of tomorrow. During the year, your company recruited 4,135 employees.

Established in 2014 with a vision to impart Technical and Application skills to the future workforce of Aurobindo, ATDC (Aurobindo Training & Development Centre) has since been making steadfast contribution in Talent space to compliment the steady yet rapid growth our APL has achieved. It is a great privilege to report our ATDC achieved major milestone with placement of 1004 trained candidates since inception and enculturated future ready workforce into Aurobindo ranks.

AWARDS

- Received "Pharmexcil Outstanding Exports Award 2016-17" in the category of highest Number of ANDAs filed in the calendar year 2016.
- Bagged two Awards in "Excellence in Skill Development" & "Excellence in Pharma Digital Innovation" for the 2nd time in row at the India Pharma Awards 2017 in South-Asia's largest pharmaceutical event- CPhI& PMEC India.
- Have won the "IDMA MARGI MEMORIAL BEST PROCESS PATENTS AWARD 2016-17" (for 2 Indian & 1 US Granted patents; supported by several other patent applications filed during the said year) awarded by Indian Drug Manufacturers' Association.
- Our HR team received certificate of appreciation from BML Munjal Awards 2018 for attaining Expert Panel evaluation level in the category of "Learning and Development".
- Received "2017 Business Award" from The East Windsor Township for best community enhancement contributions in East Windsor Township.
- Aurobindo won "Company of the Year, Asia Pacific" award at Global Generics and Biosimilars Awards 2017.
- Aurobindo's Unit 15 at Parawada Vizag awarded by the State Government of Andhra Pradesh for best management award in manufacturing sector. (in Mid-Size Industries category)

SUBSIDIARIES/JOINT VENTURES

As per the provisions of Section 129 of the Companies Act, 2013 read with the Companies (Accounts) Rules 2014, a separate statement containing the salient features of the financial statement of subsidiary companies/associate companies/joint ventures is detailed in Form AOC-1 and is in **Annexure-1** to this Report.

During the year, the following are the changes in the subsidiaries of the Company:

Ceased as subsidiaries

Raidurgam Developers Limited (formerly known as Aurobindo Antibiotics Limited) now became a joint venture

Aurobindo Pharma USA LLC (Liquidated w.e.f. 31.03.2018)

Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceuita SA effective 1st April, 2018)

Aurovitas, Unipessoal LDA (Merged with Generis Farmaceuita SA effective 1st April, 2018)

Aurobindo Ilac Sanayi Ve Ticaret Limited Sirketi (Liquidated on 31st October, 2017)

Mer Medicamentos, Lda (Merged with Generis Farmaceuita SA effective 1st April, 2018)

Farma APS (Liquidated w.e.f 25.01.2018)

Generis Mozambique (Liquidated w.e.f 19.03.2018)

Incorporation of New subsidiaries

Aurobindo Pharma Saudi Arabia Limited, Saudi Arabia

AuroLogistics LLC, USA

Auro Pharma India Pvt.Ltd, India

Aurovitas Pharma Ceska Republica s.r.o, Check Slovakia

Acquisition

Agile Pharma BV, a step down subsidiary of the Company acquired Generis Farmacêutica SA and its 4 subsidiaries viz. Mer Medicamentos, Portugal, Generis Phar, Portugal, Pharma APS, Portugal and Generis Mozambique, Portugal. Post acquisition of Generis Farmacêutica SA, Portugal, as part of restructuring of operations in Portugal, Aurobindo Pharma (Portugal) Unipessoal Limitada and Aurovitas, Unipessoal LDA, Mer Medicamentos, Lda, Farma APS and Generis Mozambique have been either merged with Generis Farmacêutica SA or liquidated.

CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Financial Statements have been prepared by the Company in accordance with the Indian Accounting Standards (Ind AS) 110 and 111 as specified in the Companies (Indian Accounting Standards) Rules, 2015 and as per the provisions of Companies Act, 2013. The Company has placed separately, the audited accounts of its subsidiaries on its website www.aurobindo.com, in compliance with the provisions of Section 136 of the Companies Act, 2013. Audited financial statements of the Company's subsidiaries will be provided to the Members, on request.

VIGIL MECHANISM

The Board of Directors has adopted the Whistle Blower Policy which is in compliance with Section 177(9) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Whistle Blower Policy aims for conducting the affairs in a fair and transparent manner by adopting highest standards of professionalism, honesty, integrity and ethical behavior. All permanent employees and whole-time directors of the Company are covered under the Whistle Blower Policy.

A mechanism has been established for employees to report their concerns about unethical behavior, actual or suspected fraud or violation of Code of Conduct and Ethics. It also provides for adequate safeguards against the victimization of employees who avail of the mechanism and allows direct access to the Chairperson of the audit committee in exceptional cases. The Whistle Blower Policy is available on the Company's website: http://www.aurobindo.com/about-us/corporategovernance.

PREVENTION AND PROHIBITION OF SEXUAL HARASSMENT

Your Company has constituted an internal complaints committee in compliance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules there under. The Company has a policy on prevention & prohibition of sexual harassment at workplace. The policy provides for protection against sexual harassment of women at workplace and for the prevention and redressal of such complaints. During the year, no complaints have been received.

RATING

India Ratings and Research (Ind-Ra) has affirmed Aurobindo's current long-term rating at 'IND AA+' with outlook positive.

MEETINGS OF THE BOARD

The Board and Committee meetings are prescheduled and a tentative calendar of the meetings is finalized in consultation with the Directors to facilitate them to plan their schedule. However, in case of special and urgent business needs, approval is taken by passing resolutions through circulation. During the year under review, five Board Meetings and six Audit Committee Meetings were convened and held. The details of the meetings including composition of Audit Committee are provided in the Corporate Governance Report. During the year, all the recommendations of the Audit Committee were accepted by the Board.

DIRECTORS

As per the provisions of the Companies Act, 2013, Mr. K.Nithyananda Reddy and Mr.Madan Mohan Reddy will retire at the ensuing annual general meeting and being eligible, seek reappointment. The Board of Directors recommends their re-appointment.

The re-appointment of Mr.K.Nithyananda Reddy, Dr.M.Sivakumaran and Mr.M. Madan Mohan Reddy as Wholetime Directors and Mr. N.Govindarajan as Managing Director with effect from June 1, 2018 are being proposed at the ensuing Annual General Meeting. The Board of directors recommends their re-appointments.

The appointment of Mrs. Savita Mahajan as an Independent Director of the Company for a period of two years up to December 15, 2019 is being proposed at the ensuing Annual General Meeting. The Board of Directors recommends her appointment.

Mr.Rangaswamy Rathakrishnan lyer resigned as Independent Director of the Company with effect from December 9, 2017. The Board has placed on record its sincere appreciation and gratitude for contributions made by him during his tenure as Independent Director of the Company.

DETAILS OF DIRECTORS & KEY MANAGERIAL PERSONNEL

Board of Directors appointed Mrs.Savita Mahajan as an Independent Director of the Company for a period of two years up to December 15, 2019.

Mr.Rangaswamy Rathakrishnan lyer resigned as Independent Director of the Company with effect from December 9, 2017 due to pre-occupation and time constraints.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) of the Companies Act, 2013 your Directors confirm that:

- a. in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- b. appropriate accounting policies have been selected and applied consistently. Judgement and estimates which are reasonable and prudent have been made so as to give a true and fair view of the state of affairs of your Company as at the end of the financial year and of the profit of your Company for the year;
- proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of your Company and for preventing and detecting fraud and other irregularities;
- d. the annual accounts have been prepared on a going concern basis;
- e. proper internal financial controls have been laid down to be followed by your Company and such internal financial controls are adequate and are operating effectively; and
- f. proper systems to ensure compliance with the provisions of all applicable laws have been devised, and such systems are adequate and are operating effectively.

DECLARATION FROM INDEPENDENT DIRECTORS

The Independent Directors have submitted the declaration of independence stating that they meet the criteria of independence as provided in sub-section (6) of Section 149 of the Companies Act, 2013.

BOARD DIVERSITY

The Company recognizes and embraces the importance of a diverse board in its success. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on the Company's website: http://www.aurobindo.com/about-us/corporategovernance.

BOARD EVALUATION

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandates that the Board shall monitor and review the Board evaluation framework. The Companies Act, 2013 states that a formal annual evaluation needs to be made by the Board of its own performance and that of its committees and individual directors. Schedule IV of the Companies Act, 2013 states that the performance evaluation of independent directors shall be done by the entire Board of Directors, excluding the director being evaluated. The evaluation of all the Directors and the Board as a whole was conducted against the parameters laid down by the Nomination and Remuneration / Compensation Committee including performance and working of its Committees.

POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

The policy of the Company on directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a director and other matters are adopted as per the provisions of the Companies Act, 2013. The remuneration paid to the Directors is as per the terms laid out in the nomination and remuneration policy of the Company. The nomination and remuneration policy as adopted by the Board is placed on the Company's website: http://www.aurobindo.com/ about-us/corporategovernance.

TRANSFER TO RESERVE

The Company has not transferred any amount to general reserve out of the profits of the year.

LOANS, GUARANTEES OR INVESTMENTS

Loans, guarantees or investments covered under Section 186 of the Companies Act, 2013 form part of the Notes to the financial statements provided in this Annual Report.

CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

The particulars of contracts or arrangements with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 is prepared in Form No. AOC-2 pursuant to clause (h) of sub-

section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014 and is in **Annexure-2** to this Report.

EXTRACT OF ANNUAL RETURN

As required under Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014, the extract of Annual Return prepared in Form MGT-9 is in **Annexure-3** to this Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS & OUTGO

Information with respect to conservation of energy, technology absorption, foreign exchange earnings & outgo pursuant to Section 134(3)(m) of the Act read with Companies (Accounts) Rules, 2014 is in **Annexure-4** to this Report.

RISK MANAGEMENT COMMITTEE

Risk Management Committee of the Company consists of the following Directors viz. Mr. M. Sitarama Murty, Mr. N. Govindarajan and Mr. P. Sarath Chandra Reddy. Mr. M. Sitarama Murty is the Chairman of the Committee. The Company has established a separate department to monitor the enterprise risk and for its management. The Committee had formulated a risk management policy for dealing with different kinds of risks which the Company faces in its day-to-day operations. Risk management policy of the Company outlines different kinds of risks and risk mitigating measures to be adopted by the Board.

The Company has adequate internal financial control systems and procedures to combat the risk. The risk management procedure is reviewed by the Audit Committee and Board of Directors on regular basis at the time of review of quarterly financial results of the Company. A report on the risks and their management is enclosed as a separate section forming part of this report.

AUDITORS & AUDITORS' REPORT

The statutory auditors' report is annexed to this report. The notes on financial statements referred to in the Auditors' Report are selfexplanatory and do not call for any further comments. There are no specifications, reservations, adverse remarks on disclosure by the statutory auditors in their report. They have not reported any incident of fraud to the Audit Committee of the Company during the year under review.

Pursuant to Section 139 (2) of the Companies Act, 2013, read with Companies (Audit and Auditors) Rules, 2014, the Company at its 30th Annual General Meeting (AGM) held on August 31, 2017, had appointed M/s. B S R & Associates LLP, Chartered Accountants as Statutory Auditors of the Company for a period of 5 years i.e. up to the conclusion of the 35th AGM to be held in the year 2022.

INTERNAL AUDITORS

The internal audit of the Company was conducted by in-house team of professionals up to December, 2017. Form January, 2018

Ernst & Young LLP has been appointed as internal auditors of the Company and they submit their report to the Audit Committee.

COST AUDIT

Pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 and the Companies (Cost Records and Audit) Rules, 2014, the Company is maintaining the cost records as its business is covered under the regulated sector viz. drugs and pharmaceuticals. Audit of the Company's cost records is not applicable since the Company's revenues from exports, in foreign exchange, exceed 75% of its total revenues.

INTERNAL FINANCIAL CONTROLS

The internal financial controls (IFC) framework institutionalized in Aurobindo last year has been evaluated in-depth for its adequacy and operating effectiveness, wherein the Company has covered financial reporting controls, operational controls, compliance related controls and also Information Technology (IT) controls, comprising IT general controls (ITGC) and application level controls. The ITGC would include controls over IT environment, computer operations, access to programs and data, program development and program changes. The application controls would include transaction processing controls in ERP Oracle system which supports accurate data input, data processing and data output, workflows, reviews and approvals as per the defined authorization levels.

In order to further strengthen the existing IFC framework and to support the growing business, the Company has redefined all the process level controls at activity level which has brought in more clarity and transparency in day-to-day processing of transactions and in addressing any related risks. All the controls so redefined & identified have been properly documented and tested with the help of an independent auditor to ensure their adequacy and effectiveness.

The internal auditors conduct ' Process & control review' on a quarterly basis as per the defined scope and submit the audit findings along with management comments and action taken reports to Audit Committee for its review.

The IFC framework at Aurobindo ensures the following:

- Establishment of policies & procedures, assignment of responsibility, delegation of authority, segregation of duties to provide a basis for accountability and controls;
- Physical existence and ownership of assets at a specified date;
- Enabling proactive anti-fraud controls and a risk management framework to mitigate fraud risks to the Company;
- Recording of all transactions occurred during a specific period. Accounting of assets, liability, and revenue and expense components at appropriate amounts;

Financial Statements

• Preparation of financial information as per the timelines defined by the relevant authorities.

SECRETARIAL AUDIT REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Mr.A.Mohan Rami Reddy, a Company Secretary in Practice to undertake the secretarial audit of the Company for the financial year 2017-18. The Secretarial Audit Report issued in form MR-3 is in **Annexure-5** to this Report.

There are no qualifications, reservations or adverse remarks in the Secretarial Audit Report.

CORPORATE SOCIAL RESPONSIBILITY

Your Company is striving to help create a healthy, improved life of people in its neighborhood. Broadly, the initiatives are to execute on the stated CSR policy of 'give back to the society' and make an impact on the lives of people.

The activities undertaken in FY2017-18 can be summarized under the following heads:

- Promoting education;
- Supporting preventive health care;
- Eradicating hunger, poverty & malnutrition;
- Making available safe drinking water;
- Encouraging environment sustainability;
- Sustaining ecological balance & conservation of natural resources;
- Developing rural sports; and
- Setting up old age homes, etc

A detailed account of the CSR activities forms part of the annual report on CSR placed on the Company's website at: http://www. aurobindo.com/social-responsibility/csr-activities. Report on Corporate Social Responsibility as per Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 is in **Annexure-6** to this Report.

STATEMENT OF PARTICULARS OF APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL

The statement of particulars of appointment and remuneration of managerial personnel as per Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is in **Annexure-7** to this Report.

INSURANCE

All properties and insurable interests of the Company including building, plant and machinery and stocks have been fully insured.

MATERIAL CHANGES AND COMMITMENTS

There are no material changes and commitments in the business operations of the Company from the financial year ended March 31, 2018 to the date of signing of the Board's Report. There were no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future. There is no change in the nature of the business of the Company during the year.

CORPORATE GOVERNANCE

A separate section on Corporate Governance standards followed by your Company, as stipulated under Schedule V (C) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as a separate section forming part of this report.

The certificate of the Practicing Company Secretary, Mr. S. Chidambaram with regard to compliance of conditions of corporate governance as stipulated under Schedule V (E) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed to the Corporate Governance Report.

MANAGEMENT DISCUSSION AND ANALYSIS

Management Discussion and Analysis Report for the year under review as stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is presented in a separate section forming part of this report.

FIXED DEPOSITS

Your Company has not accepted any fixed deposits from the public within the purview of Chapter V of the Companies Act, 2013.

INDUSTRIAL RELATIONS

Industrial relations at all units of the Company have been harmonious and cordial. The employees are motivated and have shown initiative in improving the Company's performance.

TRANSFER OF UNPAID AND UNCLAIMED AMOUNT TO IEPF

The dividends which remain unpaid/unclaimed for a period of seven years, have been transferred on due dates by the Company to the Investor Education and Protection Fund (IEPF) established by the Central Government.

Further, Section 124 of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ('the Rules') mandates that companies shall apart from transfer of dividend that has remained unclaimed for a period of seven years from the unpaid dividend account to the Investor Education and Protection Fund (IEPF), also transfer the corresponding shares with respect to the dividend, which has not been paid or claimed for seven consecutive years or more to IEPF. Accordingly, the dividends that remain unclaimed for seven years and also the corresponding shares have been transferred to IEPF account on due dates.

SHARE CAPITAL

The paid up share capital of the Company increased by ₹25,200 during the year due to the allotment of 25,200 equity shares of ₹1 each on exercise of stock options under the Employee Stock Option Plan-2006 (ESOP 2006) of the Company. The paid up share capital of the Company as on March 31, 2018 was ₹585,907,609 divided into 585,907,609 equity shares of ₹1 each.

EMPLOYEE STOCK OPTION SCHEME

The Members at the Annual General Meeting of the Company held on September 18, 2006 approved formulation of Employee Stock Option Scheme- 2006 (ESOP 2006) for the eligible employees and Directors of the Company and its subsidiaries. Details of the stock options as on March 31, 2018 is provided on the Company's <u>website: http://www.aurobindo.com/about-us/</u> <u>corporategovernance</u>. The details of the employee stock options also form part of the notes to accounts of the financial statements in this Annual Report.

BUSINESS RESPONSIBILITY REPORT

A detailed Business Responsibility Report in terms of the provisions of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is available as a separate section in this Annual Report.

ACKNOWLEDGEMENTS

Your Directors are grateful to for the invaluable contribution made by the employees and are encouraged by the support of the customers, business associates, banks and government agencies. The Directors deeply appreciate their faith in the Company and are thankful to them. The Board shall always strive to meet the expectations of all the stakeholders.

For and on behalf of the Board

Place: Hyderabad Date: 28 May 2018 K. Ragunathan Chairman DIN: 00523576

MANAGEMENT DISCUSSION & ANALYSIS

MACRO-ECONOMIC REVIEW GLOBAL ECONOMY

In 2017, the global economy witnessed a comeback with the strongest growth since 2010. According to the International Monetary Fund's (IMF's) World Economic Outlook, April 2018, the growth of developed economies was backed by improvement in investments and manufacturing output, while key developing economies, including Brazil, China, and India, posted strong momentum.

In the first quarter of 2017, export and investment growth propelled the US economy at an astounding pace. Thereafter, the recovery in household spending, healthy labor market and tax cuts helped maintain momentum in the economy. Given the strong recovery, the IMF has revised its growth forecast for the US. The US economy is now expected to gain from higher external demand and the macroeconomic impact of the tax reform. The UK experienced a declining economy due to lower-thanexpected growth in the first two quarters. The IMF estimates the economy growth to further decline to 1.8% in 2017. Softer growth in private consumption, currency depreciation, and the looming uncertainty over the UK's new economic relationship with the European Union (EU) after the Brexit phenomenon are factors responsible for this slowdown.

Overall, the IMF has predicted that the decline in tax revenues and tax reforms in the US will be responsible for carving a positive growth trajectory for the major economies in 2018 and 2019.

The US growth forecast has been raised from 2.3% to 2.7% in 2018 and from 1.9% to 2.5% in 2019. In emerging and developed economies like Europe, economic activity in 2018-19 is projected to remain stronger than previously anticipated. Moreover, the advanced Asian economies are particularly expected to deliver stronger growth. The emerging and developing economies in Asia are expected to grow at around 6.5% over 2018-19, broadly at the same pace as in 2017

Global growth pattern

			(70)
	2017	2018 (P)	2019 (P)
World Output	3.8	3.9	3.9
Advanced Economies	2.3	2.5	2.5
US	2.3	2.9	2.7
Euro Area	2.3	2.4	2.0
Japan	1.7	1.2	0.9
UK	1.8	1.6	1.5
Other Advanced Economies*	2.7	2.7	2.6
Emerging and Developing Economies	4.8	4.9	5.1
China	6.9	6.6	6.4
Brazil	1.0	2.3	2.5

P: Projections

*Excludes the G7 – Canada, France, Germany, Italy, Japan, the UK, the US, and eurozone (Source: International Monetary Fund)

Though the outlook for the global economy remains optimistic, the World Trade Organization has declared that the trade barriers getting erected by major economies could impact growth expectations.

INDIAN ECONOMY

The Indian economy witnessed temporary headwinds owing to the Goods and Service Tax (GST) transition in FY2017-18. However, the economy gained momentum and emerged as one of the fastest growing economies with a Q4 Gross Domestic Product (GDP) growth of 7.7% compared to the 7.2% and 6.5% growth in Q2 and Q3 of FY2017-18, respectively. Gross Value-Added (GVA) growth, another economic indicator, stood at 7.6% for FY2017-18, indicating a steady growth potential for the economy in the next fiscal. Transformational reforms such as the GST and structural decisions such as demonetization have improved investments and supported economic growth.

Due to higher growth in manufacturing, the farm and construction sectors have provided an impetus to the domestic economy. According to the World Bank's Global Economic Prospects report, India's GDP is expected to rise by 7.4% in FY2018-19 and 7.8% in FY2019-20.

Financial Statements

(%)

INDUSTRY REVIEW GLOBAL PHARMACEUTICAL INDUSTRY

Global healthcare spending is estimated to increase at an annual rate of 4.1% during 2017-2021, up from just 1.3% during 2012-2016.

Factors such as ageing and increasing population in key economies, developing markets expansion, advanced medical treatment needs and rising labor costs will contribute to an increase in the spending. Thus, combined healthcare spending in the world's major regions is expected to reach \$8.7 trillion by 2020, up from \$7 trillion in 2015. (Source: 2018 Global Health Care Outlook: The evolution of smart health care by Deloitte)

Future drivers of global pharma growth



Since the past few years, scientists have been developing a new generation of cell-based therapies, gene therapies, and regenerative medicines. Some of these treatments have been passing clinical trials and gaining regulatory approval. These therapies and medicines go beyond the conventional definition of a drug — they are engineered personally for each patient and some offer curative results with a single administration.

In 2018, it is forecasted that five to eight next-generation biotherapeutics will be approved and launched. Over the next five years, 20% of the 40 to 45 New Active Substances (NAS) projected to be launched each year will come from this group of drugs. Digital health

In recent years, the pharmaceutical industry is witnessing a proliferation of digital health tools, including mobile health apps and wearable sensors. With the promise of improving human health, these tools have the potential to change the face of the pharma industry. An increasing number of clinical practitioners are using various digital health apps while treating patients.

In 2018, approximately 340 digital health efficacy studies will be completed and published, continuing the trend of building strong scientific evidence to support digital tools and interventions. These studies will span a broad range of diseases. However, they will mainly focus on largepopulation chronic conditions such as diabetes and heart diseases, which can be avoided and kept in check through self-management, behavioral support or medical intervention. Specialty medicines

The past decade has seen a sustained shift in the focus of new medicines towards specialty pharmaceuticals. These healthcare products help treat chronic, complex or rare conditions. Driven by new therapies and the slowing or declining growth of traditional medicines, specialty share of global spending has risen from 19% in 2007 to 32% in 2017. In the 10 developed markets, specialty represented 39% of spending in 2017, totalling to \$297 billion, led by five major European countries (France, Germany, Italy, Spain, and the UK) and the US, all having a specialty share above 41%.

In 2018, specialty spending in developed countries will reach \$318 billion, representing 41% of market spending in these countries, up from \$172 billion in 2013. Oncology and autoimmune biologics lead the specialty categories, accounting for 46% of 2017 spending and 68% of projected growth in the next five years.

(Source for growth drivers: IQVIA Institute, 2018 and Beyond: Outlook and Turning Points)

GLOBAL MARKETS REVIEW US

The US pharma market recorded a nominal drug spending of \$452.6 billion in revenue in 2017. Despite the US administration's continuing public scrutiny of drug pricing, the industry recorded a slight growth of 1.4% in nominal spending over the previous year.


In the US pharma market, pricing pressure is fuelled by factors such as increasing competition, payer consolidation and restrictive reimbursement policies. This is further aggravated by cost control tools such as exclusionary formularies and price protection clauses. As a result, the health plan designs are changing and patients may experience a possible increase in both premiums and out-of-pocket payments for their branded medications.

Spending on traditional medicines has declined primarily due to patent expiries and associated losses of brand exclusivity, as well as a general shift in the focus of medical innovation towards next-generation medicines. In the US market, innovation and technological advances have fast-tracked the growth of specialty medicines; they account for nearly half of the market's current medical spends. According to IQVIA, the largest proportion of new medicines launched in the last five years has been specialty drugs. Also, specialty share of spending has risen, while traditional net medicine spending has declined by more than \$133 per person over the past decade. In non-retail settings, specialty drugs represent 60% of invoice spending and 2.3% of standard unit volumes.

OUTLOOK

Since 2015, the aggregate adjustment of normalized medicine spending has declined due to a strong economy and the rising off-invoice discounts and rebates, slowing overall medicine spending growth. According to the IQVIA projection, the US population's real net per capita spending on medicines will decline in 2018 and remain unchanged at almost \$800, until 2022. Any subsequent growth in the US pharma market will be primarily driven by the large number of new medicines, many of which will be specialty and orphan drugs.

Exhibit 14: U.S. Real Net Per Capita Drug Spending and Growth




Source: IQVIA Market Prognosis Sep 2017; US Census Bureau; US Bureau of Economic Analysis (BEA), Dec 2017; IQVIA Institute; Feb 2018 Notes: Real medicine spending reflected in 2009 \$

According to Quintiles IMS, net revenue from all types of prescription medicines will grow at 2-5% over the next five years, driven by new products and the wider use of existing medicines. However, this may be offset by reduced pricing of existing drugs. The volume growth for existing products in the market is expected to be highly variable, from 1.1% contribution in 2018 to 4.5% in 2021, as previously launched drugs continue to grow, and generic uptake from patent expiries lift volume. 40-45 new innovative products are expected to be launched per year, from 2018 through 2021, contributing to 3.5-4.5% growth per year.

Financial Statements

US Market: Net Medicines Revenue Growth and Contribution by Type



EUROPE

Pharma spending in Europe was \$154.4 billion in 2017 and is expected to increase to \$170-200 billion in 2021. However, the outcome of the UK's negotiations with the EU will create mediumterm headwinds for pharma companies, owing to the uncertainty around pharma planning and business strategies. In contrast, some countries in the region, such as Italy and Spain, which are not purely tender-driven markets, have witnessed steady growth in pharma spends owing to the growth in generic sales.

OUTLOOK

According to QuintilesIMS, growth in the five major markets of the EU (France, Germany, Italy, Spain, and the UK) is mixed with a projected CAGR, through 2018, of 2-5% each for Germany and Italy, better CAGR of 4-7% for the UK, but negative to minimal growth for France and Spain.

Coface India estimates that in 2018, spending on prescription drugs is set to grow by 4% for the top five EU countries to reach almost €126 million. This is explained by the increasing presence of specialty drugs (more than a third of the total sales), even though payers are reluctant to pay the pharmaceutical companies' list prices. Most importantly, there could be some modest increase in medicine spending above the base-case scenario if the UK Government continues its commitments towards innovative drug access.


Moreover, after Brexit, the UK will require to make major readjustments to the existing and pending European initiatives, ranging from clinical trials regulation to health technology assessment and from digital health to modernized pathways to medicine authorization.

PHARMERGING MARKETS

The decline in the US spending on medicines is expected to be balanced by the growth in the pharmerging markets. The contribution from these markets to global medicine spending has risen from 13% in 2007 to 24% in 2017, almost doubling in a decade. In total value, this accounts for an increase in spends from \$81 billion in 2007 to \$270 billion in 2017, growing at an average rate of 12.8%, which is estimated at more than twice the global growth rate.

This rise has been fuelled by the various governments' efforts to increase healthcare access by reducing medicine costs and the efforts of the global drug companies to expand their reach and scale through tie-ups and partnerships with local companies.

The use of and spending for generic medicines is higher in the pharmerging markets. With self-paying consumers buying these medicines, there is a directly proportional relationship between medicine spending growth and the overall economic growth.



Pharmerging Spending and Growth

(Source: IQVIA Market Prognosis, September 2017)

OUTLOOK

According to IQVIA, pharmerging markets are expected to experience significant changes. The sale of generic medicines is expected to grow by 7-8% in 2018, down from the 9.7% CAGR over the prior five years. FY2017-18 will mark the third year of less-than-10% growth.

Pharmerging markets are forecasted to grow by 6-9% to \$345-375 billion in the next five years. China, the largest pharmerging country, is projected to contribute \$145-175 billion at a tepid growth of 5-8%.

INDIA

India has among the lowest spends on healthcare, at about 4.5% of the GDP against the global average of 9%. This gap has prompted the Government of India to actively focus on policies that provide impetus to the healthcare sector.


The Government has taken a hallmark step of launching a National Health Protection Scheme (NHPS) to cover over 100 million poor and vulnerable families. The scheme provides an annual coverage of ₹5 lakh per family for secondary and tertiary care hospitalization.

Such measures by the Government saw India attract a record Foreign Direct Investment (FDI) of \$747 million in the healthcare sector during the fiscal. Further, spending on medicines is projected to grow by 9-12% in the next five years compared to China's 5-8%, according to IQVIA. This growth will thrust India forward to reach the list of the Top 10 countries in the ongoing financial year.

While this domestic growth is a massive opportunity for the Indian domestic pharma industry, it is also well-poised to serve the international markets. India is the largest maker of generic medicines, with the Indian pharma industry contributing to 20% of the global generics exports. By 2020, the Indian industry revenue is expected to touch \$55 billion.

New drugs being brought under Drug Price Control Orders (DPCO); a price cap on stents, implants, and procedures; and an increasing number of licenses being withdrawn by the regulators are among the challenges faced by the industry.





(Source: India Pharma 2020: Propelling access and acceptance by McKinsey)

Government of India's healthcare focus

- As per the Economic Survey, child and maternal malnutrition are the major causes of deaths in India. Neonatal disorders and nutritional deficiencies, as well as diarrhoea, lower respiratory infections and other common infections, are responsible for maternal and child malnutrition. The Government of India has worked towards implementing several programs and has also initiated new policy interventions to improve the health and nutritional status of women and children.
- Under the National Health Mission (NHM), the Union Government has rolled out the National Free Diagnostic Service Initiative to provide essential diagnostic services in public health facilities. The Government has approved an amount of ₹7,590 million for the initiative for 29 States/ Union Territories (UTs) in FY2017-18.
- The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacturing. The approval time for new facilities has been reduced to boost investments. Further, the Government introduced mechanisms such as the DPCO and the National Pharmaceutical Pricing Authority to make medicines affordable and easily available.

COMPANY REVIEW

Aurobindo is one of the largest vertically integrated pharmaceutical companies in India. It has carved a niche for itself in developing high-quality Active Pharmaceutical Ingredients (APIs) and finisheddosage forms. The Company is the market leader in semi-synthetic penicillin. Moreover, it has established a firm foothold in key therapeutic segments such as anti-biotics, Central Nervous System (CNS), cardiovascular (CVS), anti-retrovirals, diabetics, anti-allergies and gastroenterology, among others.

Aurobindo's state-of-the-art manufacturing facilities have been approved by the US Food and Drug Administration (FDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Medicines Control Council-South Africa (MCC-SA), EMA and ANVISA-Brazil for both APIs and formulations. Leveraging on this, the Company has Joint Ventures (JVs) and strategic alliances with 56 subsidiaries.

Aurobindo exports to over 150 countries across the globe, with around 90% of its revenues being derived from international operations. In the last fiscal, the Company focused on increasing the complexity and diversity of the portfolio, while retaining the core business and augmenting capability and capacity to strengthen it. The Company is now addressing the prescription, biopsy and consumer healthcare [Over-the-Counter (OTC) and Dietary Supplements] segments.

From a long-term growth strategy perspective, the Company is working on differentiated technologies and segments, including biologics, vaccines, and peptides.

KEY STRENGTHS

1) Scale, Diversity, and Leadership


- Among the Top 3 companies in over 60% of commercial portfolio in the US market in terms of prescriptions as per IQVIA QTR Mar 2018
- A large US portfolio comprising 478 Abbreviated New Drug Applications (ANDAs) filed, of which 327 received final approval, 34 received tentative approvals including 11 ANDAs approved under PEPFAR, and 117 are under review
- A strong foothold in the US and EU
- Extensive product portfolio and pipeline
- Experienced and forward-looking leadership team
- Wide pool of committed talent

2) Robust Operations

- Large manufacturing facilities inspected and approved by the USFDA, European Medicines Agency (EMA), and other regulators
- Dedicated and cutting-edge global Research and Development (R&D) centres for diverse technology platforms and APIs
- Focus on complying with quality and Environment, Health, and Safety (EHS) standards
- Speed and effectiveness in execution

3) Patient Focus

- Unwavering commitment to providing access to high-quality, low-cost generics to patients globally
- Continuous effort to maximize patient reach
- Continue to offer a broad, cost-competitive portfolio for all consumer needs



FY2017-18 segment-wise revenue contribution

FORMULATIONS BUSINESS

Aurobindo manufactures generic formulations that are sold across the US, Europe markets and Growth Markets. The Company also sells Antiretroviral Medicines (ARV) in various Growth Markets by participating in global tenders floated by various international bodies.

Primarily focused on developing oral and injectables generic formulations, Aurobindo is building capabilities for next level complex R&D products. Nearly 90% of the Company's revenue is driven by its international operations. With 20 manufacturing facilities in India, three manufacturing facilities in the US, one in Brazil and one in Portugal, Aurobindo has gained considerable market share in the international formulations market.

US formulations

New launches and a well-diversified portfolio have enabled Aurobindo to deliver steady growth in its US business. The Company launched 38 products, including six injectables, in FY2017-18 in the US market.

In FY2017-18, the US revenue increased by 9.0% to ₹74,421 million from ₹68,272 million in FY2016-17, accounting for 45% of consolidated revenue. The Company filed 47 ANDAs with the USFDA, including for 16 injectables and received final approvals for 49 ANDAs, including seven injectables during the year under review.

The injectables business contributed to 14% of the overall US business in FY2017-18. Currently, AuroMedics is the third largest generic injectables company by volume as per IQVIA MAT Mar 2018. AuroHealth, the Company's US OTC business, launched the first set of key products in FY2017-18. As on 31st Mar 2018, 16 OTC ANDAs were approved.


Aurobindo is building a strong product pipeline for the US market with differentiated products and believes that new injectables launches will help to improve the product mix and margins going forward.

US formulations revenue growth (FY13-FY18) (₹ Million) 33.5% CAGR in (FY13-FY18) 80,000 45 50 45 44 41 30 40 60,000 000 30 3 40,000 20 20.000 10 0 0 FY13 FY14 FY15 FY16 FY17 FY18 US Revenue ← % of Total Revenue

EU formulations

In FY2017-18, the EU formulations recorded a strong revenue growth of 32.9% reaching to ₹43,544 million, accounting for 26% of consolidated revenue. By the close of the fiscal, the manufacturing activities of around 83 products was transferred from Europe to India.


EU formulations revenue growth (FY13-FY18)



Growth markets formulations

In FY2017-18, Growth Markets recorded a revenue of ₹8,971 million, witnessing a strong growth of 18.7%, and accounted for ~6% of revenue. The key markets like Canada, Brazil and Columbia have propelled the growth.

Growth Markets formulations revenue growth (FY13-FY18)



ARV formulations

For the ARV business, the Company's focus has been on global tenders floated by multi-lateral organizations such as Global Fund, USAID/PEPFAR, and country-specific Ministry of Health (MOH) tenders. Aurobindo supplies life-saving ARVs to ~3 million HIV patients spread over more than 125 countries. The ARV formulations business booked revenues of around ₹8,396 million, a decline of 29% YoY in FY2017-18. The decline was due to an increase in pricing pressure in one of the key products and reduction in the tenders floated by various countries particularly in Q4FY2017-18.

-		
(₹ Million)		
14,000	10	15
10,500		10
7,000	8,33,402	
3,500	5	5
0		0
	FY13 FY14 FY15 FY16 FY17 FY18 evenue → % of Total Revenue	

ARV formulations revenue trend (FY13-FY18)

API BUSINESS

The API segment remains as an important strategic unit for the Company, enabling vertical integration in supplying formulations to regulated markets.

In FY2017-18, the total revenue from APIs was around ₹29,622 million, recording a marginal decline of 3% year-on-year due to increased captive consumption. The Company has also invested capital for capacity creation and capability building to ensure that the base business is strengthened for future growth opportunities. The API business continues to focus on complex products with varying volumes and is consistently evolving its manufacturing processes to meet the market needs. The API facilities meet the advanced market requirements of USFDA, UK MHRA, EMA, Japan Pharmaceuticals and Medical Devices Agency (PMDA), Mexico COFEPRIS, Brazil-ANVISA, Korea FDA, etc.

NEW INITIATIVES

The Company's priority markets are driven by a broad portfolio of products from internal pipeline coupled with acquired entities. To strengthen its foundation for sustainable growth in these markets, the Company continues to focus on building a differentiated **Financial Statements**

product portfolio through in-house research and development. Aurobindo is investing heavily in R&D efforts towards creating high-value complex products and drug delivery systems. The Company has made steady progress across its new initiatives such as oncology & hormones, penems, vaccines, biosimilars, respiratory and dermatology. In the year ahead, the Company will continue to maintain its focus on further streamlining its operations and provide affordable life-saving drugs to the world.

FINANCIAL REVIEW

In FY2017-18, Aurobindo's revenue from operations on a consolidated basis amounted to ₹164,998 million vis à-vis ₹150,899 million in FY17, recording 9.3% growth despite headwinds including pricing pressures in key markets.

This rise was driven by a healthy growth in the US, Europe, and Growth Markets. The EBITDA increased by 10.3% YoY to ₹37,885 million. EBITDA margin expanded ~20 bps to 23.0%. The net profit after JV share and minority interest was recorded at ₹24,232 million compared to ₹23,017 million in the previous year, growing by 5.3%.

The Company's total R&D spend stood at ₹6,665 million, which is 4% of its total revenue.

The Company's market capitalization as on March 31, 2018 stood at ₹326.8 billion.

MANUFACTURING REVIEW

In FY2017-18, Aurobindo conquered new frontiers through its resource debottlenecking efforts and its initiatives to reduce cycle time. The Company is now on a path to digitize manufacturing operations by integrating all process-related machines to the server to capture real-time process parameters for better operations control, improvement in productivity and enhanced compliance status. Through this initiative, Aurobindo aspires to set a benchmark for operational excellence.

With a view to increase manufacturing capabilities, the Company has successfully commissioned a Betalactum injectables manufacturing facility (Unit XVI) at Jadcherla in FY2017-18, which will improve the injectables volumes for the US, EU and Growth Markets. The establishment of Unit X for an US FDA - compliant oral manufacturing facility at Naidupet, Andhra Pradesh, is on track and will be commissioned during the ongoing fiscal. The facility has been inspected by the USFDA and EMA.

Aurobindo has also focused on strengthening manufacturing processes through operational-side training and implementation of integrated process systems such as a robust quality management system called Laboratory Information Management System (LIMS), a real-time data management system called PRISM and a stringent material management via a single Enterprise Resource Planning (ERP) system.

THREATS AND CHALLENGES

The pharmaceutical industry is highly competitive, with challenges from both the Indian manufacturers who have similar production facilities as well as those of abroad. Human resources with similar skills, talent, and experiences in the industry are mobile between competing companies.

Price pressures are expected to remain in the US market. Going forward, there is a risk of inability to maintain current margins on products. Price sensitivities are tested in a crowded market where the price tends to sag while the business achieves volume.

Competing pharmaceutical companies have several similar bioequivalent products in the same market, manufactured at facilities that have been approved by the highest regulatory authorities. All of them stay focused on the same markets, resulting in price elasticity being tested and margins eroding.

Yet, it must be appreciated that Indian manufacturers in general, and Aurobindo in particular, have etched their presence on the global stage and have worked hard to get shelf space. Aurobindo is better placed when compared to many of the other Indian manufacturers because of the Company's control over raw material sourcing. The Company is a dominant player in the API business and has been able to control its quality, improve on timelines, be competitive on costs and deliver at short notice. This is an unique advantage that Aurobindo enjoys over many other manufacturers across the world. The Company has been timing its launches to take advantage of the products going off-patent and the opportunities available in a first-mover market. This strategy is built around the in-house R&D capabilities, technology strength in manufacturing facilities and the marketing infrastructure. Aurobindo has worked on its speed-to-market abilities and is quick to convert product approvals into invoices.

The scientists and other professionals of Aurobindo have been trained to create opportunities, replicate the successes and drive business growth. The Company has unmatched strengths to cope with the challenges of the market, such as an experienced staff with the ability to anticipate market needs, plan for product launches with supportive documentation, create products that meet regulatory norms and execute plans within tight cost and time budgets.

INTERNAL FINANCIAL CONTROLS

The Internal Financial Controls (IFC) framework institutionalized in Aurobindo during FY2017-18 has been evaluated in-depth for its adequacy and operating effectiveness. Basis this Framework, the Company has covered financial reporting controls, operational controls, compliance-related controls and also Information Technology (IT) controls comprising IT General Controls (ITGC) and application-level controls. The ITGC would include controls over the IT environment, computer operations, access to programs and data, program development and program

Financial Statements

changes. The application controls would include transaction processing controls in the ERP Oracle system, which supports accurate data input, data processing and data output, workflows, reviews, and approvals as per the defined authorization levels.

To further strengthen the existing IFC framework and to support the growing business, the Company has redefined all the process-level controls at activity level. This has brought more clarity and transparency in daily processing of transactions and in addressing any related risks. All the controls that have been redefined and identified have been properly documented and tested with the help of an independent auditor to ensure their adequacy and effectiveness.

The internal auditors, on a quarterly basis, conduct 'Process and Control Review' as per the scope defined and submit the audit findings, along with management comments and action-taken reports to the Audit Committee for its review.

The IFC framework at Aurobindo ensures the following:

- Establishment of policies and procedures, assignment of responsibility, delegation of authority and segregation of duties to provide a basis for accountability and controls
- Physical existence and ownership of assets at a specified date
- Enabling of proactive anti-fraud controls and a risk management framework to mitigate fraud risks to the Company
- Recording of all transactions occurred during a specific period
- Accounting of assets, liability and revenue and expense components at appropriate amounts
- Preparation of financial information as per the timelines defined by relevant authorities

HUMAN RESOURCES

Aurobindo boasts of a tight-knit team of highly competent and committed industry professionals. The corporate promise, 'Committed to healthier life', reiterates that the team is focused on performing and delivering on patient safety. The knowledge, expertise and skills of the Aurobindo teams form a strong foundation of the Company's progress and hence, considerable strategic emphasis is laid on people development and leadership. The overall target is to enhance business growth by enabling engagement and performance. The Company aims to achieve this target by providing participative leadership for enterprising employees and creating an environment conducive to work towards organizational goals. Aurobindo's corporate values form the foundation of this development. Aurobindo Pharma has a team of over 19,000 professionals from 31 different countries working at its various divisions – API manufacturing, formulation manufacturing, chemical R&D, formulation R&D and overseas operations. About 80% of these employees are graduates, postgraduates and PhD holders.

As part of its investment in learning and development, the Company has recrafted its human resource philosophy. In brief, the policy is iterated as below:

- Attract, build and retain the right talent at all levels
- Create and nurture a performance culture through continuous capability building, performance measurement, and leveraging of IT
- Foster leadership at all levels through trust, empowerment and openness
- Strengthen collaborative approach for business excellence
- Promote a vibrant work culture based on innovation and incentivize people based on productivity/ outstanding performance

The Company emphasizes the five critical dimensions of people management:

- Establishment of a vibrant organizational culture
- Talent attraction and retention
- Continuous capability building
- Recognition of outstanding performance of the team/ individuals
- Staff welfare

The Company has undertaken the following initiatives for the holistic development of employees:

MISSION QUALITY

This is a key initiative undertaken to create and augment the quality culture across the organization. The process assesses the staff and executives on quality standards compliance. An assessment based on key performance indices and quality metrics has been carried out at the formulations unit to identify Master Quality Leaders (MQLs) who will facilitate the quality initiatives across the organization.

QUALITY MARSHAL PROGRAM (QMP)

This initiative has helped to strengthen the quality culture through continuous reinforcement of Standard Operating Procedures (SOPs) and adherence to quality standards by application of learning with the help of a qualified resource pool. For the pharma industry, in general, it is critical to ensure that the efficiency of the processes is effectively communicated during the audit interaction. This efficiency in communication needs continuous practice. The QMP was envisaged to address this need by strengthening the Company's quality culture through learning partnerships and developing confidence and communication towards increasing audit interface capabilities.

Potential Quality Marshals are mapped across the value stream with demonstrated high-compliance behaviors, training ability and audit experience. They then become part of collaborative learning with cascading methodology, leading to critical talent development. The program aims to develop close to 500 Quality Marshals across all units by 2019 and the training and certification processes are going on in full gear.

ENVIRONMENT, HEALTH AND SAFETY

Industrial relations continue to be cordial and harmonious. The Management has initiated various measures such as the formation of bipartite forums and joint management councils to promptly redress staff grievances and improve welfare amenities at the plants.

The Company places utmost importance on employee and contractor safety as well as environment protection. In its approach to business, Aurobindo integrates a robust and sustainable safety system that aims for zero incidents to ensure a high degree of safety at the workplace. Aurobindo works towards fulfilling its environmental and social responsibilities by optimizing the use of resources, minimizing waste, reusing and recycling materials, and reducing the eco-footprint to create more value with less environmental impact.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Aurobindo's CSR charter covers the following areas of activities:

- Promoting education
- Supporting preventive healthcare
- Eradicating hunger, poverty, and malnutrition
- Making safe drinking water available
- Encouraging environment sustainability
- Sustaining ecological balance and conserving natural resources
- Developing rural sports
- Setting up old-age homes

As part of its societal commitment, Aurobindo provides support in the areas of educational aids for school children, construction of toilets, and provision of safe drinking water. Its social intervention programs have benefited the neighboring communities and the Company continues to give back to the society.

MANAGEMENT OF RISKS

OVERVIEW

The objective of Enterprise Risk Management (ERM) framework at Aurobindo is to address all major risks in a proactive manner and to sustain business growth. The Company's ERM practices are based on COSO-ERM framework. The ERM is designed to minimize impacts arising from the risks and enable the Company to leverage market opportunities effectively. It also enhances Company's competitive advantage on a medium and long-term basis, thereby creating value for its stakeholders.

The Company has aligned risk management framework with critical business processes to ensure that the core functions are designed and operated effectively towards the achievement of business objectives. Risks are addressed across all key business functions in a holistic manner rather than in silos.

COMPANY'S ERM FRAMEWORK



RSK MANAGEMENT COMPONENTS

Process	Description
Business objectives	Business objectives are set by executive management and approved by the Board
Risk identification	A bottom-up approach is adopted through structured interviews, brainstorming sessions and risk questionnaire techniques for the identification of risks which could potentially impact achievement of business goals. Risk registers are updated with existing and emerging risks.
Risk assessment	It includes evaluating and prioritizing risks so that their levels are managed within defined tolerance thresholds.
	Risk evaluation is carried out using scenario-based assessments to determine the potential impact and likelihood of risk occurrence. Identified risks are compared with established thresholds to determine the priority and method of risk mitigation.
Risk mitigation & monitoring	Aurobindo adopts meaningful mitigation strategies tailored to each identified risk. Risk mitigation procedures involve undertaking appropriate actions by the business heads/process owners who are accountable to mitigate risks in a time bound manner. Risk owners are identified, and progress of mitigation actions are monitored and reviewed periodically.
	The Risk Management Committee (RMC) periodically reviews the scope adequacy and effectiveness of mitigation actions and provides necessary direction to mitigation teams.
Risk reporting	Risk reports are submitted to RMC on a periodic basis. The reports help in tracking each identified risk and its impact on business. The assessment of key risks, analysis of exposure and potential impact are carried out periodically, presented and discussed with RMC. Periodic updates are provided to the Board highlighting key risks, their subsequent impact and the required mitigation measures.

RISK CATEGORIES

The Risk management framework covers the following broad categories of risks to business objectives:

• Strategic risks are the risks arising due to the decisions taken by the management with respect to markets, product & process development, resources, business growth & revenue model, acquisitions, investment model, etc. which can impact business objectives.

Ownership of risk: Key management personnel

• **Operational risks** are attributable to business operations such as production capacities, quality assurance, customer demands, material availability, human safety etc. which can have impact on business.

Ownership of risk: Operations team.

• **Compliance risks** arise out of non-compliance with applicable laws, regulations, standards and policies that could impact the Company's reputation and business.

Ownership of risk: Functional heads

• **Financial risks** are related to financial performance targets of revenue and profit goals of the Company. These risks could have impact on the Company's financial statements and transmission of accurate financial information to stakeholders.

Ownership of risk: Finance & accounts heads and their team

• IT risks could have potential impact on information assets and processing systems.

Ownership of risk: Chief Information Officer and his team

RISK GOVERNANCE STRUCTURE

The risk management framework operates at various levels in the Company and the governance structure is as given below:



The risk governance structure of the Company is headed by Board of Directors who form the RMC. The Committee is responsible for framing, implementing and monitoring the risk management framework for the Company and responsible for reviewing the risk management process and ensuring its effectiveness.

The Audit Committee has additional oversight in the area of financial risks and controls. Risk Management Head (RMH) acts as a nodal point for coordinating risk mitigation activities. RMH also appraises the Audit Committee with identified risks and its mitigation. RMH is supported by business heads who are the risk owners to implement the risk management framework in their respective business units.

INTERNAL FINANCIAL CONTROLS (IFC) HIGHLIGHTS FOR THE YEAR

As mandated by the Companies Act 2013, the Board of Directors are responsible to ensure that the Internal Financial Controls are adequate and operating effectively. In addition, the Company's statutory auditors are required to provide an independent opinion on the adequacy and operating effectiveness of such controls in the financial year. During the FY 2017-18, the Company has taken an initiative to automate controls in key business processes and has put in place large number of 'system-driven controls' and reduced dependency on manual controls. Segregation of duties is established in every activity to prevent errors and frauds. This effort has increased the effectiveness of business processes as well as accuracy of transactions processing in ERP. All the controls have been properly documented and tested for their design and operating effectiveness.

BUSINESS RISKS AT AUROBINDO

Some of the key existing and emerging risks affecting Aurobindo's business are listed below:

Economic & geopolitical risks

Economic and political instability arising from changes in foreign policies & political leadership in countries such as USA, Europe and emerging markets (EM), where Aurobindo has business presence could adversely affect the Company's operations and revenues.

There has been a significant growth over the years in the Company's revenues backed by increased exports. The revenues are generated mainly from the sale of formulations and bulk drugs in the global markets. These include developed markets like USA and Europe and emerging markets across the world. The revenue breakup of the Company for financial year 2017-18 is as given below:

- Export sales constitute about 90% of the Company's total revenue with the rest 10% being domestic sales;
- Formulations business contributes 82% to the Company's total revenue and the rest 18% comes from active pharmaceutical ingredients (APIs);
- About 55% of the formulations sales come from the US,

about 32% from Europe, 6% from anti-retroviral (ARV) business segment and the balance 7% from Growth markets.

In the global pharmaceutical industry, there are various concerns on product quality and safety which may lead to penalties, product recalls, brand & reputation damage and revenue loss. The regulatory landscape of global pharmaceutical industry is complex and dynamic which is significantly influenced by political environment, changes in Government policies and decisions.

Aurobindo is an integrated global pharmaceutical company with operational presence across the globe and with broad portfolio of diversified dosage forms. The Company's objective is to expand further in the other untapped markets and to focus on novel technology platforms.

Mitigation strategy:

In order to mitigate the economic and geo-political risks, the Company continues to expand its business presence in other untapped and potential markets like Japan, Brazil, Africa, Canada and Middle East. New markets are added in Poland and Czech Republic. Also, to enhance presence in therapeutic areas like oncology and speciality injectable products, Aurobindo continues to take adequate care to grow in each of the product segment and is striving to improve its presence in all markets by expanding its business. Such well-designed moves would also help consolidate the Company's volumes and revenues over the long-term, thereby spreading the risk portfolio.

As a de-risking strategy, the Company continues to focus on territorial expansions, partnerships, globalization and further penetration through joint ventures and subsidiaries in potential markets.

Competition risks

Aurobindo's products face tough competition from other pharmaceutical companies in India and abroad where multiple players are present, and introduction of new products by competitors may impair the Company's competitive advantage and lead to loss of market share.

The Pharmaceutical industry is severely competitive and is affected by new technologies, new product developments, government regulations and other factors. The Company faces intense competition from other pharmaceutical companies in global and domestic markets and introduction of new products by them may impair company's competitive advantage thereby affecting revenues.

Mitigation strategy:

In order to mitigate the risk of rising and on-going competition from peers, the Company continues to focus on the following aspects.

 Producing products at competitive costs by developing new processes, upgrading existing processes and achieving operational excellence

- Timely launch of new products by talented R&D teams to build and increase market share
- Adding new manufacturing facilities with new products to
 ensure sufficient levels of production
- Providing the product quality assurance to all customers
- Redefining the production process by R&D team to have cost effective products
- Vertically integrating the manufacturing facilities for most generic formulations to ensure timely material availability
- Micro-level planning of inventory to handle inventory costs efficiently

Regulatory, Statutory & Legal compliance risks

With rigorous regulatory and legal requirements and an evolving compliance landscape, the pharmaceutical industry is constantly being challenged by critical compliance risks at an enterprise level.

Regulatory framework plays a vital role in developing and doing business in global and domestic markets. Due to constantly increasing regulatory requirements as well as globalization market, the demands and responsibilities of business in the form of regulatory readiness are becoming stringent. The regulations require registration, filings and data submission to allow the Company enter diverse markets. Therefore, the Company continues to establish and strengthen systems & controls to monitor and upgrade registrations as and when required. The Company continues to adopt a zero-tolerance approach towards non-compliance with any applications laws.

Mitigation strategy:

Aurobindo has a talent pool of over 1,500 scientists, who have adequate experience in handling complex chemistry and filing applications with the regulatory authorities. The strong scientist pool has helped Aurobindo receive a total of 361 ANDA approvals (327 final approvals including 17 for Aurolife Pharma LLC, and 34 tentative approvals) from US FDA as at March 31, 2018. Cumulative filings total 478 ANDAs.

Similarly, as on March 31, 2018, the team has filed over 427 DMFs including 227 with US FDA. So far, 669 patent applications are pending with various authorities and 106 have been granted patents.

Aurobindo is committed for supplying highest quality medicines to customers for promoting healthier lives. Hence, the Company strives to conform to regulatory and compliance standards to meet stringent requirements of regulators to ensure that our medicines provide best health care for the consumers. Robust quality systems & control measures are available to ensure that the quality is ensured by process design. Every effort is being made to ensure that there is no compromise on quality of products and processes. Continuous monitoring is being done by QC/QA team to deliver highest quality products. The Company has a robust "Statutory compliance system/ solution" (Vision 360 Tool) for ensuring compliance with all applicable laws and it is designed to meet compliance goals of the Company. Periodic updates to the system are made as and when there is a change in any applicable law. Quarterly compliance declarations generated electronically from the system are submitted to compliance officer. In case of any non-compliance, necessary steps are taken by the concerned functional heads to fix it.

Aurobindo's commitment to Environment, Health and Safety (EHS) - The Company's Board and executive management have a strong commitment towards creating and providing a safe working environment for all its employees and other stakeholders. Aurobindo has a full-fledged EHS team which is continuously addressing issues of environmental safeguarding by conducting periodical safety audits and training programs.

Pricing risks

Some of Aurobindo's products are subject to regulatory pricing controls and other pressures on pricing. The price controls limit the financial benefits of growth in the life sciences market and the timely introduction of new products.

Like most of the other companies, Aurobindo is also subject to pricing pressure. Prices are a function of demand and supply and the Company faces perfect competition in generic drug industry. This year witnessed a significant volatility in global commodity prices and there has been disruption in domestic market in the form of demonetization. Prices change in response to supplies and competitive pressures. Domestic pricing is influenced by global trends in both availability and price of imported active ingredients. The Company continues to face challenges within the industry successfully be it price cuts or increased price controls.

Mitigation strategy:

Aurobindo is able to cope with pricing pressures and focus on quality assurance to minimize the possibilities of commoditization. Also, the Company has a well-diversified product basket in the US which helps in mitigating the pricing pressure. The inhouse R&D team is striving to develop cost-effective products by redefining the production process/facility. The Company is moving up the value chain by offering differentiated and speciality products and technology platforms. The supply chain team is continuously putting in efforts to de-risk global procurement issues and is ensuring timely services to key customers in international and domestic markets.

Patent protection risks

Aurobindo's success to a great extent depends upon the Company's ability to obtain IP Rights such as patents and trademarks, protect trade secrets and other proprietary information, and operate without infringing the intellectual property rights of the other companies. Aurobindo's inability to obtain timely ANDA approval and/or launch a product immediately upon approval due to patent litigation issues or due to settlement for a late market entry date may affect the revenue.

Aurobindo has a dedicated team of IP professionals whose primary task is to ensure that the products are manufactured using essentially non-infringing composition and processes to the best possible extent and in compliance with IPrelated requirements by reviewing and monitoring IPR issues continuously.

The IPR team evaluates and provides stage-wise IP clearances during product/process developmental activities. The IPR team also provides frequent updates and alerts on all relevant IP matters (such as patent, trademark, etc.) to R&D scientists for the products and suggests suitable measures to deal with IP-related issues. The IP team is also involved in product selection activity to ensure that right products are selected for development and no potential opportunity is missed out to the best possible extent.

As of March 31, 2018, the Company has more than 563 patent applications pending with various authorities. Aurobindo takes adequate care to protect its trade secrets, know-how and other proprietary information, and ensures that the employees, vendors and suppliers associated with the Company directly or indirectly sign appropriate confidentiality agreements prior to disclosure of any such confidential information.

Market risks

Aurobindo is exposed to market risk if the Company is unable to maintain sufficient portfolio of products and manage their development and timely bringing the products to market which could ultimately affect the business and growth strategy. The Company is significantly dependent on the US market for its business. Failure to conduct profitable operations in that market could adversely affect the Company's business, operations and financial condition. This scenario poses the risk of high concentration and significant dependence on one market.

Aurobindo's success largely depends on the ability to continue the development and commercialization of new products in a timely and cost-effective manner which is a complex and timeconsuming process. Therefore, it is important for the Company to maintain a large portfolio of products and product pipeline. Most importantly, the Company needs to focus on managing development and approval process of products to bring them to market on a timely basis.

Mitigation strategy:

As part of mitigation procedure, the Company's R&D team strives to develop new, innovative processes and specialized products that allow the Company to capitalize on competitive market opportunities. As part of product portfolio growth strategy, the Company sells nutritional supplements in US & other markets which enhance revenues. It is highly challenging for the Company to retain the existing market share and increase it in the future. Any sort of delay in supplying material to customers and deviations in customers' specifications could have adverse impact on customer relationships and loss of revenues and the Company would have to face penalties. It may also affect the Company's reputation and competitiveness which could lead to loss of market share. Such failures could have major impact on the Company's business and brand value. The Company's SCM team ensures that such failures are monitored and mitigated in a real time.

Mitigation strategy:

In order to reduce the concentration risk, the Company continues to spread its business (Formulations and API) into European, Japanese and emerging markets. Aurobindo with its effective marketing strategy is increasing sales volumes for both the businesses in existing markets and is making regular efforts to widen geographical spread by entering into large potential markets in Latin America and emerging markets. The Company has the right balance between high margin-low volume products and low margin-high volume products.

The Company continues to expand the end-to-end manufacturing capacities and to ensure capacity utilization at optimum levels with effective marketing strategy and proper coordination from Production and SCM heads.

Financial risks

Failure to maintain appropriate credit ratings (Downward movement in rating) could affect the Company's cost of borrowings thereby having adverse impact on profitability. While the Company's exports are significantly high, financial obligations towards import payments and ECB payments are also high and any adverse foreign currency fluctuations could have impact on financial position.

Mitigation strategy:

The Company's treasury team continues to ensure reduction in borrowing costs with proper negotiation with banks. There exists a defined credit policy for all its customers which covers defining, approving and monitoring customer credit limits based on customer's profile and their payment history. The treasury team along with the Business Heads evaluate customer credit risk and approve credit limit that can be provided to a customer. The customer credit limits are periodically reviewed and changed in order to mitigate the credit risk. The treasury team reviews customer collections regularly and makes import payments and takes necessary actions wherever necessary. Also, the treasury team continuously monitor day-to-day fund requirements and manages the banking relations effectively.

Aurobindo is predominately an export-oriented company. Around 90% of the Company's revenue is from international markets. At the same time, the Company is having sizable imports/working capital in foreign currency and long-term ECB to fund the exportoriented projects. As such, the Company's growing exports and its collections provide the natural hedge to the imports and working capital against the foreign exchange fluctuations.

The Company is conscious of the impact that currency fluctuations can have on earnings. The forex position is reviewed on a monthly-basis by the Borrowing Committee and quarterly by the Board/Audit Committee. Based on the decision of the Borrowing Committee, the treasury team ensures the execution of transactions through forward cover.

Raw-material import risks

Aurobindo's dependency on China market for import of raw-material is very high and this may lead to risk of import disruptions, short supplies and production bottlenecks due to unforeseen changes in government regulations & economic policies of China.

The creation of stable sourcing platform is a challenge and critical for the Company in material procurement and the SCM team has taken steps in ensuring long-term supply sustainability in this space.

Mitigation strategy:

As part of strategic sourcing, our procurement team continuously focuses on the following aspects in order to mitigate sourcing risks.

- Cross-functional interaction to address long-term supply concerns and sourcing constraints
- Mapping of geographic risks with alternative vendor development
- Efficient cost management and proper alignment with budget
 constraints
- Monthly procurement review among cross-functional teams to monitor progress on risk mitigation
- Integrated planning and procurement for operational dynamism
- Continuous tracking of market trends and its dynamics

In our journey of excellence over the years, our key focus has been de-risking of single sourced material and reducing our dependency on China for raw-material procurement due to cost escalation and environmental changes therein. There exists a dedicated procurement team for managing the sourcing risks regularly and the Company is having an effective process and controls to periodically evaluate its vendors for all critical material. The procurement team ensures high quality purchases at economical costs and maintains reliability of supplies from reputed vendors with long-term relationships.

The 'Production planning & inventory control' (PPIC) continues to regularly track the material requirement in coordination with SCM and Production teams for keeping optimum levels of material so that production schedule is not affected.

People risks

Aurobindo's success depends largely upon an effective HR strategy that includes recruitment, learning & development,

succession planning and retention of competent personnel. The HR strategy is aligned to business plan and growth of the Company. It is a well-managed challenge for Aurobindo to maintain good industrial & employee relations. Labour unrest could impact the Company's operations. The industry is human capital intensive with a high rate of attrition and this could have an impact on the Company's operations.

Mitigation strategy:

Aurobindo has a committed Human Resources team to acquire, retain and develop talent considering the competition for qualified and experienced people.

Leadership development – As part of the Company's strategic talent and succession management, the HR team at Aurobindo has identified and developed people with potential to fill key business leadership positions. The Company has instituted NALANDA, online academy, to facilitate Leadership Talent Development and support management philosophy of second-line development and for promoting mentor-mentee relationships within the Company. The second-in-command across each key function and decentralized management style has developed a much stronger organization culture. The Company is continuously fine-tuning its HR strategy in order to meet its business goals.

Talent engagement & empowerment –Talent development is important for the success of business and training needs are identified for each individual on a periodic-basis. The Company understands the need to create a culture of high employee engagement as a method to retain talent. There is a proactive approach to HR management and employees are given responsible authority. Emphasis is on accountability with clear job descriptions and the employees are encouraged to perform to their optimum potential. Regular interactions and communications help the personnel to update and upgrade their knowledge and skills which helps in minimizing the operational risks.

Kaizen change management process has been initiated with focus on Shop-floor Empowerment and provides Partnershipplatform for the people to engage with continuous improvement projects. Process Care, People Care and Asset Care are the three enablers to achieve the continuous improvement mission in the Company.

Multi skilling & Quality programs – The Company has introduced multi-skilling program which promotes job enrichment of talent at operational level. Also introduced Quality Marshal Program which facilitates strengthening of Quality culture at shopfloor.

Employee performance appraisals – The Company's on-line employee appraisal system is robust for measuring performance vis-à-vis KRAs defined for the employees. HR team strives to ensure that annual performance assessments are conducted effectively with necessary feedback and counselling.

Harmonious industrial relations – Industrial Relations team is making continuous efforts to maintain a cordial relationship with employees with a view to achieve best performance. The



Company has established an online people care link to redress grievances in a proactive manner and believes in bipartite strategy to prevent and settle any outstanding issues in a peaceful manner. Further, management has initiated Social Accountability Certification process (SA 8000 series) to maintain its commitment towards fair people management.

The Company ensures that there is full adherence to code of business conduct and fair business practices are followed by employees.

Information technology (IT) risks

Achievement of business objectives for Aurobindo depends on the existence of a robust IT strategy that includes adequate IT infrastructure, data storage & processing capabilities, data confidentiality, integrity and availability at all times. Occurrence of any unforeseen threats to IT systems could have adverse impact on data processing, data availability and continuity of operations.

Mitigation strategy:

The Company continues to calibrate and update its key business processes to continuously improve efficiencies. These include controls automation and internal workflows for manufacturing, supply chain and integrating them with material planning, sales & marking, HR.

The Company has robust IT controls related to back-up, storage and system access including role-based access control for the applications and strong change management controls. There are well documented SOPs and are reviewed periodically for their effectiveness. For all mission critical IT applications and services, the Company has built highly stringent and secured infrastructure. For business continuity, the Company has a disaster recovery site which hosts backup ERP applications.

Aurobindo has an experienced IT operations team who ensures day-to-day smooth functioning of IT infrastructure and applications including network infrastructure, server & device management, computer operations, and help desk services for the Company. All incidents are tracked through ticketing tool and there is a well-defined process for its closure in a timely manner.

The IT Governance Committee of the Company periodically reviews IT-related matters around policies & practices, budgets proposals for procurement of new applications and hardware, renewal of licenses, process automation to support the business functions etc. and advises the Board for its consideration.

For any business process automation /digitalization and regulatory compliance-related solution, the IT team works very closely with business process owners for effective and timely implementation. Periodic reporting of all critical IT projects to leadership team is done by Chief Information Officer (CIO). The IT team conducts periodic evaluation of IT process and in case of any process gaps and concerns, appropriate corrective measures are taken in a time bound manner.

BUSINESS RESPONSIBILITY REPORT

OVERVIEW

Aurobindo Pharma Ltd is one of the largest generic pharmaceutical companies in the world with presence in over 150 countries, with 25 manufacturing facilities, which has requisite approvals from various regulatory authorities like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil, etc. Aurobindo has an employee base of more than 19,000 (including all subsidiaries). Aurobindo is a vertically integrated Company with around 70% of its API requirement being met in-house. The Company has presence across the world and the key markets are the US and Europe.

The Company's robust product portfolio is spread over seven major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, cardio-vascular (CVS), central nervous system (CNS), Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. Aurobindo forayed into biosimilars segment with acquisition of five cell culture derived biosimilar products. The Company also develops fermentation based semi synthetic products, and furthermore it produces novel proprietary biocatalysts.

Aurobindo generates around 90% of its consolidated revenue from the international markets and currently holds a strong position in the US market and in many European countries, including France and Italy where it ranks among the largest generic companies. In the US, it is the fifth largest generic pharmaceutical company (as per IMS National Prescription Audit, in terms of total prescriptions dispensed for the 12 months ending April 2018), The Company believes in doing business in a responsible manner. The Business Responsibility Report is aligned to the National Voluntary Guidelines (NVGs) on social, environmental and economic responsibilities of business released by the Ministry of Corporate Affairs and is in compliance with Regulation 34 (2) (f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All the facts and figures reported in the Business Responsibility Report pertains to the parent company i.e. Aurobindo Pharma Ltd.

SECTION A: GENERAL INFORMATION ABOUT THE COMPANY

- 1. Corporate Identity Number (CIN) of the Company L24239TG1986PLC015190
- 2. Name of the Company Aurobindo Pharma Limited

3. Company Address

Registered Office: Plot No2, Maitrivihar, Ameerpet, Hyderabad 500038, Telangana, India

Corporate Office: Water Mark Building | Plot No. 11, Survey No.9 | Kondapur, Hitech City | Hyderabad-500084, Telangana, India

4. Website

www.aurobindo.com

- 5. E-mail id info@aurobindo.com
- 6. Financial Year reported 1st April 2017 to 31st March 2018
- 7. Sector(s) that the Company is engaged in (industrial activity code-wise):

S. No	NIC code of product/ service	Description
1	21001/21002	Manufacturing generic pharmaceuticals and active pharmaceuticals ingredients (APIs)

- 8. List three key products/services that the Company manufactures/provides (as in balance sheet) The Company's product portfolio is spread over seven major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics.
- 9. Total number of locations where business activity is undertaken by the Company:

The Company along with its subsidiaries has Marketing and Sales offices in 31 countries and markets its products globally in over 150 countries.

(a) Number of International locations (Provide details of major 5):

The subsidiaries of the Company have manufacturing facilities in New Jersey, Los Angeles and California in USA, one each in Brazil & Portugal and two R&D centers in USA. Apart from these, the Company has offices in various European, African and Asian countries.

(b) Number of National locations:

The parent company has 15 manufacturing units and two R&D centers. In addition to these, there are three manufacturing units under construction. The subsidiaries & joint ventures of the Company have five fully commissioned manufacturing units and another one is under construction.

10. Markets served by the Company – Local/State/ National/International:

Apart from the domestic market, the Company also markets its products globally in over 150 countries across 6 continents. Around 81% of the Company's standalone sales are generated from the International markets.

SECTION B: FINANCIAL DETAILS OF THE COMPANY

1. Paid up Capital (₹): ₹585.9 million



rts Financial Statements

- Total Turnover (₹): Gross turnover of ₹103,031 million on standalone basis
- Total profit after taxes (₹):
 ₹18,128 million on standalone basis
- 4. Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax (%): CSR Spend during the financial year 2017-18 was ₹200 million (1.1% of standalone profit after tax). All unspent CSR funds of previous year(s) are carried forward for spending on CSR activities.
- 5. List of activities in which expenditure above has been incurred
 - Education
 - Health
 - Environmental sustainability
 - Rural sports promotion, old age homes and rural development

SECTION C: OTHER DETAILS

1. Does the Company have any Subsidiary Company/ Companies?

Yes, Aurobindo has 56 subsidiary companies located in India and other countries as on 31st March, 2018.

2. Do the Subsidiary Company/Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s) The parent company undertakes majority of the BR initiatives, through its 'Not for Profit' foundation called Aurobindo Pharma Foundation. Do any other entity/entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/entities? [Less than 30%, 30-60%, More than 60%] Entities like suppliers, distributors did not participate in the Company's BR initiatives for the reporting period.

SECTION D: BR INFORMATION

1. Details of Director/Directors responsible for BR

- a) Details of the Director/Director responsible for implementation of the BR policy/policies
- DIN Number: 00050482
- Name: Mr. N. Govindarajan
- Designation: Managing Director
- b) Details of the BR head

S. No	Particulars	Details
1	DIN Number (if applicable)	00050482
2	Name	Mr. N. Govindarajan
3	Designation	Managing Director
4	Telephone number	040-66725246
5	e-mail id	secretarial@aurobindo.com

2. Principle-wise (as per NVGs) BR Policy/policies

a) Details of compliance (Reply in Y/N)

S. No	Questions	Ethics	Product Life Cycle Sustainability	Employees well-being	Stakeholder Engagement	Human Rights	Environment	Policy Advocacy	Community Development (CSR)	Customer Value
1	Do you have a policy/ policies for	Y	The company	Y	Y	Y	Y		Y	The company
2	Has the policy being formulated in consultation with the relevant stakeholders?	Y	continuously focusses on	Y	Y	Y	Y	_	Y	in its operations
3	Does the policy conform to any national / international standards? If yes, specify? (50 words)	Y	the optimal utilization of resources	Y	Y	Y	Y*	_	Y	ensures the customer
4	Has the policy being approved by the Board?	Y	 from its product design to 	Y	Y	Y	Y	_	Y	value
	Is yes, has it been signed by MD/ owner/ CEO/ appropriate Board Director?		disposal							
5	Does the company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	Y	_	Y	Y	Y	Y	_	Y	
6	Indicate the link for the policy to be viewed online?	**	_	Emple Service	oyees (e in IHF		**	NA	**	
7	Has the policy been formally communicated to all relevant internal and external stakeholders?	Y	-	Y	Y	Y	Y	-	Y	
8	Does the Company have in-house structure to implement the policy/ policies?	Y	_	Y	Y	Y	Y	-	Y	
9	Does the Company have a grievance redressal mechanism related to the policy/ policies to address stakeholders' grievances related to the policy/ policies?	Y	-	Systems in place	Y	Y	Y	_		
10	Has the Company carried out independent audit/ evaluation of the working of this policy by an internal or external agency?	Y		Y	Y	Y	Y	_	The CSR assessment is done internally	

The Company abides by the law of land and the policies are framed considering the national standards. *Policy is in line with ISO 14001 international standards

The policies are available at the following link:

** http://www.aurobindo.com/social-responsibility

3. Governance related to BR

- a) Indicate the frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR performance of the Company. Within three months, three-six months, annually, more than one year Reviewed annually
- b) Does the Company publish a BR or a Sustainability Report? What is the hyperlink for viewing this report? How frequently it is published?

This is Aurobindo's 3rd Business Responsibility Report and is a part of the FY17-18 Annual Report. Previous year's Business Responsibility Report can be accessed from the following hyperlink (which is part of Annual report 2016-17): http://www.aurobindo.com/ docs/annual-reports/aurobindo-ar-2016-17.pdf

SECTION E: PRINCIPLE-WISE PERFORMANCE Principle 1 – Ethics

1. Does the policy relating to ethics, bribery and corruption cover only the Company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/ Contractors/NGOs /Others?

Aurobindo is committed to build a strong ethical organization. The Company's Code of Conduct affirms its

commitment to the highest standards of integrity and ethics. The Code of Conduct guides all supervisory, executive and managerial employees of the Company including the Board members. The policy is communicated to the employees across all the locations. The policy documents are made available in internal portal for ready reference

2. How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about 50 words or so.

During the year ended March 31, 2018, the Company has received and resolved 31 complaints from investors. All the complaints were resolved to the satisfaction of the shareholders and there were no pending complaints at the year end.

Principle 2 – Product Life Cycle Sustainability

1. List up to three of your products or services whose design has incorporated social or environmental concerns, risks and/or opportunities.

Our following products help address social or environmental concerns in their design (Electrical and Energy Savings),

- a) Levetiracetam
- b) Ceftazidime for Injection
- c) Ceftriaxone Sodium
- 2. For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product(optional)

Product-wise details are mentioned below:

Levetiracetam:

Levetiracetam has been approved as an add-on treatment for partial (focal) myoclonic and tonic-clonic seizures. It has potential benefits for treating other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder and Alzheimer's disease. However, its most serious adverse effects are behavioral, and its benefit-risk ratio in these conditions is not well understood.

Installed De-super heaters at turbines exhaust to convert the super-heated steam to saturated steam to meet the process steam requirements. This energy conservation initiative has produced 16,065 MT of additional steam and an equivalent coal savings of 3.01 MT/ Kg or ₹20.6 million / annum. This project not only fulfills the heating requirements for Levetiracetam, but also for major capacity production molecules such as Lamivudine, Cinacalcet Hydrochloride, Dabigatran, Hydralazine HCl, etc.

Ceftazidime for Injection and Ceftriaxone Sodium: Ceftazidime is used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis.

Ceftriaxone Sodium is used to prevent or treat certain infections caused by bacteria. It is given by injection only into a muscle or vein. Ceftriaxone is often used to treat infections of the lung, urinary tract, skin, abdomen, bone joint and lining of the brain (meningitis), depending on the bacteria causing them. It can also be used to treat Gonorrhea. Both these products belongs to the family of antibiotics known as Cephalosporins. 320 TR Vapor Absorption Machine (VAM) installed instead of old 300 TR- 1No & 2 compressors (160 TR & 200 TR) to save electrical energy at manufacturing blocks for these products and solvent recovery (Methylene Chloride, Acetone, Ethyl Acetate, Ethanol, Methanol). Cumulatively, the saving of 31.05 kWh/Kg of product which is equivalent to ₹17.2 million /annum was achieved with ceftazidime and ceftriaxone Sodium energy conservation initiative

3. Does the Company have procedures in place for sustainable sourcing (including transportation)? The Company has laid down a standard operating procedure for the selection of its vendors and approving the same for sourcing of material. There is a system in place for evaluating the EHS resources and compliance of key suppliers and vendors for key raw material intermediates and API sourcing.

4. Has the Company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work?

The Company follows a strict sourcing code of conduct with respect to the compliance and quality. The Company procures goods and services from local vendors near the manufacturing locations who fulfills the above key criteria of compliance and quality.

Does the Company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about 50 words or so.

Yes, the Company has a mechanism to recycle or dispose materials including waste in a responsible manner.

- The Company has the process of recovering solvents where the volume of solvent usage is maximum and wherever possible to recycle.
- Spent Catalysts are sent back to vendor for regeneration and reuse.
- All organic wastes generated from API Units (solids and liquids) and all the wastes generated from Formulations Units (with very few exceptions) are disposed to Cement Units for use as auxiliary fuel called 'co-processing' of wastes. For the financial year under discussion, approximately 60% of the waste is recycled through coprocessing.

Principle 3 – Employees Well being

- 1. Please indicate the total number of employees Company has 17,332 employees as on 31st March, 2018
- 2. Please indicate the total number of employees hired on temporary/contractual/casual basis Company has over 9.000 contractual employees as on 31st

March, 2018

 Please indicate the number of permanent women employees.
 Company has 780 women employees as on 31st March,

2018

4. Please indicate the number of permanent employees with disabilities

We don't differentiate employees on any form of disabilities. Hence, no data available.

- 5. Do you have an employee association that is recognized by management? Yes
- 6. What percentage of your permanent employees is members of this recognized employee association? As the majority of the office bearers/active members of the Association have left the organization, no activity has been observed during last financial year. Harmonious industrial relations were maintained across all the manufacturing locations.
- 7. Please indicate the number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last financial year and pending, as on the end of the financial year.

S. No	Category	No of complaints filed during the FY	No of complaints pending as on end of the FY
1	Child labour/forced labour/involuntary labour	Nil, Company does not hire child labour, forced labour, involuntary labour	Nil
2	Sexual harassment	Nil	Nil
3	Discriminatory employment	Nil	Nil

- 8. What percentage of your under mentioned employees were given safety & skill up-gradation training in the last year?
 - **Permanent Employees:** Employee training is a continuous process in the organization and all the employees are given mandatory safety training at the time of joining the organization. Further there are continuous skill-based trainings imparted to over 90% our employees.

- **Permanent Women Employees:** No separate data record is maintained.
- Casual/Temporary/Contractual Employees: All our contractual employees are imparted with trainings
- Employees with Disabilities: NA

Principle 4 – Stakeholders Engagement

- 1. Has the Company mapped its internal and external stakeholders? Yes/No Yes
- 2. Out of the above, has the Company identified the disadvantaged, vulnerable & marginalized stakeholders Yes
- 3. Are there any special initiatives taken by the Company to engage with the disadvantaged, vulnerable and marginalized stakeholders? If so, provide details thereof, in about 50 words or so.

The Company believes in greater engagement with its stakeholders and being sensitive towards their needs and expectations. This is one of the corporate values that focusses on being responsive to stakeholders' needs, proactive and transparent.

The Company has a Whistleblower Policy that provides support to employees, channel partners and vendors to report significant deviations from key management policies and report any non-compliance and wrong practices. The Company also has an Investor Grievance Cell where the investors can raise their concerns and are resolved appropriately.

Principle 5 – Human Rights

- Does the policy of the Company on human rights cover only the Company or extend to the Group/Joint Ventures/Suppliers/Contractors/NGOs/Others? The policy covers the employees of the organization.
- 2. How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management? None received

Principle 6 - Environment

1. Does the policy related to Principle 6 cover only the Company or extends to the Group/Joint Ventures/ Suppliers/Contractors/NGOs/others?

The Company has a well-defined environment, health and safety (EHS) policy that caters to the employees, group, JVs and the contractors working at our sites. The Company is committed to operate all its units in an environmentally friendly manner while protecting health and safety of its employees.

Financial Statements

2. Does the Company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc? Y/N. If yes, please give hyperlink for webpage etc.

The Company has initiated for participation and membership in Pharmaceutical Supply Chain Initiative (PSCI) and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). These international forums are engaged in addressing global environmental concerns such as Pharmaceuticals in Environment, Anti-Microbial Resistance, etc. Aurobindo is part of BDMA (Bulk Drug Manufacturer's Association, India) initiatives to address similar issues. IFPMA, agreed in principle for the request of Aurobindo for Membership.

The Antimicrobial Resistance Benchmark is a first independent, detailed evaluation of how pharmaceutical companies are halting the rise of drug resistance by Access to Medicine Foundation, an independent non-profit organization based in the Netherlands through collaboration with experts and specialists working across the spectrum of organizations working to curb antimicrobial resistance. The Access to Medicine Foundation approached Aurobindo, while describing the purpose of the benchmark, its process and the framework of the benchmark, in May, 2017 with a request to take part in the initiative. Aurobindo gladly accepted to take part in the benchmark exercise. The Antimicrobial Resistance Benchmark 2018 was published in January, 2018. Proposed 2020 AMR Benchmark will have more indicators with participation of 30 companies across 106 countries in scope for access indicators. Aurobindo is actively engaging itself for the forthcoming 2020 AMR Benchmark as well.

- 3. Does the Company identify and assess potential environmental risks? Y/N Yes
- 4. Does the Company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if yes, whether any environmental compliance report is filed? At present the Company does not have any project related to Clean Development Mechanism.

5. Has the Company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc.? Y/N. If yes, please give hyperlink for web page etc.

Yes, the Company has undertaken various initiatives to improve energy efficiency and to introduce cleaner technologies. In continuation of earlier initiatives, the Company has installed two stage RO systems that facilitates reduction in wastewater volumes requiring physical treatment like MEE, which resulted in reduction in steam consumption. In cleaner technologies, the Company is continuing with established practices of segregation, storage and disposal appropriately to secure landfill facilities or cement units. The organic wastes, liquid and solid, are disposed to cement units for co-processing where the wastes serve as auxiliary fuel for the cement units.

- 6. Are the Emissions/Waste generated by the Company within the permissible limits given by CPCB/SPCB for the financial year being reported? Yes
- Number of show cause/ legal notices received from CPCB/SPCB which are pending (i.e. not resolved to satisfaction) as on end of financial year.: No pending notices as on 31st March, 2018

Principle 7 – Policy Advocacy

1. Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with: The Company is associated with various trade organizations, chambers etc. as follows.

The Company is a member of various trade bodies and chamber associations in India as follows:

- 1) Export Promotion Council for EOU'S & SEZ'S
- 2) Indian Drug Manufacturers Association
- 3) Indian Chamber of Commerce & Industry
- The Federation TG and AP Chambers of Commerce & Industry (FAPCCI)
- 5) Confederation of Indian Industry
- 6) Andhra Chamber of Commerce
- 7) Bulk Drug Manufacturers Association
- 8) Pharmaceuticals Export Promotion Council of India
- 9) Indo American Chamber of Commerce
- 10) JNPC Manufactures Association
- 11) Telangana Chambers of Commerce and Industry
- 12) Federation of Indian Micro and Small and Medium Enterprises (FIMSE)
- 2. Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas (drop box: Governance and Administration, Economic Reforms, Inclusive Development Policies, Energy security, Water, Food Security, Sustainable Business Principles, Others)

The Company focuses on the advancement/improvement of public good through our well-defined CSR activities.

Principle 8 – Community Development (CSR)

1. Does the Company have specified programs/ initiatives/projects in pursuit of the policy related to Principle 8? If yes details thereof

Aurobindo is committed to continuously improve its social responsibilities, environment and economic practices to make a positive impact on the society. Some of the key priorities of our community-based initiatives are:

- Education
- Health
- Environmental Sustainability
- Rural sports promotion, old age homes and rural development.

The Company also provides infrastructure support to the above-mentioned projects.

2. Are the programs/projects undertaken through inhouse team/own foundation/external NGO/government structures/any other organization?

As indicated in the last year's Annual Report, Aurobindo has established a Foundation i.e. Aurobindo Pharma Foundation for undertaking mainly CSR activities. Accordingly, the Company initiates CSR activities through the said foundation.

3. Have you done any impact assessment of your initiative?

We review our projects from time to time. Each project has specific deliverables to be met. The internal teams ensure project implementations are undertaken and that the desired impact is created.

4. What is your company's direct contribution to community development projects- Amount in ₹and the details of the projects undertaken

Aurobindo has spent ₹200 million on the CSR activities during the FY2017-18. The amount was spent on areas as mentioned in point 1.

5. Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so.

The community development program revolves around education, health, sanitation etc. Overall these programs have benefitted more than 80,000 students and 1.4 lakh families during the year.

• Education: For the promotion of education, Aurobindo Pharma Foundation took various initiatives like construction of school buildings, providing desks and benches, renovating facilities, free supply of school bags and other stationery, etc.

- **Health:** Aurobindo has partnered with LV Prasad Eye Institute for providing free oncology related treatment to elderly population in Vizag and Srikakulam districts. Aurobindo Pharma Foundation installed RO plants, constructed permanent water storage tanks, etc. for providing safe drinking water in many villages across Telangana and Andhra Pradesh.
- Environmental Sustainability: Under Green-Belt program, Aurobindo team has planted numerous saplings in many places and provided cement and plastic tree guards for the protection of saplings.
- **Others:** Aurobindo has taken up many other activities like adoption of few villages, conducting sports events for promotion of sports, donating fire engines and ambulances in some districts, providing free food for thousands of poor people each day, etc.

Further details on our CSR projects undertaken during the FY2017-18 are mentioned in a separate section of the Annual Report.

Principle 9 – Customer Value

- What percentage of customer complaints/consumer cases are pending as on the end of financial year. Aurobindo has a well-defined mechanism to handle the customer complaints. As on 31st March, 2018 less than 1% of the complaints were pending beyond the acceptable timelines as per the Standard Operating Procedures (SOP).
- 2. Does the Company display product information on the product label, over and above what is mandated as per local laws? Yes/No/N.A. /Remarks (additional information)

The product labelling is to be approved by the regulatory authorities of the country where the product is to be sold. The Company mentions all the product information required by the regulatory agencies.

3. Is there any case filed by any stakeholder against the Company regarding unfair trade practices, irresponsible advertising and/or anti-competitive behavior during the last five years and pending as on end of financial year? If so, provide details thereof, in about 50 words or so.

There are no pending cases as on 31 March 2018.

1
- 44
~~
5
5
Ω
Z
Ī
A

Form AOC-I

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014) Statement containing salient features of the financial statement of subsidiaries/ associate companies/ joint ventures

Part "A": Subsidiaries (Information in respect of each subsidiary to be presented with amounts in \vec{z})

Country	The Netherlands	The Netherlands	Spain	The Netherlands		U.K.	Malta	Malta	Germany		Romania	Turkey		Portugal		The Netherlands		Poland	Czech Republic		Portugal	Portugal	Portugal	Portugal		Portugal	Italy	Portugal	L
% of share- holding	100%	100%	100%	100%				100%	100%		100%	100%		100%		100%		100%	100%		100%	100%	100%	100%		100%	100%	100%	10001
Proposed Dividend	 · 					·	•		'		•	'		.		•		'	'		'	'	'	'		·	·	•	
Profit / (Loss) after taxation	(199.24)	476.01	46.40	50.30		212.30	(1.16)	75.85	91.08		(18.55)	(29.87)		(4.82)		2.47		1.86	(0.03)		(559.85)	(0.11)	(0.03)	•		·	(98.78)	122.16	00.01.
Provision for taxation	(60.38)	171.15	15.37	17.02		50.65	•		40.92		1.64	'		17.08		0.62		0.47	'		135.38	'	'	'		•	13.35	37.34	
Profit / (Loss) before taxation	(259.62)	647.16	61.77	67.32	10000	262.95	(1.16)	75.85	132.00		(16.91)	(29.87)		12.26		3.09		2.33	(0.03)		(424.47)	(0.11)	(0.03)	'		·	(85.43)	159.50	
Tumover	, ,	31.38	925.04	524.86		5,544.39	19.46	5,018.59	1,704.35		662.57	• •		315.96		242.82		79.60	•		5,055.06	•	•	• •			2,137.36	1,233.69	
Invest- ments other than Subsi- diaries	·	'	' 			1	•		'							 		'	'		'	'	'			•	•		ĺ
Invest- ments in Subsi- diaries	6,105.38	16,386.59				'	235.49		' '		•	' '				' '					2.02			' '					
Total Liabilities	7,742.95	17,537.40	894.06	68.50		1,461.91	0.36	3,295.96	4,437.48		430.81	.		125.43		72.20		23.99	0.03		5,010.34	0.41	3.35	.		•	1,972.87	244.83	
Total Assets	12,762.04	7,298.30	1,008.89	253.27		2,580.98	414.68	3,655.68	4,886.77		574.40	•		192.66		88.21		137.26	0.31		12,689.74	2.20	3.58	0.40		0.04	2,062.54	486.42	
Reserves & surplus	(1,301.99)	1,673.58	(278.38)	183.32		787.03	239.71	68.81	151.03		(204.89)	•		(980.28)		8.74		1.86	(0.03)		(2,823.06)	1.39	(0.17)	•		•	(2,040.80)	241.19	
Share capital	12,426.46	4,473.91	393.21	1.45		332.04	410.10	290.91	298.26		348.48	'		1,047.51		7.27		111.41	0.31		10,504.48	0.40	0.40	0.40		0.04	2,130.47	0.40	
Exchange rate as on March 31, 2018	80.81	80.81	80.81	80.81	0000	92.28	80.81	80.81	80.81		17.13	17.09		80.81		80.81		18.90	3.15		80.81	80.81	80.81	80.81		80.81	80.81	80.81	
Reporting currency	EUR	EUR	EUR	EUR		GBP	EUR	EUR	EUR		RON	TRY		EUR		EUR		PLN	CZK		EUR	EUR	EUR	EUR		EUR	EUR	EUR	
The date since when subsidiary was acquired	Not Applicable	Not Applicable	Not Applicable	December 29, 2006	0 0 0 1 1	February 9, 2006	Not Applicable	Not Applicable	Not Applicable		Not Applicable	Not Applicable		Not Applicable		Not Applicable		Not Applicable	Not Applicable		May 1, 2017	May 1, 2017	May 1, 2017	May 1, 2017		May 1, 2017	Not Applicable	Not Applicable	
SI. Name of the subsidiary No.	Helix Healthcare B.V.	Agile Pharma B.V.	Laboratorios Aurobindo S.L.	Aurex B.V. (formerly known as	Pharmacin B.V.)	Milpharm Limited	Aurobindo Pharma (Malta) Ltd	APL Swift Services (Malta) Ltd	Aurobindo Pharma Gmbh	Germany	Aurobindo Pharma (Romania) s.r.l	10 Aurobindo ILAC Sanayi ve Ticaret	Limited Sirketi ¹	11 Aurobindo Pharma (Portugal)	Unipessoal Limitada	12 Pharmacin B.V. (formerly known as	Aurex B.V.)	13 Aurovitas Pharma Polska	14 Aurovitas Pharma Ceska Republica	S.r.0 ²	15 Generis Farmaceutica S.A. ³	16 Mer Medicamentos, Lda 4	Generis Phar, Unipessoal Lda ⁵	18 Farma APS - Promocao de	Medicamentos, Unipessoal Lda.,6	19 Generis MZ, Lda.,7	20 Aurobindo Pharma (Italia) S.r.l	21 Aurovitas, Unipessoal LDA	

Financial Statements

I he date since when subsidiary was acquired	Reporting currency	Exchange rate as on March 31, 2018	Share capital	Reserves & surplus	Total Assets	Total Liabilities	Irrvest- ments in Subsi- diaries	Invest- ments other than Subsi- diaries	Turnover	Profit / (Loss) before taxation	Provision for taxation	Profit / (Loss) after taxation	Proposed Dividend	% of share- holding	Country
April 1, 2014	EUR	80.81	2.02	2.30	4.87	0.55		•	0.75	0.09	0.04	0.05	, ,	100%	Germany
April 1, 2014	EUR	80.81	2.07	1,637.92	5,776.16	4,136.17			5,336.66	1,079.00	187.50	891.50	750.69	100%	Germany
April 1, 2014	EUR	80.81	48.33	813.73	1,637.35	775.29			2,345.84	276.89	72.23	204.66		100%	Spain
April 1, 2014	EUR	80.81	409.54	(15.84)	2,738.11	2,344.41			3,572.56	193.18	42.74	150.44		100%	The Netherlands
Not Applicable	HH	2.09	208.50	(45.95)	175.93	13.38			46.36	0.46	'	0.46		97.92%	Thailand
Not Applicable	BRL	19.60	198.55	1,158.00	1,544.04	187.49	 	'	1,816.88	569.61	165.08	404.53		99.97%	Brazil
Not Applicable	BRL	19.60	1.96	238.89	246.91	6.06			422.97	53.08	32.75	20.33		100%	Brazil
Not Applicable	RMB	10.38	51.93	127.45	239.54	60.16			103.53	13.17	3.52	9.65		100%	China
Not Applicable	CAD	50.65	219.17	606.99	2,457.72	1,631.56	' 	'	1,510.33	496.94	107.94	389.00		100%	Canada
Not Applicable	ZAR	5.58	233.71	565.37	994.48	287.43	• 	92.03	815.54	236.37	19.38	216.99	'	100%	South Africa
Not Applicable	NGN	0.18	12.36	(12.31)	0.39	0.34	'	'	1.12	(1.72)	'	(1.72)	'	100%	Nigeria
Not Applicable	Ydf	0.62	91.53	31.93	139.48	16.02	·	' 	237.82	(9.24)	(2.62)	(6.62)	'	100%	Japan
Aurovida Farmaceutica SA DE CV14 Not Applicable	MXN	3.56	540.01	(128.58)	848.38	436.95			126.73	0.83		0.83			Mexico
Not Applicable	Cpeso	0.02	36.95	107.66	349.12	204.51	1		522.87	140.43	54.31	86.12	1	100%	Colombia
Not Applicable	ZAR	5.58	' 		' 		• 	'	'	'	'	'		100%	South Africa
Not Applicable	SAR	17.26	172.63	(21.85)	160.30	9.52				(21.85)		(21.85)	•	100%	Soudi Arabia
Aurovitas Pharma (Taizhou) Ltd ^{9 & 14} Not Applicable	RMB	10.38	ľ	'	·		'	'	'	'	'	'		100%	China
Not Applicable		65.18	4,019.67	5,184.16	21,763.44	16,701.48	4,141.87	'	39,619.74	2,034.87	516.87	1,518.00		100%	USA
Not Applicable	NSD	65.18	3,975.68	6,252.33	11,179.70	951.69	'	'	10,389.97	1,662.53	533.55	1,128.98	' 	100%	USA
Not Applicable	NSD	65.18	13.04	924.91	3,937.81	2,999.86		'	10,686.49	318.34	81.03	237.31	•	100%	USA
Not Applicable	USD	65.18	0.64	(562.31)	1,707.90	2,269.57			1,403.40	197.36	50.26	147.10		100%	NSA
December 4, 2014	USD	65.18	32.59	2,606.45	7,944.26	5,305.22		•	7,831.26	848.34	212.46	635.88		100%	USA
Not Applicable	nsD	65.18									•			100%	USA
Not Applicable	USD	65.18	6.52	•	7,662.39	7,655.87		.		'	•	•		100%	NSA
Not Applicable	NSD	65.18	32.59	(6.37)	261.39	235.17	'	' 		(4.25)		(4.25)	'	100%	USA
Not Applicable	nsp	65.18	32.59	0.01	112.34	79.74	'	'		0.01	' 	0.01	'	100%	USA
Not Applicable	NSD	65.18	32.59	•	32.59		'	'	'	'	'	'	'	100%	USA
Not Applicable	INB	1.00	122.60	(3.06)	119.55	0.01	·	' 		(0.03)	' 	(0.03)	'	100%	India
i	INB	1.00	1,821.50	(544.01)	1,571.57	294.08		•	18.31	\sim	'	(273.74)	1		India
Auronext Pharma Private Limited Not Applicable	RN	1.00	1,249.84	(861.57)	2,543.04	2,441.92	287.15	'	1,462.56	(34.79)	,	(34.79)		100%	India

SI. Name of the subsidiary No.	The date since when subsidiary was acquired	Reporting currency	Exchange rate as on March 31, 2018	Share capital	Reserves & surplus	Total Assets	Total Liabilities	Invest- ments in Subsi- diaries	Invest- ments other than Subsi-	Turnover	Profit / (Loss) before taxation	Provision for taxation	Profit / (Loss) after taxation	Proposed Dividend	% of share- holding	Country
Auro Peptides Ltd	Not Applicable	INB	1.00	1.00	(243.79)	857.81	1,100.60	'	olaries -	141.39	(165.52)	(24.70)	(140.82)	'	95%	India
54 Curepro parenterals Ltd	Not Applicable	IN	1.00	133.10	1,857.96	2.05	0.01	'	1,989.02	1	(0.04)		(0.04)	'	100%	India
Hyacinths Pharma Pvt. Ltd	October 1, 2013	INR	1.00	149.50	(1.76)	194.08	46.34		•	1	(90:0)		(90:0)	·	100%	India
Silicon Life Sciences Pvt. Ltd.	October 11, 2013	INR	1.00	448.68	(343.40)	1,344.05	1,238.77	'	'	679.47	(5.52)	ľ	(5.52)	'	100%	India
57 AuroZymes Limited	Not Applicable	IN	1.00	0:20	(0.86)	88.13	88.49	'	'	'	(0:05)	'	(0:05)	'	100%	India
Auro Pharma India Private Limited ¹³	Not Applicable	IN IN	1.00	1.00	(0.02)	1:00	0.02				(0.02)		(0.02)		100%	India
Aurobindo ILAC Sanayi ve Ticaret Aurovitas Pharma Ceska Republic Generis Farmaceutica S.A acquire Mer Medicamentos, Lda acquirec Generis Phar, Unipessoal Lda acc Farma APS - Promocao de Medi	Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi liquidated w.e.f. October 31, 2017, results given are upto the date of liquidation. Aurovitas Pharma ceska Republica s.r.o incorporated on December 23, 2017, results given are from the date of incorporation. Generis Farmaceutica S.A acquired on May 1, 2017, results given are from the date of acquisition. Mer Medicamentos, Lda acquired on May 1, 2017, results given are from the date of acquisition. Generis Phar, Unipessoal Lda acquired on May 1, 2017, results given are from the date of acquisition. Farma APS - Promoco de Medicamentos, Unipessoal Lda., acquired on May 1, 2017 and closed w.e.f. January 25, 2018, results given are from the date of	a s.r.o in d on May on May inred on	ed Sirketi liquidated w.e.f. October 31, 2017, results given are upto the date of liquidatic incorporated on December 23, 2017, results given are from the date of incorporation. May 1, 2017, results given are from the date of acquisition. ay 1, 2017, results given are from the date of acquisition. on May 1, 2017, results given are from the date of acquisition. it was a soluted on the date of acquisition.	idated v d on De results gi esults gi oal Lda.	.e.f. Octu cember 2 given are ven are fi tts given , acquire	bber 31, 3, 2017 from the om the (are from	, results , , results ,) date of a late of a the date (1, 201)	sults gi given a acquis cquisiti of acc 7 and c	ven are re from t ition. on. luisition.	upto th∉ he date e.f. Jani	e date o of inco any 25	. f liquida rporatio , 2018,	rtion.	jiven art	from .	the date
Generis MZ, Lda. Aurobindo Pharm Aurovitas Pharma Aurobindo Pharm	Generis MZ, Lda., acquired on May 1, 2017 and closed w.e.f. March 19, 2018, results given are from the date of acquisition to the date of closure Aurobindo Pharma Saudi Arabia Limited Company incorporated on May 8, 2017, results given are from the date of incorporation. Aurovitas Pharma (Taizhou) Ltd incorporated on January 29, 2018. Aurobindo Pharma USA LLC closed w.e.f. March 31, 2018.	/ 1, 201 mited Co corporate	017 and closed w.e.f. March 19, 2018, results given are from the date of acquisition to th Company incorporated on May 8, 2017, results given are from the date of incorporation. ated on January 29, 2018. .f. March 31, 2018.	sed w.e. ncorpor: uary 29, 2018.	. March ted on N 2018.	19, 2016 ay 8, 20	3, results 17, resul	given <i>i</i> Its giver	are from are fror	the date n the di	e of acq ate of in	uisition Icorpore	to the d tion.	late of c	losure.	
AuroLogistics LL(AuroLogistics LLC incorporated on April	April 26	28, 2017, results given are from the date of incorporation.	sults giv	en are fr	om the c	late of in	corpore	ation.							
Acrotech Biophar Auro Pharma Indi. The financial year	Acrotech Biopharma LLC incorporated on January 5, 2018, results given are from the date of incorporation. Auro Pharma India Private Limited incorporated on December 20, 2017, results given are from the date of incorporation. The financial year of these companies end on December 31. However, the results given are as of March 31, 2018.	ated on incorpor ies end	on January 5, 2018, results given are from the date of incorporation. borated on December 20, 2017, results given are from the date of incorpo nd on December 31. However, the results given are as of March 31, 2018.	, 2018,)ecemb(1ber 31.	esults gi r 20, 20 ⁻ Howevei	/en are f 7, result ; the res	rom the s given ; ults giver	date of are from 1 are as	incorpo. the dat of Marc	ation. e of inc h 31, 2	orporati 018.	on.				

Company Overview

Statutory Reports

Financial Statements

Part "B": Associates and Joint Ventures

Name of Joint Venture Eugia Pharma Tergene Biotech Raidurgam Novagen Pharma (Pty) Ltd Specialities Ltd Pvt.Ltd **Developers** Limited (Formerly Aurobindo Antibiotics Limited)* March 31, 2018 March 31, 2018 March 31, 2018 March 31, 2018 Latest audited Balance Sheet Date 1. 2. Shares of Joint Venture held by the company on the year end 927,237 7,500,000 4,000,000 No. 198,901,611 Amount of Investment in Joint Venture 92.03 1,989.02 75.00 40.00 Extent of Holding % 50.00% 76.84% 40.00% 67.82% 3. Description of how there is significant influence Joint Venture Joint Venture Joint Venture Joint Venture 4. Reason why the associate/joint venture is not consolidated Not applicable Not applicable Not applicable Not applicable 281.71 1,966.16 5. Networth attributable to Shareholding as per latest audited (51.62) 35.38 Balance Sheet 6. Profit for the year 169.18 (9.17)(56.06)(3.28) Considered in Consolidation 84.59 (6.22)(43.08) (1.31)i. ii. Not Considered in Consolidation 84.59 (2.95)(12.98)(1.97)

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures (All amounts are in Indian Rupees million except share data and otherwise stated.

* Raidurgam Developers Limited (formerly Aurobindo Antibiotics Limited) ceased to be a subsidiary of the Company with effect from November 30, 2017, resulting in shareholding of 40% w.e.f November 30, 2017.

For and on behalf of the Board of Directors of Aurobindo Pharma Limited

N. Govindarajan Managing Director DIN-00050482

Santhanam Subramanian

Chief Financial Officer

Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No. 13709

Place: Hyderabad Date: 28 May 2018

Financial Statements

ANNEXURE-2

Form No. AOC-2

Particulars of Contracts/Arrangements entered into by the Company with the related parties

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014) (Referred to in sub-section(1) of Section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto)

- Details of contracts or arrangements or transactions not at arm's length basis All contracts / arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 are at arm's length basis
- 2. Details of material contracts or arrangement or transactions at arm's length basis

						(₹ In Millions)
SI. No.	Name of the related party	Nature of relationship	Nature of contracts / arrangements / transactions	Duration of the Contracts / arrangements / transactions	Salient terms of the contracts or arrangemetns or transactions including the value, if any	Amount
1	Aurobindo Pharma USA Inc., USA	Wholly owned subsidiary	Sale of Goods & Services	on going	Based on transfer pricing guidelines	27,182.9
			Purchase of Goods	on going	Based on transfer pricing guidelines	0.1

Appropriate approvals have been taken for related party transactions. No amount was paid as advance.

Place: Hyderabad Date: 28 May 2018 K. Ragunathan Chairman DIN: 00523576

ANNEXURE-3

Form No. MGT-9 EXTRACT OF ANNUAL RETURN

For the financial year ended on March 31, 2018

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i	CIN	L24239TG1986PLC015190
ii	Registration Date	26th December, 1986
iii	Name of the Company	AUROBINDO PHARMA LIMITED
iv	Category / Sub-Category of the Company	Company having share capital
V	Address of the Registered Office and	Plot No.2, Maitrivihar, Ameerpet, Hyderabad 500 038, Telangana, India
	contact details	Phone:+91 40 23736370
		Fax: +91 40 23743740
		Email: info@aurobindo.com
vi	Whether listed company Yes/No	Yes. Listed on BSE Ltd and National Stock Exchange of India Ltd.
vii	Name, Address and Contact details of	Karvy Computershare Private Limited
	Registrar and Transfer Agent, if any	Unit: Aurobindo Pharma Limited
		Karvy Selenium, Tower B, Plot No.31-32, Gachihowli, Financial District,
		Nanakramguda, Hyderabad – 500032
		Tel : 040-6716 2222
		Fax: 040-2300 1153
		E-mail: einward.ris@karvy.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated

SI. No.	Name and Description of main products / services	NIC Code of the product/service	% to total turnover of the company
1	Manufacturing generic pharmaceuticals and active pharmaceutical ingredients.	21001/21002	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

SI. No.	Name & Address of the Company	CIN/GIN	Holding / Subsidiary / Associate	% of Shares held	Applicable section
1	APL Pharma Thai Limited, 438, Soi Phattanakaran, 30 Phattanakaran, Road, Khweang Suanluang, Khet Suanluang, Bangkok –10250	Foreign Company	Subsidiary	97.92	2(87)
2	All Pharma (Shanghai) Trading Corp Ltd, Room 3304, No.8 Xingly Rd., Shanghai, P.R. China	Foreign Company	Subsidiary	100	2(87)
3	Aurobindo Pharma Industria Farmaceutica Ltda, VP –06-E Qd. 09 Mod 12 a 15, Daia Anapolis, Goias State, Brazil	Foreign Company	Subsidiary	99.97	2(87)
4	Aurobindo Pharma Produtos Farmaceuticos Ltda, 2 Andar Sala 205, Centro, Anapolis, Goias State. Brazil	Foreign Company	Subsidiary	100	2(87)
5	Aurobindo Pharma Japan KK, 9th Floor, Youth Building, 1-3-8 Nihonbashibakuro-cho, Cho-ku, 103- 0002, Tokyo Japan	Foreign Company	Subsidiary	100	2(87)

SI. No.	Name & Address of the Company	CIN/GIN	Holding / Subsidiary / Associate	% of Shares held	Applicable section
6	Aurohealthcare (Nigeria) Limited, 59, Osoloway, 2nd floor, Flat NO.2, Isolo,	Foreign Company	Subsidiary	100	2(87)
7	Lagos, Nigeria Auro Pharma Inc 3700 Steeles Ave. W. Suite # 402,Woodbridge, ON L4L 8K8, Canada	Foreign Company	Subsidiary	100	2(87)
8	Aurobindo Pharma (Pty) Ltd, 53 Phillip Engelbrecht Avenue, Woodhill Office Park, Building No 1,Meyersdal ext 12,1448, Johannesburg, South Africa	Foreign Company	Subsidiary	100	2(87)
9	Novagen Pharma Pty Ltd, 100, Sovereign Drive, Route 21, Corporate Park, Nellmapius Road, Irene, Pretoria, South Africa	Foreign Company	Joint Venture	50	2(6)
10	Aurovida Farmaceutica Sa De Cv, Av. Insurgentes sur no. 813, Col. Nápoles, Del. Benito Juárez, C.P. 03810, Ciudad de México	Foreign Company	Subsidiary	100	2(87)
11	Aurobindo Pharma Colombia Sas, Calle 100 N 17A-36 Oficina 1003 Bogota Colombia	Foreign Company	Subsidiary	100	2(87)
12	Aurogen South Africa (Pty) Ltd., 53 Phillip Engelbrecht Avenue, Woodhill Office Park, Building No 1,Meyersdal ext 12,1448, Johannesburg,	Foreign Company	Subsidiary	100	2(87)
13	Aurobindo Pharma Saudi Arabia Ltd Co Plot No. 1C 18, The Industrial Vally, Phase 1. King Abdullah Economic City, Kingdom of Arabia	Foreign Company	Subsidiary	100	2(87)
14	Aurovitas Pharma (Taizhou) Ltd Rm. 9044, Technology Building, No. 1 Yaocheng Rd.(South of Yaocheng Rd., east of Koutai Rd.), Taizhou City	Foreign Company	Subsidiary	100	2(87)
15	Aurobindo Pharma USA Inc. 279 Princeton Hightstown Road, East Windsor, NJ 08520	Foreign Company	Subsidiary	100	2(87)
16	Aurolife Pharma LLC 2400 Route 130 N, Dayton, NJ 08810, USA	Foreign Company	Subsidiary	100	2(87)
17	Auromedics Pharma LLC 279 Princeton Hightstown Road, East Windsor, NJ 08520	Foreign Company	Subsidiary	100	2(87)
18	Auro Health LLC 2572 Brunswick Pike, Lawrenceville, NJ 08648, USA	Foreign Company	Subsidiary	100	2(87)
19	Natrol LLC 21411 Prairie Street, Chatsworth, CA 91311, USA	Foreign Company	Subsidiary	100	2(87)
20	Auro AR LLC 6 Wheeling Road, Dayton, NJ 08810	Foreign Company	Subsidiary	100	2(87)
21	Aurobindo Pharma USA LLC 279 Princeton Hightstown Road, East Windsor, NJ 08520 (Liquidated w.e.f. 31.03.2018)	Foreign Company	Subsidiary	100	2(87)

SI. No.	Name & Address of the Company	CIN/GIN	Holding / Subsidiary / Associate	% of Shares held	Applicable section
22	Auro Vaccines LLC 279 Princeton Hightstown Road, East	Foreign Company	Subsidiary	100	2(87)
23	Windsor, NJ 08520 AuroLogistics LLC 279 Princeton Hightstown Road, East Windsor, NJ 08520	Foreign Company	Subsidiary	100	2(87)
24	Acrotech Biopharma LLC 279 Princeton Hightstown Road, East Windsor, NJ 08520	Foreign Company	Subsidiary	100	2(87)
25	Helix Healthcare B.V. PrinsBernhardplein 200 ,1097 JB Amsterdam, Post Bag No. 990 1000 AZ, The Netherlands	Foreign Company	Subsidiary	100	2(87)
26	Agile Pharma B.V. PrinsBernhardplein 200 ,1097 JB Amsterdam, Post Bag No. 990 1000 AZ, The Netherlands	Foreign Company	Subsidiary	100	2(87)
27	Laboratorios Aurobindo S.L.U Avda. De Burgos, 16D, 5 degPlanta - EdificioEuromor, 28036, Madrid, Spain	Foreign Company	Subsidiary	100	2(87)
28	Pharmacin B.V. Molenvliet103, 3335 LH Zwinindrecht, The Netherlands.	Foreign Company	Subsidiary	100	2(87)
29	Milpharm Limited Ares Block, Odyssey Business Park, South Ruislip, Middlesex, London, UK	Foreign Company	Subsidiary	100	2(87)
30	Aurobindo Pharma (Malta) Ltd Vault-14, Level-2, Valletta Waterfront, Floriana, Malta	Foreign Company	Subsidiary	100	2(87)
31	APL Swift Services (Malta) Ltd Vault-14, Level-2, Valletta Waterfront, Floriana, Malta	Foreign Company	Subsidiary	100	2(87)
32	Aurobindo Pharma GmbH, Germany Willy-Brandt-Allee 2, 81829 Munchen, Germany	Foreign Company	Subsidiary	100	2(87)
33	Aurobindo Pharma B.V. Baarnschedijk 1, 3741 LN Bsaaarn, The Netherlands.	Foreign Company	Subsidiary	100	2(87)
34	Aurobindo Pharma (Romania) s.r.l BucurestiSectorul 1, Soseaua, Bucuresti - Ploiesti, Nr 42-44, Complex, Baneasa Business & technology Park, Cladirea B, ARIPA B2, Etaj 2, Romania	Foreign Company	Subsidiary	100	2(87)
35	Aurobindo Pharma (Portugal) Unipessoal Limitada Av. do Forte, n.° 3, ParqueSuécia,Ed. IV, 2°, 2794-038 Carnaxide, Portugal (Merged with Generis Farmaceuita SA effective 1st April, 2018)	Foreign Company	Subsidiary	100	2(87)
36	Aurex B.V. Baarnsche dijk 1 3741 LN Baarn,The Netherlands	Foreign Company	Subsidiary	100	2(87)
37	Aurobindo Pharma (Italia) S.r.I Via San Giuseppe, 102, 20147 Saronno (Varese) Italy.	Foreign Company	Subsidiary	100	2(87)

SI. No.	Name & Address of the Company	CIN/GIN	Holding / Subsidiary / Associate	% of Shares held	Applicable section
38	Aurovitas, Unipessoal LDA	Foreign Company	Subsidiary	100	2(87)
	Do Forte, No 3, ParqueSuecia, Edificio,	0 1 3	5		()
	IV, 20 Carnaxide, Lisboa, Concelho,				
	Carnaxide, Portugal				
	(Merged with Generis Farmaceuita SA				
	effective 1st April, 2018)				
39	Arrow Generiques SAS	Foreign Company	Subsidiary	100	2(87)
00	26 avenue Tony Garnier 69007	i eleigit eenipaily	e ale eraital y	100	=(01)
	Lyon - France				
40	Aurobindo Ilac Sanayi Ve Ticaret Limited	Foreign Company	Subsidiary	100	2(87)
	Sirketi	i eleigit eenipaily	e ale eraital y	100	=(01)
	EGitim Mh.Poyraz Sk. Sadikoglu Plaza				
	5, No.27, Kadikoy, Istanbul, Turkey				
	(Liquidated on 31st October, 2017)				
41	1980 Puren Pharma GmbH	Foreign Company	Subsidiary	100	2(87)
41	Willy-Brandt-Allee 2; D-81829 München,	r oreigir oompany	Subsidially	100	2(07)
	Germany				
42	Puren Pharma GmbH & Co. KG	Foreign Company	Subsidiary	100	2(87)
42		Foreign Company	Subsidially	100	2(07)
	Willy-Brandt-Allee 2; D-81829 München,				
40	Germany				0/07)
43	Aurovitas Spain SA	Foreign Company	Subsidiary	100	2(87)
	Avda. De Burgos, 16D, 5 degPlanta -				
4.4	EdificioEuromor, 28036, Madrid, Spain	Familie Oamera		100	0(07)
44	Aurovitas Pharma Polska Spółka	Foreign Company	Subsidiary	100	2(87)
	ul. SOKRATESA, nr 13D, lok. 27, miejsc.				
	WARSZAWA, kod 01-909, poczta				
45	WARSZAWA, kraj POLSKA				
45	Generis Farmacêutica SA	Foreign Company	Subsidiary	100	2(87)
	Rua Joao De Deus, No19, 2700-487				
-10	Amadora, LISBON, Portugal				
46	Mer Medicamentos, Lda	Foreign Company	Subsidiary	100	2(87)
	Rua Joao De Deus, No19, 2700-487				
	Amadora, LISBON, Portugal.				
	(Merged with Generis Farmaceuita SA				
	effective 1st April, 2018)				
47	Generis Phar, Unipessoal Ltd.	Foreign Company	Subsidiary	100	2(87)
	WOS - 100%				
	Rua Joao De Deus, No19, 2700-487				
	Amadora, LISBON, Portugal				
48	Aurovitas Pharma Ceska Republica s.r.o	Foreign Company	Subsidiary	100	2(87)
	Branická 213/53, Braník, 147 00 Praha 4,				
	Prague, Czech Republic 14700				
49	Farma APS	Foreign Company	Subsidiary	100	2(87)
	Rua Jaao de Deus,				
	No. 19, 2700-487, Amadora				
	Lisbon, Portugal				
	(Liquidated w.e.f 25.01.2018)				
50	Generis Mozambique	Foreign Company	Subsidiary	100	2(87)
00	Rua Jaao de Deus,	i ereigit e empany	Caboratary	100	=(01)
	No. 19, 2700-487, Amadora				
	Lisbon, Portugal				
51	(Liquidated w.e.f 19.03.2018) APL Research Centre Limited	U24116TG2006PLC051171	Subsidiary	100	2(87)
01		0241101G2000PL00011/1	Subsidially	100	2(01)
	Plot No.2, Maithri Vihar, Ameerpet,				
50	Hyderabad - 500 038		<u> </u>	100	0/07)
52	APL Healthcare Limited	U24239TG2006PLC052053	Subsidiary	100	2(87)
	Plot No.2, Maithri Vihar, Ameerpet,				
	Hyderabad 500038				

SI. No.	Name & Address of the Company	CIN/GIN	Holding / Subsidiary / Associate	% of Shares held	Applicable section
53	Auronext Pharma Private Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500038	U74999DL2009PTC191842	Subsidiary	100	2(87)
54	Auro Peptides Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24232TG2012PLC078350	Subsidiary	95	2(87)
55	Raidurgam Developers Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U45100TG2012PLC081892	Joint Venture	40	2(6)
56	Curepro Parenterals Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24232TG2013PLC087101	Subsidiary	100	2(87)
57	Eugia Pharma Specialities Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24297TG2013PLC087048	Subsidiary	67.82	2(87)
58	Hyacinths Pharma Private Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24232TG2010PTC069638	Subsidiary	100	2(87)
59	Silicon Life Sciences Private Limited. Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U85100TG2008PTC057669	Subsidiary	100	2(87)
60	AuroZymes Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24232TG2013PLC091383	Subsidiary	100	2(87)
61	Tergene Biotech Private Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24230TG2008PTC113178	Subsidiary	67.82	2(87)
62	Auro Pharma India Private Limited Plot No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038	U24298TG2017PTC121342	Subsidiary	100	2(87)

IV. SHAREHOLDING PATTERN (EQUITY SHARE CAPITAL BREAKUP AS PERCENTAGE OF TOTAL EQUITY) i) Category-wise Shareholding

gory Code (I) (II) (A) PR (I) Ind (I) Ind (I) Ind (b) Ce (G) Go (C) Bo (C) Fin (I) Ind (I) Su (I) Ins (I) Qu (I) Qu (I) Ins (a) Mu (b) Fou (I) Ins (a) Mu (b) Fin	Attegory of Shareholder ROMOTER AND ROMOTER GROUP dian dividual /HUF entral Government/State overnment(s) odies Corporate nancial Institutions / Banks thers bub-Total A(1) : oreign dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING Istitutions utual Funds /UTI nancial Institutions /Banks entral Government / State		of the year 3 Physical (IV) (IV) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	at the beginni 1/03/2017 Total (V) 72,164,968 0 213,760,966 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 0 18,000,000 303,925,934	% of Total Shares (VI) 12.32 0.00 36.49 0.00 48.80 3.07 0.00 0.00 0.00 3.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	Demat (VII) 72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 0 0 0 0 18,000,000 303,925,934	of the year 3 Physical (VIII) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	eld at the end 31/03/2018 Total (IX) 72,164,968 0 213,760,966 0 213,760,966 0 285,925,934 18,000,000 0 0 0 0 18,000,000 303,925,934	% of Total Shares (X) 12.32 0.00 36.48 0.00 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 0.00 51.87	% Change during the year (XI) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.
(I) (II) (A) PR PR (1) Inc (a) Ind (b) Ce Go (c) Bo (c) Bo (d) Fin (e) Ott SL (2) Fo (a) Ind (b) Bo (c) Ins (d) Qu (e) Ott Su (f) PU (f) Ins (a) Mu (b) Fin (c) Ce	ROMOTER AND ROMOTER GROUP dian dividual /HUF entral Government/State overnment(s) oodies Corporate nancial Institutions / Banks thers bub-Total A(1) : breign dividuals (NRIs/Foreign dividuals (NRIs/Foreign dividuals) oodies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : btal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	(III) 72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 0 0 18,000,000 303,925,934 70,950,268	(M) 0 0 0 0 0 0 0 0 0 0 0 0 0	(V) 72,164,968 0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	Shares (VI) 12.32 0.00 36.49 0.00 36.49 0.00 3.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	(VII) 72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 18,000,000	(VIII) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(IX) 72,164,968 0 213,760,966 0 285,925,934 18,000,000 0 0 0 0 18,000,000	Shares (X) 12.32 0.00 36.48 0.00 36.48 0.00 3.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	the year (XI) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.
(A) PR (1) Inc (a) Ind (b) Ce (c) Bo (d) Fin (e) Ott (d) Fin (e) Ott (d) Foi (a) Ind (b) Bo (c) Ins (d) Qu (e) Ott Su Tot (f) PU (a) Mu (b) Fin	ROMOTER AND ROMOTER GROUP dian dividual /HUF entral Government/State overnment(s) oodies Corporate nancial Institutions / Banks thers bub-Total A(1) : breign dividuals (NRIs/Foreign dividuals (NRIs/Foreign dividuals) oodies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : btal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 0 0 0 18,000,000 303,925,934 70,950,268		72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 18,000,000	12.32 0.00 36.49 0.00 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 0.00 3.07	72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	72,164,968 0 213,760,966 0 0 285,925,934 18,000,000 0 0 0 18,000,000	12.32 0.00 36.48 0.00 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
PR (1) Inc (a) Ind (b) Ce Go Go (c) Bo (d) Fin (e) Ott (a) Ind (b) Boo (c) Ins (d) Qu (e) Ott Su Tot (B) PU (a) Mu (b) Fin (c) Ce	ROMOTER GROUP dian dividual /HUF entral Government/State overnment(s) odies Corporate nancial Institutions / Banks thers bub-Total A(1) : breign dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers bub-Total A(2) : btal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 285,925,934 18,000,000 0 0 18,000,000	0.00 36.49 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 3.07	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 2 85,925,934 18,000,000 0 0 18,000,000	0.00 36.48 0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
(a) Ind (b) Ce Go (c) Bo (d) Fin (e) Ott (2) Fo (a) Ind (b) Bo (c) Ins (d) Qu (e) Ott (b) PU (f) Ins (a) Mu (b) Fin (c) Ce	dividual /HUF entral Government/State overnment(s) odies Corporate nancial Institutions / Banks thers isub-Total A(1) : ororeign dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 285,925,934 18,000,000 0 0 18,000,000	0.00 36.49 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 3.07	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 2 85,925,934 18,000,000 0 0 18,000,000	0.00 36.48 0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
(b) Ce Go Go (c) Bo (d) Fin (e) Ott (2) Foo (a) Ind (b) Bo (c) Ins (d) Qu (e) Ott Su Tot (B) PU (a) Ins (a) Mu (b) Fin	entral Government/State overnment(s) odies Corporate nancial Institutions / Banks thers sub-Total A(1) : poreign dividuals (NRIs/Foreign dividuals) podies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : potal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 285,925,934 18,000,000 0 0 18,000,000	0.00 36.49 0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 3.07	0 213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0 0 0 0	0 213,760,966 0 2 85,925,934 18,000,000 0 0 18,000,000	0.00 36.48 0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Go (c) Bo (d) Fin (e) Ott (2) For (a) Ind (b) Bo (c) Ins (d) Quu (e) Ott (d) Quu (e) Ott (f) PUU (1) Ins (a) Muu (b) Fin (c) Ce	overnment(s) podies Corporate nancial Institutions / Banks thers sub-Total A(1) : poreign dividuals (NRIs/Foreign dividuals) podies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : potal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0 0 0 0	213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	36.49 0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000		213,760,966 0 285,925,934 18,000,000 0 0 0 18,000,000	36.48 0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
(d) Fin (e) Ott SL (2) Foo (a) Ind (b) Boo (c) Ins (d) Qu (e) Ott (c) Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	nancial Institutions / Banks thers iub-Total A(1) : preign dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : ptal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 0 285,925,934 18,000,000 0 0 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 285,925,934 18,000,000 0 0 0 18,000,000	0.00 0.00 48.80 0.00 0.00 0.00 0.00 0.00	0 0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0	0 0 285,925,934 18,000,000 0 0 0 18,000,000	0.00 0.00 48.80 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
(e) Ott SL (2) Foi (a) Ind (b) Bo (c) Ins (d) Qu (e) Ott Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	thers thers thers there dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : total A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 285,925,934 18,000,000 0 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0 0 0	0 285,925,934 18,000,000 0 0 18,000,000	0.00 48.80 3.07 0.00 0.00 0.00 0.00 3.07	0 285,925,934 18,000,000 0 0 0 18,000,000	0 0 0 0 0 0 0 0 0 0 0	0 285,925,934 18,000,000 0 0 18,000,000	0.00 48.80 3.07 0.00 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
St St (2) For (a) Ind (b) Boo (c) Ins (d) Qu (e) Ott Tot Tot (a) Mu (b) Fin (c) Fin	iub-Total A(1) : preign dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	285,925,934 18,000,000 0 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0 0	285,925,934 18,000,000 0 0 0 18,000,000	48.80 3.07 0.00 0.00 0.00 0.00 3.07	285,925,934 18,000,000 0 0 0 0 18,000,000	0 0 0 0 0 0 0 0	285,925,934 18,000,000 0 0 0 18,000,000	48.80 3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
(2) Formula (a) Indiana (b) Boo (c) Ins (d) Qu (e) Ott Tot Tot (a) Mu (b) Fin (c) Central	dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	18,000,000 0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0 0 0 0	18,000,000 0 0 0 18,000,000	3.07 0.00 0.00 0.00 0.00 3.07	18,000,000 0 0 0 18,000,000	0 0 0 0 0 0	18,000,000 0 0 0 18,000,000	3.07 0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00 0.00 0.00
(a) Ind (b) Bo (c) Ins (d) Qu (e) Ott Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	dividuals (NRIs/Foreign dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : total A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 0.00 3.07	0 0 0 18,000,000	0 0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00
Ind (b) Boo (c) Ins (d) Qu (e) Ott Tot Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	dividuals) odies Corporate stitutions ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	0 0 18,000,000 303,925,934 70,950,268	0 0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 0.00 3.07	0 0 0 18,000,000	0 0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00 0.00
(c) Ins (d) Qu (e) Oth Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Cei	stitutions ualified Foreign Investor thers ub-Total A(2) : total A=A(1)+A(2) UBLIC SHAREHOLDING ustitutions utual Funds /UTI nancial Institutions /Banks	0 0 18,000,000 303,925,934 70,950,268	0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 3.07	0 0 0 18,000,000	0 0 0 0	0 0 0 18,000,000	0.00 0.00 0.00 3.07	0.00 0.00 0.00 0.00
(d) Qu (e) Oth Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	ualified Foreign Investor thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING Istitutions utual Funds /UTI nancial Institutions /Banks	0 0 18,000,000 303,925,934 70,950,268	0 0 0 0	0 0 18,000,000	0.00 0.00 3.07	0 0 18,000,000	0 0 0	0 0 18,000,000	0.00 0.00 3.07	0.00 0.00 0.00
(e) Oth Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Ce	thers ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING Istitutions utual Funds /UTI nancial Institutions /Banks	0 18,000,000 303,925,934 70,950,268	0	0 18,000,000	0.00 3.07	0 18,000,000	0	0 18,000,000	0.00 3.07	0.00 0.00
Su Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Cent	ub-Total A(2) : otal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	18,000,000 303,925,934 70,950,268	0	18,000,000	3.07	18,000,000	0	18,000,000	3.07	0.00
Tot (B) PU (1) Ins (a) Mu (b) Fin (c) Cent	btal A=A(1)+A(2) UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	303,925,934 70,950,268	0					, ,		
(B) PU (1) Ins (a) Mu (b) Fin (c) Cent	UBLIC SHAREHOLDING stitutions utual Funds /UTI nancial Institutions /Banks	70,950,268		303,925,934	51.87	303,925,934	0	303,925,934	51.87	
(1) Ins (a) Mu (b) Fin (c) Ce	stitutions utual Funds /UTI nancial Institutions /Banks		0			· · · · · · · · · · · · · · · · · · ·				0.00
(a) Mu (b) Fin (c) Ce	utual Funds /UTI nancial Institutions /Banks		0							
(b) Fin (c) Ce	nancial Institutions /Banks		0							
(c) Ce		2,326.571		70,950,268	12.11	88,223,316	0	88,223,316	15.06	2.95
(c) Ce	entral Government / State		0	2,326,571	0.40	1,542,088	0	1,542,088	0.26	-0.13
GO	overnment(s)	0	0	0	0.00	0	0	0	0.00	0.00
(d) Ver	enture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
(e) Ins	surance Companies	1,456,754	0	1,456,754	0.25	1,819,681	0	1,819,681	0.31	0.06
(f) For	preign Institutional Investors	122,986,244	0	122,986,244	20.99	105,430,838	0	105,430,838	17.99	-3.00
(g) For	oreign Venture Capital vestors	0	0	0	0.00	0	0	0	0.00	0.00
(h) Qu	ualified Foreign Investor	0	0	0	0.00	0	0	0	0.00	0.00
(i) Oth	thers	0	0	0	0.00	0	0	0	0.00	0.00
Su	ub-Total B(1) :	197,719,837	0	197,719,837	33.75	197,015,923	0	197,015,923	33.63	-0.12
(2) No	on-Institutions									
	odies Corporate	18,959,315	98,910	19,058,225	3.25	16,663,996	55,530	16,719,526	2.85	-0.40
	dividuals									
(i) li	Individuals holding nominal share capital upto ₹1 lakh	39,324,003	2,468,067	41,792,070	7.13	42,959,387	1,817,997	44,777,384	7.64	0.51
	Individuals holding nominal share capital in excess of ₹1 lakh	15,298,636	0	15,298,636	2.61	15,886,710	0	15,886,710	2.71	0.10
	thers									
Cle	learing Members	2,927,903	0	2,927,903	0.50	1,128,877	0	1,128,877	0.19	-0.31
	EPF	0	0	0	0.00	564,473	0	564,473	0.10	0.10
	on Resident Indians	1,958,718	15,000	1,973,718	0.34	2,446,676	8,000	2,454,676	0.42	0.08
	RI Non-Repatriation	483,964	0	483,964	0.08	1,015,358	0	1,015,358	0.17	0.09
	usts	2,702,122	0	2,702,122	0.46	2,418,748	0	2,418,748	0.41	-0.05
	ualified Foreign Investor	0	0	0	0.00	0	0	0	0.00	0.00
	ub-Total B(2) :	81,654,661	2,581,977	84,236,638	14.38	83,084,225	1,881,527	84,965,752	14.50	0.00
	otal B=B(1)+B(2) :	279,374,498	2,581,977	281,956,475	48.13	280,100,148	1,881,527	281,981,675	48.13	0.00
	otal (A+B) :	583,300,432	2,581,977	585,882,409	100.00	584,026,082	1,881,527	585,907,609	100.00	0.00
(C) Sha	nares held by custodians, gainst which		2,301,911	303,002,409	100.00	304,020,002	1,001,021	303,907,009	100.00	0.00
De	epository Receipts have									
	romoter and Promoter Group	0	0	0	0.00	0	0	0	0.00	0.00
	ublic	0	0	0	0.00	0	0	0	0.00	0.00
	RAND TOTAL (A+B+C) :	583,300,432	2,581,977	585,882,409	100.00	584,026,082	1,881,527		100.00	

(ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding	g at the beginning	g of the year	Sharehold	ling at the end of	the year	% change
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	in share holding during the year
1	Mr. P.V. Ramprasad Reddy	18,000,000	3.07	0.00	18,000,000	3.07	0.00	0.00
2	Mrs. K. Kirthi Reddy	20,700,000	3.53	0.00	20,700,000	3.53	0.00	0.00
3	Mr. K. Nithyananda Reddy	25,359,572	4.33	0.00	25,359,572	4.33	0.41	0.00
4	Mrs. K. Rajeswari	1,975,500	0.34	0.03	1,975,500	0.34	0.03	0.00
5	Trident Chemphar Limited*	867,226	0.15	0.00	300,000	0.05	0.00	-0.10
6	Mrs. Kambam Spoorthi	7,600,000	1.30	0.26	7,600,000	1.30	0.26	0.00
7	Dr. M. Sivakumaran	14,491,360	2.47	0.00	14,491,360	2.47	0.00	0.00
8	Mrs.P.Neha Reddy	1,30,000	0.02	0.00	1,30,000	0.02	0.00	0.00
9	Axis Clinicals Ltd.	658,000	0.11	0.11	658,000	0.11	0.11	0.00
10	Mr. K. Prasad Reddy	3,01,156	0.05	0.05	3,01,156	0.05	0.03	0.00
11	Mr. M Sumanth Kumar Reddy	1,600,000	0.27	0.20	1,600,000	0.27	0.20	0.00
12	Mr.K.Suryaprakash Reddy	7,380	0.00	0.00	7,380	0.00	0.00	0.00
13	RPR Advisors Private Limited, Mrs.P.Suneela Rani (Jointly holding)	196,376,250	33.52	0.00	196,376,250	33.52	0.00	0.00
14	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (Jointly holding)*	15,859,490	2.71	0.00	16,426,716	2.81	0.00	0.10
-	Total	303,925,934	51.87	0.65	303,925,934	51.87	1.04	0.00

* On 31.03.2017 entire shareholding of Trident Chemphar Limited in the Company was transferred as capital contribution to Auryn Labs, a Partnership firm and holding shares jointly in the name of its partners viz., Axis Clinicals Limited, Trident Chemphar Limited and RPR Sons Advisors Private Limited. However, the transfer of 867,226 shares was not effected in the system of depository as on 31.03.2017. Transfer of 567,226 shares was effected in the system of depository during the FY2017-18 and 300,000 shares on April 6, 2018.

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

SI No Shareholder's Name	Shareholdir beginning o	•	Cumulative Holding during the year	
	No of Shares	% of total shares of the company	No of Shares	% of total shares of the company
At the beginning of the year	303,925,934	51.87	303,925,934	51.87
Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):	Nil	Nil		
At the end of the year			303,925,934	51.87

Notes: There is no change in shareholding of promoters during the financial year 2017-18.

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

			·		
31 No	Name of the Shareholder	Shareholdir beginning of	•	Cumulative Sh during th	
		No of Shares	% of total shares of the	No of Shares	% of tota shares of the
	HDFC TRUSTEE COMPANY LIMITED A/C HDFC GROWTH	24943173	<u>company</u> 4.26	24943173	<u>compan</u> 4.26
	FUND	0100	0.00	04045001	4.00
	07/04/2017	2188	0.00	24945361	4.26
	07/04/2017	-254	0.00	24945107	4.20
	14/04/2017	-58	0.00	24945049	4.20
	21/04/2017	104900	0.02	25049949	4.2
	21/04/2017	-231830	-0.04	24818119	4.2
	28/04/2017	167300	0.03	24985419	4.2
	28/04/2017	-684104	-0.12	24301315	4.1
	05/05/2017	24864	0.00	24326179	4.1
	12/05/2017	537200	0.09	24863379	4.2
	12/05/2017	-185264	-0.03	24678115	4.2
	19/05/2017	25969	0.00	24704084	4.2
	26/05/2017	500000	0.09	25204084	4.3
	26/05/2017	-37	0.00	25204047	4.3
	02/06/2017	904731	0.15	26108778	4.4
	09/06/2017	382000	0.07	26490778	4.5
	09/06/2017	-16406	0.00	26474372	4.5
	16/06/2017	1157275	0.20	27631647	4.7
	23/06/2017	3137000	0.54	30768647	5.2
	23/06/2017	-92671	-0.02	30675976	5.2
	30/06/2017	1212108	0.21	31888084	5.4
	30/06/2017	-104300	-0.02	31783784	5.4
	07/07/2017	724718	0.12	32508502	5.5
	14/07/2017	13630	0.00	32522132	5.5
	21/07/2017	434400	0.07	32956532	5.6
	21/07/2017	-64	0.00	32956468	5.6
	28/07/2017	300800	0.05	33257268	5.6
	28/07/2017	-93	0.00	33257175	5.6
	04/08/2017	254	0.00	33257429	5.6
	04/08/2017	-63200	-0.01	33194229	5.6
	11/08/2017	436030	0.07	33630259	5.7
	11/08/2017	-538	0.00	33629721	5.7
	18/08/2017	499200	0.09	34128921	5.8
	18/08/2017	-17	0.00	34128904	5.8
	25/08/2017	516936	0.09	34645840	5.9
	01/09/2017	310200	0.05	34956040	5.9
	08/09/2017	71350	0.01	35027390	5.9
	15/09/2017	404000	0.07	35431390	6.0
	15/09/2017	-4	0.00	35431386	6.0
	22/09/2017	200000	0.03	35631386	6.0
	22/09/2017	-3200	0.00	35628186	6.0
	29/09/2017	402400	0.07	36030586	6.1
	29/09/2017	-443	0.00	36030143	6.1
	06/10/2017	499365	0.09	36529508	6.2
	13/10/2017	40	0.00	36529548	6.2
	27/10/2017	50	0.00	36529598	6.2
	27/10/2017	-200000	-0.03	36329598	6.2
			-0.00	00023030	
	31/10/2017	127306	0.02	36456904	6.2

SI N	o Name of the Shareholder	Shareholdir beginning o		Cumulative Sh during th	
		No of Shares	% of total shares of the	No of Shares	% of total shares of the
	03/11/2017	-620000	<u>-0.11</u>	35837213	company 6.12
	10/11/2017	1581	0.00	35838794	6.12
	10/11/2017	-630000	-0.11	35208794	6.01
	17/11/2017		0.00	35211652	6.01
	24/11/2017	87285	0.01	35298937	6.02
	01/12/2017	20835	0.00	35319772	6.03
	08/12/2017	46474	0.01	35366246	6.04
	15/12/2017	30	0.00	35366276	6.04
	15/12/2017	-1600	0.00	35364676	6.04
	22/12/2017	400000	0.07	35764676	6.10
	29/12/2017	192000	0.03	35956676	6.14
	29/12/2017	-110	0.00	35956566	6.14
	05/01/2018	612834	0.10	36569400	6.24
	05/01/2018	-936444	-0.16	35632956	6.08
	12/01/2018	157117	0.03	35790073	6.11
	19/01/2018	165	0.00	35790238	6.11
	26/01/2018	118400	0.02	35908638	6.13
	26/01/2018	-7	0.00	35908631	6.13
	02/02/2018	5441	0.00	35914072	6.13
	09/02/2018	22	0.00	35914094	6.13
	16/02/2018	399200	0.07	36313294	6.20
	16/02/2018	-25414	0.00	36287880	6.19
	23/02/2018	25235	0.00	36313115	6.20
	23/02/2018	-25000	0.00	36288115	6.19
	02/03/2018	354813	0.06	36642928	6.25
	09/03/2018	361912	0.06	37004840	6.32
	09/03/2018	-340000	-0.06	36664840	6.26
	16/03/2018	640681	0.11	37305521	6.37
	16/03/2018	-1738561	-0.30	35566960	6.07
	23/03/2018	2009894	0.34	37576854	6.41
	23/03/2018	-2836000	-0.48	34740854	5.93
	30/03/2018	341000	0.06	35081854	5.99
	30/03/2018	-1273182	-0.22	33808672	5.77
2	SBI MAGNUM EQUITY FUND	14343488	2.45	14343488	2.45
	07/04/2017	92338	0.02	14435826	2.46
	07/04/2017	-1416	0.00	14434410	2.46
	14/04/2017	43420	0.01	14477830	2.47
	14/04/2017	-440000	-0.08	14037830	2.40
	21/04/2017	21108	0.00	14058938	2.40
	28/04/2017	9326	0.00	14068264	2.40
	28/04/2017	-99	0.00	14068165	2.40
	05/05/2017	11862	0.00	14080027	2.40
	05/05/2017	-21000	0.00	14059027	2.40
	12/05/2017	11254	0.00	14070281	2.40
	12/05/2017	-459	0.00	14069822	2.40
	19/05/2017	12660	0.00	14082482	2.40
	19/05/2017	-864	0.00	14081618	2.40
	26/05/2017	4743	0.00	14086361	2.40
	26/05/2017	-703	0.00	14085658	2.40
	02/06/2017	4577	0.00	14090235	2.40
	02/06/2017	-778348	-0.13	13311887	2.27
	09/06/2017	112517	0.02	13424404	2.29

SI No Name of the Shareholder	Shareholdir beginning o		Cumulative Sh during th	
	No of Shares	% of total	No of Shares	% of total
		shares of the company		shares of the company
09/06/2017	-23766	0.00	13400638	2.29
16/06/2017	15957	0.00	13416595	2.29
23/06/2017	9067	0.00	13425662	2.29
23/06/2017	-68603	-0.01	13357059	2.28
30/06/2017	35022	0.01	13392081	2.29
30/06/2017	-25000	0.00	13367081	2.28
07/07/2017	15700	0.00	13382781	2.28
07/07/2017	-311055	-0.05	13071726	2.23
14/07/2017	36595	0.01	13108321	2.24
14/07/2017	-20816	0.00	13087505	2.23
21/07/2017	10920	0.00	13098425	2.24
21/07/2017	-841233	-0.14	12257192	2.09
28/07/2017	100614	0.02	12357806	2.11
28/07/2017	-22	0.00	12357784	2.11
04/08/2017	278852	0.05	12636636	2.16
04/08/2017	-200000	-0.03	12436636	2.12
11/08/2017	26825	0.00	12463461	2.13
11/08/2017	-659	0.00	12462802	2.13
18/08/2017	17990	0.00	12480792	2.13
25/08/2017	21901	0.00	12502693	2.13
25/08/2017	-35600	-0.01	12467093	2.13
01/09/2017	24694	0.00	12491787	2.13
08/09/2017	20778	0.00	12512565	2.14
08/09/2017	-113700	-0.02	12398865	2.12
15/09/2017	86210	0.01	12485075	2.13
15/09/2017	-74400	-0.01	12410675	2.12
22/09/2017	16876	0.00	12427551	2.12
29/09/2017	1798	0.00	12429349	2.12
29/09/2017	-260897	-0.04	12168452	2.08
06/10/2017	19690	0.00	12188142	2.08
06/10/2017	-334145	-0.06	11853997	2.02
13/10/2017	30483	0.01	11884480	2.03
13/10/2017	-254300	-0.04	11630180	1.99
20/10/2017	18383	0.00	11648563	1.99
27/10/2017	25968	0.00	11674531	1.99
31/10/2017	3078	0.00	11677609	1.99
03/11/2017		0.00	11681419	1.99
10/11/2017		0.00	11684934	1.99
10/11/2017	-69678	-0.01	11615256	1.98
17/11/2017	4338	0.00	11619594	1.98
17/11/2017	-1000	0.00	11618594	1.98
24/11/2017	24886	0.00	11643480	1.99
24/11/2017	-31546	-0.01	11611934	1.98
01/12/2017	18392	0.00	11630326	1.99
01/12/2017	-82000	-0.01	11548326	1.97
08/12/2017	336104	0.06	11884430	2.03
08/12/2017	-28056	0.00	11856374	2.02
15/12/2017	24730	0.00	11881104	2.03
22/12/2017	28061	0.00	11909165	2.03
22/12/2017	-49729	-0.01	11859436	2.02
29/12/2017	16708	0.00	11876144	2.03
29/12/2017	-1748685	-0.30	10127459	1.73

SI No Name of the Shareholder	Shareholdir beginning of	•	Cumulative Sh during th	
	No of Shares	% of total	No of Shares	% of total
		shares of the company		shares of the company
05/01/2018	25973	0.00	10153432	1.73
05/01/2018	-1258272	-0.21	8895160	1.52
12/01/2018	17266	0.00	8912426	1.52
19/01/2018	-1078162	-0.18	7834264	1.34
26/01/2018	-301582	-0.05	7532682	1.29
02/02/2018	-28693	0.00	7503989	1.28
09/02/2018	204	0.00	7504193	1.28
09/02/2018	-455348	-0.08	7048845	1.20
16/02/2018	19872	0.00	7068717	1.21
16/02/2018	-700233	-0.12	6368484	1.09
23/02/2018	90	0.00	6368574	1.09
23/02/2018	-27480	0.00	6341094	1.08
02/03/2018	26696	0.00	6367790	1.09
02/03/2018	-663	0.00	6367127	1.09
09/03/2018	36250	0.01	6403377	1.09
16/03/2018	44951	0.01	6448328	1.10
23/03/2018	51648	0.01	6499976	1.11
23/03/2018	-1	0.00	6499975	1.11
30/03/2018	69370	0.01	6569345	1.12
3 RELIANCE CAPITAL TRUSTEE CO. LTD-A/C	9993486	1.71	9993486	1.71
RELIANCESMALL				
07/04/2017	657	0.00	9994143	1.71
07/04/2017	-1400	0.00	9992743	1.71
14/04/2017	-84000	-0.01	9908743	1.69
21/04/2017	199557	0.03	10108300	1.73
28/04/2017	21712	0.00	10130012	1.73
28/04/2017	-3725	0.00	10126287	1.73
05/05/2017	3500	0.00	10129787	1.73
05/05/2017	-498	0.00	10129289	1.73
12/05/2017	385640	0.07	10514929	1.79
12/05/2017	-762	0.00	10514167	1.79
19/05/2017	209700	0.04	10723867	1.83
19/05/2017	-523	0.00	10723344	1.83
26/05/2017	145600	0.02	10868944	1.86
26/05/2017	-698	0.00	10868246	1.86
02/06/2017	600347	0.10	11468593	1.96
02/06/2017	-224	0.00	11468369	1.96
09/06/2017	1051000	0.18	12519369	2.14
09/06/2017	-854392	-0.15	11664977	1.99
16/06/2017	101500	0.02	11766477	2.01
16/06/2017	-56739	-0.01	11709738	2.00
23/06/2017	-494478	-0.08	11215260	1.91
30/06/2017	200	0.00	11215460	1.91
30/06/2017	-115900	-0.02	11099560	1.89
07/07/2017	800	0.00	11100360	1.89
07/07/2017	-567	0.00	11099793	1.89
14/07/2017	320800	0.05	11420593	1.95
14/07/2017	-349	0.00	11420244	1.95
21/07/2017	312800	0.05	11733044	2.00
21/07/2017	-2123829	-0.36	9609215	1.64
28/07/2017	4800	0.00	9614015	1.64
28/07/2017	-631248	-0.11	8982767	1.53

SI No Name of the Shareholder		Shareholding at the beginning of the Year		Cumulative Shareholding during the Year	
	No of Shares	% of total shares of the	No of Shares	% of total shares of the	
		company		company	
04/08/2017	76001	0.01	9058768	1.55	
04/08/2017	-320374	-0.05	8738394	1.49	
11/08/2017	20000	0.00	8758394	1.49	
11/08/2017	-534	0.00	8757860	1.49	
18/08/2017	53600	0.01	8811460	1.50	
18/08/2017	-1794	0.00	8809666	1.50	
25/08/2017	84228	0.01	8893894	1.52	
01/09/2017	48876	0.01	8942770	1.53	
08/09/2017	67504	0.01	9010274	1.54	
08/09/2017	-250112	-0.04	8760162	1.50	
15/09/2017	269600	0.05	9029762	1.54	
15/09/2017	-101364	-0.02	8928398	1.52	
22/09/2017	-85484	-0.01	8842914	1.51	
29/09/2017	333600	0.06	9176514	1.57	
29/09/2017	-200197	-0.03	8976317	1.53	
06/10/2017	511575	0.09	9487892	1.62	
13/10/2017	320	0.00	9488212	1.62	
13/10/2017	-153200	-0.03	9335012	1.59	
20/10/2017	683	0.00	9335695	1.59	
20/10/2017	-138400	-0.02	9197295	1.57	
27/10/2017	119249	0.02	9316544	1.59	
27/10/2017	-301000	-0.05	9015544	1.54	
31/10/2017	882	0.00	9016426	1.54	
31/10/2017	-723	0.00	9015703	1.54	
03/11/2017	389174	0.07	9404877	1.61	
10/11/2017	182000	0.03	9586877	1.64	
10/11/2017	-233	0.00	9586644	1.64	
17/11/2017	-22474	0.00	9564170	1.63	
24/11/2017	201064	0.03	9765234	1.67	
24/11/2017	-136228	-0.02	9629006	1.64	
01/12/2017	140800	0.02	9769806	1.67	
01/12/2017	-913	0.02	9768893	1.67	
08/12/2017	400722	0.07	10169615	1.74	
08/12/2017	-200113	-0.03	9969502	1.70	
15/12/2017	114	0.00	9969616	1.70	
15/12/2017	-2532	0.00	9967084	1.70	
22/12/2017	2466	0.00	9969550	1.70	
22/12/2017	-196	0.00	9969354	1.70	
29/12/2017	-28451	0.00	9940903	1.70	
05/01/2018	91	0.00	9940903	1.70	
05/01/2018	-178	0.00	9940816	1.70	
12/01/2018	2405	0.00	9943221	1.70	
12/01/2018	-38	0.00	9943183	1.70	
19/01/2018	454795	0.08	10397978	1.70	
19/01/2018	-400007	-0.07	9997971	1.71	
26/01/2018	202000	0.03	10199971	1.74	
26/01/2018	-4881	0.00	10195090	1.74	
02/02/2018	150073	0.03	10345163	1.77	
02/02/2018	-11530	0.00	10333633	1.76	
09/02/2018		0.01	10381810	1.77	
16/02/2018	96302	0.02	10478112	1.79	
23/02/2018	494	0.00	10478606	1.79	

SI No Name of the Shareholder	Shareholding at the beginning of the Year		Cumulative Shareholding during the Year	
	No of Shares	% of total shares of the	No of Shares	% of total shares of the
23/02/2018	-400032	<u>-0.07</u>	10078574	company 1.72
02/03/2018	1184164	0.20	11262738	1.72
02/03/2018	-474	0.20	11262264	1.92
09/03/2018	2159228	0.37	13421492	2.29
09/03/2018	-1208800	-0.21	12212692	2.08
16/03/2018	437634	0.07	12650326	2.16
16/03/2018	-50	0.00	12650276	2.10
23/03/2018	2888	0.00	12653164	2.10
23/03/2018	-190491	-0.03	12462673	2.13
30/03/2018	122518	0.02	12585191	2.15
30/03/2018	-38401	-0.01	12546790	2.14
4 ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C	8375902	1.43	8375902	1.43
07/04/2017	217000	0.04	8592902	1.47
21/04/2017	334900	0.06	8927802	1.52
28/04/2017	-2738	0.00	8925064	1.52
05/05/2017	-454000	-0.08	8471064	1.45
12/05/2017	500000	0.09	8971064	1.53
12/05/2017	-80200	-0.01	8890864	1.52
19/05/2017	-60757	-0.01	8830107	1.51
26/05/2017	-80	0.00	8830027	1.51
02/06/2017	345	0.00	8830372	1.51
02/06/2017	-32600	-0.01	8797772	1.50
16/06/2017	100000	0.02	8897772	1.52
16/06/2017	-65800	-0.01	8831972	1.51
23/06/2017	2173800	0.37	11005772	1.88
23/06/2017	-321300	-0.05	10684472	1.82
30/06/2017	183931	0.03	10868403	1.86
07/07/2017	46000	0.01	10914403	1.86
14/07/2017	32800	0.01	10947203	1.87
21/07/2017	11200	0.00	10958403	1.87
28/07/2017	266400	0.05	11224803	1.92
04/08/2017	108800	0.02	11333603	1.93
04/08/2017	-200000	-0.03	11133603	1.90
11/08/2017	-10600	0.00	11123003	1.90
18/08/2017	380	0.00	11123383	1.90
25/08/2017	96876	0.02	11220259	1.92
01/09/2017	181653	0.03	11401912	1.95
01/09/2017	-135412	-0.02	11266500	1.92
08/09/2017	29600	0.01	11296100	1.93
08/09/2017	-1500	0.00	11294600	1.93
15/09/2017	90000	0.02	11384600	1.94
29/09/2017	57653	0.01	11442253	1.95
06/10/2017	570000	0.10	12012253	2.05
13/10/2017	181600	0.03	12193853	2.08
20/10/2017	104000	0.02	12297853	2.10
27/10/2017	42400	0.01	12340253	2.11
31/10/2017	-34243	-0.01	12306010	2.10
03/11/2017	48000	0.01	12354010	2.11
03/11/2017	-232676	-0.04	12121334	2.07
10/11/2017	-290000	-0.05	11831334	2.02
17/11/2017	655	0.00	11831989	2.02
17/11/2017	-552000	-0.09	11279989	1.93

SI No Na	ame of the Shareholder	Shareholding at the beginning of the Year		Cumulative Shareholding during the Year	
		No of Shares	% of total shares of the company	No of Shares	% of total shares of the company
2	4/11/2017	200000	0.03	11479989	1.96
	1/12/2017	212400	0.04	11692389	2.00
	8/12/2017	-2300	0.00	11690089	2.00
	5/12/2017	20000	0.00	11710089	2.00
	5/12/2017	-116000	-0.02	11594089	1.98
	2/12/2017	-181700	-0.03	11412389	1.95
	5/01/2018	182800	0.03	11595189	1.98
	2/01/2018	156800	0.03	11751989	2.01
	9/01/2018		0.00	11752067	2.01
	6/01/2018	16800	0.00	11768867	2.01
	2/02/2018	4000	0.00	11772867	2.01
	2/02/2018	-22500	0.00	11750367	2.01
	9/02/2018	83200	0.01	11833567	2.02
	9/02/2018	-203425	-0.03	11630142	1.99
	6/02/2018	169000	0.03	11799142	2.01
	3/02/2018	50000	0.01	11849142	2.02
	2/03/2018	380839	0.07	12229981	2.09
	2/03/2018	-700	0.00	12229281	2.09
-	9/03/2018	50091	0.01	12279372	2.10
	9/03/2018	-8400	0.00	12270972	2.09
	6/03/2018	-44253	-0.01	12226719	2.09
	3/03/2018	500039	0.09	12726758	2.17
-	3/03/2018	-6248	0.00	12720510	2.17
	0/03/2018	200078	0.03	12920588	2.21
	0/03/2018	-1270	0.00	12919318	2.21
	MANSA HOLDINGS PRIVATE LIMITED	0	0.00	0	0.00
-	6/05/2017	2790597	0.48	2790597	0.48
	2/06/2017	1561300	0.27	4351897	0.74
	0/06/2017	382311	0.07	4734208	0.81
	8/08/2017	206006	0.04	4940214	0.84
	6/10/2017	95350	0.02	5035564	0.86
	7/11/2017	47500	0.01	5083064	0.87
	2/12/2017	-83064	-0.01	5000000	0.85
	2/01/2018	-95380	-0.02	4904620	0.84
	2/02/2018	241127	0.04	5145747	0.88
	9/02/2018	328287	0.06	5474034	0.93
-	6/02/2018	353162	0.06	5827196	0.99
2	3/02/2018	621020	0.11	6448216	1.10
2	3/03/2018	153298	0.03	6601514	1.13
	0/03/2018	306539	0.05	6908053	1.18
	TICHTING DEPOSITARY APG EMERGING MARKETS QUITY P	6448482	1.10	6448482	1.10
-	7/04/2017	-9094	0.00	6439388	1.10
1.	4/04/2017	113174	0.02	6552562	1.12
1:	2/05/2017	233503	0.04	6786065	1.16
2	6/05/2017	-1614039	-0.28	5172026	0.88
0	2/06/2017	-571784	-0.10	4600242	0.79
0	9/06/2017	731342	0.12	5331584	0.91
1	6/06/2017	260767	0.04	5592351	0.95
1	4/07/2017	103738	0.02	5696089	0.97
2	8/07/2017	225854	0.04	5921943	1.01
0.	4/08/2017	209748	0.04	6131691	1.05

SI No	o Name of the Shareholder	Shareholding at the beginning of the Year		Cumulative Shareholding during the Year	
		No of Shares	% of total	No of Shares	% of total
			shares of the company		shares of the company
	11/08/2017	-22725	0.00	6108966	1.04
	18/08/2017	32467	0.01	6141433	1.05
-	22/09/2017	149037	0.03	6290470	1.07
	13/10/2017	512523	0.09	6802993	1.16
	20/10/2017	-17441	0.00	6785552	1.16
	27/10/2017	60536	0.01	6846088	1.17
	03/11/2017	-11837	0.00	6834251	1.17
	08/12/2017	-741842	-0.13	6092409	1.04
	15/12/2017	15349	0.00	6107758	1.04
	09/02/2018	-319444	-0.05	5788314	0.99
	16/02/2018	-1519258	-0.26	4269056	0.73
	02/03/2018	-4599	0.00	4264457	0.73
	09/03/2018	-32512	-0.01	4231945	0.72
	16/03/2018	-128699	-0.02	4103246	0.70
	23/03/2018	-177455	-0.03	3925791	0.67
7	JHUNJHUNWALA RAKESH RADHESHYAM	6350000	1.08	6350000	1.08
	02/06/2017	500000	0.09	6850000	1.17
	02/06/2017	-500000	-0.09	6350000	1.08
	30/06/2017	200000	0.03	6550000	1.12
	01/12/2017	-6550000	-1.12	0	0.00
8	ABU DHABI INVESTMENT AUTHORITY - RELVAL	5992293	1.02	5992293	1.02
0	19/05/2017	-334240	-0.06	5658053	0.97
	02/06/2017	-73917	-0.01	5584136	0.95
	09/06/2017	-810130	-0.14	4774006	0.81
	16/06/2017	-754987	-0.13	4019019	0.69
	08/09/2017	13121	0.00	4032140	0.69
	22/09/2017	-267220	-0.05	3764920	0.64
	27/10/2017	-200000	-0.03	3564920	0.61
	17/11/2017	-105537	-0.02	3459383	0.59
	24/11/2017	-187626	-0.03	3271757	0.56
	01/12/2017	-4023	0.00	3267734	0.56
	02/03/2018	-41531	-0.01	3226203	0.55
	23/03/2018	-5628	0.00	3220575	0.55
	30/03/2018	11007	0.00	3231582	0.55
	30/03/2018	-11007	0.00	3220575	0.55
9	VANGUARD EMERGING MARKETS STOCK INDEX FUND,	4621529	0.79	4621529	0.79
0	A SERI	1021020	0.10	1021020	0.10
	07/04/2017	52320	0.01	4673849	0.80
	28/04/2017	4800	0.00	4678649	0.80
	05/05/2017	38400	0.01	4717049	0.81
	12/05/2017	12000	0.00	4729049	0.81
	19/05/2017	25920	0.00	4754969	0.81
	02/06/2017	10560	0.00	4765529	0.81
	07/07/2017	16800	0.00	4782329	0.82
	14/07/2017	12000	0.00	4794329	0.82
	04/08/2017	10560	0.00	4804889	0.82
	11/08/2017	13920	0.00	4818809	0.82
	01/09/2017	17280	0.00	4836089	0.83
	08/09/2017	24480	0.00	4860569	0.83
	15/09/2017	22080	0.00	4882649	0.83
	22/09/2017	-172304	-0.03	4710345	0.80
	06/10/2017	14400	0.00	4724745	0.81
			0.00	7124140	0.01

SI No Name of the Shareholder	Shareholdir beginning of	•	Cumulative Shareholding during the Year	
	No of Shares	% of total	No of Shares	% of total
		shares of the		shares of the
		company		company
13/10/2017	14880	0.00	4739625	0.81
20/10/2017	11040	0.00	4750665	0.81
27/10/2017	10080	0.00	4760745	0.81
22/12/2017	-163716	-0.03	4597029	0.78
26/01/2018	22983	0.00	4620012	0.79
02/02/2018	20538	0.00	4640550	0.79
23/03/2018	4640550	0.79	9281100	1.58
23/03/2018	-4640550	-0.79	4640550	0.79
30/03/2018	-24500	0.00	4616050	0.79
10 MORGAN STANLEY MAURITIUS COMPANY LIMITED	4320861	0.74	4320861	0.74
07/04/2017	-67399	-0.01	4253462	0.73
14/04/2017	-6300	0.00	4247162	0.72
21/04/2017	-9333	0.00	4237829	0.72
28/04/2017	-2100	0.00	4235729	0.72
05/05/2017	-27000	0.00	4208729	0.72
12/05/2017	-21280	0.00	4187449	0.71
19/05/2017	-27655	0.00	4159794	0.71
26/05/2017	-1400	0.00	4158394	0.71
02/06/2017	-61160	-0.01	4097234	0.70
09/06/2017	-1000	0.00	4096234	0.70
16/06/2017	-3500	0.00	4092734	0.70
23/06/2017	-138500	-0.02	3954234	0.67
28/07/2017	-8147	0.00	3946087	0.67
04/08/2017	-21927	0.00	3924160	0.67
11/08/2017	-215731	-0.04	3708429	0.63
18/08/2017	-32903	-0.01	3675526	0.63
25/08/2017	-700	0.00	3674826	0.63
29/09/2017	-1005909	-0.17	2668917	0.46
27/10/2017	-2417	0.00	2666500	0.46
10/11/2017	-17472	0.00	2649028	0.45
17/11/2017	-52124	-0.01	2596904	0.44
01/12/2017	-22216	0.00	2574688	0.44
08/12/2017	-471	0.00	2574217	0.44
15/12/2017	-4827	0.00	2569390	0.44
22/12/2017	-234	0.00	2569156	0.44
29/12/2017	-21597	0.00	2547559	0.43
12/01/2018	-7787	0.00	2539772	0.43
09/02/2018	-38517	-0.01	2501255	0.43
23/02/2018	-101	0.00	2501154	0.43
02/03/2018	-66965	-0.01	2434189	0.42
09/03/2018	-398634	-0.07	2035555	0.35
16/03/2018	-374557	-0.06	1660998	0.28
23/03/2018	-800	0.00	1660198	0.28

(v) Shareholding of Directors and Key Managerial Personnel:

Directors and Key Managerial Personnel		Shareholdir beginning of	0	Cumulative Shareholding during the year	
		No. of shares	% of total shares of the Company	No. of shares	% of total shares of the Company
Dir	ectors				
1	Mr. K. Ragunathan	-	-	-	-
	At the End of the year	-	-	-	-
2	Mr. K. Nithyananda Reddy	25,359,572	4.33	25,359,572	4.33
	At the End of the year			25,359,572	4.33
3	Mr. N. Govindarajan	-	-	-	-
	At the End of the year	-	-	-	-
4	Dr. M.Sivakumaran	14,491,360	2.47	14,491,360	2.47
	At the End of the year			14,491,360	2.47
5	Mr. M. Madan Mohan Reddy	2,010	0.00	2,010	0.00
	At the End of the year			2,010	0.00
6	Mr.P.V.Ramprasad Reddy	18,000,000	3.08	18,000,000	3.07
	At the End of the year			18,000,000	3.07
7	Mr. M.Sitarama Murty	-	-	-	-
	At the End of the year	-	-	-	-
8	Mr. P. Sarath Chandra Reddy	-	-	-	-
	At the End of the year	-	-	-	-
9	Dr.(Mrs.) Avnit Bimal Singh	-	-	-	-
	At the End of the year	-	-	-	-
10	Mrs.Savita Mahajan		-	-	-
	At the End of the year		-	-	-
Key	Managerial Personnel				
1	Mr.S. Subramanian	7,126	0.00	7,126	0.00
	At the End of the year			7,126	0.00
2	Mr. B. Adi Reddy	800	0.00	800	0.00
	At the End of the year			800	0.00

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

				(₹ in Millions)
Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	4,486.5	26,052.6	-	30,539.1
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	20.5	-	-	20.5
Total (i+ii+iii)	4,507.0	26,052.6	-	30,559.6
Change in Indebtedness during the financial year				
Addition	-	7,380.1	-	7,380.1
Reduction	739.0	-	-	739.0
Net Change	-739.0	7,380.1	-	6,641.1
Indebtedness at the end of the financial year				
i) Principal Amount	3,761.9	33,428.1	-	37,190.0
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	6.1	4.6	-	10.7
Total (i+ii+iii)	3,768.0	33,432.7	-	37,200.7

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

	Remuneration to Managing Directol, who						(₹ in million)
		Name of MD/WTD/ Manager					
SI. no.	Particulars of Remuneration	Mr. K. Nithyananda Reddy	Mr. N. Govindarajan	Dr. M. Sivakumaran	Mr. M. Madan Mohan Reddy	Mr.P.Sarath Chandra Reddy	
1	Gross salary	13.80	42.38	13.80	24.42	7.50	101.90
	(a) Salary as per provisions contained in						
	section 17(1) of the Income Tax Act, 1961						
	(b) Value of perquisites u/s 17(2) Income	1.30	3.87	1.30	2.30	0.75	9.52
	tax Act, 1961						
	(c) Profits in lieu of salary under section	-	-	-	-	-	-
	17(3) Income tax Act, 1961						
2	Stock Option	-	-	-	-	-	-
3	Sweat Equity	-	-	-	-	-	-
4	Commission	-		-	-	-	-
	- as % of profit	-	100.00	-	-	-	100.00
	- others, specify	-		-	-	-	
	Others, please specify	0.02	0.02	0.02	0.02	0.02	0.10
	- Contribution to PF						
	Total (A)	15.12	146.27	15.12	26.74	8.27	211.52
	Ceiling as per the Act (being 10% of the net p	rofits of the Co	ompany calcul	ated as per S	ection 198 of		2,394.51
	the Companies Act, 2013)		. ,				-

B. Remuneration to other directors:

Sl. no.	Particulars of Remuneration Name of Directors					Total Amount	
1	Independent Directors	Mr. K. Ragunathan	Mr. M Sitarama Murty	Mr. Rathakrishnan Rangaswamy Iyer *	Dr. (Mrs). Avnit Bimal Singh	Mrs. Savita Mahajan	
	Fee for attending board / committee meetings	1.00	1.05	0.60	0.55	0.10	3.30
	Commission	-	-	-	-	-	-
	Others, please specify	-	-	-	-	-	-
	Total (1)	1.00	1.05	0.60	0.55	0.10	3.30
2	Other Non-Executive Directors	Mr.P.V. Ramprasad Reddy					
	Fee for attending board / committee meetings	0.20					0.20
	Commission	-					
	Others, please specify	-					
	Total (2)	0.20					0.20
	Total B)=(1+2)						3.50
	Total managerial Remuneration						215.02
	Overall Ceiling as per the Act (being 11% Companies Act, 2013)	of the net profits of	f the Compa	any calculated a	as per Sectior	198 of the	2,633.96

* Resigned during the year.

C. Remuneration to Key Managerial Personnel Other than MD/Manager/WTD

				(₹ in million)
		K	ey Managerial Personnel	
Deuti	culars of Remuneration	CFO	Company Secretary	Total
Paru	culars of Hemuneration	Mr. S. Subramanian	Mr.B.Adi Reddy	
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income	13.24	3.04	16.28
	Tax Act, 1961			
	(b) Value of perquisites u/s 17(2) Income Tax Act, 1961	1.01	0.27	1.28
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-
2	Stock Option	-	-	-
3	Sweat Equity	-	-	-
4	Commission			
	- as % of profit	-	-	-
	- others, specify	-	-	-
5	Others, please specify - Contribution to PF	0.02	0.02	0.04
	Total	14.27	3.33	17.60

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Against the Company, Directors and other officers in default under the Companies Act, 2013: None

For and on behalf of the Board

Hyderabad May 28, 2018 K. Ragunathan Chairman DIN: 00523576

ANNEXURE-4

Conservation of energy, technology absorption, foreign exchange earnings and outgo

(Pursuant to the provisions of section 134(3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014.)

(A) CONSERVATION OF ENERGY

(i) Steps taken or impact on conservation of energy;

- At unit 3 all areas lighting is replaced by LED lamps saving about 1.5 lakh units annually. Lighting transformers are kept under operation with reduced voltage resulting in further lighting savings of 6%. STP permeate water of cooling towers now is getting recycled resulting in reduction of 40KL per day effluent and 40KL per day fresh water intake. Steam condensate recovery improved from 55% to 70% resulting in reduction of 30KL water. Air compressor cooling mechanism modification reduced another 20KL water per day
- At unit 7 installation of hot well and cold well system at chillers area resulted in energy savings of 41 lakh units per annum. Lighting system at OCB area replaced by LED which gives savings of about 10,000 units per annum. 200KL water per day saved at unit 7 by recycling purified water system rejects to cooling towers, toilets, dining wash area etc.,
- Lighting system at unit 6 is replaced by LED lamps, which gives annual savings of 54000 units. VFD's usage resulted in another 15000units savings. 5400KL water annually saved at unit 6 by the reuse of water from autoclave and vial washing machine for garden and other areas
- At unit 4, water saving components is used for all taps and faucets.
- By modification of chiller network system one 110TR chiller at unit 12 is completely stopped which gives the savings of about 21lakh units annually
- OPL's (One point Lessons) are created at various units to improve the awareness levels among employees for disciplined usage of energy.
- Arranged Nitrogen blanketing systems to Centrifuges for reduction of Nitrogen consumption and at the same time safety measures also improved while operating in Unit-1 & Unit-11U
- Optimization of chilling plant operations during winter season taking the benefit of environmental coldness by modifying the existing pipelines and pumps etc.,
- Replacement of old and high energy consuming coal crushing plants with low energy consumption coal plant for improving the productivity and efficiency.
- Installed multi stage Multi Effect Evaporator (MEE) by replacing old MEE plant for improving the operational efficiency in Unit-5
- Installation of double effect Vapor Absorption Machines (VAMs) replacing single effect old VAM & Vapor Compression Refrigeration (VCR) systems.

- Waste Heat Recovery (WHR) system implemented to pre heat the Boiler feed water from the process waste heat in Unit-11
- De-Super heaters arranged for converting superheated steam in to saturated steam for using in process applications.
- Installed of flash steam recovery units for recovering heat from the flash steam in Unit-11U
- GLR Reactors 60 W Vessel Lamps replaced with 7 W LED Lamps in Unit-11U
- Replaced old low efficiency pump sets with high efficient pump sets, replacement of old impellers with new efficient impellers in pumping systems.
- Provision of interlocks for avoiding operation of standby equipment.
- RO rejected water using for cooling tower and saving the water consumption from outside.

(ii) Steps taken by the company for utilizing alternate sources of energy;

- Steam coils are provided for dehumidification system at unit 15 to reduces power consumption
- At unit7, 75 no.s day lights installed to reduce lighting energy.
 200 wind blowers installed to reduce heat load of HVAC system
- At unit 4, rain water harvesting water is used for cooling towers after softening. This resulted in about 50KL water reduction per day
- Trading of Power through open access using wind /solar power in UNIT-XI and XIU.
- Utilization of waste heat available in the process for pre heating of Boiler Feed Water

(iii) Capital investment on energy conservation equipments;

- At unit 3, Low efficiency reciprocating air compressors are replaced with oil free screw air compressors
- VFDs installed for coating AHU's at unit 6
- LED lighting system replaced conventional lighting at units 3, 6 and 7
- Hot well, cold well system implemented at chillers area in unit 7
- As energy conservation is one of the priority areas for Aurobindo, the company has invested in FY 2017-18 on energy conservation projects

(B) TECHNOLOGY ABSORPTION

Efforts made towards technology absorption:

The Company has a robust in-house R&D team which works on research, development, and commercialization of various APIs and Formulations. The Company along with various subsidiaries & Joint ventures intensely works on R&D projects to fulfill the medical needs of many people across the globe. Technology absorption is one of the key priorities for the Company as it facilitates long-term sustainability. The technologies developed will be protected through patent registration which will directly create value for the stakeholders of the company.

Benefits derived like product improvement, cost reduction, product development or import substitution:

The Company actively works on optimizing the costs across the value chain which makes the products and services more competitive. These activities resulted in the improvement of operational efficiency. The Company maximized the efforts to further vertically integrate the operations which decreases the dependency on import of intermediaries and APIs. These efforts include in-house development, local sourcing, etc.

In case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-

Not Applicable

Expenditure Incurred on Research and Development

		₹ Millions
Particulars	2017-18	2016-17
Capital	596.3	940.7
Recurring	5,895.2	4,963.3
Total R&D Expenditure	6,491.5	5,904.0
As a % of total gross turnover	6.32	6.04

(C) FOREIGN EXCHANGE EARNINGS AND OUTGO-

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows.

Foreign Exchange Earned

		₹ Millions
Particulars	2017-18	2016-17
Exports	80,680.5	75,760.7
Others	46.7	77.0
	80,727.2	75,837.7

Foreign Exchange Outgo

		₹ Millions
Particulars	2017-18	2016-17
Imports	31,852.8	27,088.8
Others	2,847.6	3,135.5
	34,700.3	30,224.3

For and on behalf of the Board

Place: Hyderabad Date: 28 May 2018 K. Ragunathan Chairman DIN: 00523576

~

ANNEXURE-5

Form No. MR-3

[Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

SECRETARIAL AUDIT REPORT

For the financial year ended 31st March, 2018

To The Members **Aurobindo Pharma Limited** (CIN: L24239TG1986PLC015190) Plot No.2, Maitri Vihar, Ameerpet, Hyderabad - 500 038

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Aurobindo Pharma Limited** (hereinafter referred to as 'the Company') for the year ended 31st March, 2018. Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided and declarations made by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2018 (i.e. from 1st April, 2017 to 31st March, 2018) complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2018 according to the provisions/clauses of:

- 1. The Companies Act, 2013 (the Act) and the rules made thereunder;
- 2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- 3. The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder;
- Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- The Following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT'):
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

- The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and amendments from time to time;
- d. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- 6. Factories Act, 1948 and allied state Laws
- 7. Telangana Shops and Establishment Act, 1988 (erstwhile AP Shops and Establishment Act, 1988);
- 8. Employees' State Insurance Act, 1948 and the Employees' State Insurance (General) Regulations, 1950;
- The Employees' Provident Funds and Miscellaneous Provisions Act, 1952 and the Employees' Provident Funds Scheme, 1952;
- 10. The Payment of Bonus Act, 1965 and the Payment of Bonus Rules, 1965;
- The Contract Labour (Regulation and Abolition) Act, 1970 and the Contract Labour (Regulation and Abolition) Central Rules, 1971;
- 12. The Payment of Gratuity Act, 1972
- 13. The Maternity Benefits Act, 1961
- 14. The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
- 15. Drugs (Control) Act, 1950
- The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945;
- 17. The Narcotic Drugs and Psychotropic Substances Act, 1985;
- 18. The Food Safety and Standards Act, 2006
- The Indian Boilers Act, 1923 and the Indian Boiler Regulations, 1950 and the Rules framed under the Act.
- 20. The Inflammable Substances Act, 1952
- 21. The Poisons Act, 1919
- 22. The Air (Prevention and control of pollution) Act, 1981 and Air (Prevention and control of pollution) Rules, 1982
- 23. The Water (Prevention and control of pollution) Act, 1974 and Water (Prevention and control of pollution) Rules, 1975

Financial Statements

- 24. Environment Protection Act, 1986 and the rules, notifications issued thereunder.
- 25. Memorandum and Articles of Association of the Company.

I have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by the Institute of Company Secretaries of India;
- ii. The Listing Agreement entered into by the Company with BSE Limited and National Stock Exchange of India Limited;
- iii. Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review the company has generally complied with the provisions of the acts, rules, regulations, guidelines, and standards etc., mentioned above.

I further report that

 a) the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

- b) Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- c) All the decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.
- d) the compliance by the Company of the applicable financial laws like direct and indirect tax laws and maintenance of financial records and books of accounts has not been reviewed by me since the same have been subject to review by statutory auditors and other professionals.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Place: Hyderabad Date: 28 May 2018 A. Mohan Rami Reddy

Practicing Company Secretary FCS No: 2147; COP No: 16660

This Report is to be read with my letter which is annexed as Annexure and forms an integral part of this report

'ANNEXURE'

To The Members **M/s. Aurobindo Pharma Limited** (CIN: L24239TG1986PLC015190) Plot No.2, Maitri Vihar, Ameerpet, Hyderabad- 500 038

My report of even date is to be read along with this letter.

- 1. Maintenance of Secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
- 2. I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the

Place: Hyderabad Date: 28 May 2018 process and practices followed by me provide a reasonable basis for my opinion.

- 3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- 4. Wherever required, I have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events, etc.
- 5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.
- 6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

A. Mohan Rami Reddy Practicing Company Secretary FCS No: 2147; COP No: 16660



ANNEXURE-6

Annual Report of Corporate Social Responsibility activities

1. A brief outline of the Company's Corporate Social Responsibility (CSR) policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs.

Promoting Education, Promoting Preventive Health Care, Eradicating Hunger, Poverty & Malnutrition and Preventive Health Care. Making Available Safe Drinking Water, Environment Sustainability, and Ecological Balance & Conservation of Natural Resources. Rural sports and Setting up Old Age Homes etc.

The CSR Policy has been placed on the Company's website at: http://www.aurobindo.com/about-us/corporate-governance

The Company has established Aurobindo Pharma Foundation for primarily undertaking CSR activities. Accordingly, the Company has started CSR activities under the said foundation.

Annual report on the CSR activities of the Company during the year are also placed on the Company's website at: http://www. aurobindo.com/social-responsibility/csr-activities

2. Composition of CSR Committee:

Name	Designation
Mr. K. Nithyananda Reddy	Chairman
Mr. K. Ragunathan	Member
Dr. M. Sivakumaran	Member
Mr. P. Sarath Chandra Reddy	Member

3. Average net profit (as per section 198 of the Companies Act, 2013) for the past three financial years:

			₹ Millions
Particulars	2016-17	2015-16	2014-15
Net profit as per Section 198 of the Companies Act, 2013 for the	21,965.3	21,802.4	19,968.4
preceding three financial years.			

	₹ Millions
4 Average net profit for three years	21,245.4
Prescribed CSR expenditure (2% of Average Net Profit)	424.9
CSR amount unspent as on March 31, 2017	345.1
Total CSR amount available for the financial year 2017-18	770.0
Total value of CSR activities approved during financial year 2017-18	345.7
Contribution made by the Company to Aurobindo Pharma Foundation for CSR Expenditure during the financial year 2017-18*	200.0
CSR amount unspent as on March 31, 2018 and carried forward to next year	570.0

* Out of the total contribution of ₹200 millions, Aurobindo Pharma Foundation paid an amount of ₹177.3 millions to the vendors and the balance amount of ₹22.7 millions is yet to be paid to the vendors for ongoing projects.

Purposes for which the amount was spent on CSR during the financial year is detailed below:

SI. No.	CSR Project or Activity identified	Sector in which the Project is Covered	Projects or Programs (1) Local area or other (2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs sub heads: (1) Direct expenditure on projects or	Cumulative expenditure upto the reporting period	₹ Amount spent: Direct or through implementing agency
ī	Construction, maintenance and repair of classrooms at government schools, compound walls, and play grounds and provided other amenities like furniture, dual desks, etc. Aurobindo Pharma Foundation has provided funds for summer special coaching to 10th class students in various government schools. Provided assistance towards employment enhancing vocational skills for the socially & economically backward students. Provided financial Support to pursue education by economically poor students. Financial assistance for providing free education to orphans, semi- orphans and underprivileged girl children. Aurobindo Pharma Foundation has given financial support for hearing Impaired children towards skill development activities and also for construction of skill development centre and to provide education, health, science and cultural activities at various places.	Promoting Education	Ramachandrapuram, Tellapur village, Bhadurpura, Bachupally & Mallampet, Narsapur, Shivampet, Masaipet, Kodugal, Gaddapotharam and various other villages situated in Hatnoora mandal, Patancheru, Narsapur, Quthbullapur, Sircilla, Jedcherla and Jinnaram Mandals of Telangana State. Pydibhimavaram, Chillapeta, Lankapeta, OVpeta, Nelivada & Mukshumpuram and surrounding villages in Srikakulam, Visakhapatnam & Vizianagaram Districts of Andhra Pradesh state Menakur village, Naidupeta mandal and other villages in Nellore and Chittor districts of Andhra Pradesh state. Chintalapudi village, Guntur District of Andhra Pradesh state Ashray-Akruthi, Srinagar Colony, Hyderabad for hearing impaired children. Skill development centre at "Alluri Sita Rama Raju Vignana Kendram", Visakahapatnam District, Andhra Pradesh State. Sundarayya Vignana Kendram and Makineni Basvapunniah memorial	81,486,297	· · ·	61,486,297	Direct, Visakha- patnam District Collector and through NGO ," GIVE", "Nachiketa Tapovan", "Sai Seva sangh", "Sai Seva sangh", "Sai Rama Raju Vignana Kendhram", "Sundarayya Vignana Kendram", "Sundarayya Vignana Kendram", "Sundarayya Vignana Kendram", "Sundarayya Vignana Kendram", "Sundarayya Vignana Kendram", "Sundarayya Vignana Vedika", "Vande- mataram Foundation" "Sri Srinivasa Charitable Trust".

SI. No.	CSR Project or Activity identified	Sector in which the Project is Covered	Projects or Programs (1) Local area or other (2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs sub heads: (1) Direct expenditure on projects or programs (2) Overheads	Cumulative expenditure upto the reporting period	Amount spent Direct or through implementing agency
	Aurobindo Pharma Foundation has provided - free eye checkup camp with doctors of LV Prasad Eye Institute, Visakhapatnam and provided spectacles to government school children. -financial support for the treatment of poor children suffering from heart defects and facilitated surgeries. - funds for the Treatment of mentally handicapped persons at Chennai and - funds for mentally retarded children at Malkapet, Hyderabad. -funds for treatment of Poor Patient's suffering from Cancer and Kidney Disease. -funds for organizing free health camps, free volunteer services for patients and support for the respiratory intensive care unit at Government General Hospital located at Vijayawada, Andhra Pradesh. -TATA ACE vehicle to collect the garbage from households. -monthly maintenance expenses to three fire stations. Provided 2 sets of forcible entry kits door opener to fire department. - Six Patrolling vehicles two wheelers for Police Department towards public safety purpose. - "Elbow crutches, Wheel chairs, Walkers for the disabled and mentally challenged persons. Provided funds for construction of 30 bed hospital and towards health & education, provided funds to Mallu Venkata Narsimha Reddy Vignana Kendram and for health purpose provided funds towards repairs and renovation of toilets at girls' orphanage.	Promoting preventive health care & Sanitation, Road Safety for Public.	Pydibhimavaram village, Ranasthalam mandal, Srikakulam district, Andhra Pradesh State. Vijayawada , Krishna district, Andhra Pradesh state. Parwada, Visakhapatnam District, Andhra Pradesh state. Little Heart Foundation, Hyderabad. SCARF Foundation, Chennai, Tamilnadu state. Malakpet, Isnapur, Borapatla, Gundlamachnoor, Pashamylaram, and other villages and places in Telangana State.	22,664,133	19,940,328	81,426,625	Direct, and through NGO "Innova Little Heart Foundation", Direct, "SCARF Foundation", NGO "Prema Welfare Society" " UCDS NGO" "Mallu Venkata Narsimha Reddy Vignana Kendram", " Family Eduvision".

SI. No.	CSR Project or Activity identified	Sector in which the Project is Covered	Projects or Programs (1) Local area or other (2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs sub heads: (1) Direct expenditure on projects or programs (2) Overheads	Cumulative expenditure upto the reporting period	Amount spent: Direct or through implementing agency
iii	Aurobindo Pharma Foundation has constructed and also provided financial assistance for construction and maintenance of Water Purification Plants (RO), digging of bore-wells, laid underground water pipelines, supplying drinking water through water tankers, construction of sheds to install RO water plants. Aurobindo Pharma Foundation has provided funds for construction of 40 KL capacity RCC water tank.	Making Available Safe drinking water	Mukshumpuram village, Nalgonda district, and at Indrakaran village, Kandi mandal of Telangana state. Gaddapotharam village, Jinnaram Mandal, Sangareddy District, Telangana state. Singupuram, Dhonipeta Sancham, Naruva and Chillapeta, Alladapalem villages in Ranasthalam mandal, Srikakulam district, Andhra Pradesh state.	3,152,920	3,152,920	84,579,545	Direct.
iv	Aurobindo Pharma Foundation has started a project to set up fully automated centralized kitchen to cook hot nutritious food for 25,000 underprivileged people. Aurobindo Pharma Foundation has distributed Food and water and distributed provisions to the poor families for immediate relief from the fire mishap that occured at Chinna kovvada village, and at Sancham punnapem village, Srikakulam district, Andhra Pradesh state.	Eradicating Hunger, Poverty, Malnutrition and Preventive Health care	Singupuram, Chinna Kovvada, Sancham Punnapalem villages in Ranasthalam mandal, Srikakulam district, Andhra Pradesh state.	19,760,000	19,760,000	104,339,545	Through Hare Krishna Movement Charitable Foundation, Direct.
V	Pradesh state. Aurobindo Pharma Foundation has provided funds to rural sportswomen & men for taking training in rural sports, and other nationally recognised sports. Provided funds for conducting inter district school games for government school children in Indrakarars Village, Kandi Mandal, Sangareddy Dist, Telangana State and at Visakhapatnam Dist., in Andhra Pradesh State.	Promotion of Rural Sports	Sports meet at Indrakaran village, Kandi mandal, Sangareddy district, Telangana state and sports meet at Visakhapatnam district, Andhra Pradesh State. Kothapalli Village, Kothamunchur post, Valmikipuram mandal, Chittoor District of Andhra Pradesh,	2,130,910	2,130,910	106,470,455	Direct
			Kowkuntla Village, Chevella Mandal of Telangana State.				

31. 10.	CSR Project or Activity identified	Sector in which the Project is Covered	Projects or Programs (1) Local area or other (2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs sub heads: (1) Direct expenditure on projects or programs (2) Overheads	Cumulative expenditure upto the reporting period	Amount spent: Direct or through implementing agency
<i>i</i>	Aurobindo Pharma Foundation under Rural Development projects, provided funds for infrastructure facilities for laying / widening/repairing of roads in rural areas and construction of village sewage water drainage system. Construction of culverts for public purpose, laying of roads for welfare of farmers. Aurobindo Pharma Foundation has Adopted villages and done various development works. Under 'Haritha Haram' Program, planted trees and erected plastic tree guards and providing funds for monthly maintenance of plants. Provided funds towards skill development & employment enhancing programs for the rural youth and development of poor and marginal farmers. Towards safety of public, repaired and renovated Police Station. Provided funds to improve livelihood of 50 small farmers by installing solar fencing to protect crops from wild animals. Aurobindo Pharma Foundation has installed CC Cameras for public safety and also provided funds to "Sri Rama Jeeva Seva Sadan goshala" and goshala located at "Avadhana Saraswathi Peetham". Aurobindo Pharma Foundation has provided Solar street lights in rural areas, and also road stoppers for public safety purpose. Aurobindo Pharma Foundation has provided funds towards protection of rivers banks.	Rural Development Projects, Environmental Sustainability, ecological balance & conservation of natural resources & Animal Welfare.	Janwada, Reddy Khanapur, Chitkul, Paniyal, Nandigama Village, Gaddapotharam, Jadcherla, Borapatla, Polepally village, Hatnoora Mandal, Sangareddy District. Polepally village, Jadcherla mandal, Mahboobnagar district and at Nagar Kurnool district, Telangana State. Kandivalassa gadda, Urvakonda, Pydibhimavaram and Parwada villages in Ananthapur, Srikakulam and Visakhapatnam Districts, Andhra Pradesh. Adopted Borapatla village in sangareddy district, Telangana state and Peyalapalem village in Nellore district, Andhra Pradesh. Skill development and medical camps in rural areas of Nalgonda district, Telangana state, and at Krishna District of Andhra Pradesh State. Goshala at Avadhana Saraswathi Peetham, Madhapur, Hyderabad, Telangana State. Provided 588 nos. of solar street lights at various villages in Pali District of Rajasthan State. 130 nos. of street lights at Nimmada village, Kotabommali mandal, Andhra Pradesh State.	61,696,048	61,696,048	168,166,503	Direct, and through NGO's "Green Revolution" "MAS", "Nava Chethana Vignana Samithi" "Consortium of Indian Farmer's Association". "Cornell Sathguru Foundation for Develop- ment" Direct.
/ii	Aurobindo Pharma Foundation has contributed towards old age home expansion and maintenance.	Setting up of Old age homes	Anadha Sharan Charitable Trust – Old Age home at K.V. Pally village, Chittoor district, Andhra Pradesh State.	1,500,000	1,500,000	169,666,503	Direct
			Old Age Home at Sri Ganapathi Sachidananda Avadhoota Peetha Trust at Dundigal, Medchal Malkajgiri District, Telangana state.				

							र
SI. No.	CSR Project or Activity identified	Sector in which the Project is Covered	Projects or Programs (1) Local area or other (2) Specify the state and district where projects or programs was undertaken	Amount outlay (budget) project or programs wise	Amount spent on the projects or programs sub heads: (1) Direct expenditure on projects or programs (2) Overheads	Cumulative expenditure upto the reporting period	Amount spent: Direct or through implementing agency
Viii	Salaries paid by Aurobindo Pharma Foundation to CSR staff exclusively working on CSR activities being carried on through Aurobindo Pharma Foundation, printing, stationery & other administration expenses of Aurobindo Pharma Foundation.	CSR Expenditure	Aurobindo Pharma Foundation India Offices and facilities.	7,609,692	7,609,692	177,276,195	Direct
то	TAL:			200,000,000	177,276,195	177,276,195	

5. The Company could not spend entire two percent of average net profits of the last three financial years. Out of the sanctioned amounts some of the works are ongoing and once the works are completed the committed amounts will be released. The Company is making efforts to identify the projects for spending the unspent and carried forward CSR funds. All unspent CSR funds of previous year (s) are carried forward for spending on CSR activities.

6. We hereby confirm that the implementation and monitoring of CSR Policy, is in compliance with CSR objectives and Policy of the Company.

Place: Hyderabad Date: 28 May 2018 K. Nithyananda Reddy Chairman of the CSR Committee DIN: 01284195 N. Govindarajan Managing Director DIN: 00050482

ANNEXURE-7

Information pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

(i) Ratio of the remuneration of each director to the median remuneation of the employees of the Company for the financial year

	Name & designation	Ratio
а	Mr. K. Nithyananda Reddy, Vice Chairman & Wholetime Director	37 : 1
b	Mr. N. Govindarajan, Managing Director	354:1
С	Dr. M. Sivakumaran, Wholetime Direcetor	37 : 1
d	Mr. M. Madan Mohan Reddy, Wholetime Director	75 : 1
е	Mr.P.Sarath Chandra Reddy	20:1

(ii) The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officers, Company Secretary or Manager in the financial year

	Name & category	Increment Percentage
а	Mr. K. Nithyananda Reddy, Vice Chairman & Wholetime Director*	0.00
b	Mr. N. Govindarajan, Managing Director	17.65
С	Dr. M. Sivakumaran, Wholetime Direcetor*	0.00
d	Mr. M. Madan Mohan Reddy, Wholetime Director*	0.00
е	Mr. S. Subramanian, Chief Financial Officer**	31.15
f	Mr.P.Sarath Chandra Reddy***	0.00
h	Mr.B Adi Reddy, Company Secretary ****	10.43

* No increment given during the financial year 2017-18. The increase in remuneration is due to EL encashment.

** Increase in remuneration is inclusive of long term incentive payable biennial.

*** Joined on June 1, 2016. No increment given during the financial year 2017-18

- **** Joined on June 1, 2016. Hence, increment percentage adjusted proportionately.
- (iii) The percentage increase in the median remuneration of employees in the financial year was 9.06%
- (iv) The number of permanent employees on the rolls of the Company as on March 31, 2018 was 16,356.
- (v) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration

The percentage increase in the salaries of the employees other than managerial personnel in the last financial year is 13.76% as against 23.79% increase in the salaries of managerial persons. The increase in salary in case of managerial persons is mainly on account of revision in the salary.

(vi) The remuneration paid to Key Managerial Persons is as per the Remuneration policy of the Company.

Financial Statements

Statement of particulars of employees pursuant to the provisions of Rule (5) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Financial Year 2017-18

Top 10 employees in terms of remuneration drawn during the financial year

S No	Name & designation	Designation	Remuneration Received (₹Million)	Qualification & Experience	Date of Commencement of employment	Age (Years)	The last employment held by such employee before joining the Company;
1	Mr. N. Govindarajan	Managing Director	146.27	B.E., 28 Years	7-Oct-10	50	Shasun Chemicals & Drugs Ltd.
2	Mr. Sanjeev Indravadan Dani	Chief Operating Officer- Head Formulations	32.12	B.Pharm., M.B.A., 34 Years	9-Jul-15	58	Ranbaxy Laboratories Ltd.
3	Dr. V. K. Handa	President - Chemical Research	29.70	Ph.D, 35 Years	1-Jan-99	66	Ranbaxy Research Laboratories
4	Mr. M. Madan Mohan Reddy	Wholetime Director	26.74	M.Sc, 28 Years	27-May-03	58	Ranit Pharma Limited
5	Mr. V. Naga Prasad	President-FRD	21.47	M.Pharm., 26 Years	16-Mar-06	51	Ranbaxy Research Laboratories
6	Dr. A. Rama Mohana Rao	President -Corporate QA	21.47	Ph.D, 30 Years	7-May-01	56	Biological E Limited
7	Dr. S Vijaya Kumar	President-Technical	17.00	M.Tech., Ph.D, 29 Years	2-Nov-16	52	Jubilant Generics Ltd.,
8	Dr. A. T. Bapuji	Associate President- CPD-BIO	16.61	Ph.D, 26 Years	25-Oct-04	51	Ranbaxy Research Laboratories
9	Mr. Atul Sadashiv Shastri	Associate President- Operations	15.88	M.Pharm., 28 Years	8-Dec-14	52	Ranbaxy Laboratories Ltd.
10	Dr. Hemant Kumar Sharma	Associate President- Analytical Research	15.76	Ph.D, 24 Years	14-Jul-00	50	Ranbaxy Research Laboratories

Employees drawing a remuneration of ₹1.02 crore or above per annum

S No	Name & designation	Designation	Remuneration Received (₹Million)	Qualification & Experience	Date of Commencement of employment	Age (Years)	The last employment held by such employee before joining the Company;
1	Mr. K. Nithyananda Reddy	Vice Chairman & Wholetime Director	15.12	M.Sc, 31 years	1-Jan-89	60	Tini Pharma Ltd.
2	Dr. M. Sivakumaran	Wholetime Director	15.12	M.Sc, Ph.D., 45 Years	1-Jan-89	75	TTK Pharma Ltd.
3	Mr. S. Subramanian	Chief Financial Officer	14.27	B.Sc., ACA, ACS, AICWA, 32 Years	1-Nov-13	57	RSB Global, Pune
4	Dr. Gita Rao	Associate President- RAD- II	13.56	Ph.D, 21 Years	1-Jan-04	51	Lupin Limited,
5	Dr. Makkapati Satakarni	President-Biologics	12.71	Ph.D, 11 Years	3-Feb-16	37	Intas Pharma
6	Mr. G. Bhaskar Reddy	Vice President -Operations	11.43	B.Pharm., 22 Years	8-Jun-95	47	Rhonac Lab Pvt Ltd.,
7	Mr. I.V.S.S. Prasad	Vice President -Operations	11.17	B.Sc., 30 Years	2-Nov-11	52	Hetero Drugs Limited
8	Mr. Sudhanshu Radhakrishna Kamat	Vice President- Business Development	10.62	B.Com., 27 Years	1-Feb-16	53	Mylan Laboratories
9	Mr. Medisetti V Rama Krishna	Vice President -Operations	10.38	B.E., 24 Years	12-Aug-16	48	Dr. Reddy's Laboratories Ltd.,
10	Mr. Sudhir B Singhi	Head-Global Finance Operations	10.17	B.Com., C.A., I.C.W.A.I. 29 Years	23-Mar-05	49	Procon Financials and Investiments Pvt Ltd

Employed for part of the year with average salary abvoe ₹8.5 lakhs per month.

S No Name & designation		Received Experience (₹Million)		Qualification & Experience	Date of Commencement of employment	Age (Years)	The last employment held by such employee before joining the Company;	
1	Mr. Satnam Singh	Senior Vice President -	9.50	B.Tech.,	1-Dec-15	50	Sun Pharmaceutical	
	Loomba	Operations		27 Years			Industries Ltd	
2	Mr. D Surya Narayana	Vice President-Process	6.83	Ph.D, 31 Years	16-Aug-17	47	Mylan Laboratories	
		Development						
3	Mr. Ashok Kumar	Senior Vice President -	5.08	B.Pharm.,	17-Dec-15	48	Shaline Healthcare,	
	Saxena	Operations		P.G.D.M.,			Dubai	
				26 Years				

Note: 1. Gross Remuneration includes salary, taxable allowances, commission, value of perquisites as per the Income Tax Rules, 1962 and Company contribution to Providend fund.

- 2. Nature of employment and duties: Contractual and in accordance with the terms and conditions as per Company's rules.
- 3. No employee is a relative of any Director or Key Managerial Personnel of the Company except Mr. K. Nithyananda Reddy, who is relative of Mr.P.Sarath Chandra Reddy, Director of the Company.
- 4. The percentage of equity shares hedl by each of the employee in the Company within the meaning of clause (III) of sub-rule(2) of Rule 5 is not applicable.

For and on behalf of the Board

Place: Hyderabad Date: 28 May 2018 K. Ragunathan Chairman DIN: 00523576

REPORT ON CORPORATE GOVERNANCE

The Directors present the Company's Report on Corporate Governance pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations 2015).

COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

Aurobindo has always attached great importance to good and responsible corporate governance. The Company belongs to all the stakeholders and the corporate objective is to maximize shareholder value ethically and legally. Efforts are therefore made to raise the level of transparency, trust and confidence of stakeholders in the way the Company is run. The team at Aurobindo operates as a trustee on behalf of every shareholder large or small.

The Company will continue to strive to be a wealth creator to meet stakeholder expectations and be a responsible citizen in its societal commitments. In the achievement of its goals, the Company utilizes its resources with accountability and professionalism to meet the needs of customers and deliver on their expectations; meet the commitments with vendors, partners, employees, governments and the community.

BOARD OF DIRECTORS

The Board of Directors guides, directs and oversees the management and protects long term interests of shareholders, employees and the society, at large. The Board also ensures compliance of the applicable provisions and code of ethical standards wherever the Company and its subsidiaries are present.

SIZE AND COMPOSITION OF THE BOARD

As on March 31, 2018, the Board consists of ten Directors. Five of them are Executive and five are Non-Executive Directors, including four independent of which two are women. Your Company has taken all necessary steps to strengthen the Board with optimum combination of executive and non-executive/ independent directors.

Composition of Board of Directors as on March 31, 2018

Name	Category	Number of Board Meetings attended	Attendance at the last AGM held on August 31, 2017	Number of Director- ships in other companies*	held ir	e positions other	No. of equity shares of ₹1 each held in the Company
Mr.K.Ragunathan	Non-executive Independent	5	Yes	2	-	-	-
Mr.K.Nithyananda Reddy	Promoter and Executive	4	Yes	10	-	1	25,359,572
Mr. N. Govindarajan	Executive	5	Yes	-	-	-	-
Dr.M.Sivakumaran	Executive	5	Yes	6	-	-	14,491,360
Mr.M.Madan Mohan Reddy	Executive	5	Yes	9	-	-	2,010
Mr.P.V.Ramprasad Reddy	Promoter and Non-Executive	2	Yes	2	-	-	18,000,000
Mr.P.Sarath Chandra Reddy	Executive	5	Yes	7	-	-	-
Mr.M.Sitarama Murty	Non-executive Independent	5	Yes	1	1	-	-
Dr. (Mrs.) Avnit Bimal Singh	Non-executive Independent	4	Yes	-	-	-	-
Mrs.Savita Mahajan^	Non-executive Independent	-	-	1	_	-	

* The directorships are in the companies incorporated under the Companies Act, 1956/2013.

** Includes only Audit and Stakeholders Relationship Committee

^ Appointed w.e.f. 16 December, 2017.

Note:

- 1. Leave of absence was granted on request to those directors who could not attend the meeting(s).
- 2. Mrs. Savita Mahajan, who was appointed as an Independent Director of the Company with effect from December 16, 2017 has not attended any meeting during the year held from that date.
- 3. Mr. Rangaswamy Rathakrishnan lyer who resigned from the Board with effect from December 9, 2017 attended four meetings during the year held up to that date.

During the year, five Board Meetings were held on the following dates:

Date of Meeting	Board Strength	Number of Directors Present
May 29, 2017	10	9
June 20, 2017	10	9
August 9, 2017	10	9
November 9, 2017	10	9
February 7, 2018	10	8

Disclosure of relationships between directors inter-se

Mr. P. Sarath Chandra Reddy, Whole-time Director of the Company, is son of Mr. P.V. Ramprasad Reddy, Director and sonin-law of Mr. K. Nithyananda Reddy, Vice Chairman. Other than Mr. P.Sarath Chandra Reddy, Mr. P.V.Ramprasad Reddy and Mr. K. Nithyananda Reddy, none of the Directors are related to any other Director.

Details about familiarization program

Senior management personnel of the Company make presentations to the Board Members on periodical basis, briefing them on the operations of the Company, plans, strategy, risks involved, new initiatives etc., and seek their opinions and suggestions on the same. Also, the Directors are briefed on their specific responsibilities and duties that may arise from time to time. Any new Director who joins the Board is presented with a brief background of the Company, its operations and is informed of the important policies of the Company including the Code of Conduct for Directors and Senior Management Personnel and the Code of Conduct for Prevention of Insider Trading, Policy on Related Party Transactions, Policy on Remuneration, Policy on material subsidiaries, Whistle Blower Policy, Risk Management Policy, Corporate Social Responsibility Policy etc.

The details of the familiarization program are placed on the Company's website at: http://www.aurobindo.com/aboutus/ corporate-governance

Details of Directors proposed for appointment /reappointment at the Annual General Meeting

Mr. K.Nithyananda Reddy and Mr.M.Madan Mohan Reddy retire by rotation and being eligible, seek reappointment.

Mr. K. Nithyananda Reddy, Dr. M.Sivakumaran and Mr.M. Madan Mohan Reddy are proposed to be re-appointed as Whole-time Directors of the Company.

Mr. N. Govindarajan is proposed to be re-appointed as Managing Director of the Company.

Mrs. Savita Mahajan is proposed to be appointed as an Independent Director of the Company.

Further details of aforesaid directors seeking appointment/ reappointment at the forthcoming Annual General Meeting as required pursuant to Regulation 36 of SEBI (LODR) Regulations, 2015 and Secretarial Standard on General Meetings, are annexed to the Notice convening the Annual General Meeting and forming part of this Annual Report

AUDIT COMMITTEE

The scope and function of the Audit Committee is to regularly review the internal control systems and procedures, accounting policies and other matters that protect the interest of the stakeholders, ensure compliance with the laws of the land, and monitor with a view to provide effective supervision of the management's process, ensure accurate, timely and proper disclosures, transparency, integrity and quality of financial reporting. The composition, procedures, powers and role/ functions of the Audit Committee constituted by the Company comply with the requirements of Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and provisions of the Companies Act, 2013.

Role of Audit Committee

The role of the Audit Committee includes the following:

- Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommendation for appointment, remuneration and terms of appointment of auditors of the company;
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- Review, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013;
 - Changes, if any, in accounting policies and practices and reasons for the same;
 - Major accounting entries involving estimates based on the exercise of judgment by management;
 - Significant adjustments made in the financial statements arising out of audit findings;
 - Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions;
 - Qualifications in the draft audit report;
- Review, with the management, the quarterly financial statements before submission to the Board for approval;
- Review, with the management, the statement of uses/ application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds

utilized for purposes other than those stated in the offer document/prospectus/notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;

- Review and monitor the auditor's independence and performance, and effectiveness of audit process;
- Approval or any subsequent modification of transactions of the company with related parties;
- Scrutiny of inter-corporate loans and investments;
- Valuation of undertakings or assets of the company, wherever it is necessary;
- Evaluation of internal financial controls and risk management systems;
- Review, with the management, performance of statutory and internal auditors, adequacy of the internal financial control systems;
- Review the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there on;
- Review the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- Examine into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- Review the functioning of the Whistle Blower mechanism;
- Approval of appointment of CFO (i.e. the whole-time finance director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
- Carry out any other function as is mentioned in the terms of reference of the Audit Committee under Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations and Companies Act, 2013.
- To review:
 - Management discussion and analysis of financial condition and results of operations;
 - Adequacy of internal control systems and the Company's statement on the same prior to

endorsement by the Board, such review to be done in consultation with the management, Statutory and Internal Auditors;

- Reports of Internal Audit and discussion with Internal Auditors on any significant findings and follow-up thereon;
- System for storage, retrieval, security etc. of books of account maintained in the electronic form;
- Functioning of Whistle Blower mechanism in the Company.

Composition and other details of Audit Committee

The Audit Committee comprises of three Non-Executive Directors, all of them being independent directors. The heads of finance & accounts, internal auditors and the representative of the statutory auditors are invitees to the meetings of the Audit Committee. The Company Secretary is the Secretary to the Committee.

Mr. M. Sitarama Murty, Chairman of the Committee, is a Non-Executive, Independent Director having expertise in accounting and financial management. Mr. K.Ragunathan and Mr.Rangaswamy Rathakrishnan lyer (up to December 9, 2017) and Mrs.Savita Mahajan (w.e.f. December 16, 2017) are the members of the Committee.

During the year, the Audit Committee met six times on May 29, 2017; June 20, 2017; August 9, 2017; November 9, 2017; February 7, 2018 and March 28, 2018.

The attendance at the Audit Committee meetings during the financial year 2017-18 is as under:

Name of the Committee Member	No. of Meetings held during his/her tenure	Attended
Mr. M Sitarama Murty	6	6
Mr. K.Ragunathan	6	6
Mr. Rangaswamy	4	4
Rathakrishnan lyer ¹		
Mrs. Savita Mahajan ²	2	1

- Note: 1. Mr. Rangaswamy Rathakrishnan lyer ceased to be member w.e.f. December 9, 2017. He attended four meetings held during his tenure.
 - 2. Mrs Savita Mahajan was appointed as a member of Audit Committee with effect from December 16, 2017. She attended one meeting held after her appointment.

NOMINATION AND REMUNERATION / COMPENSATION COMMITTEE

Brief description of terms of reference of the Nomination and Remuneration/Compensation Committee

• Identifying persons who are qualified to become directors

and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board their appointment and removal;

- Carry out evaluation of every director's performance;
- Formulation of the criteria for determining qualifications, positive attributes and independence of a director;
- Recommend to the Board a policy, relating to the remuneration for the directors, key managerial personnel and other employees;
- Formulation of the criteria for evaluation of Independent Directors and the Board;
- Devising a policy on Board diversity;
- Grant of options to eligible employees and administering the employee stock option scheme of the Company;
- Any other matter as the Board may decide from time to time.

Composition and other details of Nomination and Remuneration/Compensation Committee

The composition of the Nomination and Remuneration/ Compensation Committee comprises of three Non-Executive Directors; all of them are independent directors.

Dr. (Mrs) Avnit Bimal Singh is the Chairperson of the Committee and Mr.M.Sitarama Murty, and Mr.K.Ragunathan are other Members of the Committee. During the year, the Nomination and Remuneration/Compensation Committee met two times on May 29, 2017 and March 28, 2018.

Meetings and attendance during the year

The attendance at the Nomination and Remuneration/ Compensation Committee meetings during the financial year 2017-18 is as under:

Name of the Committee Member	No. of Meetings held during his / her tenure	Attended	
Dr.(Mrs.) Avnit Bimal Singh	2	2	
Mr. M Sitarama Murty	2	2	
Mr. K.Ragunathan	2	2	

Nomination/Remuneration Policy

The compensation of the Executive Directors comprises of fixed component, perquisites and commission. The compensation is determined based on the remuneration prevailing in the industry and the performance of the Company. The remuneration package of the Executive Directors is periodically reviewed and suitable revision is recommended to the Board by the Committee. The Non-Executive Directors are paid sitting fees for attending meetings of Board/Committee.

The nomination and remuneration policy as adopted by the Board is placed on the Company's website at: http://www.aurobindo. com/about-us/corporate-governance

Performance evaluation criteria for independent directors

The performance evaluation shall be done on an annual basis. Each Director shall be provided an evaluation sheet in the form of questionnaire. The ratings shall be provided by all the Directors except the Independent Director being evaluated.

On the basis of the report of performance evaluation, it shall be determined by the Nomination and Remuneration/Compensation Committee and Board whether to extend or continue the term of appointment of Independent Director subject to all other applicable provisions.

REMUNERATION OF DIRECTORS

Details of remuneration paid to the Directors during the financial year 2017-18 are as follows:

a. Executive Directors

							(₹)
Name	Salary	Benefits (Perquisites)	Bonus	Pension	Commission	Contribution to P.F.	Total
Mr. K.Nithyananda Reddy	12,999,996	2,100,004	-	-	-	21,600	15,121,600
Dr. M.Sivakumaran	12,999,996	2,100,004	-	-	-	21,600	15,121,600
Mr. M.Madan Mohan Reddy	22,999,992	3,715,381	-	-	-	21,600	26,736,973
Mr. N. Govindarajan	38,718,792	7,535,771	-	-	100,000,000	21,600	146,276,163
Mr. P.Sarath Chandra Reddy	7,500,000	750,000	-	-	-	21,600	8,271,600
Total	95,218,776	16,201,160	-	-	100,000,000	108,000	211,527,936

Mr. K.Nithyananda Reddy, Dr. M.Sivakumaran, Mr. M.Madan Mohan Reddy and Mr. N. Govindarajan were re-appointed as executive directors w.e.f June 01, 2015 for a period of 3 years and Mr. P.Sarath Chandra Reddy was appointed as an executive director w.e.f June 01, 2016 for a period of 3 years on the terms and conditions contained in the respective resolutions passed by the Members in the General Meetings. The Notice period is as per the rules of the Company. There was no severance fee.

Mr. N. Govindarajan, Managing Director was granted options under Employee Stock Option Plan (ESOP) of the Company and all the options were vested and exercised during the year 2016-17. No other directors were granted options under ESOP.

b. Non-Executive Directors

There were no pecuniary transactions with any non-executive director of the Company.

Non-Executive Directors are paid Sitting Fee for attending the Board and Committee Meetings. Sitting fee of ₹100,000 is being paid to Non-Executive Directors for attending each meeting of the Board of Directors and ₹50,000 for each meeting of the Committees of Board of Directors. During the year, the sitting fees paid was as follows:

Name	
Mr.M.Sitarama Murty	1,050,000
Mr.K.Ragunathan	1,000,000
Dr.(Mrs.) Avnit Bimal Singh	550,000
Mr.P.V. Ramprasad Reddy	
Mr. Rangaswamy Rathakrishnan lyer (up to December 9, 2017)	
Mrs. Savita Mahajan (w.e.f December 16, 2017)	100,000

STAKEHOLDERS RELATIONSHIP COMMITTEE

Composition

Dr. (Mrs) Avnit Bimal Singh, a Non-Executive Independent Director is the Chairperson of the Committee and Mr. K. Nithyananda Reddy, Mr. M. Madan Mohan Reddy and Mr. P. Sarath Chandra Reddy are the other members of the Committee.

Terms of reference

Stakeholders Relationship Committee considers and resolves all matters of the grievances of the security holders of the Company including complaints related to transfer of shares, non-receipt of annual reports, dividends, issue of duplicate share certificates etc.

Name and designation of Compliance Officer

Mr. B.Adi Reddy, Company Secretary

E-mail ID for investor grievances: ig@aurobindo.com

Investor Complaints

During the year ended March 31, 2018, the Company has received and resolved 31 complaints from investors. Number of complaints not resolved to the satisfaction of shareholders is nil and there were no pending complaints at the year end.

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

As per the Companies Act, 2013, the Company is required to constitute a Corporate Social Responsibility (CSR) Committee of the Board consisting of three or more directors, at least one of whom will be an independent director. The constitution of CSR Committee is as under:

Mr. K. Nithyananda Reddy, Chairman

Mr. K. Ragunathan, Member

Dr. M. Sivakumaran, Member

Mr. P. Sarath Chandra Reddy, Member

The purpose of the Committee is to formulate CSR Policy of the Company and monitor its implementation.

The CSR Policy has been placed on the Company's website at: http://www.aurobindo.com/about-us/corporate-governance.

Annual report on the CSR activities of the Company during the year is also placed on the Company's website at: http://www. aurobindo.com/social-responsibility/csr-activities.

GENERAL BODY MEETINGS

Details of the last three Annual General Meetings are as under:

Year	Location	Date	Time	No. of Special Resolutions passed
2015	Taj Deccan, Hyderabad	August 27,2015	3.00 p.m	1
2016	Hotel Taj Krishna, Hyderabad	August 24,2016	3.30 p.m	Nil
2017	Hotel Trident, Hyderabad	August 31,2017	3.00 p.m	Nil

No special resolution passed last year through postal ballot and no special resolution is proposed to be passed through postal ballot.

MEANS OF COMMUNICATION

The Company has a website www.aurobindo.com. The quarterly and half yearly financial statements are not sent to the individual households of the Members; however, the same are placed on the Company's website for the information of Members and general public and also published in leading newspapers in English and Telugu (Regional language). Further all material information which has some bearing on the operations of the Company is sent to the stock exchanges and also placed on the Company's website www. aurobindo.com.

The presentations made to the investors, analysts are placed on the Company's website www.aurobindo.com.

The Management Discussion and Analysis forms part of this Report and is provided separately in the Annual Report.

GENERAL SHAREHOLDERS INFORMATION

31st Annual General Meeting

As mentioned in the Notice, the 31st Annual General Meeting of the Company will be held on Thursday, 30th day of August, 2018 at 3.00 p.m. at Kaveri Ball Room, Hotel Trident, Hi-tech City,Near Cyber Towers, Madhapur, Hyderabad 500 081.

Financial Year

The financial year of the Company is April to March.

Financial calendar (tentative and subject to change) of the financial year 2018-19 is as follows:

Unaudited Financial results for	Declaration on or before
1st Quarter	August 14, 2018
2nd Quarter	November 14, 2018
3rd Quarter	February 14, 2019
4th Quarter	May 30, 2019

Payment of Dividend

The Company has paid interim dividend of 150% (₹1.50 per equity share of ₹1 each) in the month of November 2017 and second interim dividend of 100% (₹1/- per equity share of ₹1 each) in the month of February 2018, on the equity share capital of the Company for the financial year 2017-18. The total dividend, for the year ended March 31, 2018 was 250% (₹2.50 per equity share of ₹1/-) on the equity share capital of the Company. The Board of Directors does not recommend any further dividend for the financial year 2017-18.

Name and address of each stock exchange(s) at which the shares are listed

The Company's shares are listed on the following stock exchanges:

Name and address Stock Exchange(s)	Stock Code
BSE Limited (BSE) 5248	
Phiroze Jeejeebhoy Towers	
25th Floor, Dalal Street, Mumbai - 400 001	
National Stock Exchange of India Limited (NSE)	AUROPHARMA
Exchange Plaza, Bandra-Kurla Complex	
Bandra (East), Mumbai - 400 051	


Listing fees for the financial year 2018-19 has been paid to the above stock exchanges.

ISIN: INE406A01037

Market Price data:


High, low during each month in last financial year and volume of shares traded on NSE

Month			NSE (₹)			S & P CNX Nifty	
		High	Low	Close	Volume	High	Low
	April	687.00	604.10	606.75	3,03,28,919	9367.15	9075.15
	May	626.80	503.05	574.15	8,45,23,502	9649.60	9269.90
	June	692.65	570.25	684.60	8,42,02,349	9709.30	9491.25
	July	794.70	669.50	718.60	6,02,44,956	10114.85	9543.55
2017	August	750.40	665.00	725.25	5,44,52,956	10137.85	9685.55
	September	776.00	665.05	691.65	5,58,92,461	10178.95	9687.55
	October	775.00	694.85	760.00	4,14,80,647	10384.50	9831.05
	November	809.45	689.05	692.85	6,61,29,611	10490.45	10094.00
	December	702.60	650.00	687.95	3,90,46,164	10552.40	10033.35
	January	698.80	623.00	629.55	4,05,24,452	11171.55	10404.65
2018	February	631.35	560.70	613.90	5,65,31,963	11117.35	10276.30
	March	628.00	544.10	557.85	5,94,95,881	10525.50	9951.90
	March	628.00	544.10	557.85	5,94,95,881	10525.50	ç



High, low during each month in last financial year and volume of shares traded on BSE

Month			BSE (₹)			BSE Se	BSE Sensex	
		High	Low	Close	Volume	High	Low	
	April	686.85	603.60	606.05	31,96,584	30,184.22	29,241.48	
	May	627.75	504.00	574.15	89,26,610	31,255.28	29,804.12	
	June	692.50	571.00	683.45	79,07,578	31,522.87	30,680.66	
	July	794.50	670.00	719.40	58,22,824	32,672.66	31,017.11	
2017	August	751.10	666.25	725.25	50,81,766	32,686.48	31,128.02	
	September	775.30	666.40	691.75	56,64,874	32,524.11	31,081.83	
	October	774.00	695.85	761.30	30,04,372	33,340.17	31,440.48	
	November	808.95	690.00	694.70	51,84,531	33,865.95	32,683.59	
	December	702.50	650.25	688.30	32,37,772	34,137.97	32,565.16	
	January	699.20	624.00	629.50	30,40,177	36,443.98	33,703.37	
2018	February	631.05	560.25	613.45	43,73,308	36,256.83	33,482.81	
	March	627.65	544.30	557.25	36,98,230	34,278.63	32,483.84	



There was no suspension of trading in Securities of the Company during the year under review.

Registrar to an issue and share transfer agents

M/s. Karvy Computershare Private Limited is the Registrar & Share Transfer Agent and Depository Transfer Agent of the Company. Any request pertaining to investor relations may be forwarded to them at the following address:

Ms. C. Shobha Anand Karvy Computershare Private Limited Unit: Aurobindo Pharma Limited Karvy Selenium, Tower B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 Phone: +91 40 6716 2222 Fax: +91 40 2300 1153 E-mail: einward.ris@karvy.com

Share transfer system and dematerialization of shares and liquidity

The Company's shares are covered under the compulsory dematerialization list and are transferable through the depository system. The Company has appointed M/s. Karvy Computershare Private Limited as its Registrar and Share Transfer Agent and also Depository Transfer Agent. Shares received for physical transfer are generally registered within a period of 15 days from the date of receipt, subject to fulfillment of other legal formalities. The Compliance Officer has been delegated the power to approve the share transfers and the information is placed to the Board in each meeting. Further, the Company has signed a tripartite agreement with NSDL/CDSL and M/s. Karvy Computershare Private Limited to facilitate dematerialization of shares. The Members may contact for the redressal of their grievances either M/s. Karvy Computershare Private Limited or to the Company Secretary, Aurobindo Pharma Limited. Further, SEBI has decided that securities of listed companies can be transferred only in dematerialized form, from a cut-off date, to be notified.

Distribution of shareholding Distribution Schedule - As on March 31, 2018

Category	No. of Shareholders	% of No. of shareholders	Total Shares	Amount (₹)	% of Amount
1-5000	222,358	99.09	34,556,785	34,556,785	5.90
5001-10000	918	0.41	6,820,830	6,820,830	1.17
10001-20000	382	0.17	5,591,973	5,591,973	0.95
20001-30000	149	0.07	3,654,798	3,654,798	0.62
30001-40000	84	0.04	2,941,953	2,941,953	0.50
40001- 50000	47	0.02	2,123,318	2,123,318	0.36
50001- 100000	144	0.06	10,481,195	10,481,195	1.79
100001& Above	313	0.14	519,736,757	519,736,757	88.71
Total	224,395	100.00	585,907,609	585,907,609	100.00

Categories of shareholders as on March 31, 2018

Category	No. of Shares	%
Promoters & Directors	303,927,944	51.87
NRIs/FPIs/Foreign Nationals	108,901,790	18.59
Fls / Banks	1,542,088	0.26
Mutual Funds	88,223,316	15.06
Insurance companies	1,819,681	0.31
Body corporates	1,699,511	0.29
General public and others	79,793,279	13.62
Total	585,907,609	100.00

Outstanding GDR/ADR/warrants or any convertible instruments, conversion date and likely impact on equity

The Company has not issued any GDR/ADR and there are no outstanding warrants or any convertible instruments.

Commodity Price Risk or Foreign Exchange risk and hedging activities

Detailed information on commodity price risk and foreign exchange risk has been provided under Management of Risks which forms part of this annual report. The Company has not undertaken any hedging activities for commodity price risk and foreign exchange risk.

Plant locations of manufacturing and R&D facilities

Address
Survey No.379, 385, 386, 388 to 396 & 269, Borpatla Village, Hatnoor Mandal, Sangareddy District, 502296, Telangana.
Plot No.103/A & 104/A, SVCIE, Industrial Development Area, Bollaram, Jinnaram Mandal Sangareddy District, 500 092, Telangana.
Survey No.313 & 314 Bachupally Village, Bachupally Mandal, Medchal Malkajgiri District, 500090, Telangana.
Plot No.4 in Sy. No.151 and Plot Nos.34 to 48 in Sy. Nos. part of 146, 150, 151, 152, 153 and 154 situated in Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Pattahcneru Revenue Mandal , Sangareddy District 502307, Telangana.
Plot Nos.68 to 70, 73 to 91, 95, 96, 260 & 261, Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana.
Survey No. 329/39 & 329/47, Chitkul Village, Patancheru Mandal, Sangareddy District, 502307, Telangana.
Sy.Nos.411/P, 425/P, 434/P, 435/P & 458/P, Plot No.S1/A, Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboob Nagar District, 509302, Telangana.
Survey No.10 & 13, Gaddapothram, Industrial Development Area – Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana.
Survey No.305, 369, 370, 371, 372, 373, 374& 377, Gundlamachanoor Village, Hatnoora Mandal, Sangareddy District, 502296, Telangana.
Plot No 16, APIIC, Multi product SEZ at Sy.No.3 (P) to 6(P) & 413(P) & 416(P) Palchur village and 113 Part of Palepalem Village Naidupeta Mandal, PSR Nellore District 524126, Andhra Pradesh.
Survey No. 52-78, of Pydibhimavaram Village, Survey No.2-11 & 29-32 of Chittivalasa Village Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam District, 532409, Andhra Pradesh
Survey No.314, Bachupally Village, Bachupally Mandal, Medchal Malkajgiri District, 500090, Telangana.
JN Pharma City, Plot No. 17, Road No.10,11 & 19,20, E Bonangi Village, Parawada Mandal, Visakhapatnam District, 531021, Andhra Pradesh.
JN Pharma City, Plot No. 17A, Road No.10,11 & 19,20, E Bonangi Village, Parawada Mandal, Visakhapatnam District, 531021, Andhra Pradesh.
Plot No.S-5/B,S-6&S-7, Sy No.408 to 412,418 to 435,437 to 445,452 to 459, TSIIC,SEZ,Polepally-Village, Jadcherla-Mandal, Mahaboob nagar-Dist, -509302 Telangana.
Survey No.77 & 78, Indrakaran Village, Kandi Mandal, Sangareddy Dist, 502203, Telangana.
Survey No.69, 70, 71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy Dist, 502203, Telangana.
Survey No. 313 & 314, Bachupally Village, Bachupally Mandal, Medchal Malkaigiri District, 500090, Telangana.
Survey No.71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy Dist, 502203, Telangana.
1128, RIICO Phase–III, Bhiwadi – 301 019, Rajasthan (under sub lease to Auronext Pharma Private Limited, a wholly owned subsidiary of the Company)

* Facilities under construction/development

@ Research and Development Centers

Address for correspondence:

Registered Office	Corporate Office	Name & Designation of Compliance Officer
Aurobindo Pharma Limited	Water Mark Building,	Mr. B.Adi Reddy
(CIN - L24239TG1986PLC015190)	Plot No.11, Survey No.9,	Company Secretary
Plot No.2, Maitrivihar, Ameerpet	Kondapur, Hitech City	Aurobindo Pharma Limited,
Hyderabad - 500 038, Telangana	Hyderabad – 500 084, Telangana	Water Mark Building, Plot No. 11, Survey
Phone : +91 40 2373 6370	Phone : +91 40 6672 5000	No. 9, Kondapur, Hitech City,
Fax : +91 40 2374 7340	Fax : +91 40 6707 4044/4059	Hyderabad - 500 084, Telangana
E-mail : info@aurobindo.com	E-mail : info@aurobindo.com	Phone : +91 40 6672 5333
		Fax : +91 40 6707 4044/4059
		E-mail : cs@aurobindo.com

Contact address for investor grievances

E-mail: ig@aurobindo.com

OTHER DISCLOSURES

Related Party Transactions

No transaction of material nature has been entered into by the Company with its Directors/management and their relatives, etc. that may have a potential conflict with the interests of the Company. The Register of Contracts containing transactions, in which Directors are interested, is placed before the Board regularly.

Transactions with related parties are disclosed in the Notes to Accounts in the Annual Report.

In terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audit Committee and Board of Directors of the Company have adopted a policy to determine Related Party Transactions. The policy is placed on the Company's website at: http://www.aurobindo.com/about-us/ corporate-governance

Details of Non-Compliance and Penalties

There were no instances of non-compliance or penalties/ strictures by the stock exchanges/SEBI/statutory authorities on any matter related to capital markets during the last three years.

Details of establishment of Vigil Mechanism (Whistle Blower policy)

The Board of Directors of the Company had adopted the Whistle Blower policy. The Company has established a mechanism for employees to report to the management, concerns about unethical behavior, actual or suspected fraud or violation of the Company's code of conduct or ethics. The employees have been appropriately communicated within the organization about the mechanism and have been provided direct access to the Chairman of the Audit Committee. The mechanism also lays emphasis on making enquiry into whistle blower complaint received by the Company. The Audit Committee reviews periodically the functioning of whistle blower mechanism. No employee has been denied access to the Audit Committee. A copy of the Whistle Blower Policy is hosted on the Company's website at http://www.aurobindo.com/about-us/corporate-governance

Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has complied with all the mandatory requirements of Corporate Governance as per Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is in the process of implementation of non-mandatory requirements.

Policy on Material Subsidiaries

In terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company has adopted a policy with regard to determination of material subsidiaries. The policy is placed on the Company's website: http://www.aurobindo.com/about-us/corporategovernance

Non-compliance of any requirement of corporate governance report of sub-paras (2) to (10) of Schedule-V

The Company has complied with the requirements of corporate governance report of sub-paras (2) to (10) of Schedule-V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Adoption of discretionary requirements as specified in Part E of Schedule II of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With regard to discretionary requirements, the Company has adopted clauses relating to the following:

Separate persons were appointed for the post of Chairman and Managing Director and Internal Auditors report directly to the Audit Committee. The Disclosures of the compliance with Corporate Governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 are as follows:

Regulation	Particulars of Regulations	Compliance status(Yes/No)	
17	Board of Directors	Yes	
18	Audit Committee	Yes	
19	Nomination and Remuneration	Yes	
	Committee		
20	Stakeholders Relationship Committee	Yes	
21	Risk Management Committee	Yes	
22	Vigil mechanism	Yes	
23	Related Party Transactions	Yes	
24	Corporate Governance requirements	Yes	
	with respect to subsidiary of listed		
	entity		
25	Obligations with respect to	Yes	
	Independent Directors		
26	Obligation with respect to Directors	Yes	
	and senior management		
27	Other Corporate Governance	Yes	
	requirements		
46(2)(b)	Website	Yes	
to (i)			

Code of Conduct

The Board of Directors has laid down a 'Code of Conduct' (Code) for all the Board members and the senior management of the Company and this Code is posted on the website of the Company. Annual declaration is obtained from every person covered by the Code.

The Company has a comprehensive Code of Conduct for

prevention of insider trading in accordance with the requirements of SEBI (Prohibition of Insider Trading) Regulations, 2015. Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, which is effective from May 15, 2015, the Board has formulated a Code of Conduct to regulate, monitor and report trading by insiders and the Board has also adopted a code of practices and procedures for fair disclosure of un-published price sensitive information.

Risk Management

The Company recognizes that it faces various financial, market, technical and operational risks including regulatory and compliance risks and needs to take appropriate steps to minimize such risks. The Board regularly discusses the significant business risks identified by the management and the mitigation process being taken up. The Board has constituted a Risk Management Committee comprising of Mr. M. Sitarama Murty, as the Chairman of the Committee and Mr. N. Govindarajan and Mr. P. Sarath Chandra Reddy as other members of the Committee. The objectives of the Committee include identifying, measuring monitoring the various risks the Company is exposed to and initiate appropriate mitigating measures on an ongoing basis.

Letter of appointment

Each independent director upon appointment is given a letter of appointment. The terms and conditions of the appointment of the independent directors is available on the Company's website at: http://www.aurobindo.com/about-us/corporate-governance

CEO and CFO Certification

The Managing Director (Chief Executive officer) and Chief Financial Officer have submitted a compliance certificate to the Board as contemplated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Declaration

I, N. Govindarajan, Managing Director, hereby declare that as provided under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board Members and the senior management personnel have confirmed compliance with the Code of Conduct and Ethics for the year ended March 31, 2018.

For Aurobindo Pharma Limited

N. Govindarajan Managing Director

Place: Hyderabad Date: 28 May 2018

CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE UNDER REGULATION 34(3) READ WITH SCHEDULE V OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The Members of **Aurobindo Pharma Limited**

I have examined the compliance of conditions of corporate governance by Aurobindo Pharma Limited (The Company) for the financial year ended March 31, 2018, as stipulated in Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The compliance of conditions of corporate governance is the responsibility of the management. My examination was limited to review the procedures and implementation thereof, adopted by the Company, for ensuring the compliance of the conditions of the corporate governance. It is neither an audit nor an expression of opinion on financial statements of the Company.

In my opinion and to the beset of our information and according to the explanations given to me, I certify that the Company has complied with the conditions of corporate governance as stipulated in the above Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: Hyderabad Date: 28 May 2018 S. Chidambaram Company Secretary in Practice

mpany Secretary in Practice C.P. No. 2286

CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

We hereby certify that:

- a. We have reviewed financial statement and cash flow statement for the financial year ended March 31, 2018 and that to the best our knowledge and belief:
 - i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b. There are to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- c. We accept responsibility for establishing and maintaining internal controls for financials reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we have aware and the steps we have taken or propose to take to rectify these deficiencies.
- d. We have indicated to the Auditors and the Audit Committee that there are no:
 - i. Significant changes in internal control over financial reporting during the year.
 - ii. Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - iii. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having significant role in the Company's internal control system financial reporting.

For Aurobindo Pharma Limited

Place: Hyderabad Date: 28 May 2018 N. Govindarajan Managing Director S. Subramanian Chief Financial Officer

INDEPENDENT AUDITOR'S REPORT

То

The Members of Aurobindo Pharma Limited

REPORT ON THE AUDIT OF THE STANDALONE IND AS FINANCIAL STATEMENTS

We have audited the accompanying standalone Ind AS financial statements of Aurobindo Pharma Limited ("the Company"), which comprise the Balance Sheet as at 31 March 2018, the Statement of Profit and Loss, the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information (herein after referred to as "standalone Ind AS financial statements").

MANAGEMENT'S RESPONSIBILITY FOR THE STANDALONE IND AS FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the state of affairs, profit (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on these standalone Ind AS financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing

specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the standalone Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind AS financial statements.

We are also responsible to conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify the opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause an entity to cease to continue as a going concern.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

OPINION

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2018, its profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

OTHER MATTER

Corresponding figures for the year ended 31 March 2017 have been audited by another auditor who expressed an unmodified opinion dated 29 May 2017 on the standalone Ind AS financial statements of the Company for the year ended 31 March 2017.

Our opinion on the standalone Ind AS financial statements is not modified in respect of the above matter.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

- As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 2. As required by Section 143(3) of the Act, we report that:
 - We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
 - In our opinion, the aforesaid standalone Ind AS financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act.
 - e) On the basis of the written representations received from the directors as on 31 March 2018 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2018 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - The Company has disclosed the impact of pending litigations on its financial position in its standalone Ind AS financial statements; - Refer Note 30(C) to the standalone Ind AS financial statements;
 - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company; and
 - iv. The disclosures in the standalone Ind AS financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made since they do not pertain to the financial year ended 31 March 2018. However, amounts as appearing in the audited Standalone Ind AS financial statements for the period ended 31 March 2017 have been disclosed.

For **BSR & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE IND AS FINANCIAL STATEMENTS

With reference to the "Annexure A" referred to in Report on Other Legal and Regulatory Requirements of the Independent Auditor's Report to the Members of the Company on the audit of standalone Ind AS financial statements for the year ended 31 March 2018, we report that:

- i. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment.
 - (b) All property, plant and equipment have not been physically verified by the Management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and nature of its assets. No material discrepancies were noticed on such verification.
 - (c) In our opinion and according to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties, included in the property, plant and equipment except for the following are held in the name of the Company. As explained to us, registration of title deeds is in progress in respect of these immovable properties:

Category	No. of instances	Freehold / Leasehold	Gross Block as at 31 March 2018	Net Block as at 31 March 2018
Land	5	Freehold land	131,177,536	131,177,536
Building	1	Freehold building	35,341,469	15,199,937
Total			166,519,005	146,377,473

- ii. The inventory, except goods-in-transit and stock lying with third parties, has been physically verified by the Management during the year. In our opinion, the frequency of such verification is reasonable. The discrepancies noticed on verification between the physical stock and the book records were not material. Inventories lying with third parties as at 31 March 2018 have been confirmed by them and no material discrepancies were noticed in respect of such confirmations.
- iii. According to information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the Register maintained under Section 189 of the Companies Act, 2013 ("the Act"). Accordingly, the Provisions of clause 3(iii)(a), (b) and (c) of the Order are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, the Company has not advanced loans to directors / to a Company in which the director is interested to which, the provisions of Section 185 of the Act apply and hence not commented upon. However, the Company has made investments and given guarantees / provided security which is in compliance with the provisions of Section 186 of the Act.
- v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended).
 Accordingly, the provisions of clause 3(v) of the Order are not applicable.

- vi. We have broadly reviewed the books of account maintained by the Company pursuant to the Rules made by the Central Government for the maintenance of cost records under Section 148(1) of the Act related to the manufacture of Active Pharmaceutical Ingredients and Formulations and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- vii. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Duty of Customs, Duty of Excise, Value added tax, Goods and Services tax, Cess and other material statutory dues have generally been regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Incometax, Sales-tax, Service tax, Duty of Customs, Duty of Excise, Value added tax, Goods and Services tax, Cess and any other material statutory dues were in arrears as at 31 March 2018, for a period of more than six months from the date they became payable. (b) According to the information and explanations given to us and based on our examination of the records of the Company, there are no dues of Sales tax, Goods and Services tax, Value added tax and Cess. According to the information and explanations given to us, the following dues of Income-tax, Service Tax, Duty of Customs, Duty of Excise have not been deposited by the company on account of disputes:

Nature of the Statue	Nature of Dues	Disputed Amount (₹)	Paid under Protest (₹)	Period to which the amount relates	Forum where dispute is pending	
Central Excise	Central Excise	33,988,653	13,591,862	F.Y 2004-2016	CESTAT*	
Act ,1944	Central Excise	277,750	277,750	F.Y 1996-2000	Commissioner (Appeals)	
and Customs	Central Excise	7,963,132	7,634,604	F.Y 2007-2014	Revisionary Authority	
Act,1962	Central Excise	4,760,055	-	F.Y 2006-2008	Honorable AP High court	
	Central Excise-Interest	463,652	181,308	F.Y 2006-2010	CESTAT*	
	Central Excise-Interest	13,549,864	1,000,000	F.Y 2004-2010	Appellate Authority up to Commissioner's level	
	Customs	13,942,994	738,855	F.Y 2002-2015	CESTAT*	
	Customs	4,689,566	3,739,566	F.Y 2011-2012	Commissioner (Appeals)	
Finance Act,	Service tax	1,759,819	132,000	F.Y 2014-2015	Commissioner (Appeals)	
1994	Service tax	508,575,636	25,483,138	F.Y 2005-2016	CESTAT*	
	Service tax	260,105	-	F.Y 2004-2005	Honorable AP High court	
Income-tax	Income-tax	221,655,739	-	A.Y 2009-2012	ITAT**	
Act, 1961	Income-tax	3,543,130	-	A.Y 2013-2015	Commissioner (Appeals)	

*Customs, Excise and Service Tax Appellate Tribunal **Income Tax Appellate Tribunal

- viii. In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings to bank. The Company did not have any dues to any financial institution, government or debenture holder during the year.
- ix. The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). According to the information and explanation given to us, the monies raised by way of term loans have been applied, on an overall basis, for the purpose for which they are obtained.
- x. Based on the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the Management, we report that no fraud by the Company or no fraud on the Company by its officers and employees of the Company has been noticed or reported during the year.
- xi. According to the information and explanations given to us and based on examination of the records of the Company, the Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
- xii. According to the information and explanations given to us, in our opinion, the Company is not a nidhi company as prescribed under Section 406 of the Act. Accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- xiii. According to the information and explanations given to us and based on our examination of the records of the

Company, transactions with related parties are in compliance with Sections 177 and 188 of the Act, where applicable, and the details of such transactions have been disclosed in the standalone Ind AS financial statements as required by the applicable accounting standards.

- xiv. Based on our examination of the records of the Company and according to the information and explanations given to us, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, provisions of Clause 3(xiv) of the Order are not applicable.
- xv. Based on our examination of the records of the Company and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with him, as referred to in Section 192 of the Act.
- xvi. According to the information and explanations given to us and in our opinion, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.

For **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018



ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE IND AS FINANCIAL STATEMENTS

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of the Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Aurobindo Pharma Limited ("the Company"), as of 31 March 2018 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

MANAGEMENT'S RESPONSIBILITY FOR INTERNAL FINANCIAL CONTROLS

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by the ICAI and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of Internal Financial Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

MEANING OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the Standalone Ind AS financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

OPINION

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018

STANDALONE BALANCE SHEET

		Notes	As at 31 March 2018	As at 31 March 2017
I ASSET	S			
Non - C	Current Assets			
	operty, plant and equipment	3	33,929.7	32,116.2
	apital work-in-progress	3	11,002.3	8,783.1
	angible assets under development	33	437.5	286.7
1-1	nancial assets			
(i)	Investments	4(A)	19,674.8	16,819.3
(ii)	Trade receivables	5(A)	-	-
(iii)		<u> </u>	132.6	463.6
	Other financial assets	7(A)	964.1	807.4
	eferred tax assets (net)	8	-	0.8
	on-current tax assets (net)	9	826.0	579.6
	her non-current assets	10(A)	1,159.4	1,339.0
	on-current assets		68,126.4	61,195.7
	t assets			
	ventories		34,092.3	24,336.2
1-1	nancial assets			
(i)	Investments	4(B)	0.2	0.2
(ii)	Trade receivables	<u>5(B)</u>	44,774.4	37,736.3
(iii)		<u></u>	2,459.0	336.4
(iv)		6(B)	97.6	102.5
(V)	her current assets	<u> </u>	8,399.2	6,356.1
(-)	urrent assets		<u> </u>	<u>69,033.5</u>
	ASSETS		157,980.0	130,229.2
	Y AND LIABILITIES		157,900.0	150,229.2
Equity				
	uity share capital	13	585.9	585.9
	her equity		99.239.9	83.775.9
Total e			99.825.8	84,361.8
Liabilit			00,02010	0 1,00 110
	urrent liabilities			
	nancial liabilities			
(i)	Borrowings	15(A)	-	1,189.0
(b) Pro	ovisions		336.0	208.7
(c) De	eferred tax liability (net)	8	234.8	-
	on-current liabilities		570.8	1,397.7
Curren	t liabilities			
(a) Fir	nancial liabilities			
(i)	Borrowings	15(B)	36,538.3	27,512.7
(ii)	Trade payables	17	16,334.0	12,176.0
(iii)		18	2,526.5	3,364.6
	her current liabilities	19	1,439.2	801.4
(-)	ovisions	16(B)	745.4	615.0
	urrent liabilities		57,583.4	44,469.7
TOTAL	EQUITY AND LIABILITIES		157,980.0	130,229.2
Summa	ary of significant accounting policies	2.2		

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

The accompanying notes are an integral part of the standalone financial statements. As per our Report of even date attached.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198 for and on behalf of the Board of Directors of **Aurobindo Pharma Limited**

N. Govindarajan

Managing Director DIN-00050482

Santhanam Subramanian

Chief Financial Officer

Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709

Place: Hyderabad Date: 28 May 2018

142 AUROBINDO

STANDALONE STATEMENT OF PROFIT AND LOSS

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

		Note	Year ended 31 March 2018	Year ended 31 March 2017
I	INCOME			
	Revenue from operations	20	103,031.5	97,812.1
	Other income	21	806.5	1,359.5
	TOTAL INCOME (I)		103,838.0	99,171.6
II	EXPENSES			
	Cost of materials consumed	22	48,932.7	46,041.9
	Purchases of stock-in-trade		37.2	112.1
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	23	(3,341.8)	313.2
	Employee benefits expense	24	11,316.4	9,273.0
	Finance costs	25	528.9	451.6
	Depreciation expense	26	3,548.3	2,861.7
	Other expenses	27	19,386.9	18,332.4
	TOTAL EXPENSES (II)		80,408.6	77,385.9
	PROFIT BEFORE TAX (I-II)		23,429.4	21,785.7
IV	TAX EXPENSE :	28		
	Current tax		5,053.4	4,620.6
	Tax credit - Minimum Alternate Tax (MAT)		(433.2)	(642.8)
	Deferred tax		681.5	740.3
	TOTAL TAX EXPENSE (IV)		5,301.7	4,718.1
V	PROFIT FOR THE YEAR (III-IV)		18,127.7	17,067.6
VI	OTHER COMPREHENSIVE INCOME (OCI)			
	Items that will not to be reclassified subsequently to profit or loss:			
	(a) Re-measurement of defined benefit liability		(34.5)	(85.7)
	(b) Income-tax relating to items that will not be reclassified to profit or loss		12.7	29.7
	TOTAL OTHER COMPREHENSIVE INCOME FOR THE YEAR (NET OF TAX) (VI)		(21.8)	(56.1)
VII	TOTAL COMPREHENSIVE INCOME FOR THE YEAR (NET OF TAX) (V+VI)		18,105.9	17,011.5
VIII	EARNINGS PER EQUITY SHARE	29		
	Basic (in ₹)		30.94	29.16
	Diluted (in ₹)		30.94	29.16
	Nominal value per equity share		1.00	1.00
	Summary of significant accounting policies	2.2		

The accompanying notes are an integral part of the standalone financial statements. As per our Report of even date attached.

For B S R & Associates LLP

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Place: Hyderabad Date: 28 May 2018

Partner Membership No.214198 for and on behalf of the Board of Directors of **Aurobindo Pharma Limited**

N. Govindarajan Managing Director

DIN-00050482

Santhanam Subramanian Chief Financial Officer

Dr. M. Sivakumaran

Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709 Company Overview Stat

STANDALONE STATEMENT OF CHANGES IN EQUITY

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(A) EQUITY SHARE CAPITAL (Refer Note 13)

	Number	Balance
As at 01 April 2016	585,169,586	585.2
Changes in equity share capital during the year	712,823	0.7
As at 31 March 2017	585,882,409	585.9
Changes in equity share capital during the year	25,200	0.0
As at 31 March 2018	585.907.609	585.9

(B) OTHER EQUITY

			Reserves and surplus	blus			Items of other	Total
I	Capital reserve	Capital redemption	Employee stock options outstanding account	Securities premium	General reserve	Retained earnings	Remeasurements of net defined benefit plans	l
Balance at 01 April 2016	91.1	90.0	12.7	3,339.7	7.888.4	56.729.9	(78.5)	68,073,3
Total comprehensive income for the year ended 31								÷
Profit for the year	'	1	1		'	17,067.6	1	17,067.6
Other comprehensive income (net of tax)				1	1	1	(26.1)	(56.1)
Total comprehensive income	•	•		•	1	17,067.6	(20.1)	17,011.5
Issue of equity shares on exercise of employee stock options				62.9		1		65.9
Share based payment (refer note 31)			(1.4)			1	1	(1.4)
Exercise of share options			(10.4)	10.4	1	1	1	
Dividend paid					1	(1,141.1)	1	(1,141.1)
Dividend distribution tax				1	1	(232.3)		(232.3)
Balance at 31 March 2017	91.1	0.06	0.9	3,416.0	7,888.4	72,424.1	(134.6)	83,775.9
Total comprehensive income for the year ended 31 March 2018								
Profit for the year		1	1	1	1	18,127.7	1	18,127.7
Other comprehensive income (net of tax)	'	I	1	1	I	1	(21.8)	(21.8)
Total comprehensive income	•	•	•	•	•	18,127.7	(21.8)	18,105.9
Issue of equity shares on exercise of employee stock options	'		1	2.3		1	1	2.3
Share based payment (refer note 31)	ı	1	0.2	1	ı	1		0.2
Exercise of share options			(0.4)	0.4		1	1	
Dividend paid	'	1	1	1		(2,197.1)	1	(2,197.1)
Dividend distribution tax	ı	1		1	ı	(447.3)		(447.3)
Balance at 31 March 2018	91.1	0.06	0.7	3,418.7	7,888.4	87,907.4	(156.4)	99,239.9

For **B** S R & Associates LLP

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Membership No.214198 Place: Hyderabad Date: 28 May 2018 Partner

for and on behalf of the Board of Directors of Aurobindo Pharma Limited

Managing Director DIN-00050482 N. Govindarajan

Dr. M. Sivakumaran Director DIN-01284320

Company Secretary Membership No.13709 Santhanam Subramanian B. Adi Reddy Chief Financial Officer Company Secr

AUROBINDO 144

STANDALONE STATEMENT OF CASH FLOW

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

		Note	Year ended 31 March 2018	Year ended 31 March 2017
1	CASH FLOW FROM OPERATING ACTIVITIES			
	Net profit before tax		23,429.4	21,785.7
	Adjustments to reconcile profit before tax to net cash flow:			
	Depreciation expense		3,548.3	2,861.7
	Provision for doubtful receivables, advances and other assets (net)		(94.8)	(60.2)
	Bad debts		9.9	41.0
	Provision for diminution on non-current investment		200.0	
	Loss on sale of non-current investment		-	145.3
	Change in fair value of current investment		0.0	-
	Provisions no longer required written back		(0.0)	(81.8)
	Unrealised foreign exchange gain (net)		(843.9)	(37.6)
	Mark-to-market loss/(gain) on derivative financial instruments		23.3	(94.8)
	Loss on sale of property, plant and equipment (net)		0.7	34.3
	Employee share-based payment expense - equity settled		-	0.2
	Dividend accrued on investment			(95.6)
	Finance cost		482.7	402.0
	Interest income		(74.5)	(75.5)
	Dividend income		(14.3)	(10.0)
	Operating profit before working capital changes		26,681.1	24,824.7
	Movements in working capital:		20,001.1	24,024.7
	(Increase) /decrease in trade receivables		(5.005.0)	<u>_</u>
	Increase in inventories		(5,225.3) (9,756.1)	5,320.2
	Decrease / (increase) in loans			(20.2)
			7.8	(10.8)
	Increase in other financial assets		(61.9)	(179.5)
	Increase in other current/non-current assets		(2,038.2)	(661.0)
	Increase in trade payables		3,966.7	380.2
	Increase in provision for retirement benefits		223.2	26.0
	Increase/ (decrease) in other financial liabilities		0.0	(0.0)
	Increase/ (decrease) in other current liabilities		637.9	(284.7)
	Cash generated from operating activities		14,435.2	29,394.9
	Income-tax paid (net of refunds)		(5,299.7)	(4,822.9)
	Net cash flow generated from operating activities	(A)	9,135.5	24,572.0
2	CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of plant, property equipment, capital work-in-progress, capital		(9,606.9)	(9,909.3)
	advances and capital creditors			
	Purchase of intangibles assets under development		(150.8)	(286.7)
	Proceeds from sale of property, plant and equipment		2,556.0	20.9
	Purchase of non-current investments (refer Note "c" below)		(2,573.5)	(5,407.5)
	Proceeds from sale of non - current investments		-	287.1
	Loans made to subsidiaries/ joint venture		(1,258.2)	(164.5)
	Loans repaid by subsidiaries/ joint venture (refer Note "c" below)		1,110.0	
	Interest received (refer Note "c" below)		108.9	39.5
	Dividend received			0.0
	Net cash flow used in investing activities	(B)	(9,814.5)	(15,420.5)
3	CASH FLOW FROM FINANCING ACTIVITIES		(3,017.3)	(10,720.0)
5	Proceeds from issuance of equity share capital		2.3	66.6
	Repayment of non-current borrowings		(2,377.9)	(4,522.0)
	Proceeds from current borrowings (net)		9,906.2	(7,043.4)
	Interest paid		(492.4)	(419.3)

STANDALONE STATEMENT OF CASH FLOW

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

	Note	Year ended 31 March 2018	Year ended 31 March 2017
Dividends paid on equity shares		(2,194.0)	(1,139.5)
Tax paid on equity dividend		(447.3)	(232.3)
Net cash flow generated from/(used in) financing activities	(C)	4,396.9	(13,289.9)
Net increase in cash and cash equivalents	(A+B+C)	3,718.0	(4,138.4)
Cash and cash equivalents at the beginning of the year		(1,299.5)	2,839.0
Cash and cash equivalents at the end of the year (refer note 12(C))		2,418.5	(1,299.4)

Note:

a) The above statement of cash flow has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7(Ind AS-7) "Statement of Cash Flow"

b) Cash and cash equivalents comprises of:

	As at	As at
	31 March 2018	31 March 2017
COMPONENTS OF CASH AND CASH EQUIVALENTS		
Cash and bank balances includes :		
Cash on hand	0.7	3.9
Cheques on hand	191.9	-
Balance with banks:	-	-
Current accounts	1,933.6	285.3
Cash credit accounts	273.3	(1,604.5)
Unpaid dividend accounts *	19.0	15.9
Total cash and cash equivalents (refer note 12(C))	2,418.5	(1,299.4)

* The Company can utilise these balances only toward settlement of unpaid dividend.

c) The following items in the nature of non-cash transactions are not included in determining cash flow from investing activities:

Particulars	31 March 2018	31 March 2017
(i) Loans converted into preference shares/optionally convertible debentures	476.2	-
(ii) Interest converted into optionally convertible debentures	5.7	-
Total	481.9	-

 Reconciliation between the opening and closing balances in balance sheet for financial liabilities arising from financing activities are given below:

Particulars	As at 31 March 2017	Cash flows	Non-cash transactions Foreign exchange loss	As at 31 March 2018
Non-current borrowings	3,026.4	(2,377.9)	3.2	651.7
Current borrowings	25,876.8	9,906.2	714.8	36,497.8
Summary of significant accounting policies 2.2				

The accompanying notes are an integral part of the standalone financial statements. As per our Report of even date attached.

For **B S R & Associates LLP** Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal Partner Membership No.214198 for and on behalf of the Board of Directors of Aurobindo Pharma Limited

N. Govindarajan Managing Director DIN-00050482

Santhanam Subramanian Chief Financial Officer **Dr. M. Sivakumaran** Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709

Place: Hyderabad Date: 28 May 2018



for the year ended 31 March 2018

1. CORPORATE INFORMATION

Aurobindo Pharma Limited ("the Company") is a public company domiciled in India and was incorporated under the provisions of the Companies Act applicable in India. The registered office of the Company is located at Plot No.2, Maitri Vihar, Ameerpet, Hyderabad - 500038, India and the Corporate office is located at The Water Mark Building, Plot No. 11, Survey No. 9, Hi-tech City, Hyderabad - 500084, India. The Company's shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in India.

The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The standalone financial statements for the year ended 31 March 2018 were approved by the Board of Directors and authorised for issue on 28 May 2018.

2. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

a) Statement of compliance

These standalone financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the "Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

These standalone financial statements comprise the Balance Sheets as at 31 March 2018 and 31 March 2017, the Statements of Profit and Loss, the Statements of Cash Flows and the Statements of Changes in Equity for the year ended 31 March 2018 and for the year ended 31 March 2017, and a summary of the significant accounting policies and other explanatory information (together hereinafter referred to as "Financial Statements")

These standalone financial statements have been prepared on accrual and going concern basis. The accounting policies are applied consistently to all the periods presented in these standalone financial statements.

b) Functional and presentation currency

These standalone financial statements are presented in Indian rupees (₹), which is also the functional currency of the Company. All amounts have been rounded-off to the nearest million, unless otherwise indicated. Transactions and balances with values below ₹ one lac have been reflected as "0.0" in the financial statements.

c) Basis of measurement

The standalone financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following;

- certain financial assets and liabilities (including derivative instruments) are measured at fair value or amortised cost.

- employee defined benefit assets / liability recognised as the net total of the fair value of plan assets, and actuarial losses/gains, and the present value of defined benefit obligation.

d) Use of estimates and judgements

The preparation of the standalone financial statements in conformity with Ind AS requires management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the standalone financial statements.

Judgements

Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the standalone financial statements is included in the following notes:

- Note 30(A) - leases: whether an arrangement contains a lease; lease classification.

- Note 2.2(r) and 42: Financial instruments

- Note 2.2(k), 8 and 28: Provision for income taxes and evaluation of recoverability of deferred tax assets.

- Note 2.2(e): Useful lives of property, plant and equipment

- Note 31: Share based payments

- Note 32: Assets and obligations relating to employee benefits

Assumptions and estimation uncertainties

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions

for the year ended 31 March 2018

and estimates on parameters available when the standalone financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

(i) Share-based payments

The grant date fair value of employee stock options granted is recognised as an employee expense over the period that the employee becomes unconditionally entitled to the options. Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimation requires determination of the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. The Black Scholes valuation model has been used by the Management for share-based payment transactions. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 31.

(ii) Defined employee benefit plans (Gratuity)

The cost of the defined benefit gratuity plan and other accumulated leave entitlement and the present value of the gratuity obligation and accumulated leave obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its longterm nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation.

The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates. Further details about gratuity obligations are given in Note 32.

(iii) Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See note 41 and 42 for further disclosures.

(iv) Depreciation on property, plant and equipment

Depreciation on property, plant and equipment is calculated on a straight-line basis based on the useful lives estimated by the management. Considering the applicability of Schedule II of Companies Act, 2013, the management has reestimated useful lives and residual values of all its property, plant and equipment. The management believes that useful lives currently used fairly reflect its estimate of the useful lives and residual values of property, plant and equipment, though these in certain cases are different from lives prescribed under Schedule II of the Companies Act, 2013.

(v) Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length, for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a DCF model.

(vi) Impairment of investments

The Company reviews its carrying value of investments annually, or more frequently when there is an indication for impairment. If the recoverable amount is less than its carrying amount, the impairment loss is accounted for.

(vii) Intangible assets under development

The Company capitalises acquired intangible asset under development for a project in accordance with the accounting policy. In determining the amounts to be capitalised, management makes assumptions regarding the expected future cash generation of the project, discount rates to be applied and the expected period of benefits. The innovative nature

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

of the product gives rise to some uncertainty as to whether the final approval for the products will be obtained.

(viii) Inventories

The Company estimates the net realisable value (NRV) of its inventories by taking into account their estimated selling price, estimated cost of completion, estimated costs necessary to make the sale, obsolescence by applying certain percentages over different age category of such inventories, expected loss rate considering the past trend and future outlook. Inventories are written down to NRV where such NRV is lower than their cost.

(ix) Recognition and measurement of other provisions:

The recognition and measurement of other provisions is based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the closing date. The actual outflow of resources at a future date may therefore, vary from the amount included in other provisions.

2.2 Significant accounting policies

a. Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in the Company normal operating cycle;

- Held primarily for the purpose of trading;

- Expected to be realised within twelve months after the reporting period; or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in the Company normal operating cycle;

- It is held primarily for the purpose of trading;

- It is due to be settled within twelve months after the reporting period; or

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as noncurrent assets and liabilities. The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

b. Foreign exchange transactions and translations

The standalone financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates.

Initial recognition: Foreign currency transactions are recorded in the functional currency, by applying to the foreign currency amount the exchange rate between the functional currency and foreign currency at the date of the transaction.

Conversion: Foreign currency monetary items are reported at functional currency spot rate of exchange at the reporting date. 'Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date with the exchange rates at the date with the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or profit or loss are also recognised in OCI or profit or loss are also recognised in OCI or profit or loss.

Exchange differences: Exchange differences arising on the settlement of monetary items or on reporting monetary items of the Company at rates different from those at which they were initially recorded during the year, or reported in previous standalone financial statements, are recognised as income or as expenses in the year in which they arise.

c. Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or

- In the absence of a principal market, in the most advantageous market for the asset or liability.

for the year ended 31 March 2018

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the standalone financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities.

- Level 2 — inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

- Level 3 — inputs for the asset or liability that are not based on observable market data (unobservable inputs).

For assets and liabilities that are recognised in the standalone financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's CFO determines the appropriate valuation techniques and inputs for fair value measurements. In estimating the fair value of an asset or a liability, the Company uses market observable data to the extent it is available. Where Level 1 inputs are not available, the Company engages third party qualified valuers to perform the valuation. Any change in the fair value of each asset and liability is also compared with relevant external sources to determine whether the change is reasonable.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

The specific recognition criteria described below must also be met before revenue is recognised:

Sale of goods: Revenue from sale of goods is recognised on dispatch (in respect of exports, on the date of the bill of lading or airway bill) which coincides with the transfer of significant risks and rewards to customer is net of trade discounts, volume discounts, sales returns and any taxes or duties collected on behalf of the government which are levied on sales such as sales tax, value added tax, goods and services tax, etc., where applicable and recognised based on the terms of the agreements entered into with the customers. However, it includes excise duty upto 30 June 2017. Any additional amounts based on terms of agreement entered into with customers, is recognised in the period when the collectability becomes probable and a reliable measure of the same is available.

Rendering of services: Revenue from sale of dossiers/ licenses/services is recognised in accordance with the terms of the relevant agreements as accepted and agreed with the customers. Revenue from contract research operations is recognised in accordance with the terms of the relevant contracts with customers and when the agreed milestones are achieved, which are substantiated by the performance of related service work.

Interest income: For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the EIR, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in other income in the standalone statement of profit and loss.

Company Overview Sta

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

е.

Dividend income: Revenue is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

Export benefits, incentives and licenses: Export incentives are recognised as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Property, plant and equipment & Depreciation Freehold land and buildings (property) held for use in the production or supply of goods or services, or administrative purposes are stated at cost less accumulated depreciation and accumulated impairment. Freehold land is not depreciated.

The cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

Capital work in progress, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful life. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

Depreciation is provided on the straight-line method, based on the useful life of the assets as estimated by the Management.

The Company, based on technical assessment and management estimate, depreciates property, plant

and equipment over estimated useful lives which are different from the useful life prescribed in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used. The Company has estimated the following useful life to provide depreciation on its fixed assets:

Nature of the assets	Useful life as estimated by the management (in years)	Useful life as stated in the Companies Act, 2013
		(in years)
Leasehold buildings	20	10 - 60
Freehold buildings	15-60	10 - 60
Plant and equipment	5 - 20	3 - 40
Furniture and fixtures	10	10
Vehicles	4 - 8	8
Office equipment	5	5

Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognised.

The residual values, useful life and methods of depreciation of property, plant and equipment are reviewed at each financial period/year end and adjusted prospectively, if appropriate.

f. Intangibles

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The

for the year ended 31 March 2018

amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

Research and development costs:

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Company can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale

- Its intention to complete and use or sell the asset
- Its ability to use or sell the asset
- How the asset will generate future economic benefits
- The availability of resources to complete the asset
- The ability to measure reliably the expenditure during development

Acquired research and development intangible assets that are under development are recognised as Intangible assets under development. These assets are not amortised, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment is recognised as an expense in the statement of profit and loss.

Subsequent expenditure on in process research and development project acquired separately and recognised as an intangible asset is:

- recognised as an expense, if it is research expenditure.

- recognised as an expense, if its development expenditure that does not satisfy the criteria for recognition as an Intangible asset; and

- added to the carrying amount of acquired in process research and development project, if it is development expenditure that satisfies the recognition criteria.

Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation expense is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets relating to products in development and other intangible assets not available for use is tested for impairment annually.

g. Government grants and subsidies

Government grants are recognised when there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is deducted from the related expense. When the grant relates to an asset, it is recognised as deferred income and amortised over the useful life of such assets.

h. Inventories

Inventories are valued at lower of cost, determined on "Weighted average" basis and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows:

Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Finished goods and work-in-progress: cost includes direct materials, labour and a proportion of manufacturing overheads based on the normal operating capacity, but excludes borrowing costs.

Trading goods: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

Raw materials, components and other supplies held for use in the production of finished products are not written down below cost except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value.

The comparison of cost and net realisable value is made on an item-by-item basis.

i. Retirement and other employee benefits Provident fund

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the

Statutory Reports Fi

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

provident fund. The Company recognizes contribution payable to the provident fund scheme as an expense, when an employee renders the related service. If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognized as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognized as an asset to the extent that the pre-payment will lead to, for example, a reduction in future payment or a cash refund.

Gratuity

The Company operates a defined benefit gratuity plan in India, which requires contributions to be made to a separately administered fund. The cost of providing benefits under the defined benefit plan is determined based on actuarial valuation.

Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Past service costs are recognised in profit or loss on the earlier of:

- The date of the plan amendment or curtailment, and
- The date that the Company recognises related restructuring costs

Net interest is calculated by applying the discount rate to the net defined liability or asset. The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:

- Service costs comprising current service costs, pastservice costs, gains and losses on curtailments and non-routine settlements; and

- Net interest expense or income

Compensated absences

Short term compensated absences are provided for based on estimates. The Company treats accumulated leave, as a long-term employee benefit for measurement purposes. Such accumulated leaves are provided for based on an actuarial valuation using the projected unit credit method at the period-end/ year-end. The Company presents the entire liability in respect of leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond twelve months after the reporting date.

J Share-based payments

Employees of the Company receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments.

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That cost is recognised, together with a corresponding increase in employee stock options reserves in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The statement of profit and loss expense or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period and is recognised in employee benefits expense. Service and non-market based performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Company's best estimate of the number of equity instruments that will ultimately vest. No expense is recognised for awards that do not ultimately vest because of non-market performance and/or service conditions have not been met.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

K. Taxes

Income tax expense comprises of current and deferred tax. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the tax authorities in accordance with the Indian Income-tax Act, 1961. Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. The Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provision where appropriate. The tax rate and tax laws used to compute the amount are those that are enacted or substantially enacted, at the reporting date.

Deferred tax is provided using the balance sheet

for the year ended 31 March 2018

method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period/year when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date. Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxation authority.

Taxes paid on acquisition of assets or on incurring expenses which are not subsequently recoverable:

Expenses and assets are recognised net of the taxes paid, except:

- (i) When the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable
- (ii) When receivables and payables are stated with the amount of tax included The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet."

I. Leases

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

Where the Company is lessee

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease. Finance leases are capitalised at the commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in finance costs in the statement of profit and loss, unless they are directly attributable to qualifying assets, in which case they are capitalized in accordance with the Company's general policy on the borrowing costs. Contingent rentals are recognised as expenses in the periods in which they are incurred.

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term. Operating lease payments are recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the lease term.

Where the Company is lessor

Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Company to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect

for the year ended 31 March 2018

a constant periodic rate of return on the net investment outstanding in respect of the lease.

m. Earnings per share

Basic earnings per share is calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of shares outstanding during the year is adjusted for events such as bonus issue that have changed the number of shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

n. Provision and contingent liabilities

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Onerous contracts

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

Contingencies

Provision in respect of loss contingencies relating to claims, litigations, assessments, fines and penalties are recognised when it is probable that a liability has been incurred and the amount can be estimated reliably.

o. Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cheques, cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

p. Borrowing cost

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

q. Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of

for the year ended 31 March 2018

five years. Impairment losses of continuing operations, including impairment on inventories, are recognised in the statement of profit and loss.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior periods/ years. Such reversal is recognised in the statement of profit or loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

r. Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, a 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the standalone statement profit or loss. The losses arising from impairment are recognised in the standalone statement profit or loss. This category generally applies to trade and other receivables.

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- a) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- b) The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income (OCI). However, the group recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the statement of profit and loss. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of profit and loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. In addition, the company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The Company has not designated any debt instrument as at FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Equity investments:

All equity investments in subsidiaries are measured at cost less diminution other than temporary. All equity investments in scope of Ind AS 109 - Financial Instruments are measured at fair value. Equity investments which are held for trading are classified as FVTPL. For all other equity investments, the Company may make an irrevocable election to present in OCI subsequent changes in fair value. The Company makes such election on an instrument by instrument basis. The classification is made on initial recognition and is irrevocable.

for the year ended 31 March 2018

If the Company decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in OCI. There is no recycling of amounts from OCI to statement of profit and loss, even on sale of investment. However, the Company may transfer the cumulative gain/loss within equity. Equity instruments included within the FVTPL category are measured at fair value with all changes recognised in the statement of profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- i) the rights to receive cash flows from the asset have expired, or
- ii) the Company has transferred its rights to receive cash flows from the asset, and the Company has transferred substantially all the risks and rewards of the asset, or the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

Impairment of financial assets

In accordance with Ind AS 109 - Financial Instruments, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets:

- Financial assets that are debt instruments, and are measured at amortised cost, e.g. loans, deposits, debt securities, etc.
- (ii) Trade receivables that result from transactions that are within the scope of Ind AS 18 - Revenue Recognition.

The Company follows 'simplified approach' for recognition of impairment loss allowance. The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- (i) All contractual terms of the financial instrument (including prepayment, extension, call and similar options) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument
- Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

ECL impairment loss allowance (or reversal) recognized during the period is recognized as income/ expense in the statement of profit and loss. This amount is reflected under the head other expenses/other income in the statement of profit and loss. ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

For assessing increase in credit risk and impairment loss, the Company combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis. The Company does not have any purchased or originated credit-impaired (POCI) financial assets, i.e., financial assets which are credit impaired on purchase/ origination.

for the year ended 31 March 2018

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ loss are not subsequently transferred to statement of profit and loss. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss.

Loans and borrowings

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Reclassification of financial assets

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines the change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to the external parties. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

The following table shows various reclassification and how they are accounted for:

Original classification	Revised classification	Accounting treatment
Amortised cost	FVTPL	Fair value is measured at reclassification date. Difference between previous amortized cost and fair value is recognised in statement of profit and loss.
FVTPL	Amortised cost	Fair value at reclassification date becomes its new gross carrying amount. EIR is calculated based on the new gross carrying amount.
Amortised cost	FVTOCI	Fair value is measured at reclassification date. Difference between previous amortised cost and fair value is recognised in OCI. No change in EIR due to reclassification.
FVTOCI	Amortised cost	Fair value at reclassification date becomes its new amortised cost carrying amount. However, cumulative gain or loss in OCI is adjusted against fair value. Consequently, the asset is measured as if it had always been measured at amortised cost.

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

Original classification	Revised classification	Accounting treatment
FVTPL	FVTOCI	Fair value at reclassification date becomes its new carrying amount. No other adjustment is required.
FVTOCI	FVTPL	Assets continue to be measured at fair value. Cumulative gain or loss previously recognized in OCI is reclassified to statement of profit and loss at the reclassification date.

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

s. Derivative financial instruments

The Company uses derivative financial instruments, such as forward currency contracts to hedge its foreign currency risks. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value.

Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. The forward contracts that meet the definition of a derivative under Ind AS 109 are recognised in the statement of profit and loss. Any gains or losses arising from changes in the fair value of derivatives are taken directly to profit or loss.

t. Cash dividend and non cash distribution to equity holders

The Company recognises a liability to make cash and non cash distribution to equity holders when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the Corporate laws in India, a final dividend distribution is authorised when it is approved by the shareholders whereas for interim dividend when authorised by board. A corresponding amount is recognised directly in equity. Non cash distribution are measured at fair value of the assets distributed with fair value re-measurement recognised directly in equity.

u. Recent accounting pronouncements

Standards issued but not yet effective & not early adopted by the Company:

Ind AS 115, Revenue from Contracts with Customers

In March 2018, the Ministry of Corporate Affairs issued the Companies (Indian Accounting Standards) Amendment Rules, 2018, notifying Ind AS 115 'Revenue from Contracts with Customers' (New Revenue Standard), which replaces Ind AS 11 'Construction Contracts' and Ind AS 18 'Revenue'. This establishes a comprehensive framework for determining whether, how much and when revenue should be recognised. It replaces existing revenue recognition guidance, including Ind AS 18 Revenue, Ind AS 11 Construction Contracts and Guidance Note on Accounting for Real Estate Transactions. Ind AS 115 is effective for annual periods beginning on or after 1 April 2018 and will be applied accordingly.

The core principle of Ind AS 115 is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Specifically, the standard introduces a 5-step approach to revenue recognition.

Step 1: Identify the contract(s) with a customer

Step 2: Identify the performance obligation in contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation

For the sale of goods, revenue is currently recognised when related risks and rewards of ownership are transferred. Revenue is recognised at this point provided that the revenue and costs can be measured reliably, the recovery of the consideration is probable and there is no continuing management involvement with the goods.

Under Ind AS 115, revenue will be recognised when a customer obtains control of the goods.

For certain contracts that permit the customer to return an item, revenue is currently recognised when a reasonable estimate of the returns can be made, provided that all other criteria for revenue recognition are met. If a reasonable estimate cannot be made, then revenue recognition is deferred until the return period lapses or a reasonable estimate of returns can be made. Some of the key changes introduced by Ind AS 115 include additional guidance for measurement approaches for variable consideration.

for the year ended 31 March 2018

Under Ind AS 115, revenue will be recognised for these contracts to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognised will not occur. As a consequence, for those contracts for which the Company is unable to make a reasonable estimate of return, revenue is expected to be recognised sooner than when the return period lapses or a reasonable estimate can be made. A refund liability and an asset for recovery will be recognised for these contracts and presented separately in the balance sheet.

Significant additional disclosures in relation to revenue are also prescribed. The New Revenue Standard also provides two broad alternative transition options – Retrospective Method and Cumulative Effect Method – with certain practical expedients available under the Retrospective Method. The Company is in the process of evaluating the impact of the New Revenue Standard on the present and future arrangements and shall determine the appropriate transition option once the said evaluation has been completed.

Ind AS 21, The effect of changes in foreign exchange rates

The amendment clarifies on the accounting of transactions that include the receipt or payment of advance consideration in a foreign currency. The appendix explains that the date of the transaction, for the purpose of determining the exchange rate, is the date of initial recognition of the non-monetary prepayment asset or deferred income liability. If there are multiple payments or receipts in advance, a date of transaction is established for each payment or receipt. The Company is evaluating the impact of this amendment on its standalone financial statements.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

PROPERTY, PLANT AND EQUIPMENT с,

	Leasehold	Freehold	Leasehold	Freehold	Plant and	Furniture and	Vehicles	Office	Total
	land	land	buildings	buildings	equipment	fixtures		equipment	
Gross carrying value (at cost)									
As at 01 April 2016	136.0	2,145.1	12.0	5,949.1	19,297.6	506.7	105.1	156.2	28,307.8
Additions		1,087.9	ı	1,592.5	6,261.9	243.1	124.1	46.1	9,355.6
Disposals		1	ı	0.2	70.1	0.2	10.8	0.3	81.6
As at 31 March 2017	136.0	3,233.0	12.0	7,541.4	25,489.4	749.6	218.4	202.0	37,581.8
Additions	2.0	5.6		1,193.0	6,461.5	190.0	35.0	34.1	7,921.2
Disposals		2,508.6		ı	62.0		10.2	0.4	2,581.2
As at 31 March 2018	138.0	730.0	12.0	8,734.4	31,888.9	939.6	243.2	235.7	42,921.8
Accumulated depreciation									
As at 01 April 2016	4.2		1.3	247.2	2,236.8	66.2	27.6	43.2	2,626.5
			1	0000		1	1		- LOO 0

As at 01 April 2016	4.2		1.3	247.2	2,236.8	66.2	27.6	43.2	2,626.5
Charge for the year	4.2	I	1.3	269.8	2,440.1	77.0	37.0	36.0	2,865.4
Disposals	ı		T	1	20.4	T	5.6	0.3	26.3
As at 31 March 2017	8.4		2.6	517.0	4,656.5	143.2	59.0	78.9	5,465.6
Charge for the year	4.3		1.3	342.9	3,008.7	100.4	54.6	38.7	3,550.9
Disposals			1	ı	19.5	0.0	4.7	0.2	24.4
As at 31 March 2018	12.7		3.9	859.9	7,645.7	243.6	108.9	117.4	8,992.1
								ı	
Net carrying value									
As at 31 March 2017	127.6	3,233.0	9.4	7,024.4	20,832.9	606.4	159.4	123.1	32,116.2
As at 31 March 2018	125.3	730.0	8.1	7,874.5	24,243.2	696.0	134.3	118.3	33,929.7

Capital work-in-progress ₹11,002.3 (31 March 2017: ₹8,783.1) (including expenditure during construction period) (refer note 33)

Intangible assets under development ₹437.5 (31 March 2017: ₹286.7)

<u>.</u>--

The title deeds of land and buildings aggregating to ₹166.5 (31 March 2017: ₹ 166.5) are pending transfer to the Company's name. Depreciation for the year include ₹2.6 (31 March 2017: ₹ 3.7) taken as pre-operative capital expenditure on capital projects pending capitalisation.

0. 4. 0. iv

Refer note 30 (A) for details of finance lease. Refer note 36 for details of capital research and development expenditure.

Refer note 15 for details of property, plant and equipment subject to charge on secured borrowings.

Financial Statements

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

4. INVESTMENTS

(A) Non-current investments

at 31 Marcl	h 2018	As at 31 Mar	ch 2017
Quantity	Amount	Quantity	Amount
paid-in-	2,832.5	100% of	2,832.3
capital		paid-in-capital	
979,200	145.6	979,200	145.6
,124,795	80.0	10,124,795	80.0
,377,851	7,683.7	100% of	7,298.9
presents		paid-in-	
paid-in-		capital	
capital			
,260,000	122.6	12,260,000	122.6
,150,000	1,821.5	130,000,000	1,300.0
paid-in-	27.5	100% of	27.5
capital		paid-in-capital	
99,000	2.1	99,000	2.1
,984,028	1,298.6	124,984,028	1,298.6
95,000	1.0	95,000	1.0
-	-	900,000	9.0
,310,107	1,989.5	13,310,107	1,989.5
,950,000	219.2	10,540,998	175.3
50,000	0.5	50,000	0.5
100,000	1.0	-	-
,500,000	75.0	3,390,000	33.9
,000,000	40.0	-	-
753	0.1	753	0.1
103,709	1.0	103,709	1.0
1,000	0.1	1,000	0.1
А	16,341.5		15,318.0
830,000	830.0	7,350,000	735.0
000,000	000.0	,,000,000	100.0
,861,520	986.2	6,161,520	616.1
,551,520	500.2	0,101,020	010.1
600,000	60.0	600,000	60.0
000,000	00.0		00.0
,510,000	651.0		
,010,000	001.0		
i,51(0,000	0,000 651.0	0,000 651.0 -

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Face	As at 31 March	2018	As at 31 Marcl	n 2017
value	Quantity	Amount	Quantity	Amoun
_				
₹ 100	950,000	95.0	900,000	90.0
	В	2,622.2		1,501.1
₹ 1000	710,933	710.9		-
	С	710.9		-
		0.2		0.2
	D	0.2		0.2
	A+B+C+D	19,674.8		16,819.3
		19,674.8		16,819.3
		3,175.0		2,975.0
	value ₹ 100	Value Quantity ₹ 100 950,000 B B ₹ 1000 710,933 C C D D	value Quantity Amount ₹ 100 950,000 95.0 B 2,622.2 B 2,622.2 C 710,933 710,933 710.9 C 710.9 Output 0.2 A+B+C+D 19,674.8 19,674.8	Value Quantity Amount Quantity ₹ 100 950,000 95.0 900,000 B 2,622.2 900,000 ₹ 1000 710,933 710.9 C 710.9 0.2 D 0.2 A+B+C+D 19,674.8 19,674.8 19,674.8

* Includes employee stock options given to group employees considered as investment as per Ind AS-102 share based payments

(B) Current investments

	Face	As at 31 Marc	h 2018	As at 31 March	2017
	value	Quantity	Amount	Quantity	Amount
Investments in unquoted equity shares (fully paid,					
carried at fair value through profit and loss)					
Citadel Aurobindo Biotech Limited, India	₹ 100	70,000	-	70,000	-
(Aggregate impairment of ₹7.0 (31 March 2017: ₹7.0)					
Investments in quoted equity shares (fully paid,					
carried at fair value through profit and loss)					
Andhra Bank	₹ 10	4,520	0.2	4,520	0.2
			0.2		0.2
Aggregate value of unquoted investments			-		-
Aggregate value of quoted investments			0.2		0.2
Market value of quoted investments			0.2		0.2
Aggregate amount of impairment in value of			7.0		7.0
investments					

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

5. TRADE RECEIVABLES

(Unsecured, considered good unless stated otherwise)

	As at	As at
	31 March 2018	31 March 2017
(A) Non current		
Doubtful	175.6	175.6
Loss allowance for doubtful receivables	175.6	175.6
	-	-
(B) Current		
Considered good	44,774.4	37,736.3
Doubtful	285.4	355.0
	45,059.8	38,091.3
Loss allowance for doubtful receivables	285.4	355.0
	44,774.4	37,736.3

No trade receivable are due from directors or other officers of the Company either severally or jointly with any other person. Refer note 39 for dues from related parties.

Refer Note 42 for the Company's credit risk management process.

6. LOANS

(Unsecured, considered good)

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
Loans to related parties (refer note 39)*	79.0	407.0
Loans to employees	53.6	56.6
	132.6	463.6
*Loan of ₹79.0 (31 March 2017: 407.0) has been given to wholly owned subsidiaries towards proje	ct development co	st, at interest

rate of 9.5% p.a.

(B) Current		
Loans to employees	97.6	102.5
	97.6	102.5

No loans are due from directors or other officers of the Company either severally or jointly with any other person. Refer note 39 for dues from related parties.

7. OTHER FINANCIAL ASSETS

(Unsecured, considered good unless stated otherwise)

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
Dividend accrued on investments in preference shares	149.8	149.8
Security deposits		
Considered good *	814.3	657.6
Doubtful	0.4	0.4
	814.7	658.0
Provision for doubtful deposits	0.4	0.4
	814.3	657.6
	964.1	807.4

* Non-current deposits include restricted deposits pledged with Enforcement Directorate of ₹131.6 (31 March 2017: ₹32.6)

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

7. OTHER FINANCIAL ASSETS (CONTD.)

(Unsecured, considered good unless stated otherwise)

		As at 31 March 2018	As at 31 March 2017
(B)	Current		
	Derivatives - foreign currency forward contracts	-	94.8
	Interest accrued on deposits	22.5	32.0
	Interest accrued but not due on loans to subsidiaries	8.4	39.0
		30.9	165.8

8. DEFERRED TAX ASSETS/(LIABILITIES) (NET)

	As at 31 March 2018	As at 31 March 2017
Deferred tax asset		
Receivables, financial assets at amortised cost	190.4	223.2
Employee benefits	360.7	275.7
Unused tax credits *	3,269.5	2,836.3
Deferred tax liability		
Property, plant and equipment	4,055.4	3,334.4
	(234.8)	0.8

Movement in deferred tax assets/deferred tax liabilities

	As at 01 April 2017	Recognised in statement of profit and loss	Recognised in OCI	31 March 2018
Deferred tax asset				
Receivables, financial assets at amortised cost	223.2	(32.8)	-	190.4
Employee benefits	275.7	72.3	12.7	360.7
Unused tax credits	2,836.3	433.2	-	3,269.5
Deferred tax liability				
Property, plant and equipment	3,334.4	721.0	-	4,055.4
	0.8	(248.3)	12.7	(234.8)

* The Company based on its business plan along with supporting convincing evidence including future projections of profit believes that the Unused tax credits would be utilised within the stipulated time period as per the Income-tax Act, 1961.

9. NON-CURRENT TAX ASSETS (NET)

	As at 31 March 2018	As at 31 March 2017
Advance income-tax (net of provision for taxation)	826.0	579.6
	826.0	579.6

Refer note 28 for details of income tax expense

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

10. OTHER ASSETS

(Unsecured, considered good unless stated otherwise)

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
Export incentives receivable		
Considered good	566.9	418.5
Doubtful	19.6	44.8
	586.5	463.3
Provision for doubtful receivables	19.6	44.8
	566.9	418.5
Export rebate claims receivable	288.8	288.8
Capital advances		
Considered good	209.6	409.5
Doubtful	0.8	0.8
	210.4	410.3
Provision for doubtful advances	0.8	0.8
	209.6	409.5
Advances other than capital advances		
Considered good	15.5	18.0
Doubtful	30.1	30.1
	45.6	48.1
Provision for doubtful advances	30.1	30.1
	15.5	18.0
Balances with government authorities		
Considered good	78.6	204.2
Doubtful	38.1	38.1
	116.7	242.3
Provision for doubtful receivables	38.1	38.1
	78.6	204.2
	1,159.4	1,339.0
(B) Current		
Export rebate claims receivable	1,768.0	782.0
Export incentives receivable	2,438.5	2,479.5
Advances other than capital advances	1,031.4	1,838.2
Balances with government authorities	3,160.5	1,256.4
Insurance claim receivable	0.8	-
	8,399.2	6,356.1

11. INVENTORIES

(Valued at lower of cost and net realisable value)

	As at	As at
	31 March 2018	31 March 2017
Raw materials	17,967.6	12,297.8
Packing materials	2,207.3	1,577.9
Work-in-progress	9,399.3	7,788.2
Finished goods (including stock-in-trade)	3,230.1	1,499.4
Stores, spares and consumables	1,288.0	1,172.9
	34,092.3	24,336.2
Details of material in transit included in inventories above		
Raw materials	888.3	665.9
Finished goods	1,359.7	80.6

for the year ended 31 March 2018

12. CASH AND CASH EQUIVALENTS

(A) Cash and cash equivalents

	As at 31 March 2018	As at 31 March 2017
Balances with banks:		
in current accounts	1,933.6	285.3
in cash credit accounts	313.8	31.3
in unpaid dividend account	19.0	15.9
Cash on hand	0.7	3.9
Cheques on hand	191.9	-
	2,459.0	336.4

(B) For the purpose of statement of cash flows, cash and cash equivalents comprise of following:

	As at 31 March 2018	As at 31 March 2017
Cash and cash equivalents as above	2,459.0	336.4
Less: Cash credit (refer note 15(B))	(40.5)	(1,635.8)
	2,418.5	(1,299.4)

(C) Details of Specified Bank Notes (SBN) held and transacted during the period 8 November 2016 to 30 December 2016

	SBN*	Other denominations	Total
Closing cash on hand as on 8 November 2016	2.3	4.1	6.4
Add: Permitted receipts	-	0.8	0.8
Add: Withdrawal from bank	-	0.9	0.9
Less: Permitted payments	-	2.2	2.2
Less: Amount deposited into bank	2.3	0.6	2.9
Closing cash on hand - 30 December 2016	-	3.0	3.0

* For the purposes of this clause, the term "Specified Bank Notes" shall have the same meaning provided in the notification of the Government of India, in the Ministry of Finance, Department of Economic Affairs number S.O.3407(E), dated the 8 November 2016.

13. EQUITY SHARE CAPITAL

		As at 31 March 2018	As at 31 March 2017
(a)	Authorised		
	660,000,000 (31 March 2017: 660,000,000) equity shares of ₹1 each	660.0	660.0
	1,000,000 (31 March 2017: 1,000,000) preference shares of ₹100 each	100.0	100.0
		760.0	760.0

(b) Issued, subscribed and fully paid-up equity shares

	Equity Shar	Equity Shares	
	Numbers	Value	
As at 01 April 2016	585,169,586	585.2	
Issued during the year under Employees Stock Option Plan (ESOP) (refer note 31)	712,823	0.7	
As at 31 March 2017	585,882,409	585.9	
Issued during the year under Employees Stock Option Plan (ESOP) (refer note 31)	25,200	0.0	
As at 31 March 2018	585,907,609	585.9	

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

196,376,250

33.52%

c) Terms/rights attached to equity shares

RPR Sons Advisors Private Limited & Mrs.P.Suneela Rani

The Company has only one class of equity shares having a par value of ₹1 per share. Each holder of equity shares is entitled to one vote per share.

The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

For the year ended 31 March 2018, the amount of dividend per share declared as distributions to equity shareholders was ₹ 2.5 (31 March 2017: ₹ 2.5).

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

d) Details of shareholders holding more than 5% of total number of equity shares in the Company:

	As at 31 Ma	As at 31 March 2017	
	Numbers	% holding	
RPR Sons Advisors Private Limited & Mrs.P.Suneela Rani	196,376,250	33.52%	
	As at 31 M	arch 2018	
	Numbers	% holding	

As per records of the Company, including its register of shareholders/members and other declarations received from shareholders, the above shareholding represents legal ownerships of shares and the beneficial ownership is with RPR Enterprises, a partnership firm.

e) Aggregate number of bonus shares issued, shares issued for consideration other than cash during the period of five years immediately preceding the reporting date:

	Value
Equity shares allotted as fully paid bonus shares by capitalisation of securities premium	
Year ended 31 March 2018	-
Year ended 31 March 2017	-
Year ended 31 March 2016	291,982,275
Year ended 31 March 2015	-
Year ended 31 March 2014	-

f) For details of shares reserved for issue under Employee stock option plan (ESOP) of the Company, refer note 31.

14. OTHER EQUITY

	As at 31 March 2018	As at 31 March 2017
Capital reserve	91.1	91.1
Capital redemption reserve	90.0	90.0
Employee stock options outstanding account	0.7	0.9
Securities premium account	3,418.7	3,416.0
General reserve	7,888.4	7,888.4
Retained earnings	87,907.4	72,424.1
OCI	(156.4)	(134.6)
	99,239.9	83,775.9

a) For details of stock options refer note 31.

b) The disaggregation of changes in reserves and surplus and OCI are disclosed in statement of changes in equity.

Company Overview Stat

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

c) The details of distribution of dividend made and proposed are as under:

	As at	As at
	31 March 2018	31 March 2017
Cash dividends on equity shares declared and paid during the year		
Interim dividend for the year ended 31 March 2018: ₹3.75 per share (31 March 2017: ₹1.95 per share)	2,197.1	1,141.1
Dividend distribution tax on interim dividend	447.3	232.3
	2,644.4	1,373.4
	As at 31 March 2018	As at 31 March 2017
Proposed dividend on equity shares declared at the year end *		
Interim dividend for the year ended 31 March 2018: ₹Nil per share (31 March 2017: ₹ 1.25 per share)	-	732.4
Dividend distribution tax on interim dividend	-	149.1
	-	881.5

* Under Ind AS dividend is recognised as liability in the period in which it is declared by the Company. Accordingly, the above dividend and dividend distribution tax has not been recognised in the standalone financial statements as at 31 March 18 and 31 March 17 respectively.

B. Nature and purpose of reserves

(a)	Capital Reserve :	Represents capital reserve balances of acquired entities which are transferred to the Company upon mergers in the earlier years.
(b)	Capital redemption reserve :	The Company has recognised Capital Redemption Reserve on redemption of non- convertible preference shares. The amount in Capital Redemption Reserve is equal to nominal amount of the non convertible preference shares redeemed.
(C)	Employee stock options outstanding account :	The fair value of the equity-settled share based payment transactions with employees is recognised in statement of profit and loss with corresponding credit to Employee Stock Options Outstanding Account.
(d)	Securities premium account :	The amount received in excess of face value of the equity shares is recognised in Securities Premium Reserve. In case of equity-settled share based payment transactions, the difference between fair value on grant date and nominal value of share is accounted as securities premium reserve.
(e)	General reserve :	The Company has transferred a portion of the net profit of the Company before declaring dividend to general reserve pursuant to the earlier provisions of Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013.
(f)	Retained Earnings:	Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends or other distribution to share holders.
(g)	OCI represents Re-measurement on defined employee benefit plans :	Difference between the interest income on plan assets and the return actually achieved, any changes in the liabilities over the year due to changes in actuarial assumptions or experience adjustments within the plans, are recognised in other comprehensive income and subsequently not reclassified in to statement of profit and loss.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

15. BORROWINGS

		As at	As at
		31 March 2018	31 March 2017
(A)	Non current		
	Term loans from Banks (Secured)		
	Foreign currency term loans	-	1,189.0
		-	1,189.0
(B)	Current		
	Term loans from Banks (Secured)		
	Current maturities of foreign currency term loans	651.7	1,837.4
	Loans repayable on demand from Banks - working capital loans		
	Cash credit facilities (secured)	40.5	1,635.8
	Working capital demand loan (unsecured)	-	750.0
	Packing credit loans (secured)	3,069.7	324.3
	Packing credit loans (unsecured)	31,995.3	24,100.3
	Bill discounting (unsecured)	1,432.8	702.3
		37,190.0	29,350.1
	Amount disclosed under the head "Other financial liabilities" (refer note 18)	(651.7)	(1,837.4)
		36,538.3	27,512.7
(C)	Details of secured and unsecured borrowings		
	The aggregate amount of borrowing includes:		
	Secured borrowings	3,761.9	4,986.5
	Unsecured borrowings	33,428.1	25,552.6

(D) Terms of borrowings

- (i) Secured term loans in foreign currency carry interest in the range of LIBOR plus 1.2% to 1.5%. Out of these loans, loans amounting to ₹ Nil (31 March 2017: ₹ 1,080.9) are repayable in Nil (31 March 2017: two) equal annual instalments and loan amounting to ₹ 651.7 (31 March 2017: ₹1,945.5) is repayable in equal half yearly installment of one (31 March 2017: three).
- (ii) Term loans are secured by first pari passu charge on all the present and future property, plant and equipment, both movable and immovable property of the Company.
- (iii) All secured demand loans are secured by first pari passu charge by way of hypothecation of all the stocks, book debts and other current assets (both present and future). All secured packing credit foreign currency loans carry intrest rate in the range of LIBOR plus 20 to 50 basis points.
- (iv) All unsecured packing credit foreign currency loans carry interest rate in the range of 1 month's LIBOR plus -20 to 50 basis points with maturity within 6 months.

16. PROVISIONS

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
For employee benefits		
Gratuity [refer note 32(b)]	336.0	208.7
	336.0	208.7
(B) Current		
For employee benefits		
Gratuity [refer note 32(b)]	90.0	65.0
Compensated absences	655.4	550.0
	745.4	615.0

Company Overview St

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

17. TRADE PAYABLES

	As at 31 March 2018	As at 31 March 2017
Total outstanding dues of micro enterprises and small enterprises (refer note 34)	296.7	238.6
Total outstanding dues of creditors other than micro enterprises and small enterprises	16,037.3	11,937.4
	16,334.0	12,176.0

(Refer Note 42 for the Company's liquidity risk management process)

18. OTHER FINANCIAL LIABILITIES

	As at 31 March 2018	As at 31 March 2017
Current maturities of non-current borrowings (refer note 15(B))	651.7	1,837.4
Interest accrued but not due on borrowings	10.7	20.5
Unclaimed dividend (refer note 35)	19.0	15.9
Capital creditors	1,820.3	1,489.3
Security deposits	1.5	1.5
Derivatives - foreign currency forward contracts	23.3	-
	2,526.5	3,364.6

19. OTHER LIABILITIES

	31	As at I March 2018	As at 31 March 2017
Advance from customers		61.7	71.0
Statutory liabilities		288.8	229.4
Employee payables		1,088.7	501.0
		1.439.2	801.4

20. REVENUE FROM OPERATIONS

	For the year ended 31 March 2018	For the year ended 31 March 2017
Sale of products (including excise duty) *	100,382.2	95,321.9
Sale of services	37.4	71.7
Other operating revenues		
Scrap sales	133.2	86.5
Export incentives	2,478.7	2,332.0
	103,031.5	97,812.1

*The Company is liable to Goods and Services Tax (GST) with effect from 01 July 2017. The revenues for the year ended 31 March 2018 is net of such GST. However, the revenues for the period ended upto 30 June 2017 are inclusive of excise duty.

21. OTHER INCOME

	For the year ended 31 March 2018	For the year ended 31 March 2017
Interest income on financials assets (carried at amortised cost)		
Other deposits and receivables	39.8	138.2
Loans to subsidiaries	34.7	32.8
Dividend income on investments (carried at fair value through profit and loss)	-	0.0
Provision for doubtful receivables/advances written back (net)	94.8	60.2
Bad debts recovered from trade receivables	-	0.7
Foreign exchange gain (net)	585.3	989.3
Miscellaneous income	51.9	138.3
	806.5	1,359.5

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

22. COST OF MATERIALS CONSUMED

	For the year ended 31 March 2018	For the year ended 31 March 2017
Raw material consumed		
Opening stock	12,297.8	12,118.0
Add: Purchases	49,010.0	41,326.3
	61,307.8	53,444.3
Less: Closing stock	17,967.6	12,297.8
Cost of raw material consumed	43,340.2	41,146.5
Packing materials consumed	5,592.5	4,895.4
	48,932.7	46,041.9

23. CHANGES IN INVENTORY OF FINISHED GOODS (INCLUDING STOCK-IN-TRADE) AND WORK IN PROGRESS

	For the year ended 31 March 2018	For the year ended 31 March 2017
Inventories at the end of the year		
Finished goods	3,230.1	1,499.4
Work-in-progress	9,399.3	7,788.2
	12,629.4	9,287.6
Inventories at the beginning of the year		
Finished goods	1,499.4	1,646.2
Work-in-progress	7,788.2	7,954.6
	9,287.6	9,600.8
	(3,341.8)	313.2

24. EMPLOYEE BENEFITS EXPENSE

	For the year ended 31 March 2018	For the year ended 31 March 2017
Salaries, wages and bonus	10,403.1	8,537.0
Contribution to provident and other funds (refer note 32(a))	331.0	272.7
Gratuity expense (refer note 32(b))	203.5	121.6
Leave encashment expense	204.9	189.5
Staff welfare expenses	173.9	152.0
Employee share-based payment expense - equity settled (refer note 31)	-	0.2
	11,316.4	9,273.0

25. FINANCE COSTS

	For the year ended 31 March 2018	For the year ended 31 March 2017
Interest expense on financial liabilities measured at amortised cost	482.7	402.0
Bank and other financial charges	46.2	49.6
	528.9	451.6

26. DEPRECIATION EXPENSE

	For the year ended 31 March 2018	For the year ended 31 March 2017
Depreciation of property, plant and equipment	3,548.3	2,861.7
	3,548.3	2,861.7

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

27. OTHER EXPENSES

31 March 2016 31 March 2016 Conversion charges 526.6 326.2 Consumption of stores and spares 1,446.6 1,395.0 Chemicals consumed 2,166.9 1.647.9 Power and fuel 4,330.2 4,050.9 Carriage inward 4449.6 413.8 Factory maintenance 307.6 2266.0 Effluent treatment expenses 189.7 156.8 Excise duty on charges in inventory (30.2) 4.1 Repairs and maintenance		For the year ended	For the year ended
Consumption of stores and spares 1,446.6 1,395.0 Chemicals consumed 2,166.9 1,647.9 Power and fuel 4,330.2 4,050.9 Carriage inward 449.6 413.8 Factory maintenance 307.6 266.0 Effuent treatment expenses 189.7 156.8 Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance 332.5 1,741.6 (i) Plant and machinery (30.2) 4.1 (ii) Buildings (34.7) 409.9 (iii) Others 68.0 19.3 Ret (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurace 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 31.6 16.6 Sales commission 438.1 351.0		· · · · · · · · · · · · · · · · · · ·	
Chemicals consumed 2,166.9 1,647.9 Power and fuel 4,330.2 4,050.9 Carriage inward 449.6 413.8 Factory maintenance 307.6 266.0 Effluent treatment expenses 156.8 232.5 Excise duty on sales 332.5 1,741.6 Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance 334.7 409.9 (i) Plant and machinery 68.0 19.3 Rent (refer note: 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurace 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 35.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Salies commission 4.9 4.5 Carriage outwards 2,625.0 1.97.9	Conversion charges	526.6	326.2
Power and fuel 4,330.2 4,050.9 Carriage inward 449.6 413.8 Factory maintenance 307.6 2660. Effluent treatment expenses 189.7 156.8 Excise duty on changes in inventory 332.5 1,741.6 Excise duty on changes in inventory 332.7 14.1 Repairs and maintenance (30.2) 4.1 (i) Plant and machinery 343.3 751.8 (ii) Buildings 334.7 409.9 (iii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 13.6 1.9 Remuneration to statutory auditors (refer note 37) 13.6 1.9 Selling expenses 311.6 181.0 Cariage outwards 2,625.0 1.979.8 Selling expenses 311.6 183.5 Oralize conneyance <	Consumption of stores and spares	1,446.6	1,395.0
Carriage inward 449.6 413.8 Factory maintenance 307.6 266.0 Effluent treatment expenses 189.7 156.8 Excise duty on sales 332.5 1,741.6 Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance (30.2) 4.1 (1) Plant and machinery 843.3 751.8 (1) Buildings 334.7 409.9 (10) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Selling expenses 311.6 181.0 179.9 Travelling and conveyance 49 4.5 Analytical charges	Chemicals consumed	2,166.9	1,647.9
Factory maintenance 307.6 266.0 Effluent treatment expenses 189.7 156.8 Excise duty on changes in inventory (3.0.2) 4.1 Repairs and maintenance (3.0.2) 4.1 (i) Plant and machinery 843.3 751.8 (ii) Buildings 334.7 409.9 (iii) Others 68.0 19.3 Rent (refer note 30/A) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Analytical charges 10.0 8.3 Provision for impa	Power and fuel	4,330.2	4,050.9
Effluent treatment expenses 189.7 156.8 Excise duty on sales 332.5 1,741.6 Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance 334.7 409.9 (i) Buildings 334.7 409.9 (ii) Others 66.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Pates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 11,77.7 1,052.1 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 1,35 1.9 Remuneration to statutory auditors (refer note 37) 33.6 15.6 Sales commission 2,665.0 1,979.8 36.1 Gardage outwards 2,665.0 1,979.8 36.5 Selling expenses 311.6 181.0 183.0 Tavelling and conveyance 4.9 4.5 4.9 4.5	Carriage inward	449.6	413.8
Excise duty on sales 332.5 1,741.6 Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance 843.3 751.8 (i) Plant and machinery 843.3 751.8 (ii) Buildings 334.7 409.9 (iii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 31.6 15.6 Sales commission 438.1 351.0 Carriage outwards 2,625.0 1,97.98 Selling expenses 191.5 183.5 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Analytical charges 70.0 - Donations (refer note 38) 1.0	Factory maintenance	307.6	266.0
Excise duty on changes in inventory (30.2) 4.1 Repairs and maintenance 843.3 751.8 (i) Plant and machinery 843.3 751.8 (ii) Others 843.3 751.8 (iii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 1147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 1144.0 137.8 Legal and professional charges 11,77.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Sales commission 438.1 351.0 351.0 Carriage outwards 2,625.0 1,979.8 Selling expenses 311.6 181.0 Travelling and conveyance 1,068.8 709.7 Provision for impairment of investments (refer note 4) 200.0 - Donations (refer note 38	Effluent treatment expenses	189.7	156.8
Repairs and maintenance 843.3 751.8 (i) Plant and machinery 843.3 751.8 (ii) Buildings 334.7 409.9 (iii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 11,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Sales commission 438.1 351.0 Carriage outwards 2,625.0 1,979.8 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Analytical charges 70.7 34.3 Provision for impairment of investments (refer note 4) 200.0 - Donations (refer note 38) 1.0 8.3 <td>Excise duty on sales</td> <td>332.5</td> <td>1,741.6</td>	Excise duty on sales	332.5	1,741.6
(i) Plant and machinery 843.3 751.8 (ii) Buildings 334.7 409.9 (iii) Others 334.7 409.9 (iii) Others 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 3.6 15.6 Sales commission 2625.0 1,979.8 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Vehicle maintenance expenses 1.068.8 709.7 Provision for impairment of investments (refer note 4) 200.0 - Donations (refer note 38) 0.7 34.3 34.3 Bad debts	Excise duty on changes in inventory	(30.2)	4.1
(i) Buildings 334.7 409.9 (iii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Sales commission 438.1 351.0 Carriage outwards 2,625.0 1,978.8 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Charley charges 1,068.8 709.7 Provision for impairment of investments (refer note 4) 200.0 - Donations (refer note 38) 0.7 34.3 Bad debts 9.9 41.0	Repairs and maintenance		
(ii) Others 68.0 19.3 Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 66.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Sales commission 438.1 351.0 Carriage outwards 2,625.0 1,979.8 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Analytical charges 717.7 856.2 Loss on sale of property, plant and equipment (net) 0.7 34.3 Bad debts 9.9 41.0 Loss on sale of non current investments - 145.3 Fair value changes to current investments 0.0 -	(i) Plant and machinery	843.3	751.8
Rent (refer note 30(A)) 89.5 73.9 Rates and taxes 245.2 304.8 Printing and stationery 147.7 107.9 Postage, telegram and telephones 65.2 59.1 Insurance 144.0 137.8 Legal and professional charges 1,177.7 1,052.1 Directors sitting fees 3.5 1.9 Remuneration to statutory auditors (refer note 37) 13.6 15.6 Sales commission 438.1 351.0 Carriage outwards 2,625.0 1,979.8 Selling expenses 311.6 181.0 Travelling and conveyance 191.5 183.5 Vehicle maintenance expenses 4.9 4.5 Analytical charges 70.7 868.3 Provision for impairment of investments (refer note 4) 200.0 - Donations (refer note 38) 1.0 8.3 Registration and filing charges 717.7 866.2 Loss on sale of property, plant and equipment (net) 0.7 34.3 Bad debts 9.9 41.0	(ii) Buildings	334.7	409.9
Rates and taxes245.2304.8Printing and stationery147.7107.9Postage, telegram and telephones65.259.1Insurance144.0137.8Legal and professional charges1,177.71,052.1Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value charges to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	(iii) Others	68.0	19.3
Printing and stationery147.7107.9Postage, telegram and telephones65.259.1Insurance144.0137.8Legal and professional charges1,177.71,052.1Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1.08.3Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges9.941.0Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Rent (refer note 30(A))	89.5	73.9
Postage, telegram and telephones65.259.1Insurance144.0137.8Legal and professional charges1,177.71,052.1Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.9411.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Rates and taxes	245.2	304.8
Insurance144.0137.8Legal and professional charges1,177.71,052.1Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses707.8707.8	Printing and stationery	147.7	107.9
Legal and professional charges1,177.71,052.1Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges1.108.3Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Postage, telegram and telephones	65.2	59.1
Directors sitting fees3.51.9Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges1.08.3Loss on sale of property, plant and equipment (net)0.734.3Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses707.8707.8	Insurance	144.0	137.8
Remuneration to statutory auditors (refer note 37)13.615.6Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Legal and professional charges	1,177.7	1,052.1
Sales commission438.1351.0Carriage outwards2,625.01,979.8Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Directors sitting fees	3.5	1.9
Carriage outwards2,625.01,979.8Selling expenses311.6181.0Traveling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Remuneration to statutory auditors (refer note 37)	13.6	15.6
Selling expenses311.6181.0Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Sales commission	438.1	351.0
Travelling and conveyance191.5183.5Vehicle maintenance expenses4.94.5Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Carriage outwards	2,625.0	1,979.8
Vehicle maintenance expenses4.9Analytical charges1,068.8Analytical charges1,068.8Provision for impairment of investments (refer note 4)200.0Donations (refer note 38)1.0Registration and filing charges717.7Loss on sale of property, plant and equipment (net)0.7Bad debts9.9Loss on sale of non current investments-It value changes to current investments-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0Miscellaneous expenses765.8	Selling expenses	311.6	181.0
Analytical charges1,068.8709.7Provision for impairment of investments (refer note 4)200.0-Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Travelling and conveyance	191.5	183.5
Provision for impairment of investments (refer note 4)200.0Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Vehicle maintenance expenses	4.9	4.5
Donations (refer note 38)1.08.3Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8		1,068.8	709.7
Registration and filing charges717.7856.2Loss on sale of property, plant and equipment (net)0.734.3Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Provision for impairment of investments (refer note 4)	200.0	-
Loss on sale of property, plant and equipment (net)0.7Bad debts9.9Loss on sale of non current investments-Loss on sale of non current investments-Fair value changes to current investments0.0Corporate Social Responsibility expenditure (CSR) (refer note below)200.0Miscellaneous expenses765.8	Donations (refer note 38)	1.0	8.3
Bad debts9.941.0Loss on sale of non current investments-145.3Fair value changes to current investments0.0-Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8	Registration and filing charges	717.7	856.2
Loss on sale of non current investments145.3Fair value changes to current investments0.0Corporate Social Responsibility expenditure (CSR) (refer note below)200.0Miscellaneous expenses765.8707.8	Loss on sale of property, plant and equipment (net)	0.7	34.3
Fair value changes to current investments0.0Corporate Social Responsibility expenditure (CSR) (refer note below)200.0Miscellaneous expenses765.8		9.9	-
Corporate Social Responsibility expenditure (CSR) (refer note below)200.0193.6Miscellaneous expenses765.8707.8		-	145.3
Miscellaneous expenses 765.8 707.8		0.0	-
	Corporate Social Responsibility expenditure (CSR) (refer note below)	200.0	193.6
19,386.9 18,332.4	Miscellaneous expenses	765.8	707.8
		19,386.9	18,332.4

Note: Details of CSR expenditure

a) Gross amount required to be spent by the Company during the year

	in cash	Yet to be paid in cash	Total
b) Amount spent during the year ending on 31 March 2018:			
i) Construction/acquisition of any asset;	-	-	-
ii) On purposes other than (i) above.	200.0	-	200.0
Amount spent during the year ending on 31 March 2017:			
i) Construction/acquisition of any asset;	-	-	-
ii) On purposes other than (i) above.	193.6	-	193.6

424.9

424.5

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

28. INCOME TAX

	For the year ended 31 March 2018	For the year ended 31 March 2017
The major components of income tax expense for the year ended 31 March 2018 and 31 March		
2017 are:		
Statement of profit and loss		
Current income tax charge	5,053.4	4,620.6
Deferred tax/ Tax credit - relating to origination and reversal of temporary differences	248.3	97.5
	5,301.7	4,718.1
Other comprehensive income		
Deferred tax - net loss on remeasurements of defined benefit plans	12.7	29.7
· · · · · · · · · · · · · · · · · · ·	12.7	29.7
Reconciliation of effective tax rate for the year ended 31 March 2018 and 31 March 2017:		
Profit before tax	23,429.4	21,785.7
Enacted tax rate in India	34.608%	34.608%
Tax at statutory tax rate	8,108.4	7,539.6
Effect of :		
Tax holidays (refer Note "a" below)	(2,132.1)	(1,313.4)
Weighted deduction allowed for research and development expenditure	(765.0)	(1,278.3)
Others (net)	90.4	(229.8)
Total	(2,806.7)	(2,821.5)
Income tax expense	5,301.7	4,718.1
Effective tax rate	22.628%	21.657%

Notes:

- (a) The Company benefits from the tax holiday available for units set up under the Special Economic Zone Act, 2005. These tax holidays are available for a period of fifteen years from the date of commencement of operations. Under the SEZ scheme, the unit which begins providing services on or after 01 April 2005 will be eligible for deductions of 100% of profits or gains derived from export of services for the first five years, 50% of such profit or gains for a further period of five years and 50% of such profits or gains for the balance period of five years subject to fulfillment of certain conditions. From 01 April 2011 units set up under SEZ scheme are subject to Minimum Alternate Tax (MAT).
- (b) During the year ended 31 March 2018 and 31 March 2017, the Company has paid dividend to shareholders, this has resulted in payment of dividend distribution tax to the taxation authorities. The Company believes that dividend distribution tax represents additional payment to tax authorities on behalf of shareholders. Hence, dividend distribution tax paid is charged to equity.
- (c) There are no unrecognised deferred tax assets and liabilities as at 31 March 2018 and 31 March 2017.

29 EARNINGS PER SHARE

The following reflects the income and share data used in the basic and diluted EPS computations:

	31 March 2018	31 March 2017
Earnings		
Profit after taxation considered for calculation of basic and diluted earnings per share	18,127.7	17,067.6
Shares		
Weighted average number of Equity Shares considered for calculation of basic earnings	585,882,685	585,213,641
per share (a)		
Effect of dilution on account of Employee Stock Options granted (b)	5,039	9,782
Weighted average number of equity Shares considered for calculation of diluted earnings	585,887,724	585,223,423
per share (a+b)		
Earnings per share of face value ₹1/-		
- Basic	30.94	29.16
- Diluted	30.94	29.16

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

30 COMMITMENTS AND CONTINGENCIES

A. Leases

Operating lease commitments - Company as lessee

- i) The Company has operating leases agreements, which are mainly in the nature of lease of office premises for a period up to five years, with no restrictions and are renewable/ cancellable at the option of either of the parties except for details in (ii) below. These leases include a general clause to enable upward revision of the rental charge on an annual basis according to the prevailing market conditions. There is no other escalation clause in the lease agreement. There are no sub-leases. There are no restrictions imposed by lease arrangements. The aggregate amount of operating lease payments recognised in the statement of profit and loss is ₹ 89.5 (31 March 2017: ₹73.9). The Company has not recognised any contingent rent as expense in the statement of profit and loss.
- ii) The Company has entered into non cancellable leases for office premises in current year and previous year. These leases have remaining non cancellable period of 6 months (31 March 2017: 5 months). The lease includes an escalation clause in the lease agreement. Future minimum lease rentals under non cancellable operating leases are as follows:

	31 March 2018	31 March 2017
a) Within one year	6.0	21.1
b) After one year and not more than three years	-	-
c) After three years and not more than five years	-	-

Finance lease - Company as lessee

Buildings includes factory buildings acquired on finance lease. The lease term is for major part of the economic life of the buildings and the agreement is silent on renewal terms and transfer of legal title at the end of lease term.

The lease agreement did not specify minimum lease payments over the future period. The factory building has been acquired on lease at a consideration of ₹ **25.5** (31 March 2017: ₹ 25.5).

The net carrying amount of the buildings obtained on finance lease - ₹ 8.2 (31 March 2017: ₹ 9.5).

Lease commitments - the Company as lessor

The Company has entered into agreement to non cancellable leases for office premises. The Company has identified assets under operating and finance lease based on the factors indicated under Appendix C to Ind AS 17 and terms of the agreement, viz., economic life of the asset vs. lease term, ownership of the asset after the lease term.

Lease commitments - the Company as lessee

The Company has entered into leases for land and office premises. The Company has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a major part of the economic life of the land and office premises and the fair value of the asset, that it does not retain significant risks and rewards of ownership of the land and the office premises and accounts for the contracts as operating leases.

B. Capital and other commitments

	31 March 2018	31 March 2017
Estimated amount of contracts (net of advances) remaining to be executed on capital	2,656.9	4,115.1
account and not provided for		

C. Contingent liabilities

31 March 2018	31 March 2017
317.6	320.4
568.8	586.3
150.3	150.3
10,060.5	2,339.5
1,048.2	877.6
	317.6 568.8 150.3 10,060.5

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

* in respect of above matters, future cash outflows in respect of contingent liabilities are determinable only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company. The Company is contesting these demands and the Management, including its advisors, believe that its position will likely be upheld in the appellate process. No expense has been accrued in the standalone financial statements for the demands raised. The Management believes that the ultimate outcome of this proceeding will not have a material adverse effect on the Company's financial position and results of operations.

** Guarantees furnished towards business requirement in respective subsidiaries. The Company has assessed that it is only possible, but not probable, that outflow of economic resources will be required.

^ The Company is involved in disputes, claims, Governmental and /or regulatory inspection, inquires, including patents and commercial maters that arise from time to time in the ordinary course of business. The same are subject to uncertain future events not wholly within the control of the Company. The management does not expect the same to have materially adverse effect on its financial position, as it believes the likely hood of any loss is not probable.

31 SHARE BASED PAYMENTS

Employee Stock Option Plan "ESOP-2006"

The Company instituted an Employee Stock Option Plan "ESOP-2006" for issue of shares to eligible employees of the Company as per the special resolution passed in the 19th Annual General Meeting held on 18 September 2006. The compensation committee of the Board of directors accordingly, granted 3,240,500 options under eight grants of 175,000, 25,000, 90,000, 1,205,000, 300,000, 500,000, 915,500 and 30,000 options to eligible employees on 30 October 2006, 31 July 2007, 31 October 2007, 16 December 2011, 19 June 2012, 09 January 2013, 28 January 2013 and 09 August 2013 respectively. The method of settlement under scheme is by issue of equity shares of the Company and there are no cash settlement alternatives for the employees. Each option comprises of one underlying Equity Share of ₹1/- each. The said options vest on an annual basis at 10%, 15%, 25% and 50% over a period of four years and can be exercised over a period of six years from the date of grant of options. The options have been granted at the then prevailing market price of ₹ 120.70, ₹ 132.35, ₹ 114.50, ₹ 91.60, ₹ 106.05, ₹ 200.70, ₹ 187.40 and ₹ 161.30 per share respectively. The fair value of share options grants is estimated at the date of grant using Black-Scholes model, taking into account the terms and conditions upon which the share options were granted.

The details of ESOP 2006 Scheme are summarised below:

Grant	Grant date	Number of options Granted	Exercise price*	Weighted Average Fair value of option at grant date*
1st Grant	30 October 2006	175,000	60.35	73.10
2nd Grant	31 July 2007	25,000	66.18	78.82
3rd Grant	31 October 2007	90,000	57.25	68.18
4th Grant	16 December 2011	1,753,800	45.80	54.35
5th Grant	19 June 2012	300,000	53.03	57.42
6th Grant	09 January 2013	500,000	100.35	119.22
7th Grant	28 January 2013	1,483,170	93.70	111.32
8th Grant	09 August 2013	57,000	80.65	96.30

*Adjusted for bonus issue.

The details of activity under the Scheme ESOP 2006 are summarised below :

	31 March 2018	31 March 2017
Options outstanding at the beginning of the year	56,219	1,027,120
Granted during the year	-	-
Vested / exercisable during the year	56,219	638,932
Exercised during the year	25,200	712,823
Forfeited during the year subject to reissue	-	258,078
Options outstanding at end of the year	31,019	56,219
Exercisable at the end of the year	31,019	27,719
Weighted average exercise price for all the above options (₹)	80.66	88.76
Weighted average fair value of options at the date of grant (₹)	96.30	105.63

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

The details of share options outstanding are summarised below:

	Range of exercise prices	Number of options outstanding	Weighted average remaining contractual life of options (in years)
As at 31 March 2018	80 to 94	31,019	1.36
As at 31 March 2017	80 to 94	56,219	2.23

The following table lists the assumptions used for the plan:

	31 March 2018				
Grant	Dividend yield	Expected volatility	Risk-free interest rate	Expected life of options granted in years	
7th Grant	0.80%	0.31%	8%	4	
8th Grant	0.61%	0.31%	8%	4	
		31 Ma	rch 2017		
		0.1110			
Grant	Dividend yield	Expected volatility	Risk-free interest rate	Expected life of options granted in years	
Grant 7th Grant	Dividend yield 0.80%	Expected	Risk-free	options granted in	

32 EMPLOYEE BENEFITS

		31 March 2018	31 March 2017
a)	Disclosures related to defined contribution plan		
	Provident fund contribution *	311.9	266.4
	Contribution to ESI**	39.1	21.9

* Includes ₹19.3 (31 March 2017: ₹14.3) transferred to capital work in progress

** Includes ₹0.7 (31 March 2017: ₹1.3) transferred to capital work in progress

b) Disclosures related to defined benefit plan

The Company has a defined benefit gratuity plan governed by the Payment of Gratuity Act, 1972. Every employee who has completed five years or more of service is entitled to gratuity on departure at 15 days last drawn salary for each completed year of service or part thereof in excess of six months.

This defined benefit plan exposes the Company to acturial risk, such as longevity risk, currency risk, interest rate risk and market (investment) risk.

The plan is funded with Life Insurance Corporation in the form of a qualifying insurance policy. The following tables summarise the components of net benefit expense recognised in the statement of profit and loss, the fund status and amounts recognised in the balance sheet:

Net employee benefit expense (included under employee benefit expenses)

	31 March 2018	31 March 2017
Current service cost	143.5	114.4
Past service cost	55.3	-
Interest on defined benefit liability	12.8	18.1
Net employee benefit expenses*	211.6	132.5

* Includes ₹8.2 (31 March 2017: ₹10.9) transferred to capital work in progress

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Details of the employee benefits obligations and plan assets are as follows:

	31 March 2018	31 March 2017
Present value of funded obligation	1,054.5	818.3
Fair value of plan assets	628.5	544.6
Net defined benefit liability	426.0	273.7

Details of changes in present value of defined benefit obligation are as follows:

	31 March 2018	31 March 2017
Opening defined benefit obligation	818.3	618.1
Current service cost	143.5	114.4
Past service cost	55.3	-
Interest on defined benefit obligation	59.0	47.9
Benefits paid	(49.9)	(47.3)
Remeasurement due to:		
Actuarial loss arising from changes in experience	43.8	14.4
Actuarial loss arising from changes in demographic assumptions	6.3	-
Actuarial (gain)/loss arising from changes in financial assumptions	(21.8)	70.8
Closing defined benefit obligation	1,054.5	818.3

Details of changes in fair value of plan assets are as follows:

	31 March 2018	31 March 2017
Opening fair value of plan assets	544.6	340.5
Interest on plan assets	46.1	29.8
Employer Contribution	93.9	222.2
Benefits paid	(49.9)	(47.3)
Remeasurement due to - actual return on plan assets less interest on plan assets	(6.2)	(0.6)
Closing fair value of plan assets	628.5	544.6

Sensitivity analysis

The sensitivity of over all plan obligations to changes in key assumptions are as follows:

	04.14	04.14
	31 March 2018	31 March 2017
Defined benefit obligation without effect of projected salary growth rate	677.4	381.1
Add: effect of salary growth rate	377.1	437.2
Defined benefit obligation with effect of projected salary growth	1,054.5	818.3
Defined benefit obligation, using discount rate plus 50 basis points	1,019.8	769.2
Defined benefit obligation, using discount rate minus 50 basis points	1,091.3	871.9
Defined benefit obligation, using salary growth rate plus 50 basis points	1,089.9	864.4
Defined benefit obligation, using salary growth rate minus 50 basis points	1,020.8	774.8

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

	31 March 2018	31 March 2017
Funds managed by Insurers	100.00%	100.00%

The principal assumptions used in determining gratuity obligations for the Company's plans are shown below Financial assumptions

	31 March 2018	31 March 2017
Discount rate (p.a.)	7.70%	7.40%
Expected salary increase (p.a)		
Until 2 years	-	10.00%
Beyond 2 years	-	7.00%
Until 1 year	10.00%	-
Beyond 1 year	7.00%	
Demographic assumptions		
Mortality rate (% of IALM 06-08)	100%	100%

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Attrition rate	2018	2018		2017	
	Age (years)	Rates (p.a)	Age (years)	Rates (p.a)	
	21 - 30	16%	21 - 30	8%	
	31 - 40	12%	31 - 40	4%	
	41 - 50	3%	41 - 57	1%	
	51 - 57	23%	-	-	

Discount rate : The discount rate is based on the prevailing market yields of Indian Governmet securities as at the balance sheet date for the estimated term of obligations.

Salary escalation rate : The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other related factors.

Maturity profile of the defined benefit obligation

	31 March 2018	31 March 2017
Weighted average duration of defined benefit obligation (in years)	6.77	12.53
Expected future cash flow of gratuity		
Within 12 months	143.2	43.0
Between 2 and 5 years	488.3	160.8
Between 5 and 10 years	399.6	223.5
Beyond 10 years	984.3	2,099.6

Notes:

- 1. The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.
- 2. The Company expects to contribute ₹ 90.0 (31 March 2017: ₹ 65.0) during the year ended 31 March 2019 to the qualifying insurance policy .
- 3. The sensitivity analysis above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period by varying one actuarial assumption, keeping all other actuarial assumptions constant.

33 CAPITAL WORK-IN-PROGRESS INCLUDES EXPENDITURE DURING CONSTRUCTION PERIOD PENDING CAPITALISATION

	31 March 2018	31 March 2017
Balance brought forward	1,335.8	960.2
Add: Incurred during the year		
Salaries, wages and bonus	338.7	443.5
Consumption of material for testing	173.5	249.1
Consumption of stores and spares	95.1	208.3
Carriage inward	1.5	1.5
Power and fuel	122.9	270.2
Conversion charges	39.2	50.8
Rates and taxes	9.0	30.7
Printing and stationery	5.7	8.6
Postage, telegram and telephones	2.0	2.5
Insurance	1.9	(1.0)
Legal and professional charges	9.2	8.9
Travelling and conveyance	7.6	10.4
Depreciation	2.6	3.7
Factory maintenance	42.4	46.5
Miscellaneous expenses	31.1	69.7
	2,218.2	2,363.6
Less: Capitalised to property, plant and equipment during the year	623.3	1,027.8
Balance carried forward	1,594.9	1, 335.8

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

34 DETAILS OF DUES TO MICRO AND SMALL ENTERPRISES AS DEFINED UNDER THE MSMED ACT,2006

31 March 2018	31 March 2017
307.7	238.6
Nil	Nil
Nil	Nil
Nil	Nil
Nil	Nil
Nil	Nil
	307.7 Nil Nil Nil Nil

35 In respect of the amounts mentioned under section 125 of the Companies Act, 2013 there are no dues that are to be credited to the Investor Education and Protection Fund as at 31 March 2018 (31 March 2017: ₹ Nil).

36 RESEARCH AND DEVELOPMENT EXPENSES

a. Details of Research and development expenses incurred during the year, debited under various heads of statement of profit and loss is given below

	31 March 2018	31 March 2017
Material and stores and spares consumption	1,258.7	894.0
Power and fuel	127.5	106.3
Repairs and maintenance	42.0	41.6
Employee benefits expense	1,445.1	1,196.6
Analytical charges	1,015.0	659.3
Legal & Professional charges	886.2	846.0
Registration and filing fee	618.2	793.2
Depreciation	290.4	238.7
Others	212.0	187.6
Total	5,895.1	4,963.3

b. Details of capital expenditure incurred for Research and development are given below:

	31 March 2018	31 March 2017
Buildings	44.6	129.6
Plant and equipment		
- Plant and equipment	119.3	145.4
- Lab equipment	334.8	530.1
- Pipes and valves	17.7	14.3
- Data processing equipment	27.8	28.5
- Electrical installations	17.0	48.0
Office equipment	3.9	4.2
Furniture and fixtures	31.2	40.6
Total	596.3	940.7

Company Overview

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

37 REMUNERATION TO STATUTORY AUDITORS

	31 March 2018	31 March 2017
As Auditors :		
Statutory audit	8.6	7.9
Limited review - standalone	2.1	2.1
Limited review - consolidation	1.8	3.0
In other capacity:		
Certification	0.7	0.2
Others	-	1.5
Reimbursement of expenses and taxes	0.4	0.9
	13.6	15.6

38 DONATION TO POLITICAL PARTIES

	31 March 2018	31 March 2017
Communist Party of India (Marxist)	0.5	0.5
Communist Party of India	0.5	-
Bharatiya Janata Party	-	2.0
	1.0	2.5

39 RELATED PARTY DISCLOSURES

Names of related parties and description of relationship Subsidiaries

- 1 APL Pharma Thai Limited, Thailand
- 2 All Pharma (Shanghai) Trading Company Limited, China
- 3 Aurobindo Pharma USA Inc., USA
- 4 Aurobindo Pharma Industria Farmaceutica Ltda, Brazil
- 5 Helix Healthcare B.V., The Netherlands
- 6 Aurobindo Pharma Produtos Farmaceuticos Limitada, Brazil
- 7 APL Healthcare Limited, India
- 8 Auronext Pharma Private Limited, India
- 9 APL Research Centre Limited, India
- 10 Auro Pharma Inc., Canada
- 11 Aurobindo Pharma (Pty) Limited, South Africa
- 12 Agile Pharma B.V., The Netherlands
- 13 Auro Healthcare (Nigeria) Limited, Nigeria
- 14 Aurobindo Ilac Sanayi Ve Ticaret Limited Sirketi, Turkey (liquidated w.e.f. 31 October 2017)
- 15 Aurobindo Pharma Japan K.K., Japan
- 16 Aurex B.V. (formerly Pharmacin B.V.), The Netherlands
- 17 Aurobindo Pharma GmbH, Germany
- 18 Aurobindo Pharma (Portugal) Unipessoal Limitada., Portugal**
- 19 Laboratorios Aurobindo S.L., Spain
- 20 Aurobindo Pharma B.V., The Netherlands (formerly known as Actavis B.V.)
- 21 Aurobindo Pharma (Romania) S.r.I, Romania
- 22 Aurobindo Pharma (Italia) S.r.I, Italy
- 23 Aurobindo Pharma (Malta) Limited, Malta
- 24 APL Swift Services (Malta) Limited, Malta
- 25 Milpharm Limited, UK
- 26 Aurolife Pharma LLC, USA
- 27 Auro Peptides Limited, India
- 28 Auromedics Pharma USA LLC, USA (dissolved w.e.f. 31 March 2018)
- 29 Aurovida Farmaceutica S.A. DE C.V., Mexico
- 30 Curepro Parenterals Limited, India
- 31 Hyacinths Pharma Private Limited, India
- 32 Silicon life sciences Private Limited, India
- 33 AuroZymes Limited, India

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

- 34 Aurobindo Pharma Colombia S.A.S, Columbia
- 35 Aurovitas, Unipessoal LDA, Portugal**
- 36 Arrow Generiques SAS, France
- 37 Auro Health LLC, USA
- 38 Pharmacin B.V. (formerly Aurex B.V.), The Netherlands
- 39 1980 Puren Pharma GmbH (formerly Actavis Management GmbH), Germany
- 40 Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG), Germany
- 41 Aurovitas Spain SA (formerly Actavis Spain SA)
- 42 Natrol LLC, USA
- 43 Aurovitas Pharma Polska, Poland (w.e.f 31 March 2017)
- 44 Aurogen South Africa (Pty) Ltd, South Africa (w.e.f. 25 January 2017)
- 45 Aurobindo Pharma USA LLC, USA (w.e.f 14 April 2016 and dissolved w.e.f. 31 March 2018)
- 46 Auro AR LLC, USA (w.e.f. 2 May 2017)
- 47 Auro Vaccines LLC, USA (w.e.f. 27 January 2017)
- 48 Auro Logistics LLC, USA (w.e.f. 28 April 2017)
- 49 Acrotech Biopharma LLC, USA (w.e.f. 05 January 2018)
- 50 Generis Farmaceutica S.A, Portugal (w.e.f. 01 May 2017)
- 51 Mer Medicamentos, Lda, Portugal (w.e.f. 01 May 2017)**
- 52 Generis Phar Unipessoal Lda., Portugal (w.e.f. 01 May 2017)
- 53 Farma APS Promoção de Medicamentos, Unipessoal Lda. (w.e.f. 01 May 2017 and dissolved w.e.f. 25 January 2018)
- 54 Aurobindo Pharma Saudi Arabia Limited Company (w.e.f 08 May 2017)
- 55 Auro Pharma India Private Limited, India (w.e.f 20 December 2017)
- 56 Aurovitas Pharma Ceska Republica s.r.o , Czech Republic (w.e.f.23 December 2017)
- 57 Generis MZ, Lda., Mozambique (w.e.f. 01 May 2017 and dissolved w.e.f. 19 March 2018)
- 58 Aurovitas Pharma (Tazihou) Ltd, China(w.e.f. 29 January 2018)

**Mer Medicamentos, Lda, Portugal, Aurovitas, Unipessoal LDA, Portugal and Aurobindo Pharma (Portugal) Unipessoal Limitada., Portugal were merged with Generis Farmaceutica S.A., w.e.f. 01 April 2018.

Joint ventures

- 1 Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a Subsidiary, Aurobindo Pharma (Pty) Limited, South Africa)
- 2 Eugia Pharma Specialities Limited, India
- 3 Tergene Biotech Private Limited, India (w.e.f. 01 April 2015)
- 4 Raidurgam developers limited, India (formerly known as Aurobindo Antibiotics limited, India)

Enterprises over which key management personnel or their relatives exercise significant influence

- 1 Pravesha Industries Private Limited, India
- 2 Sri Sai Packaging, India (Partnership firm)
- 3 Trident Chemphar Limited, India
- 4 Auropro Soft Systems Private Limited, India
- 5 Axis Clinicals Limited, India
- 6 Pranit Projects Private Limited, India
- 7 Pranit Packaging Private Limited, India
- 8 SGD Pharma India Limited (formerly Cogent Glass Limited), India
- 9 Orem Access Bio Inc, India
- 10 Veritaz Healthcare Limited, India
- 11 Alex Merchant PTE. LTD, Singapore
- 12 Trident Petrochemicals DMCC, Dubai
- 13 Axis Clinicals LLC, USA
- 14 Alex Merchant DMCC, Dubai
- 15 Crest Cellulose Private Limited, India
- 16 East Pharma Technologies, India (Partnership firm)
- 17 Axis Clinicals Latina SA DE CV, Mexico
- 18 Viwyn Pharma Private limited, India
- 19 Gelcaps Industries, India



Company Overview Statutory Reports

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Key managerial personnel

- 1 Mr. K. Nityananda Reddy, Whole-time Director
- 2 Dr. M. Sivakumaran, Whole-time Director
- 3 Mr. M. Madan Mohan Reddy, Whole-time Director
- 4 Mr. P. Sarath Chandra Reddy, Whole-time Director (from 01 June 2016)
- 5 Mr. N. Govindarajan, Managing Director
- 6 Mr. Santhanam Subramanian, Chief Financial Officer
- 7 Mr. A. Mohan Rami Reddy, Company Secretary (upto 31 May 2016)
- 8 Mr. B. Adireddy, Company Secretary (w.e.f. 01 June 2016)
- 9 Mr. K. Ragunathan, Independent Director
- 10 Mr. M. Sitarama Murty, Independent Director
- 11 Mr. D. Rajagopala Reddy, Independent Director (Upto 08 February 2017)
- 12 Dr. (Mrs.) Avnit Bimal Singh, Independent Director
- 13 Mr.Rangaswamy Rathakrishnan Iyer, Independent Director (Upto 09 December 2017)
- 14 Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director
- 15 Mrs.Savitha Mahajan, Independent Diretor (w.e.f. 16 December 2017)

Relatives to key managerial personnel

1 Mr. Vishnu M Sriram (son-in-law of Dr. M. Sivakumaran, Wholetime Director)

Transactions with related parties

Particulars	31 March 2018	31 March 2017
a. Loans given and repayment thereof		
Transactions with subsidiaries		
AuroZymes Limited, India		
Receipt against loan and interest	4.2	0.9
Interest accrued	6.6	6.1
Loan given	23.0	16.0
Balance receivable	87.5	62.1
Silicon life sciences Private Limited, India		
Receipt/Converted into 9.5% cumulative redemable preferece shares against loan	311.6	-
and interest		
Interest accrued	6.1	31.4
Loan given	-	108.5
Balance receivable	36.8	342.4
Auronext Pharma Private Limited, India		
Receipt/Converted into 9.5% cumulative redemable preferece shares against loan	221.5	40.0
and interest		
Interest accrued	10.0	1.5
Loan given	170.0	80.0
Balance receivable	-	41.5
Transactions with Joint venture		
Raidurgam developers limited		
Receipt/Converted into optionally convertible debentures against loan and interest	t 1,071.8	-
Interest accrued	8.3	-
Loan given	1,065.2	-
Balance receivable	1.8	-
b. Sale/purchase of goods, services and other transactions		
Transactions with subsidiaries		

for the year ended 31 March 2018

ars	31 March 2018	31 March
APL Pharma Thai Limited, Thailand		
Sale of goods/(returns)	21.5	(
All Pharma (Shanghai) Trading Company Limited, China Purchase of goods	0.4	
*	0.4	
Reimbursement of expenses Aurobindo Pharma Produtos Farmaceuticos Ltda, Brazil	10.5	
	114.0	
Sale of goods	114.8	1
Reimbursement of expenses		
Sales Commission APL Swift Services (Malta) Limited, Malta	17.8	
Sale of goods	2 550 0	0.7
	3,550.9	2,7
Reimbursement of expenses	48.4	
Reimbursement of expenses received	3.2	
Aurobindo Pharma USA Inc., USA	07.100.0	
Sale of goods	27,182.9	20,6
Purchase of goods	0.1	
Aurobindo Pharma Industria Farmaceutica Ltda, Brazil		
Sale of goods	625.0	5
Sale of asset	0.7	
Reimbursement of expenses	0.8	
Auro Pharma Inc., Canada	744.0	
Sale of goods	744.3	4
Reimbursement of expenses	1.9	
Aurobindo Pharma (Pty) Limited, South Africa		
Sale of goods	209.1	1
Reimbursement of expenses		
Sales Commission	8.2	
Pharmacin B.V., The Netherlands (formerly Aurex B.V.)		
Sale of goods	8.4	
Sales Commission	0.2	
Aurex B.V., The Netherlands (formerly Pharmacin B.V.)		
Sale of goods	40.6	
Sales Commission	19.9	
Reimbursement of expenses	0.2	
Milpharm Limited, UK		
Sale of goods	3,150.4	1,5
Reimbursement of expenses	25.7	
Aurolife Pharma LLC, USA		
Sale of goods	2,127.0	2,9
Reimbursement of expenses	1.3	
Reimbursement of expenses received	-	
Aurobindo Pharma Japan K.K., Japan		
Sale of goods	152.3	3
Sales Commission	22.2	
Aurobindo Pharma (Malta) Limited, Malta		
Reimbursement of expenses	4.0	
Auronext Pharma Private Limited, India		
Sale of goods	276.5	3
Purchase of goods	30.3	
Purchases of asset	1.1	
Rent received	1.8	
Reimbursement of expenses received	0.9	
Laboratorios Aurobindo S.L, Spain		
Sale of goods	10.6	3

for the year ended 31 March 2018

ars	31 March 2018	31 Marcl
Reimbursement of expenses	0.0	
Reimbursement of expenses received	2.9	
Auro Medics Pharma LLC, USA		
Sale of goods	8,166.2	9,
Purchase of goods	0.9	
Reimbursement of expenses received	7.6	
Auro Healthcare (Nigeria) Limited, Nigeria		
Sales Commission	0.8	
Reimbursement of expenses	0.3	
APL Healthcare Limited, India	0.0	
Sale of goods	30.2	
Sale of fixed assets		
Reimbursement of Expenses Received	1.4	
Auro Peptides Ltd, India		
Rent Received	9.9	
Reimbursement of Expenses Received	43.5	
Sale of goods	0.8	
Purchase of goods	63.6	
Silicon Life Sciences Private Limited, India		
Sale of goods	184.0	
Purchase of goods	11.8	
Purchase of asset	4.4	
Reimbursement of Expenses Received	2.6	
Aurovida Farmaceutica, SA DE CV, Mexico		
Sale of goods	64.8	
Reimbursement of expenses	79.1	
Aurobindo Pharma Portugal	73.1	
Reimbursement of expenses	22.5	
Aurobindo Colombia S.A.S., Colombia	22.5	
	455.5	
Sale of goods	155.5	
Reimbursement of expenses	4.1	
Arrow Generiques S.A.S., France		
Sale of goods	0.7	
Reimbursement of expenses received	2.1	
Aurobindo Pharma B.V. (formerly Actavis B.V.), The Netherlands*		
Sale of goods	346.2	
Reimbursement of expenses	3.7	
Aurovitas Spain SAS, Spain		
Sale of goods	2.9	
Reimbursement of expenses received	1.5	
Reimbursement of expenses	0.2	
Aurovitas Unipessol, Portugal		
Reimbursement of expenses	23.7	
Aurobindo Pharma GmbH	23.7	
Reimbursement of expenses received		
	0.5	
Reimbursement of expenses	-	
Aurobindo Pharma (Italia) S.r.I, Italy		
Sale of goods	20.2	
Reimbursement of expenses	0.1	
Reimbursement of expenses received	1.0	
Auro Health LLC, USA		
Sale of goods	509.7	
Puren Pharma GmbH & Co., KG		

for the year ended 31 March 2018

articulars	31 March 2018	31 March 2017
Hyacinths Pharma Private Limited, India		
Sale of asset	2.0	
Aurovitas Pharma Polska, Poland		
Reimbursement of expenses	75.3	
Generis Farmaceutica SA		
Sale of goods	70.6	
Helix Healthcare B.V., The Netherlands		
Corporate guarantee given	4,235.0	
Agile Pharma BV, The Netherlands		
Corporate guarantee given	7,827.3	
2. Sale/purchase of goods, services and other transactions		
Transactions with Joint Venture		
Novagen Pharma (Pty) Limited, South Africa		
Sale of goods	209.7	274.9
Raidurgam developers limited		
Sale of land	1,681.2	
Reimbursement of expenses	152.1	
Eugia Pharma Specialities Ltd, India		
Sale of goods	10.2	0.8
Purchase of goods	0.5	
Reimbursement of Expenses Received	3.4	2.
I. Transactions with enterprises over which key management personnel or their		
relatives exercise significant influence		
Pravesha Industries Private Limited, India		
Sale of goods	0.3	0.7
Purchase of goods	2,155.8	1,804.3
Rent and electricity charges received	-	0.2
Sri Sai Packaging, India		
Sale of goods	0.5	0.3
Purchase of goods	210.5	194.
Axis Clinicals Limited, India		
Purchase of services	830.7	553.
Axis Clinicals LLC, USA		
Purchase of services	-	31.
Axis Clinicals Latina SA DE CV, Mexico		011
Purchase of services	11.9	
Trident Chemphar Limited, India		
Sale of goods		22.
Purchase of goods	757.7	764.
Auropro Soft Systems Private Limited, India		7.04.
Purchase of services	0.2	
Pranit Packaging Private Limited, India	0.2	
Purchase of goods	109.0	165
Pranit Projects Private Limited, India	198.9	165.
Purchase of services (civil services)	-	0.
SGD Pharma India Limited (formerly Cogent Glass Limited)		
Purchase of goods	919.1	675.
Orem Access Bio Inc, India		
Purchase of goods	201.1	204.
Veritaz Healthcare Limited, India		
Vala at gooda	127.3	95.
Sale of goods		
Rent received	0.3	

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Particulars	31 March 201	18 31 March 20
Crest Cellulose Private limited, India		
Purchase of goods	255.	.8 52
East PharmaTechonologies, India		
Purchase of goods	57.	.0
Viwyn Pharma Private limited		
Purchase of services	58.	.1
Reimbursement of Expenses Received	0.	.7
Gelcaps Industries		
Purchase of goods	130.	0
e. Transactions with key managerial personnel or their re	latives	
Mr. K Nityananda Reddy		
Managerial remuneration	15.	.1 15
Rent expense	2	
Dr. M Sivakumaran		
Managerial remuneration	15.	1 15
Mr. M Madan Mohan Reddy	13.	<u> </u>
Managerial remuneration	00	7 00
Mr. P Sarath Chandra Reddy	26.	.7 26
Managerial remuneration		
· ·		
Director sitting fees		- (
Mr. Vishnu M Sriram		
Remuneration	5.	.4
Mr.N Govindarajan		
Managerial Remuneration	146.	.3 124
Mr.Santhanam Subramanian		
Remuneration	14.	.3 10
Mr.A. Mohanrami Reddy		
Remuneration		- (
Mr.B. Adi Reddy		
Remuneration	3.	.3
Mr. P.V. Ramaprasad Reddy		
Director sitting fees	0.	.2 (
Mr. K.Ragunathan, Independent Director		
Director sitting fees	1.	.0 (
Mr. M. Sitarama Murty, Independent Director		
Director sitting fees	1.	.1 (
Mr. D.Rajagopala Reddy, Independent Director (upto	09 Feberuary 2017)	
Director sitting fees		- (
Dr. (Mrs.) Avnit Bimal Singh, Independent Director		
Director sitting fees	0.	.6 (
Mr.RangaswamyRathakrishnanIyer,IndependentDire	ector (from 09 February 2017)	
Director sitting fees	0.	.6 (
Mrs.Savitha Mahajan, Independent Director		
Director sitting fees	0.	1

Note: i) Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.
ii) All transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances for trade receivable, trade payable and other payables are unsecured, interest free and settlement occurs in cash. The Company has not recorded any impairment of balances relating to amouts owed by related parties during the year ended 31 March 2018 (31 March 2017), provision for bad and doubtful debts will be made on an aggregate basis i.e. not specific to party. The assessment is undertaken each financial year through evaluating the financial position of the related party and the market in which the related party operates.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

f. Loans and advances in the nature of loans to subsidiaries - Maximum amount outstanding

Name of the Companies	Closing Balance	e as at 31 March *		anding at any time ended 31 March *
	2018	2017	2018	2017
AuroZymes Limited, India	79.0	56.0	79.0	56.0
Silicon Life Sciences Private Limited, India	-	311.0	311.0	311.0
Auronext Pharma Private Limited, India	-	40.0	210.0	40.0
Raidurgam Developers Limited, India	-	-	1,065.2	-

* Excluding interest on loan

g. Balances with Subsidiaries at the year end

lars	31 March 2018	31 March 20
APL Pharma Thai Limited, Thailand		
Balance payable	3.7	22
All Pharma (Shanghai) Trading Company Limited, China		
Balance payable	19.0	13
Helix Healthcare B.V., The Netherlands		
Equity contribution	584.8	
Corporate guarantee for loans	7,676.7	
Aurobindo Pharma Produtos Farmaceuticos Ltda, Brazil		
Balance receivable	3.4	72
APL Swift Services (Malta) Limited, Malta		
Balance receivable	3,395.1	1,840
Balance payable	36.0	25
Aurobindo Pharma USA Inc., USA		-
Balance receivable	15,736.0	9,990
Balance payable	-	5
Corporate guarantee for loans	-	953
Aurobindo Pharma Industria Farmaceutica Ltda, Brazil		-
Balance receivable	213.9	248
Balance payable	-	(
Auro Pharma Inc., Canada		
Balance receivable	589.5	279
Balance payable	1.9	
Aurobindo Pharma (Pty) Limited, South Africa		
Balance receivable	66.3	46
Balance payable	6.2	6
Pharmacin B.V., The Netherlands (formerly Aurex B.V.)		
Balance receivable	5.4	5
Aurex B.V., The Netherlands (formerly Pharmacin B.V.)		
Balance payable	-	۷
Balance receivable	-	
Milpharm Limited, UK		
Balance receivable	1,040.2	794
Balance payable	9.9	11
Aurolife Pharma LLC, USA		
Balance receivable	264.3	1,254
Aurobindo Pharma Japan K.K., Japan		
Balance receivable	11.7	95
Balance payable	2.7	Z
Aurobindo Pharma (Malta) Limited, Malta		
Balance payable	0.1	1

for the year ended 31 March 2018

691.5 370.0 0.3 3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0 37.4	435 0 336 167 4,810 1 1 425 8 8
- 370.0 0.3 3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0	0 336 167 4,810 1 4,825 8
0.3 3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0	336 167 4,810 1 425 8
0.3 3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0	167 4,810 1 425 8
3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0	4,810 1 425 8
3,083.7 0.6 0.4 28.2 521.5 44.1 2.0 95.0	4,810 1 425 8
0.6 0.4 28.2 521.5 44.1 2.0 95.0	425
0.6 0.4 28.2 521.5 44.1 2.0 95.0	425
0.4 28.2 521.5 44.1 2.0 95.0	425
28.2 521.5 44.1 2.0 95.0	425
28.2 521.5 44.1 2.0 95.0	425
521.5 44.1 2.0 95.0	8
521.5 44.1 2.0 95.0	8
44.1 2.0 95.0	8
2.0 95.0	
2.0 95.0	
95.0	
37.4	75
	26
425.6	222
651.0	
56.5	26
38.6	
-	3
240.1	195
0.2	5
2.1	5
117.0	168
-	2
0.000.0	
2,383.8	1,385
0.5	
0.1	
0.0	
0.0	2
-	0
0.1	
0.1	C
001 0	11
361.0	
	2,383.8 0.5 0.1 0.0 - 20.8 0.1 0.1 361.0 44.0

for the year ended 31 March 2018

Parti	culars	31 March 2018	31 March 2017
	Aurovitas Pharma Polska, Poland		
	Balance payable	75.3	-
	Auro Pharma India Private Limited, India		
	Equity allotment	1.0	-
	Curepro Parenterals Limited, India		
	Equity allotment	-	1,129.0
Not	e: For closing balance of investments and provision for diminution in value of investments, r	efer note 4.	
h.	Balances with Joint venture at the year end		
	Novagen Pharma (Pty) Limited, South Africa		
	Balance receivable	59.9	74.2
	Raidurgam developers limited, India		
	Balance receivable	152.1	-
	Equity allotment	31.0	-
	Investment in optionally convertible debentures	710.9	-
	Tergene Biotech Pvt. Ltd, India		-
	Equity allotment	41.1	-
	Investment in 10.5% Cumulative Redeemable Preference shares	5.0	-
	Eugia Pharma Specialities Ltd, India		-
	Balance receivable	4.8	-
i.	Balances with enterprises over which key management personnel or their	-	
	relatives exercise significant influence at the year end.		
	Pravesha Industries Private Limited, India		
	Balance payable	431.7	25.9
	Balance receivable	-	0.1
	Sri Sai Packaging, India		
	Balance payable	15.6	0.6
	Axis Clinicals Limited, India		
	Balance payable	77.1	62.4
	Trident Chemphar Limited, India		
	Balance payable	153.7	202.4
	Pranit Packaging Private Limited, India		
	Balance payable	8.3	2.6
	SGD Pharma India Limited (formerly Cogent Glass Limited)		
	Balance payable	295.4	121.1
-	Veritaz Healthcare Limited, India		
	Balance receivable		

Company Overview Statutory Reports

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

ticulars	31 March 2018	31 March 2017
Alex Merchants DMCC		
Balance receivable	38.2	173.7
Orem Access Bio Inc, India		
Balance Payable	39.6	-
Crest Cellulose Private limited		
Balance Payable	35.9	16.5
East PharmaTechonologies		
Balance Payable	6.8	2.5
Viwyn Pharma Private limited		
Balance receivable	2.0	
Gelcaps Industries		
Balance Payable	25.5	
Balances with key managerial personnel or their relatives at the year end		
Mr.N Govindarajan		
Balance payable	100.0	90.0

j. Details of advances due from private companies in which Company's director is a director. Pranit Packaging Private Limited, India ₹ Nil (March 31, 2017 ₹ Nil)

- k. i) Details of trade receivables due from private companies in which Company's director is a director. Pravesha Industries Private Limited, India ₹Nil (March 31, 2017: ₹0.1)
 - ii) Details of trade receivables due from partnership firm in which Company's director is a partner. Sri Sai Packaging, India ₹Nil (March 31, 2017: ₹0.0)
- 40 The Board of Directors at their meeting held on 12 September 2013, had approved to transfer its Injectable Unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said Unit to its wholly owned subsidiary viz., Curepro Parenterals Limited. The same was subject to requisite consents, approvals or permissions of the statutory or regulatory authorities. Pending such approvals, no effect of this Scheme has been given till date. The Board of Directors at their meeting held on 29 May 2017 decided not to transfer the Unit, considering the expansion and growth plans of the Company.

41 HEDGING ACTIVITIES AND DERIVATIVES - DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS

The Company uses foreign currency denominated borrowings and foreign exchange forward contracts to manage some of its transaction exposures. The foreign exchange forward contracts are not designated as cash flow hedges and are entered into for periods consistent with foreign currency exposure of the underlying transactions, generally from one week to twelve months.

L STATEMENTS	
ALONE FINANCIAL S	ch 2018
NOTES TO STANDA	for the year ended 31 Marc

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

FINANCIAL INSTRUMENTS - FAIR VALUE AND RISK MANAGEMENT 4

A. Accounting classifications and fair values The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

31 March 2018

	Notes		Carrying a	mount			Fair value	alue	
Particulars	I	FVTPL	Other financial fina assets - liabil Amortised Amo cost	Other financial liabilities - Amortised cost	Total carrying amount	Level 1	Level 2	Level 3	Total
Financial assets measured at fair									
value									
Non-current investments in others*	4A	1.2	1	T	1.2	T	1	1.2	1.2
Non-current investments in government	4A	0.2	1	I	0.2	1	I	0.2	0.2
securities*									
Current investments*	4B	0.2	1	T	0.2	0.2	1	1	0.2
Derivative assets	7B	1	1	T	1	T	1	1	1

Financial assets not measured at fair

1.6

1 1 **1**.4

0.2

1.6

1 1 1

1 1 1

1.6

value					
Non-current investments in preference	4A	I	2,622.2	1	2,622.2
shares					
Trade receivables	5B	1	44,774.4	1	44,774.4
Loans	6A&6B	I	230.2	1	230.2
Cash and cash equivalents	12	1	2,459.0	1	2,459.0
Other financial assets	7A&7B	1	995.0	1	995.0
		1	51,080.8		51,080.8

Financial liabilities measured at fair value

Derivative liabilities	18	23.3	1	1	23.3	1	23.3	1	23.3
		23.3	1		23.3		23.3	1	23.3
Financial liabilities not measured at									

fair value

- 37,190.0 37,190.0		- 16,334.0 16,334.0	1,851.5 1,851.5	
1		1		•
15A, 15B	& 18	17	18	
Borrowings (including current maturities of	non-current borrowings)	Trade payables	Other financial liabilities	

NTS	
EME	
L STATEMENTS	
IAL S	
NOTES TO STANDALONE FINANCIAL 5	
FIN	
-ONE	
NDAI	
STAI	
5 TO	
OTES TO	
ž	

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

FINANCIAL INSTRUMENTS - FAIR VALUE AND RISK MANAGEMENT (CONTD.) 4

A. Accounting classifications and fair values The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

~
T
0
20
4
5
<u> </u>
g
5
~
-
ъ

	Notes		Carrying amount	mount			Fair value	le	
Particulars		FVTPL	Other financial assets - Amortised cost	Other financial liabilities - Amortised cost	Total carrying amount	Level 1	Level 2	Level 3	Total
Financial assets measured at fair									
value Non-current investments in others*	44	1.2	'		1.2		.	1.2	1.2
Non-current investments in government	4A	0.2		1	0.2	1		0.2	0.2
Securities	ļ								
Current investments*	4B	0.2	1	1	0.2	0.2	I	ı	0.2
Derivative assets	7B	94.8	I	I	94.8	ı	94.8		94.8
		96.4	•	•	96.4	0.2	94.8	1.4	96.4
Financial assets not measured at fair									
Non-current investments in preference	4A		1.106,1	I	1.106,1				
SIIdres									
Trade receivables	5B	I	37,736.3	1	37,736.3				
Loans	6A&6B	I	566.1	I	566.1				
Cash and cash equivalents	12	1	336.4		336.4				
Other financial assets	7A&7B		878.4	1	878.4				
		•	41,018.3	•	41,018.3				
Financial liabilities measured at fair									
value									
Derivative liabilities	18	I	I	I	1	I	I	I	I
		I	1	1	T	1	I	1	1
Financial liabilities not measured at									
fair value									
Borrowings (including current maturities of	15A, 15B	1	1	30,539.1	30,539.1				
non-current borrowings)	& 18								
Trade payables	17	I	1	12,176.0	12,176.0				

*These are for operational purposes and the Company estimates that the fair value of these investments are not materially different as compared to their cost.

1,527.2 44,242.3

1,527.2

44,242.3

ı.

ī

10

Other financial liabilities

Company Overview

Statutory Reports

Financial Statements

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

B. Measurement of fair values

i. Valuation techinque and significant unobservable inputs

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the balance sheet, as well as the significant unobservable inputs used:

Туре	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value
Derivative instruments	Forward pricing: The fair value is determined using quoted forward exchange rates at the reporting date and present value calculations based on high credit quality yield curves in the respective currency.	Not applicable	Not applicable

ii. Transfer between Level 1 and 2

There have been no transfers from Level 2 to Level 1 or vice-versa in 2017-18 and no transfers in either direction in 2016-17.

C. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the Risk Management Committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports to the board of directors on its activities.

The Company's risk management policies are estabilished to identify and analyse the risks being faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framwork in relation to the risks faced by the company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the result of which are reported to the audit committee.

The Company is exposed primarily to credit risk, liquidity risk and market risk (including currency risk, interest rate risk and other price risk). The Company uses derivative financial instruments such as forwards to minimise any adverse effect on its financial performance.

i. Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk encompasses of both, the direct risk of default and the risk of deterioration of creditworthiness as well as concentration of risks. Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom the credit has been granted after obtaining necessary approvals for credit. Financial instruments that are subject to concentrations of credit risk principally consist of trade receivables, investments, derivative financial instruments, cash and cash equivalents, loans and other financial assets. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

Trade receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, the Management also evaluates the factors that may influence the credit risk of its customer base, including the default risk and country in which the customers operate. The Management has established a credit policy under which each new customer is analysed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are

Financial Statements

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

offered. The Company's review includes external ratings, if available, financial statements, credit agency information, industry information and in some case bank references. Sales limits are established for each customer and reviewed quarterly.

The Companies receivables turnover is quick and historically, there was no significant default on account of trade and other receivables. An impairment analysis is performed at each reporting date on an individual basis for major clients. In addition, a large number of minor receivables are grouped into homogenous groups and assessed for impairment collectively. The company assesses at each reporting date whether a financial asset or a group of financial assets is impaired. Expected credit losses are measured at an amount equal to the 12 months expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. The Company has used a practical expedient by computing the expected credit loss experience and is adjusted for forward looking information. The maximum exposure to credit risk at the reporting date is the carrying value of trade and other receivables. The Company does not hold collateral as security. The Company evaluates the concentration of risk with respect to trade receivables as low, as its customers are located in several jurisdictions and operate in largely independent markets.

Other financial assets

The Company maintains exposure in cash and cash equivalents and derivative instruments with financial institutions. The Company has loan receivables outstanding from its wholly owned subsidiaries amounting to ₹ 7.9 (31 March 2017 : ₹ 407.0).

The Company's maximum exposure to credit risk as at 31 March 2018 and 31 March 2017 is the carrying value of each class of financial assets.

ii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. The following are the remaining contractual maturities of financial liabilities at reporting date:

As at 31 March 2018	Carrying amount		Contractual	cash flows	
	-	< 12 months	1 to 5 years	> 5 years	Total
Non-derivative financial liabilities					
Non-current borrowings	651.7	655.7	-	-	655.7
Current borrowings	36,538.3	36,735.8	-	-	36,735.8
Trade payables	16,334.0	16,334.0	-	-	16,334.0
Other current financial liabilities	1,851.5	1,851.5	-	-	1,851.5
Derivative financial liabilities					
Foreign exchange forward contracts	23.3	23.3	-	-	23.3

As at 31 March 2017	Carrying amount		Contractual ca	sh flows	
	-	< 12 months	1 to 5 years	> 5 years	Total
Non-derivative financial liabilities					
Non-current borrowings	3,026.4	1,882.6	1,192.5	-	3,075.1
Current borrowings	27,512.7	27,562.5	-	-	27,562.5
Trade payables	12,176.0	12,176.0	-	-	12,176.0
Other current financial liabilities	1,527.2	1,527.2	-	-	1,527.2
Derivative financial liabilities Foreign exchange forward contracts		 			

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

iii. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Such changes in the values of financial instruments may result from changes in the foreign currency exchange rates, interest rates, credit, liquidity and other market changes. The Company's exposure to market risk is primarily on account of foreign currency exchange rate risk and interest rate risk.

a) Foreign Currency risk:

The fluctuation in foreign currency exchange rates may have potential impact on the statement of profit or loss, where any transaction references more than one currency or where assets / liabilities are denominated in a currency other than the functional currency of the Company. The Company is subject to foreign exchange risk primarily due to its foreign currency revenues, expenses and borrowings. Considering the countries and economic environment in which the Company operates, its operations are subject to risks arising from fluctuations in exchange rates in those countries. The risks primarily relate to fluctuations in US Dollar, Euro and GBP against the functional currency of the Company. The Company, as per its risk management policy, uses derivative instruments primarily to hedge foreign exchange. The Company has a treasury team which evaluates the impact of foreign exchange rate fluctuations by assessing its exposure to exchange rate risks and advises the Management of any material adverse effect on the Company. It hedges a part of these risks by using derivative financial instruments in line with its risk management policies. The information on foreign exchange risk from derivative instruments is as follows:

The summary of quantitative data about the Company's exposure to currency risk (based on the notional amounts) as reported to the management is as follows:

				Amount in ₹
USD	Euro	GBP	Others	Total
30,093.0	4,506.7	1,048.2	771.4	36,419.3
1,205.3	395.0	294.7	5.4	1,900.4
31,298.3	4,901.7	1,342.9	776.8	38,319.7
(2,038.3)	(767.7)	(645.9)	(288.8)	(3,740.7)
29,260.0	4,134.0	697.0	488.0	34,579.0
32,946.9	3,128.6	1,074.1	-	37,149.6
10.7	-	-	-	10.7
6,403.8	414.2	35.6	36.6	6,890.2
39,361.4	3,542.8	1,109.7	36.6	44,050.5
(195.5)	(242.4)	(184.6)	-	(622.5)
39,165.9	3,300.4	925.1	36.6	43,428.0
(9,905.9)	833.6	(228.1)	451.4	(8,849.0)
	30,093.0 1,205.3 31,298.3 (2,038.3) 29,260.0 32,946.9 10.7 6,403.8 39,361.4 (195.5) 39,165.9	30,093.0 4,506.7 1,205.3 395.0 31,298.3 4,901.7 (2,038.3) (767.7) 29,260.0 4,134.0 32,946.9 3,128.6 10.7 - 6,403.8 414.2 39,361.4 3,542.8 (195.5) (242.4) 39,165.9 3,300.4	30,093.0 4,506.7 1,048.2 1,205.3 395.0 294.7 31,298.3 4,901.7 1,342.9 (2,038.3) (767.7) (645.9) 29,260.0 4,134.0 697.0 32,946.9 3,128.6 1,074.1 10.7 - - 6,403.8 414.2 35.6 39,361.4 3,542.8 1,109.7 (195.5) (242.4) (184.6) 39,165.9 3,300.4 925.1	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

As at 31 March 2018

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

As at 31 March 2017

					Amount in ₹
Particulars	USD	Euro	GBP	Others	Total
Financial assets					
Trade receivables	26,689.7	2,927.9	788.5	452.8	30,858.9
Cash and cash equivalents	181.2	30.4	4.8	7.5	223.9
Total	26,870.9	2,958.3	793.3	460.3	31,082.8
Less:					
Foreign exchange forward contracts	(586.9)	(55.8)	(606.8)	-	(1,249.5)
Net exposure in financial assets	26,284.0	2,902.5	186.5	460.3	29,833.3
Financial liabilities					
Borrowings	21,963.6	5,518.2	671.5	-	28,153.3
Interest accrued but not due	20.5	-	-	-	20.5
Trade payables (including payable for capital goods)	3,746.0	84.6	12.6	22.7	3,865.9
	25,730.1	5,602.8	684.1	22.7	32,039.7
Less:					
Foreign exchange forward contracts	(324.3)		-		(324.3)
Net exposure in financial liabilities	25,405.8	5,602.8	684.1	22.7	31,715.4
Net exposure in respect of	878.2	(2,700.3)	(497.6)	437.6	(1,882.1)
recognised assets/(liabilities)					

Sensitivity analysis:

A reasonably possible strengthening (weakening) of the Indian Rupee against US dollars at 31 March would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

	Profit or	(loss)	Equity, net	of tax
Particulars	Strengthening	Weakening	Strengthening	Weakening
31 March 2018				
USD (5% movement)	(495.3)	495.3	(389.6)	389.6
Euro (5% movement)	41.7	(41.7)	32.8	(32.8)
GBP (5% movement)	(11.4)	11.4	(9.0)	9.0
Others (5% movement)	22.6	(22.6)	17.8	(17.8)
31 March 2017				
USD (5% movement)	43.9	(43.9)	34.5	(34.5)
Euro (5% movement)	(135.0)	135.0	(106.2)	106.2
GBP (5% movement)	(24.9)	24.9	(19.6)	19.6
Others (5% movement)	21.9	(21.9)	17.2	(17.2)

b) interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rates. The Company's exposure to risk of change in market interest rates because it borrows funds at both fixed and floating interest rates. The Company manages its interest rate risk by having a balances portfolio of fixed and variable rate loans and borrowings. As the company has no significant interest bearing assets, the income and operating cash flows are substantially independent of changes in market interest rates.

Particulars	31 March 2018	31 March 2017
Variable rate borrowings including current maturities	37,190.0	30,539.1
Total borrowings	37,190.0	30,539.1

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Sensitivity analysis:

		Impact on pro	ofit and loss	
Particulars		31 March 2018		31 March 2017
	0.5% increase	0.5% decrease	0.5% increase	0.5% decrease
Variable rate instruments	(186.0)	186.0	(172.0)	172.0

c) commodity risk:

Exposure to market risk with respect to commodity prices primarily arises from the Company's purchase of active pharmaceutical ingredients and other raw material components for its products. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Company's raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company's business are generally more volatile. Cost of raw materials forms the largest portion of the Company's cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of 31 March 2018, the Company had not entered into any derivative contracts to hedge exposure to fluctuations in commodity prices.

43 CAPITIAL MANAGEMENT

For the purpose of the Company's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximise the shareholder value.

44 SEGMENT REPORTING

In accordance with Indian Accounting Standard (Ind AS) 108 on Operating segments, segment information has been given in the consolidated financial statements of the Company, and therefore no separate disclosure on segment information is given in these financial statements.

As per our Report of even date attached.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018 for and on behalf of the Board of Directors of Aurobindo Pharma Limited

N. Govindarajan Managing Director DIN-00050482

Santhanam Subramanian Chief Financial Officer Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709 То

The Members of Aurobindo Pharma Limited

REPORT ON THE AUDIT OF CONSOLIDATED IND AS FINANCIAL STATEMENTS

We have audited the accompanying consolidated Ind AS financial statements of Aurobindo Pharma Limited (hereinafter referred to as "the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its joint ventures, which comprise the Consolidated Balance Sheet as at 31 March 2018, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow, for the year then ended, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated Ind AS financial statements").

MANAGEMENT'S RESPONSIBILITY FOR THE CONSOLIDATED IND AS FINANCIAL STATEMENTS

The Holding Company's Board of Directors is responsible for the preparation of these consolidated Ind AS financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as "the Act") that give a true and fair view of the consolidated state of affairs, consolidated profit (including other comprehensive income), consolidated statement of changes in equity and consolidated cash flows of the Group including its joint ventures in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and of its joint ventures and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated Ind AS financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated Ind AS financial statements, the respective Board of Directors of the companies included in the Group and of its joint ventures are responsible for assessing the ability of the Group and of its joint ventures to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on these consolidated Ind AS financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit of the consolidated Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143 (10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated Ind AS financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated Ind AS financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated Ind AS financial statements.

We are also responsible to conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of Group and of its joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the consolidated Ind AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause Group and its joint ventures to cease to continue as a going concern.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph 2 of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated Ind AS financial statements.

OPINION

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate financial statements and on the other financial information of the subsidiaries and joint ventures, the aforesaid consolidated Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group and its joint ventures as at 31 March 2018, their consolidated profit (including other comprehensive income), consolidated statement of changes in equity and consolidated cash flows for the year ended on that date.

OTHER MATTERS

 Corresponding figures of the Group and its joint ventures for the year ended 31 March, 2017 have been audited by another auditor who expressed an unmodified opinion dated 29 May, 2017 on the consolidated Ind AS Financial Statements of the Group and its joint ventures for the year ended 31 March 2017.

Our opinion on the consolidated Ind AS Financial Statements is not modified in respect of the above matter.

2. We did not audit the financial statements and other financial information of fifty five subsidiaries and four joint ventures, whose financial statements reflect total assets of ₹ 147,473 million and net assets of ₹ 61,292 million as at 31 March 2018, total revenues of ₹ 116,566 million and net cash inflows amounting to ₹ 5,169 million for the year ended on that date, as considered in the consolidated Ind AS financial statements. The consolidated Ind AS financial statements also include the Group's share of net profit of ₹ 25 million for the year ended 31 March, 2018, as considered in the consolidated Ind AS financial statements, in respect of four joint ventures, whose financial statements and other financial information have not been audited by us. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated Ind AS financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and ioint ventures and our report in terms of sub-section (3) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries and joint ventures is based solely on the reports of the other auditors.

Certain of these subsidiaries and joint ventures are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries and joint ventures located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries and joint ventures located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and audited by us.

Our opinion above on the consolidated Ind AS financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

As required by Section 143(3) of the Act, based on our audit and on the consideration of report of the other auditors on separate financial statements and the other financial information of subsidiaries and joint ventures, as noted in the 'Other Matters' paragraph, we report, to the extent applicable, that:

- a) We / the other auditors whose reports we have relied upon have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated Ind AS financial statements;
- b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated Ind AS financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors;
- c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash flow dealt with by this report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated IND AS financial statements;
- In our opinion, the aforesaid consolidated Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act;
- e) On the basis of the written representations received from the directors of the Holding Company as on 31 March 2018 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies and joint ventures incorporated in India, none of the directors of the Group companies and joint ventures incorporated in India is disqualified as on 31 March 2018 from being appointed as a director in terms of Section 164(2) of the Act;

- f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, its subsidiary companies and joint ventures incorporated in India and the operating effectiveness of such controls, refer to our separate Report in "Annexure A";
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditors on separate financial statements as also the other financial information of the subsidiaries and joint ventures, as noted in the 'Other Matters' paragraph:
 - The consolidated Ind AS financial statements disclose the impact of pending litigations on the consolidated financial position of the Group and its joint ventures. Refer Note 33 to the consolidated Ind AS financial statements;
 - The Group and its joint ventures did not have any longterm contracts including derivative contracts for which there were any material foreseeable losses;

- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company, its subsidiary companies and joint ventures incorporated in India during the year ended 31 March 2018; and
- iv. The disclosures in the consolidated Ind AS financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made since they do not pertain to the financial year ended 31 March 2018. However amounts as appearing in the audited consolidated Ind AS financial statements for the period ended 31 March 2017 have been disclosed.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018

REPORT ON THE INTERNAL FINANCIAL CONTROLS UNDER CLAUSE (I) OF SUB-SECTION 3 OF THE SECTION 143 OF THE COMPANIES ACT, 2013 ("THE ACT")

In conjunction with our audit of the consolidated Ind AS financial statements of Aurobindo Pharma Limited as of and for the year ended 31 March 2018, we have audited the internal financial controls over financial reporting of Aurobindo Pharma Limited (hereinafter referred to as the "Holding Company"), its subsidiary companies, and joint ventures which are companies incorporated in India, as of that date.

MANAGEMENT'S RESPONSIBILITY FOR INTERNAL FINANCIAL CONTROLS

The respective Board of Directors of the Holding Company, its subsidiary companies, and joint ventures, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('Guidance note") issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, both issued by ICAI, and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Financial Statements

MEANING OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated Ind AS financial statements for external purposes in accordance with the generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

OPINION

In our opinion, the Holding Company, its subsidiary companies and joint ventures, which are companies incorporated in India, have maintained in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2018, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

OTHER MATTERS

Our report under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting of the Holding Company, insofar as it relates to these nine subsidiary companies, and three joint ventures companies, which are companies incorporated in India, is based on the corresponding reports of the auditors of such subsidiary, and joint venture companies incorporated in India.

For **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018

CONSOLIDATED BALANCE SHEET

		Notes	As at 31 March 2018	As at 31 March 2017
-	ASSETS			
-	Non-current assets		-	
	(a) Property, plant and equipment	3	47,365.6	40,830.5
	(b) Capital work-in-progress	3	13.995.4	12.373.6
	(c) Goodwill		8.165.5	4,063.0
	(d) Other intangible assets		9.675.7	3.444.3
	(e) Intangible assets under development	5	1,835.0	2,207.2
	(f) Financial assets		1,000.0	
	(i) Investments	6(A)	3.115.2	2.458.5
	(ii) Trade receivables		-	
	(iii) Loans		54.4	57.0
	(iv) Other financial assets		874.6	751.7
	(q) Deferred tax assets (net)	<u>10(A)</u>	1.588.0	1.677.6
	(h) Non-current tax assets (net)	11(A)	825.9	579.8
	(i) Other non-current assets		1,678.3	1,989.2
	Total non-current assets		89.173.6	70.432.4
	Current assets			
	(a) Inventories	13	58,584.1	43.305.4
	(b) Financial assets			
	(i) Investments	6(B)	0.2	0.2
	(ii) Trade receivables		30.843.6	27.653.3
	(iii) Cash and cash equivalents	<u>14(A)</u>	12.159.0	4.894.4
	(iv) Bank balances other than (iii) above	14(B)	457.2	240.4
	(v) Loans		101.9	108.9
	(vi) Other financial assets	<u>9(B)</u>	7.942.0	7,576.5
	(c) Current tax assets (net)	11(B)	645.5	175.1
	(d) Other current assets	12(B)	11,144.9	8,107.6
	Total current assets		121.878.4	92.061.8
	TOTAL ASSETS		211.052.0	162,494,2
П.	EQUITY AND LIABILITIES			
	Equity			
-	(a) Equity share capital	15	585.9	585.9
	(b) Other equity	16	116,218.3	93,133.2
	Equity attributable to equity holders of Parent company		116,804.2	93,719.1
-	(c) Non-controlling interest		18.2	20.8
	Total equity		116.822.4	93,739,9
	Liabilities			
	Non-current liabilities			-
	(a) Financial liabilities			
	(i) Borrowings	17(A)	4,512.0	1,814.0
	(b) Provisions	18(A)	558.6	391.3
	(c) Deferred tax liabilities (net)	10(B)	2,352.8	493.0
	Total non-current liabilities		7,423.4	2,698.3
	Current liabilities			· · · · ·
	(a) Financial liabilities			
	(i) Borrowings	17(B)	40,313.4	29,027.2
	(ii) Trade payables	19	26,274.4	21,547.0
	(iii) Other financial liabilities	20	5,100.0	4,693.8
	(b) Other current liabilities	21	12,678.0	8.174.4
	(c) Provisions	18(B)	2,009.3	2,349.0
	(d) Current tax liabilities (net)	22	431.1	264.6
	Total current liabilities		86,806.2	66,056.0
	TOTAL EQUITY AND LIABILITIES		211,052.0	162,494.2
	Summary of significant accounting policies	2.3		

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

The accompanying notes are an integral part of the consolidated financial statements.

As per our Report of even date attached.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198 for and on behalf of the Board of Directors of Aurobindo Pharma Limited

N. Govindarajan Managing Director

DIN-00050482

Santhanam Subramanian

Chief Financial Officer

Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709

Place: Hyderabad Date: 28 May 2018



CONSOLIDATED STATEMENT OF PROFIT AND LOSS

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

		Note	Year ended 31 March 2018	Year ended 31 March 2017
1	INCOME			
	Revenue from operations	23	164,998.3	150,898.6
	Other income	24	1,019.8	1,158.9
	TOTAL INCOME (I)		166,018.1	152,057.5
Ш	EXPENSES	25		
	Cost of materials consumed		56,293.8	51,849.2
	Purchases of stock-in-trade	26	16,058.8	15,585.4
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	27	(4,825.2)	(3,092.0)
	Employee benefits expense	28	21,308.4	17,677.6
	Finance costs	29	777.2	667.2
	Depreciation and amortisation expense	30	5,579.7	4,276.3
	Other expenses		38,445.0	34,535.6
	TOTAL EXPENSES (II)		133,637.7	121,499.3
III	PROFIT BEFORE SHARE OF PROFIT OF JOINT VENTURES AND TAX (I-II)		32,380.4	30,558.2
IV	Share of profit of joint ventures (net of tax)		31.4	50.2
V	PROFIT BEFORE TAX (III+IV)		32,411.8	30,608.4
VI	TAX EXPENSE :	31		
	Current tax		7,123.0	6,917.0
	Tax credit - Minimum Alternate Tax (MAT)		(433.2)	(642.8)
	Deferred tax		1,492.9	1,322.3
	TOTAL TAX EXPENSE (VI)		8,182.7	7,596.5
VII	PROFIT FOR THE YEAR ATTRIBUTABLE TO (V-VI)		24,229.1	23,011.9
	Owners of the Parent Company		24,231.7	23,016.6
	Non-controlling interest		(2.6)	(4.7)
	PROFIT FOR THE YEAR (VII)		24,231.7	23,016.6
VIII	OTHER COMPREHENSIVE INCOME			
	(A) Items that will not to be reclassified subsequently to profit or loss:			
	(i) Re-measurement of defined employee benefit liability		(36.7)	(87.6)
	(ii) Income-tax relating to items that will not be reclassified to profit or loss		13.1	29.7
	(B) Items that will be reclassified subsequently to profit or loss:			
	(i) Exchange differences on translating the financial statements of foreign operations		1,519.1	(804.4)
	(ii) Income-tax on items that will be reclassified subsequently to profit or loss		-	
	TOTAL OTHER COMPREHENSIVE INCOME FOR THE YEAR (NET OF TAX) (VIII)		1,495.5	(862.3)
IX	TOTAL COMPREHENSIVE INCOME FOR THE YEAR (NET OF TAX) ATTRIBUTABLE TO (VII+VIII)		25,727.2	22,154.3
	Owners of the Parent Company		25,729.8	22,159.0
	Non-controlling interest		(2.6)	(4.7)
Х	EARNINGS PER EQUITY SHARE:	34		
-	(i) Basic (in ₹)		41.36	39.33
	(ii) Diluted (in ₹)		41.36	39.33
	Nominal value per equity share		1.00	1.00
	Summary of significant accounting policies	2.3		

The accompanying notes are an integral part of the consolidated financial statements. As per our Report of even date attached.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198 for and on behalf of the Board of Directors of **Aurobindo Pharma Limited**

N. Govindarajan

Managing Director DIN-00050482

Santhanam Subramanian

Chief Financial Officer

Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709 Statutory Reports

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(A) EQUITY SHARE CAPITAL (Refer Note 15)

	Number	Balance
As at 01 April 2016	585,169,586	585.2
Changes in equity share capital during the year	712,823	0.7
As at 31 March 2017	585,882,409	585.9
Changes in equity share capital during the year	25,200	0.0
As at 31 March 2018	585,907,609	585.9

(B) OTHER EQUITY

		Attrib	Attributable to the owners of the Group	wners of the G	aroup						
•			Reserves and surplus	nd surplus						- Attributable	
	Capital reserve	Capital redemption reserve	Employee stock options outstanding account	Securities premium	General reserve	Retained earnings	Exchange differences on translating the financial statements of foreign operations	Re- measure- ments of net defined benefit plans	Total attributable to owners of the Group	to non- controlling interest	Total
Balance at 31 March 2016	818.9	0.06	12.8	4,096.8	8,131.6	58,887.1	329.5	(78.9)	72,287.8	25.5	72,313.3
Total comprehensive income for the year ended 31 March 2017											
Profit for the year	1	1	. 	I	I	23,016.6		1	23,016.6	(4.7)	23,011.9
Other comprehensive income (net of tax)	1	I	I	I	I	I		(57.9)	(57.9)	1	(57.9)
Total comprehensive income	•	•	•	•		23,016.6	•	(57.9)	22,958.7	(4.7)	22,954.0
Issue of equity shares on exercise of employee stock options	1	1		65.9	1		I	I	65.9	1	65.9
Foreign currency translation adjustment	1	1	1	1	1	1	(804.4)		(804.4)	1	(804.4)
Share based payment (refer note 35)	1	1	(1.4)	I	1	I		1	(1.4)	1	(1.4)
Exercise of share options	1	I	(10.4)	10.4	1	I	I		I	1	1
Dividend paid		'	1	'	I	(1,141.1)	1		(1,141.1)		(1,141.1)

(232.3) **93,154.0**

(232.3) **93,133.2**

20.8

-(136.8)

- (474.9)

-8,131.6

' <mark>9</mark>

- 0.06

818.9

Dividend distribution tax Balance at 31 March 2017

(232.3) **80,530.3**

4,173.1

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Attributable to the owners of the Group

			Reserves and surplus	nd surplus						Attributable	
	Capital reserve	Capital redemption reserve	Employee stock options outstanding account	Securities	General reserve	Retained earnings	Exchange differences on translating the financial statements of foreign operations	Re- measure- ments of net defined benefit plans	Total attributable to owners of the Group	to non- controlling interest	Total
Profit for the year	1	1	1	'		24,231.7	1	1	24,231.7	(2.6)	24,229.1
Other comprehensive income (net of tax)	•				I	•		(23.7)	(23.7)	•	(23.7)
Total comprehensive income						24,231.7	•	(23.7)	24,208.0	(2.6)	24,205.4
Issue of equity shares on exercise of employee stock options			'	2.3	'	'	I		2.3	'	2.3
Foreign currency translation adjustment	•	•	•	1	•	•	1,519.1	•	1,519.1	•	1,519.1
Share based payment (refer note 35)	•	•	(0.3)	0.4	•	•	•	•	0.1	•	0.1
Exercise of share options	•	I	•	I			•	•		I	1
Dividend paid	1	•	1	•		(2,197.1)			(2,197.1)	1	(2,197.1)
Dividend distribution tax	'	'	'	'		(447.3)		'	(447.3)	'	(447.3)
Balance at 31 March 2018	818.9	90.06	0.7	4,175.8	8,131.6	102,117.6	1,044.2	(160.5)	(160.5) 116,218.3	18.2	116,236.5

As per our Report of even date attached.

For **B** S R & Associates LLP

ICAI Firm Registration Number: 116231W/ W-100024 Chartered Accountants

Amit Kumar Agarwal

Membership No.214198 Date: 28 May 2018 Place: Hyderabad Partner

for and on behalf of the Board of Directors of **Aurobindo Pharma Limited**

Managing Director DIN-00050482 N. Govindarajan

Dr. M. Sivakumaran Director DIN-01284320

Santhanam Subramanian B. Adi Reddy Chief Financial Officer Company Secr

Membership No.13709 Company Secretary

Financial Statements

CONSOLIDATED STATEMENT OF CASH FLOW

			Year ended 31 March 2018	Year ended 31 March 2017
1 CAS	H FLOW FROM OPERATING ACTIVITIES			
	profit before tax		32,411.8	30,608.4
	stments to reconcile profit before tax to net cash flows:			
	Depreciation and amortisation expense		5.579.7	4,276.3
	Provision no longer required on doubtful receivables written back (net)		(95.9)	-
	Balances no longer required written back (net)		(371.4)	(83.7)
	Bad debts/advances written off			(70.8)
F	Product destruction expenses / stock written off		109.4	221.2
	Market-to-market loss/(gain) on derivative financial instruments		23.3	(94.8)
	Jnrealised foreign exchange gain (net)		(867.9)	(69.3)
	Loss on sale / write-off of property, plant and equipment (net)		163.5	62.7
	Share of profit of joint ventures		(31.4)	(50.2)
	Share based payment		0.1	(1.4)
	Change in fair value of current investment		0.1	
	ist expense		628.9	545.1
	ist income		(120.2)	(161.5)
	ating profit before working capital changes		37,430.0	35,182.0
	gn currency translation adjustments		332.0	(484.4)
	ements in working capital:		002.0	(+0+.+)
	ase/(decrease) in trade payables		4,098.1	(1,572.7)
	ase in inventories		(14,126.7)	(2,965.1)
	ase)/decrease in trade receivables		(723.2)	17,728.6
	ase in other financial assets		(705.8)	(7,341.3)
	ase in current / non current other assets		(705.8)	(878.0)
			9.6	
	ease/(increase) in loans and advances			(8.3)
	ease)/increase in provisions		(249.2)	639.1
	ase in other current liabilities		3,958.0	253.4
	ease in other financial liabilities		(20.5)	(30.5)
	generated from operating activities		27,072.2	40,522.8
	t taxes paid (net of refunds)	(•)	(7,524.0)	(7,737.0)
Net c	ash flow generated from operating activities	(A)	19,548.2	32,785.8
	H FLOW USED IN INVESTING ACTIVITIES		((= = = = = = = = = = = = = = = = = = =	(10.0.11.5)
	nase of property, plant and equipment, including capital work- in- progress,		(15,299.2)	(16,941.5)
	al advances and capital creditors			
	eeds from sale of property, plant and equipment		2,892.9	95.4
	isition of subsidiary		(6,658.9)	-
	nase of non-current investments made in joint ventures (refer Note "c" below)		(677.6)	(1,179.0)
	given to joint venture		(1,065.2)	-
	repaid by joint venture (refer Note "c" below)		960.0	-
Intere	st received (refer Note "c" below)		115.1	154.7
	end received		163.4	-
	cash flow used in investing activities	(B)	(19,569.5)	(17,870.4)
	H FLOW FROM FINANCING ACTIVITIES			
	eds from issuance of equity share capital		2.3	66.6
	eeds from non-current borrowings		9,164.2	-
	yment of non-current borrowings		(9,370.9)	(9,132.6)
	eeds from/(repayment) of current borrowings (net)		12,228.9	(8,146.5)
	st paid		(741.7)	(568.3)
	ends paid on equity shares		(2,194.0)	(1,139.5)
	aid on equity dividend		(447.3)	(232.3)
Net o	cash flow generated from/(used in) financing activities	(C)	8,641.5	(19,152.6)

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

		Year ended 31 March 2018	Year ended 31 March 2017
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	8,620.2	(4,237.2)
Cash and cash equivalents at the beginning of the year		3,196.3	7,434.9
Add: Cash and cash equivalents on acquisition		303.6	-
Effect of exchange differences on cash and cash equivalents		(1.7)	(1.4)
Cash and cash equivalents at the end of the year		12,118.4	3,196.3

Note:

a) The above statement of cash flow has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7(Ind AS-7) "Statement of Cash Flow".

b) Cash and cash equivalents comprises of:

	As at 31 March 2018	As at 31 March 2017
COMPONENTS OF CASH AND CASH EQUIVALENTS		
Cash on hand	3.3	5.8
Cheques on hand	191.9	-
Balance with banks		
- on current account	11,314.5	4,611.9
- on cash credit account	273.2	(1,666.7)
- on deposit account	316.5	229.4
- on unpaid dividend account *	19.0	15.9
Cash and Cash equivalents considered for cash flows (refer note 14)	12,118.4	3,196.3

* The Group can utilise these balances only towards settlement of unpaid dividend.

c) The following items in the nature of non-cash transactions are not included in determining cash flow from investing activities:

Particulars	31 March 2018	31 March 2017
(i) Loans converted into optionally convertible debentures	105.2	-
(ii) Interest converted into optionally convertible debentures	5.7	-
Total	110.9	-

 Reconciliation between the opening and closing balances in balance sheet for financial liabilities arising from financing activities are given below:

Particulars	As at 31 March 2017	Borrowings taken over upon business combination	Cash flows	Non-cash transactions Foreign exchange loss	As at 31 March 2018
Non-current borrowings	4,614.2	2,984.4	(206.7)	(5.9)	7,386.0
Current borrowings	27,329.1	-	12,228.9	714.8	40,272.8
Summary of significant accounting policies (Refe	r Note 2.3)				

As per our Report of even date attached.

For **B S R & Associates LLP** Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal

Partner Membership No.214198 for and on behalf of the Board of Directors of Aurobindo Pharma Limited

N. Govindarajan Managing Director DIN-00050482

Santhanam Subramanian Chief Financial Officer **Dr. M. Sivakumaran** Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709

Place: Hyderabad Date: 28 May 2018

for the year ended 31 March 2018

1. CORPORATE INFORMATION

The consolidated financial statements comprise financial statements of Aurobindo Pharma Limited ("APL" or "the Parent Company" or "Holding Company" or "the company") together with its subsidiaries (collectively termed as "the Group") and joint ventures (collectively termed as "the Consolidated Entities") for the year ended 31 March 2018. Aurobindo Pharma Limited is a public Company domiciled in India and was incorporated under the provisions of the Companies Act applicable in India. The registered office of the Company is located at Plot No.2, Maitri Vihar, Ameerpet, Hyderabad - 500038, India and the Corporate office is located at The Water Mark Building, Plot No. 11, Survey No. 9, Hi-tech City, Hyderabad - 500084, India. The Company's shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in India.

The Group is principally engaged in manufacturing and marketing of Active pharmaceutical ingredients, generic pharmaceuticals and related services. These consolidated financial statements were approved by the Board of Directors and authorised for issue on 28 May 2018.

2. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

2.1. Basis of preparation

a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the "Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

These consolidated financial statements comprise the consolidated balance Sheets as at 31 March 2018 and 31 March 2017, the consolidated statements of profit and loss, the consolidated statements of cash flows and the statements of changes in equity for the year ended 31 March 2018 and for the year ended 31 March 2018 and for the year ended 31 March 2017, and a summary of the significant accounting policies and other explanatory information (together hereinafter referred to as "Consolidated Financial Statements").

These consolidated financial statements have been prepared on accrual and going concern basis. The accounting policies are applied consistently to all the periods presented in these consolidated financial statements.

b) Functional and presentation currency

These consolidated financial statements are presented in Indian rupees (₹), which is also the functional currency of the Parent Company. All amounts have been rounded-

off to the nearest million, unless otherwise indicated. Transactions and balances with values below ₹ one lac have been reflected as "0.0" in the financial statements.

c) Basis of measurement

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following;

 certain financial assets and liabilities (including derivative instruments) are measured at fair value or amortised cost.

- employee defined benefit assets / liability recognised as the net total of the fair value of plan assets, and actuarial losses/gains, and the present value of defined benefit obligation.

- Investment in joint venture which are accounted for using the equity method.

d) Use of estimates and judgements

The preparation of the consolidated financial statements in conformity with Ind AS requires management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the standalone financial statements.

Judgements

Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

- Note 32 (A) - leases: whether an arrangement contains a lease; lease classification.

- Note 2.3(g) and 46: Financial instruments

- Note 2.3(k), 10, 11 and 31: Provision for income taxes and evaluation of recoverability of deferred tax assets.

- Note 2.3(e): Useful lives of property, plant and equipment

- Note 35: Share based payments

- Note 36: Assets and obligations relating to employee benefits



Company Overview Stat

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

Assumptions and estimation uncertainties

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

(i) Share-based payments

The grant date fair value of employee stock options granted is recognised as an employee expense over the period that the employee becomes unconditionally entitled to the options. Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimation requires determination of the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. The Black Scholes valuation model has been used by the Management for share-based payment transactions. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 35.

(ii) Defined employee benefit plans (Gratuity)

The cost of the defined benefit gratuity plan and other accumulated leave entitlement and the present value of the gratuity obligation and accumulated leave obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its longterm nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation.

The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates. Further details about gratuity obligations are given in Note 36.

(iii) Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See notes 45 and 46 for further disclosures.

(iv) Depreciation on property, plant and equipment

Depreciation on property, plant and equipment is calculated on a straight-line basis based on the useful lives estimated by the management. Considering the applicability of Schedule II of Companies Act, 2013, the management has reestimated useful lives and residual values of all its property, plant and equipment. The management believes that useful lives currently used fairly reflect its estimate of the useful lives and residual values of property, plant and equipment, though these in certain cases are different from lives prescribed under Schedule II of the Companies Act, 2013.

(v) Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length, for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a DCF model.

(vi) Impairment of investments

The Group reviews its carrying value of investments annually, or more frequently when there is an indication for impairment. If the recoverable amount is less than its carrying amount, the impairment loss is accounted for.

for the year ended 31 March 2018

(vii) Intangible assets under development

The Group capitalises acquired intangible asset under development for a project in accordance with the accounting policy. In determining the amounts to be capitalised, management makes assumptions regarding the expected future cash generation of the project, discount rates to be applied and the expected period of benefits. The innovative nature of the product gives rise to some uncertainty as to whether the final approval for the products will be obtained.

(viii) Inventories

The Group estimates the net realisable value (NRV) of its inventories by taking into account their estimated selling price, estimated cost of completion, estimated costs necessary to make the sale, obsolescence by applying certain percentages over different age category of such inventories, expected loss rate considering the past trend and future outlook. Inventories are written down to NRV where such NRV is lower than their cost.

(ix) Recognition and measurement of other provisions:

The recognition and measurement of other provisions is based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the closing date. The actual outflow of resources at a future date may therefore, vary from the amount included in other provisions.

2.2. Basis of consolidation

(i) Business combinations

In accordance with Ind AS 101 provisions related to first time adoption, the Group has elected to apply Ind AS accounting for business combinations prospectively from 01 April 2015. As such, Indian GAAP balances relating to business combinations entered into before that date, including goodwill, have been carried forward with minimal adjustment. The same first time adoption exemption is also used for joint ventures.

Business combinations are accounted for using the Acquisition method. The acquisition date is the date on which control is transfered to the acquirer. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any noncontrolling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred. At the acquisition date, the identifiable assets acquired and the liabilities assumed are at their acquisition date fair value. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. However, the following assets and liabilities acquired in a business combination are measured at the basis indicated below:

Deferred tax assets or liabilities, and the assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Tax and Ind AS 19 Employee Benefits respectively.

- Assets (or disposal Groups) that are classified as held for sale in accordance with Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations are measured in accordance with that standard.

- Reacquired rights are measured at a value determined on the basis of the remaining contractual term of the related contract. Such valuation does not consider potential renewal of the reacquired right.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. If the business combination is achieved in stages, any previously held equity interest is re-measured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss or OCI, as appropriate.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of Ind AS 109 Financial Instruments, is measured at fair value with changes in fair value recognised in profit or loss. If the contingent consideration is not within the scope of Ind AS 109, it is measured in accordance with the appropriate Ind AS. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and subsequent its settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests, and any previous interest held, over the net identifiable assets acquired and liabilities assumed. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Group re-assesses whether it has correctly identified all of the assets

for the year ended 31 March 2018

acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognised at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognised in OCI and accumulated in equity as capital reserve. However, if there is no clear evidence of bargain purchase, the entity recognises the gain directly in equity as capital reserve, without routing the same through OCI.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

A cash generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted through goodwill during the measurement period, or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date. These adjustments are called as measurement period adjustments. The measurement period does not exceed one year from the acquisition date.

(ii) Subsidiaries

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee)

- Exposure, or rights, to variable returns from its involvement with the investee, and

- The ability to use its power over the investee to affect its returns

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee

- Rights arising from other contractual arrangements
- The Group's voting rights and potential voting rights

- The size of the Group's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the Group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that Group member's financial statements in preparing the consolidated financial statements to ensure conformity with the Group's accounting policies. The financial statements of all entities used for the

for the year ended 31 March 2018

purpose of consolidation are drawn up to same reporting date as that of the Parent Company, i.e., year ended on 31 March.

Consolidation procedures:

- (a) Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the consolidated financial statements at the acquisition date.
- (b) Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary. Business combinations policy explains how to account for any related goodwill.
- (c) Eliminate in full intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the Group (profits or losses resulting from intra-group transactions that are recognised in assets, such as inventory and fixed assets, are eliminated in full). Intra-group losses may indicate an impairment that requires recognition in the consolidated financial statements. Ind AS12 Income Taxes applies to temporary differences that arise from the elimination of profits and losses resulting from intra-group transactions.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-Group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary

- Derecognises the carrying amount of any noncontrolling interests

- Derecognises the cumulative translation differences recorded in equity

- Recognises the fair value of the consideration received
- Recognises the fair value of any investment retained
- Recognises any surplus or deficit in profit or loss

 Reclassifies the parent's share of components previously recognised in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities

(iii) Investment in joint ventures (accounted under equity method)

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control. The considerations made in determining whether joint control are similar to those necessary to determine control over the subsidiaries.

The Group's investments in its joint venture are accounted for using the equity method. Under the equity method, the investment in a joint venture is initially recognised at cost. The carrying amount of the investment is adjusted to recognise changes in the Group's share of net assets of the joint venture since the acquisition date.

The consolidated statement of profit and loss reflects the Group's share of the results of operations of the joint venture. Any change in OCI of those investees is presented as part of the Group's OCI. In addition, when there has been a change recognised directly in the equity of the joint venture, the Group recognises its share of any changes, when applicable, in the statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and the joint venture are eliminated to the extent of the interest in the joint venture.

If an entity's share of losses of a joint venture equals or exceeds its interest in the joint venture (which includes any long term interest that, in substance, form part of the Group's net investment in the joint venture), the entity discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the joint venture. If the joint venture subsequently reports profits, the entity resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.

The aggregate of the Group's share of profit or loss of a joint venture is shown on the face of the consolidated

for the year ended 31 March 2018

statement of profit and loss. The financial statements of the joint venture are prepared for the same reporting period as the Group.

After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the joint venture and its carrying value, and then recognises the loss as 'Share of profit of a joint venture' in the consolidated statement of profit or loss.

Upon loss of joint control over the joint venture, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the joint venture upon loss of joint control and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

Group information:

The Consolidated Financial Statements have been prepared on the basis of the financial statements of the following subsidiaries and joint ventures:

No. Name of the Consolidated Entities Incorporation Interest 31 March 2018 31 March 2017 1 Agile Pharma [Na. [7] The Netherlands Subsidiary 100% 100% 3 APL Healthcare Limited India Subsidiary 100% 100% 4 APL Framma Thai Ltd Thaland Subsidiary 100% 100% 6 APL Swift Services (Maria) Limited India Subsidiary 100% 100% 6 APL Swift Services (Maria) Limited Mata Subsidiary 100% 100% 7 Arrow Generiques SAS France Subsidiary 100% 100% 7 Arrow Rel LLC (w.ef. 20 May 2016) USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Paptides Limited India Subsidiary 100% 100% 12 Auro Medics Pharma ILC USA Subsidiary 100% 100% 14 Auror Pharma Incla <	S.		Country of	Nature of	% of Inter	est as at
2 All Pharma (Shanghai) Trading Company Limited India Subsidiary 100% 100% 3 APL Heatmar Imited India Subsidiary 97.9% 97.9% 4 APL Pharma Thai Ltd Thailand Subsidiary 100% 100% 5 APL Switt Services (Mata) Limited India Subsidiary 100% 100% 6 APL Switt Services (Mata) Limited Mata Subsidiary 100% 100% 7 Arrow Generiques SAS France Subsidiary 100% 100% 9 Auro AR LLC (w.et. 20 May 2016) USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Health CLC USA Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 12 Auro Medics Pharma (LC USA Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary </th <th>No.</th> <th>Name of the Consolidated Entities</th> <th></th> <th></th> <th>31 March 2018</th> <th>31 March 2017</th>	No.	Name of the Consolidated Entities			31 March 2018	31 March 2017
3 APL Healthcare Limited India Subsidiary 100% 4 APL Pharma Thai Ltd Thailand Subsidiary 97.9% 97.9% 6 APL Research Centre Limited India Subsidiary 100% 100% 6 APL Swift Services (Mata) Limited Mata Subsidiary 100% 100% 6 Arrox Generiques SAS France Subsidiary 100% 100% 7 Arrox Generiques SAS France Subsidiary 100% 100% 9 Auro AR LLC (we.f. 02 May 2016) USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Pharma Inc. Canada Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 16 Raidurgam Developers Limited Formerly Aurobindo India Joint Venture <t< td=""><td></td><td></td><td>The Netherlands</td><td>Subsidiary</td><td></td><td></td></t<>			The Netherlands	Subsidiary		
4 APL Pharma Thai Ltd Thailand Subsidiary 97.9% 97.9% 5 APL Research Centre Limited India Subsidiary 100% 100% 6 APL Switt Services (Matta) Limited Matta Subsidiary 100% 100% 7 Arrow Generiques SAS France Subsidiary 100% 100% 8 Aurex BV. (formerly Pharmacin B.V.) The Netherlands Subsidiary 100% 100% 9 Auro AR LLC (w.e.f. 02 May 2016)' USA Subsidiary 100% 100% 10 Auro Heatthcare (Nigeria) Limited Nigeria Subsidiary 100% 100% 11 Auro Peptides Limited India Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Maccines LLC (w.ef. 7 January 2017)' <td>2</td> <td>All Pharma (Shanghai) Trading Company Limited</td> <td>China</td> <td>Subsidiary</td> <td>100%</td> <td></td>	2	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary	100%	
6 APL Research Centre Limited India Subsidiary 100% 100% 6 APL Swift Services (Malta) Limited Maita Subsidiary 100% 100% 6 Arrow Generiques SAS France Subsidiary 100% 100% 7 Arrow Generiques SAS France Subsidiary 100% 100% 9 Auro AR LLC (w.e.f. 02 May 2016)' USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Medics Pharma LLC USA Subsidiary 100% 100% 12 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017)' USA Subsidiary 100% 100% 16 Raichurgam Developers Limited (Formerly Aurobindo India Joint Venture 40% 100% 17 Aurobindo Pharma (Malta) Limited Sirketi ³ Turkey Subsidiary 100% 100% 10 Aurobindo Pharma		APL Healthcare Limited	India	Subsidiary	100%	
6 APL Swift Services (Malta) Limited Malta Subsidiary 100% 100% 7 Arrow Generiques SAS France Subsidiary 100% 100% 8 Aurex B.V. (formerly Pharmacin B.V.) The Netherlands Subsidiary 100% 100% 9 Auro AR LLC (w.ef. 02 May 2016)' USA Subsidiary 100% 100% 10 Auro Health LCC USA Subsidiary 100% 100% 11 Auro Health Care (Nigeria) Limited Nigeria Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Pharma Inc. Canada Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 16 Raidugram Developers Limited (Formerly Aurobindo India Joint Venture 40% 100% 17 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 10 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% <td></td> <td>APL Pharma Thai Ltd</td> <td>Thailand</td> <td>Subsidiary</td> <td></td> <td>97.9%</td>		APL Pharma Thai Ltd	Thailand	Subsidiary		97.9%
7 Arrow Generiques SAS France Subsidiary 100% 8 Aurex B.V. (formerly Pharmacin B.V.) The Netherlands Subsidiary 100% 100% 9 Auro AR LLC (w.c.f. 02 May 2016) ¹ USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Health LLC USA Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Peptides Limited India Subsidiary 100% 100% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017) ¹ USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo India Joint Venture 40% 100% 17 Aurobindo Pharma (Italia) S.r.l Italy Subsidiary 100% 100% 10 Aurobindo Pharama (Portugal) Unipescal Lda		APL Research Centre Limited	India	Subsidiary	100%	100%
8 Aurex B.V. (formerly Pharmacin B.V.) The Netherlands Subsidiary 100% 100% 9 Auro AR LLC (w.ef. 02 May 2016)' USA Subsidiary 100% 100% 10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Health LC USA Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.ef. 27 January 2017)* USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd)* India Joint Venture 40% 100% 17 Aurobindo Pharma (Matta) Limited Malta Subsidiary 100% 100% 18 Aurobindo Pharma (Romania) S.r.I Italy Subsidiary 100% 100% 20 Aurobindo Pharma RombiA Germany Subsidiary 100% 100% 21 <td< td=""><td></td><td>APL Swift Services (Malta) Limited</td><td>Malta</td><td>Subsidiary</td><td>100%</td><td>100%</td></td<>		APL Swift Services (Malta) Limited	Malta	Subsidiary	100%	100%
9 Auro AR LLC (w.e.f. 02 May 2016) ¹ USA Subsidiary 100% 100% 10 Auro Heatht LLC USA Subsidiary 100% 100% 11 Auro Heathtcare (Nigeria) Limited Nigeria Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Peptides Limited India Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017) ¹ USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) ⁶ - 100% 100% 17 Aurobindo Pharma (Italia) S.r.I Italy Subsidiary 100% 100% 19 Aurobindo Pharma (Romania) S.r.I Romania Subsidiary 100% 100% 20 Aurobindo Pharma (Romania) S.r.I Romania Subsidiary 100% 100% 21 Aurobindo Pharma	7	Arrow Generiques SAS	France	Subsidiary	100%	100%
10 Auro Health LLC USA Subsidiary 100% 100% 11 Auro Health Care (Nigeria) Limited Nigeria Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Peptides Limited India Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017) ¹ USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo India Joint Venture 40% 100% 17 Aurobindo Pharma (Italia) S.r.l Italy Subsidiary 100% 100% 18 Aurobindo Pharma (Mata) Limited Malta Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) S.r.l Romania Subsidiary 100% 100% 22 Aurobindo Pharma B.W. (formerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 23 Aurobindo Pharma B.M. (formerly Actavis B.V.) The Netherlands Subsidiary	8	Aurex B.V. (formerly Pharmacin B.V.)	The Netherlands	Subsidiary	100%	100%
11 Auro Healthcare (Nigeria) Limited Nigeria Subsidiary 100% 100% 12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Peptides Limited India Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017) ¹ USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobio Antibiotits Ltd) ⁹ Joint Venture 40% 100% 17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³ Turkey Subsidiary 100% 100% 18 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 19 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) s.r.l Romania Subsidiary 100% 100% 23 Aurobindo Pharma B.V. (formerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 24 Aurobindo Pharma Gnoma Japan K.K. Japan <td></td> <td>Auro AR LLC (w.e.f. 02 May 2016)1</td> <td></td> <td>Subsidiary</td> <td>100%</td> <td>100%</td>		Auro AR LLC (w.e.f. 02 May 2016)1		Subsidiary	100%	100%
12 Auro Medics Pharma LLC USA Subsidiary 100% 100% 13 Auro Peptides Limited India Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 16 Raidvrgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) ⁶ India Joint Venture 40% 100% 17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³ Turkey Subsidiary 100% 100% 18 Aurobindo Pharma (Italia) S.r.I Italy Subsidiary 100% 100% 19 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Rortugal) Unipessoal Lda Portugal Subsidiary 100% 100% 22 Aurobindo Pharma (Romania) s.r.I Romania Subsidiary 100% 100% 23 Aurobindo Pharma Colombia S.A.S. Colombia Subsidiary 100% 100% 24 Aurobindo Pharma Japan K.K.	10	Auro Health LLC	USA	Subsidiary	100%	100%
13 Auro Peptides Limited India Subsidiary 100% 95% 14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017) ¹ USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) ⁶ India Joint Venture 40% 100% 17 Aurobindo Pharma (Italia) S.r.I Italy Subsidiary 100% 100% 18 Aurobindo Pharma (Italia) S.r.I Italy Subsidiary 100% 100% 20 Aurobindo Pharma (Ronania) S.r.I Romania Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) S.r.I Romania Subsidiary 100% 100% 22 Aurobindo Pharma (Romania) S.r.I Romania Subsidiary 100% 100% 22 Aurobindo Pharma B.V. (ormerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 24 Aurobindo Pharma B.V. (ormerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 24 Aurobindo Pharma Industria Farmaceu	11	Auro Healthcare (Nigeria) Limited	Nigeria	Subsidiary	100%	100%
14 Auro Pharma Inc. Canada Subsidiary 100% 100% 15 Auro Vaccines LLC (w.e.f. 27 January 2017)1 USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) ⁶ India Joint Venture 40% 100% 17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³ Turkey Subsidiary 100% 100% 18 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) s.r.l Romania Subsidiary 100% 100% 22 Aurobindo Pharma B.V. (formerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 23 Aurobindo Pharma B.N. (formerly Actavis B.V.) The Netherlands Subsidiary 100% 100% 24 Aurobindo Pharma Bndustria Farmaceutica Ltda Brazil Subsidiary 100% 100% 25 Aurobindo Pharma Industria Farmaceutica Ltda Brazil Subsidiary 100% 100% 100	12	Auro Medics Pharma LLC	USA	Subsidiary	100%	
15 Auro Vaccines LLC (w.e.f. 27 January 2017)1 USA Subsidiary 100% 100% 16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd)6 India Joint Venture 40% 100% 17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi3 Turkey Subsidiary - 100% 18 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 19 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 22 Aurobindo Pharma (Portugal) Aurobindo Pharma (Romania) s.r.l Romania Subsidiary 100% 100% 23 Aurobindo Pharma Colombia S.A.S. Colombia Subsidiary 100% 100% 24 Aurobindo Pharma Industria Farmaceutica Ltda Brazil Subsidiary 100% 100% 26 Aurobindo Pharma Brodutos Farmaceuticos Ltda Brazil Subsidiary 100% 100%		Auro Peptides Limited		Subsidiary	100%	95%
16 Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) ⁶ Joint Venture 40% 100% 17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³ Turkey Subsidiary - 100% 18 Aurobindo Pharma (Italia) S.r.I. Italy Subsidiary 100% 100% 20 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) s.r.I Romania Subsidiary 100% 100% 22 Aurobindo Pharma Colombia S.A.S. Colombia Subsidiary 100% 100% 23 Aurobindo Pharma GmbH Germany Subsidiary 100% 100% 24 Aurobindo Pharma Japan K.K. Japan Subsidiary 100% 100% 25 Aurobindo Pharma USA Inc. USA Subsidiary 100% 100% 26 Aurobindo Pharma USA Inc. USA Subsidiary 100% 100%	14	Auro Pharma Inc.		Subsidiary	100%	100%
Antibiotics Ltd) ⁶ Image: Constraint of the second se	15	Auro Vaccines LLC (w.e.f. 27 January 2017) ¹	USA	Subsidiary	100%	100%
17 Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³ Turkey Subsidiary - 100% 18 Aurobindo Pharma (Italia) S.r.I Italy Subsidiary 100% 100% 19 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Romania) s.r.I Romania Subsidiary 100% 100% 23 Aurobindo Pharma Colombia S.A.S. Colombia Subsidiary 100% 100% 24 Aurobindo Pharma GmbH Germany Subsidiary 100% 100% 25 Aurobindo Pharma Industria Farmaceutica Ltda Brazil Subsidiary 100% 100% 26 Aurobindo Pharma Japan K.K. Japan Subsidiary 100% 100% 27 Aurobindo Pharma USA Inc. USA Subsidiary 100% 100% 28 Aurobindo Pharma USA Inc. USA Subsidiary 100% 100% 30 Aurobindo Pharma Produtos Farmaceuticos Ltda Brazil Subsidia	16	Raidurgam Developers Limited (Formerly Aurobindo	India	Joint Venture	40%	100%
18 Aurobindo Pharma (Italia) S.r.I. Italy Subsidiary 100% 19 Aurobindo Pharma (Malta) Limited Malta Subsidiary 100% 100% 20 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 21 Aurobindo Pharma (Portugal) Unipessoal Lda Portugal Subsidiary 100% 100% 22 Aurobindo Pharma (Romania) s.r.I Romania Subsidiary 100% 100% 23 Aurobindo Pharma Colombia S.A.S. Colombia Subsidiary 100% 100% 24 Aurobindo Pharma GmbH Germany Subsidiary 100% 100% 25 Aurobindo Pharma Industria Farmaceutica Ltda Brazil Subsidiary 100% 100% 26 Aurobindo Pharma Industria Farmaceuticos Ltda Brazil Subsidiary 100% 100% 29 Aurobindo Pharma USA Inc. USA Subsidiary 100% 100% 29 Aurobindo Pharma Industria Farmaceuticos Ltda Brazil Subsidiary 100% 100% 29 Aurobindo Pharma USA Inc. USA Subsidiary<						
19Aurobindo Pharma (Malta) LimitedMaltaSubsidiary100%100%20Aurobindo Pharma (Portugal) Unipessoal LdaPortugalSubsidiary100%100%21Aurobindo Pharma (Pty) LimitedSouth AfricaSubsidiary100%100%22Aurobindo Pharma (Romania) s.r.lRomaniaSubsidiary100%100%23Aurobindo Pharma B.V. (formerly Actavis B.V.)The NetherlandsSubsidiary100%100%24Aurobindo Pharma Golombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary100%100%27Aurobindo Pharma NK.K.JapanSubsidiary100%100%28Aurobindo Pharma Noutoria Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1&8} USASubsidiary100%100%31Auropindo Pharma LLCUSASubsidiary100%100%100%33Aurovitas Pharma Private LimitedIndiaSubsidiary100%100%34Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%36Au	17	Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi ³	Turkey	Subsidiary	-	100%
20Aurobindo Pharma (Portugal) Unipessoal LdaPortugalSubsidiary100%100%21Aurobindo Pharma (Pty) LimitedSouth AfricaSubsidiary100%100%22Aurobindo Pharma (Romania) s.r.lRomaniaSubsidiary100%100%23Aurobindo Pharma B.V. (formerly Actavis B.V.)The NetherlandsSubsidiary100%100%24Aurobindo Pharma Colombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%33Aurovitas Pharma Private LimitedIndiaSubsidiary100%100%100%34Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidia	18	Aurobindo Pharma (Italia) S.r.I	Italy	Subsidiary	100%	100%
21Aurobindo Pharma (Pty) LimitedSouth AfricaSubsidiary100%100%22Aurobindo Pharma (Romania) s.r.lRomaniaSubsidiary100%100%23Aurobindo Pharma B.V. (formerly Actavis B.V.)The NetherlandsSubsidiary100%100%24Aurobindo Pharma Colombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Auropindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1&8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%33Auronext Pharma LLCUSASubsidiary100%100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%36Aurovitas Unipessoal LDAPortugalSubsidiary100%100% <td>19</td> <td>Aurobindo Pharma (Malta) Limited</td> <td>Malta</td> <td>Subsidiary</td> <td>100%</td> <td>100%</td>	19	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary	100%	100%
22Aurobindo Pharma (Romania) s.r.lRomaniaSubsidiary100%100%23Aurobindo Pharma B.V. (formerly Actavis B.V.)The NetherlandsSubsidiary100%100%24Aurobindo Pharma Colombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Industria Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{18.8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%36Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38Aurozymes LimitedIndiaSubsidiary100%100%38Aurozymes LimitedIndiaSubsidiary100%100%			Portugal	Subsidiary		100%
23Aurobindo Pharma B.V. (formerly Actavis B.V.)The NetherlandsSubsidiary100%100%24Aurobindo Pharma Colombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%33Auronext Pharma LLCUSASubsidiary100%100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Unipessoal LDAPortugalSubsidiary100%100%100%38Aurozymes LimitedIndiaSubsidiary100%100%38Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	21	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary	100%	
24Aurobindo Pharma Colombia S.A.S.ColombiaSubsidiary100%100%25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%32Aurolife Pharma LLCUSASubsidiary100%100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%36Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Unipessoal LDAPortugalSubsidiary100%100%100%38AuroZymes LimitedIndiaSubsidiary100%100%100%	22	Aurobindo Pharma (Romania) s.r.l	Romania	Subsidiary	100%	100%
25Aurobindo Pharma GmbHGermanySubsidiary100%100%26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%32Aurolife Pharma LLCUSASubsidiary100%100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	23	Aurobindo Pharma B.V. (formerly Actavis B.V.)	The Netherlands	Subsidiary	100%	100%
26Aurobindo Pharma Industria Farmaceutica LtdaBrazilSubsidiary99.97%27Aurobindo Pharma Japan K.K.JapanSubsidiary100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%29Aurobindo Pharma USA Inc.USASubsidiary100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%32Aurolife Pharma LLCUSASubsidiary100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%38Aurozymes LimitedIndiaSubsidiary100%100%38Aurozymes LimitedIndiaSubsidiary100%100%38Aurozymes LimitedIndiaSubsidiary100%100%	24	Aurobindo Pharma Colombia S.A.S.	Colombia	Subsidiary	100%	100%
27Aurobindo Pharma Japan K.K.JapanSubsidiary100%100%28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%100%29Aurobindo Pharma USA Inc.USASubsidiary100%100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%100%32Aurolife Pharma LLCUSASubsidiary100%100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	25	Aurobindo Pharma GmbH	Germany	Subsidiary	100%	100%
28Aurobindo Pharma Produtos Farmaceuticos LtdaBrazilSubsidiary100%29Aurobindo Pharma USA Inc.USASubsidiary100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%32Aurolife Pharma LLCUSASubsidiary100%100%33Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	26	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary	99.97%	99.97%
29Aurobindo Pharma USA Inc.USASubsidiary100%30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1 & 8} USASubsidiary100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%32Aurolife Pharma LLCUSASubsidiary100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%37Aurozymes LimitedIndiaSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	27	Aurobindo Pharma Japan K.K.	Japan	Subsidiary		100%
30Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) ^{1&8} USASubsidiary100%31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) ¹ South AfricaSubsidiary100%32Aurolife Pharma LLCUSASubsidiary100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) ¹ PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	28	Aurobindo Pharma Produtos Farmaceuticos Ltda	Brazil	Subsidiary	100%	100%
31Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) 1South AfricaSubsidiary100%32Aurolife Pharma LLCUSASubsidiary100%100%33Auronext Pharma Private LimitedIndiaSubsidiary100%100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	29	Aurobindo Pharma USA Inc.	USA	Subsidiary	100%	100%
32Aurolife Pharma LLCUSASubsidiary100%33Auronext Pharma Private LimitedIndiaSubsidiary100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1PolandSubsidiary100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%38AuroZymes LimitedIndiaSubsidiary100%	30	Aurobindo Pharma USA LLC (w.e.f. 14 April 2016) 1 & 8	USA	Subsidiary	100%	100%
33Auronext Pharma Private LimitedIndiaSubsidiary100%34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1PolandSubsidiary100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%38AuroZymes LimitedIndiaSubsidiary100%	31	Aurogen South Africa (PTY) Ltd (w.e.f. 25 January 2017) 1	South Africa	Subsidiary	100%	100%
34Aurovida Farmaceutica S.A. de C.V.MexicoSubsidiary100%35Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1PolandSubsidiary100%100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%	32	Aurolife Pharma LLC	USA	Subsidiary	100%	100%
35Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1PolandSubsidiary100%36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%38AuroZymes LimitedIndiaSubsidiary100%	33	Auronext Pharma Private Limited	India	Subsidiary	100%	100%
36Aurovitas Spain SA (formerly Actavis Spain S.A.)SpainSubsidiary100%37Aurovitas Unipessoal LDAPortugalSubsidiary100%100%38AuroZymes LimitedIndiaSubsidiary100%100%			Mexico	Subsidiary	100%	
37Aurovitas Unipessoal LDAPortugalSubsidiary100%38AuroZymes LimitedIndiaSubsidiary100%	35	Aurovitas Pharma Polska (w.e.f. 31 March 2017) 1		Subsidiary	100%	100%
38AuroZymes LimitedIndiaSubsidiary100%100%	36	Aurovitas Spain SA (formerly Actavis Spain S.A.)	Spain	Subsidiary	100%	100%
	37	Aurovitas Unipessoal LDA	Portugal	Subsidiary	100%	100%
	38	AuroZymes Limited	India	Subsidiary	100%	100%
	39	Curepro parenterals Limited	India	Subsidiary	100%	100%

for the year ended 31 March 2018

S.		Country of	Nature of	% of Inter	est as at
No.	Name of the Consolidated Entities	Incorporation	Interest	31 March 2018	31 March 2017
40	Eugia Pharma Specialities Limited	India	Joint Venture	67.82%	67.82%
41	Helix Healthcare B.V.	The Netherlands	Subsidiary	100%	100%
42	Hyacinths Pharma Private Limited	India	Subsidiary	100%	100%
43	Laboratorios Aurobindo, S.L.	Spain	Subsidiary	100%	100%
44	Milpharm Limited	UK	Subsidiary	100%	100%
45	Natrol LLC	USA	Subsidiary	100%	100%
46	Novagen Pharma (Pty) Ltd	South Africa	Joint Venture	50%	50%
47	Pharmacin B.V. (formerly Aurex B.V.)	The Netherlands	Subsidiary	100%	100%
48	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary	100%	100%
49	Silicon Life Sciences Private Limited	India	Subsidiary	100%	100%
50	Tergene Biotech Pvt.Ltd 7	India	Joint Venture	76.84%	60%
51	1980 Puren Pharma GmbH (formerly Actavis	Germany	Subsidiary	100%	100%
	Management GmbH)	·			
52	Aurovitas Pharma Ceska Republica s.r.o	Czech Republic	Subsidiary	100%	-
	(w.e.f. 23 December 2017) ²	·			
53	Generis Farmaceutica S.A. (w.e.f. 01 May 2017) ²	Portugal	Subsidiary	100%	-
54	Mer Medicamentos, Lda (w.e.f. 01 May 2017) ²	Portugal	Subsidiary	100%	-
55	Generis Phar, Unipessoal Lda (w.e.f. 01 May 2017) ²	Portugal	Subsidiary	100%	-
56	Farma APS - Promocao de Medicamentos,	Portugal	Subsidiary	-	-
	Unipessoal Lda., (w.e.f. 01 May 2017 and Closed				
	w.e.f. 25 January 2018) ²⁸⁴				
57	Generis MZ, Lda., (w.e.f. 01 May 2017 and closed	Mozambique	Subsidiary	-	-
	w.e.f 19 March 2018) ^{2&5}				
58	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary	100%	-
	(w.e.f. 08 May 2017) ²				
59	Aurovitas Pharma (Taizhou) Ltd (w.e.f. 29 January, 2018) ²	China	Subsidiary	100%	-
60	AuroLogistics LLC (w.e.f 28 April 2017) ²	USA	Subsidiary	100%	-
61	Acrotech Biopharma LLC (w.e.f. 05 January 2018) ²	USA	Subsidiary	100%	-
62	Auro Pharma India Private Limited	India	Subsidiary	100%	-
	(w.e.f 20 December 2017) ²				

Notes:

- 1. Incorporated during the financial year 2016-17.
- 2. Incorporated / Acquired during the financial year 2017-18.
- 3. Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi liquidated w.e.f. 31 October 2017
- 4. Farma APS Promocao de Medicamentos, Unipessoal Lda., Closed w.e.f. 25 January 2018
- 5. Generis MZ, Lda., Closed w.e.f. 19 March 2018
- 6. With effect from 30 November 2017 ceased to be a subsidiary of Parent Company, resulting in shareholding of 40% w.e.f 30 November 2017.
- 7. During the financial year 2017-18 Parent Company shareholding increased from 60% to 76.84%
- Aurobindo Pharma USA LLC closed w.e.f. 31 March 2018 The figures for the subsidiaries have been considered from the date of acquisition/incorporation/and upto the date of disposal/ liquidation as applicable.

for the year ended 31 March 2018

2.3. Significant accounting policies

- a. Current versus non-current classification The Group presents assets and liabilities in the consolidated balance sheet based on current/ noncurrent classification. An asset is treated as current when it is:
 - Expected to be realised or intended to be sold or consumed in the Group normal operating cycle
 - Held primarily for the purpose of trading;
 - Expected to be realised within twelve months after the reporting period; or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in the Group normal operating cycle;

- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as noncurrent assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

b. Foreign exchange transactions

The Group's consolidated financial statements are presented in Indian rupees, which is the functional currency of the Parent Company. For each entity the Group determines the functional currency and items included in the financial statements of each entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation the gain or loss that is reclassified to profit or loss reflects the amount that arises from using this method.

Initial recognition

Foreign currency transactions are recorded by the Group's entities at their respective functional currency, by applying to the foreign currency amount the exchange rate between the functional currency and foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported at functional currency spot rate of exchange at reporting date. 'Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or profit or loss are also recognised in OCI or profit or loss, respectively).

Exchange differences

Exchange differences arising on the settlement of monetary items or on reporting monetary items of Company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or as expenses in the year in which they arise.

Group companies

On consolidation, the assets and liabilities of foreign operations are translated into Indian rupees at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions. For practical reasons, the Group uses an average rate to translate income and expense items, if the average rate approximates the exchange rates at the dates of the transactions. The exchange differences arising on translation for consolidation are recognised in OCI. On disposal of a foreign operation, the component of OCI relating to that particular foreign operation is recognised in profit or loss.

Any goodwill / capital reserve arising in the acquisition/ business combination of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.

Any goodwill / capital reserve or fair value adjustments arising in business combinations/ acquisitions, which occurred before the date of transition to Ind AS (01 April 2015), are treated as assets and liabilities of the entity rather than as assets and liabilities of the foreign operation. Therefore, those assets and liabilities are non-monetary items already expressed in the functional currency of the parent and no further translation differences occur.

for the year ended 31 March 2018

Cumulative currency translation differences for all foreign operations are deemed to be zero at the date of transition, viz., 01 April 2015. Gain or loss on a subsequent disposal of any foreign operation excludes translation differences that arose before the date of transition but includes only translation differences arising after the transition date.

c. Fair value measurement

The Group / Consolidated entities measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or

- In the absence of a principal market, In the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group / Consolidated entities. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group / Consolidated entities uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — quoted (unadjusted) market prices in active markets for identical assets or liabilities.

- Level 2 — inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). - Level 3 — inputs for the asset or liability that are not based on observable market data (unobservable inputs).

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group / Consolidated entities determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Group's CFO determines the appropriate valuation techniques and inputs for fair value measurements. In estimating the fair value of an asset or a liability, the Group uses market observable data to the extent it is available. Where Level 1 inputs are not available, the Group engages third party qualified valuers to perform the valuation. Any change in the fair value of each asset and liability is also compared with relevant external sources to determine whether the change is reasonable.

For the purpose of fair value disclosures, the Group / Consolidated entities has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group / Consolidated Entities and the revenue can be reliably measured regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Group / Consolidated entities has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

The specific recognition criteria described below must also be met before revenue is recognised:

i) Sale of goods: Revenue from sale of goods is recognised on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, volume discounts, sales returns, chargeback, medicaid payments, rebates, shelf stock adjustments, where applicable and any taxes or duties collected on behalf of the government which are levied on sales such as sales tax, value added tax, goods and services tax, etc., where applicable and recognised based on the terms of

for the year ended 31 March 2018

the agreements entered into with the customers. However, it includes excise duty upto 30 June 2017. Any additional amounts based on the terms of agreements entered into with customers, is recognised in the period when the collectability becomes probable and reliable measure of the same is available.

- ii) Rendering of services: Revenue from sale of dossiers/licenses/services is recognised in accordance with the terms of the relevant agreements as accepted and agreed with the customers. Revenue from contract research operations is recognised in accordance with the terms of the relevant contracts with customers and when the agreed milestones are achieved, which are substantiated by the performance of related service work.
- iii) Interest income: For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the EIR, the Group estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in finance income in the consolidated statement of profit and loss.
- iv) Dividend income: Revenue is recognised when the Group's right to receive the payment is established, which is generally when shareholders approve the dividend.
- v) Export benefits, incentives and licenses: Export incentives are recognised as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

e. Property, plant and equipment

Freehold land and buildings (property) held for use in the production or supply of goods or services, or administrative purposes are stated at cost less accumulated depreciation and accumulated impairment. Freehold land is not depreciated.

The cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Capital work in progress, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

Depreciation is provided on the straight-line method, based on the useful life of the assets as estimated by the Management.

The Group / Consolidated entities, based on technical assessment and management estimate, depreciates certain items of property, plant and equipment over estimated useful lives which are different from the useful life prescribed in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used. The Group has estimated the following useful lives to provide depreciation on its fixed assets.

for the year ended 31 March 2018

Nature of the assets	Useful life as estimated by the	Useful life as stated in the
Nature of the assets	management (in	Companies Act,
	years)	2013 (in years)
Leasehold land	10	-
Leasehold buildings	20	10 - 60
Freehold land	25	-
development		
expenditure		
Freehold buildings	5 - 60	10 - 60
Plant and equipment	3 - 20	3 - 40
Furniture & fixtures	5 - 10	10
Vehicles	4 - 8	8
Office equipment	3 - 10	5

Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Group will obtain ownership by the end of the lease term.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial period/year end and adjusted prospectively, if appropriate.

f. Intangibles

Intangible assets consists of goodwill, licenses, patents, brands and product development costs.

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the consolidated statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Goodwill represents the excess of purchase consideration over the net book value of assets acquired of the subsidiary companies as on the date of investment. Goodwill on consolidation and acquisition is not amortised but is tested for impairment on a periodic basis and impairment losses are recognised where applicable.

The management has estimated following useful life to amortise intangible assets.

Nature of the assets	Useful life as estimated by the
Nature of the assets	management
	(in years)
Product development cost	10
Licenses & patents	5 - 10
Brands	10

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the consolidated statement of profit or loss when the asset is derecognised.

Research and development costs:

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Group can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale

- Its intention to complete and use or sell the asset
- Its ability to use or sell the asset
- How the asset will generate future economic benefits
- The availability of resources to complete the asset

- The ability to measure reliably the expenditure during development

The expenditure to be capitalised include the cost of materials and other costs directly attributable to preparing the assets for its intended use. Other development expenditure are recognised as an expense in the consolidated statement of profit and loss.

for the year ended 31 March 2018

Payments to third parties that generally take the form of upfront/milestone payments are capitalised as per the guidance in Ind AS 38.

Acquired research and development intangible assets that are under development are recognised as Intangible assets under development. These assets are not amortised, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment is recognised as an expense in the consolidated statement of profit and loss.

Subsequent expenditure on in process research and development project acquired separately and recognised as an intangible asset is:

- recognised as an expense, if it is research expenditure

- recognised as an expense, if its development expenditure that does not satisfy the criteria for recognition as an Intangible asset; and

- added to the carrying amount of acquired in process research and development project, if it is development expenditure that satisfies the recognition criteria.

Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the estimated useful lives of the assets or any other basis that reflect the period of expected future benefit. Amortisation expense is recognised in the consolidated statement of profit and loss unless such expenditure forms part of carrying value of another asset. The amortisation period and method are reviewed at each reporting date.

Intangible assets relating to products in development and other intangible assets not available for use is tested for impairment annually. The same are derecognised either on disposal or when no future economic benefits are expected. Losses on derecognition are recorded in the consolidated statement of profit and loss, and are measured as difference between the net disposal proceeds and the carrying amount of respective assets.

g. Government grants and subsidies

Government grants are recognised when there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is deducted from the related expense. When the grant relates to an asset, it is recognised as deferred income and amortised over the useful life of such assets.

h. Inventories

Inventories are valued at lower of cost, calculated on "Weighted average" basis and net realisable value. Cost incurred in bringing each product to its present location and condition are accounted as follows:

Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Finished goods and work-in-progress: cost includes direct materials, labour and a proportion of manufacturing overheads based on the normal operating capacity, but excludes borrowing costs.

Trading goods: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

Raw materials, components and other supplies held for use in the production of finished products are not written down below cost except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value.

The comparison of cost and net realisable value is made on an item-by-item basis.

i. Retirement and other employee benefits Provident fund

Retirement benefit in the form of provident fund is a defined contribution scheme. The Group / Consolidated entities has no obligation, other than the contribution payable to the provident fund. The Group / Consolidated entities recognizes contribution payable to the provident fund scheme as an expense, when an employee renders the related service. If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognized as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognized as an asset to the extent that the pre-payment will lead to, for example, a reduction in future payment or a cash refund.

The Group's / Consolidated Entities contribution towards defined contribution benefit plan is accrued in compliance with the requirements of the domestic

for the year ended 31 March 2018

laws of the countries in which the consolidated entities operate in the year of which the contributions are due.

Gratuity

The Group operates a defined benefit gratuity plan in India, which requires contributions to be made to a separately administered fund. The cost of providing benefits under the defined benefit plan is determined based on actuarial valuation.

Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the Consolidated balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to consolidated profit or loss in subsequent periods.

Short term compensated absences are provided for based on estimates. The Group / Consolidated entities treats accumulated leave, as a long-term employee benefit for measurement purposes. Such accumulated leaves are provided for based on an actuarial valuation using the projected unit credit method at the periodend/ year-end. The Group / Consolidated entities presents the entire liability in respect of leave as a current liability in the consolidated balance sheet, since it does not have an unconditional right to defer its settlement beyond twelve months after the reporting date.

Past service costs are recognised in consolidated profit or loss on the earlier of:

- The date of the plan amendment or curtailment, and
- The date that the Group recognises related restructuring costs

Net interest is calculated by applying the discount rate to the net defined liability or asset. The Group recognises the following changes in the net defined benefit obligation as an expense in the Consolidated Statement of profit and loss:

- Service costs comprising current service costs, pastservice costs, gains and losses on curtailments and non-routine settlements; and

- Net interest expense or income

Compensated absences

Short term compensated absences are provided for based on estimates. The Group treats accumulated leave, as a long-term employee benefit for measurement purposes. Such accumulated leaves are provided for based on an actuarial valuation using the projected unit credit method at the period-end/ year-end. The Group presents the entire liability in respect of leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond twelve months after the reporting date.

j. Share-based payments

Employees of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity settlement transactions).

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That cost is recognised, together with a corresponding increase in employee stock options reserves in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The consolidated statement of profit and loss expense or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period and is recognised in employee benefits expense. Service and non-market based performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Parent Company's best estimate of the number of equity instruments that will ultimately vest. No expense is recognised for awards that do not ultimately vest because of non-market performance and/or service conditions have not been met.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

k. Taxes

Income tax expense comprises of current and deferred tax. Current income tax assets and liabilities is measured at the amount expected to be recovered from or paid to the tax authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Group / Consolidated entities operates and generates taxable income. Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

for the year ended 31 March 2018

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provision where appropriate. The tax rate and tax laws used to compute the amount are those that are enacted or substantially enacted, at the reporting date.

Deferred tax is provided using the balance sheet method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences, except :-

- (i) When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- (ii) In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized, except:-

- (i) When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- (ii) In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that

it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period/year when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date. Deferred tax relating to items recognised outside profit or loss is recognised outside Consolidated profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxation authority.

Taxes paid on acquisition of assets or on incurring expenses which are not subsequently recoverable : Expenses and assets are recognised net of the amount of sales/ value added taxes paid, except:

- (i) When the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable
- (ii) When receivables and payables are stated with the amount of tax included The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated balance sheet.

I. Leases

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfillment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

Where the Group/Consolidated entities are lessee

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Group / Consolidated is classified as a finance lease. Finance leases are capitalised at the

for the year ended 31 March 2018

commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in finance costs in the Consolidated statement of profit and loss, unless they are directly attributable to qualifying assets, in which case they are capitalized in accordance with the Group's general policy on the borrowing costs. Contingent rentals are recognised as expenses in the periods in which they are incurred.

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Group / Consolidated will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term. Operating lease payments are recognised as an expense in the consolidated statement of profit and loss on a straight-line basis over the lease term.

Where the Group/Consolidated entities are lessor

Leases in which the Group / Consolidated does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognised on a straightline basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Group/Consolidated entities to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Group's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

m. Earnings Per Share

Basic earnings per share is calculated by dividing the net consolidated profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of shares outstanding during the year is adjusted for events such as bonus issue that have changed the number of shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net consolidated profit for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

n. Provision and contingent liabilities

Provisions are recognised when the Group/Consolidated entities has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group/ Consolidated entities expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the consolidated statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Onerous contracts

A contract is considered to be onerous when the expected economic benefits to be derived by the Group from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Group recognises any impairment loss on the assets associated with that contract.

Contingencies

Provision in respect of loss contingencies relating to claims, litigations, assessments, fines and penalties are recognised when it is probable that a liability has been incurred and the amount can be estimated reliably.

o. Cash and cash equivalents

Cash and cash equivalent in the consolidated balance sheet comprise cheques, cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Groups/consolidated entities cash management.

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

p. Borrowing cost

Borrowing cost directly attributable to the acquisition, construction or production of an asset that necessarily takes substantial period of time to get ready for its intended use or sale or capitalised as part of cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

q. Impairment of non-financial assets

The Group/Consolidated entities assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group/Consolidated entities estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Groups of assets. When the carrying amount of an asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

The Group/Consolidated entities bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group/Consolidated entities CGUs to which the individual assets are allocated. The budgets and forecast generally cover a period of five years. Impairment losses of continuing operations, including impairment on inventories, are recognised in the consolidated statement of profit and loss.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Group/Consolidated entities estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior periods/ years. Such reversal is recognised in the consolidated statement of profit or loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or Group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. Impairment losses relating to goodwill cannot be reversed in future periods.

r. Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through consolidated profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Group/Consolidated entities commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, a 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Group/ Consolidated entities. After initial measurement,

for the year ended 31 March 2018

such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the consolidated profit or loss. This category generally applies to trade and other receivables.

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- The objective of the business model is achieved both by collecting contractual cashflows and selling the financial assets, and
- (ii) The assets contractual cashflows represents SPPI

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income (OCI). However, the Group recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the consolidated statement of profit and loss. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to consolidated statement of profit and loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. In addition, the Group may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The Group has not designated any debt instrument as at FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated statement of profit and loss.

Equity investments:

All equity investments in subsidiaries are measured at cost less diminution other than temporary. All equity investments in scope of Ind AS 109 are measured at fair value. Equity investments which are held for trading are classified as FVTPL. For all other equity investments, the Group/Consolidated entities may make an irrevocable election to present in OCI subsequent changes in fair value. The Group/Consolidated entities makes such election on an instrument by instrument basis. The classification is made on initial recognition and is irrevocable. If the Group/Consolidated entities decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in OCI. There is no recycling of amounts from OCI to Consolidated Profit and loss, even on sale of investment. However, the Group/Consolidated entities may transfer the cumulative gain/loss within equity. Equity instruments included within the FVTPL category are measured at fair value with all changes recognised in the consolidated profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Group of similar financial assets) is primarily derecognised (i.e. removed from the Group/Consolidated entities Consolidated balance sheet) when:

- (i) the rights to receive cash flows from the asset have expired, or
- (ii) the Group/Consolidated entities has transferred its rights to receive cash flows from the asset, and the Group/Consolidated entities has transferred substantially all the risks and rewards of the asset, or the Group/Consolidated entities has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a passthrough arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Group/Consolidated entities applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets:

 (i) Financial assets that are debt instruments, and are measured at amortised cost, e.g. loans, deposits, debt securities, etc.

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

 Trade receivables that result from transactions that are within the scope of Ind AS 18 - Revenue Recognition.

The Group/Consolidated entities follows 'simplified approach' for recognition of impairment loss allowance. The application of simplified approach does not require the Group/Consolidated entities to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Group/Consolidated entities determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Group/Consolidated entities in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- (i) All contractual terms of the financial instrument (including prepayment, extension, call and similar options) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument
- Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms

As a practical expedient, the Group/Consolidated entities uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

ECL impairment loss allowance (or reversal) recognized during the period is recognized as income/ expense in the Consolidated statement of profit and loss. This amount is reflected under the head other expenses / other income in the consolidated statement of profit and loss. ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the Consolidated balance sheet. The allowance reduces the net carrying amount. Until the asset meets writeoff criteria, the Group/Consolidated entities does not reduce impairment allowance from the gross carrying amount.

For assessing increase in credit risk and impairment loss, the Group/Consolidated entities combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis. The Group/Consolidated entities does not have any purchased or originated credit-impaired (POCI) financial assets, i.e., financial assets which are credit impaired on purchase/ origination.

Financial liabilities Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group/Consolidated entities financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI.

for the year ended 31 March 2018

These gains/ loss are not subsequently transferred to consolidated statement of profit and loss. However, the Group may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the Consolidated statement of profit or loss. The Group/Consolidated entities has not designated any financial liability as at fair value through profit and loss.

Loans and borrowings

This is the category most relevant to the Group/ Consolidated entities. After initial recognition, interestbearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in consolidated profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the consolidated statement of profit and loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the consolidated statement of profit or loss.

Reclassification of financial assets

The Group/Consolidated entities determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Group's senior management determines change in the business model as a result of external or internal changes which are significant to the Group's operations. Such changes are evident to external parties. A change in the business model occurs when the Group either begins or ceases to perform an activity that is significant to its operations. If the Group/Consolidated entities reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the

immediately next reporting period following the change in business model. The Group/Consolidated entities does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

The following table shows various reclassification and how they are accounted for:

Original classification	Revised classification	Accounting treatment
Amortised	FVTPL	Fair value is measured
cost		at reclassification date.
		Difference between previous
		amortized cost and fair value
		is recognised in consolidated
		statement of profit and loss.
FVTPL	Amortised	Fair value at reclassification
	Cost	date becomes its new gross
		carrying amount. EIR is
		calculated based on the new
		gross carrying amount.
Amortised	FVTOCI	Fair value is measured
cost		at reclassification date.
		Difference between previous
		amortised cost and fair
		value is recognised in OCI.
		No change in EIR due to
		reclassification.
FVTOCI	Amortised	Fair value at reclassification
	cost	date becomes its new
		amortised cost carrying
		amount. However,
		cumulative gain or loss in
		OCI is adjusted against fair
		value. Consequently, the
		asset is measured as if it had
		always been measured at
		amortised cost.
FVTPL	FVTOCI	Fair value at reclassification
		date becomes its new
		carrying amount. No other
		adjustment is required.
FVTOCI	FVTPL	Assets continue to be
		measured at fair value.
		Cumulative gain or loss
		previously recognized in OCI
		is reclassified to consolidated
		statement of profit and loss
		at the reclassification date.

Financial assets and financial liabilities are offset and the net amount is reported in the consolidated balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

s. Derivative financial instruments

The Group / Consolidated entities uses derivative financial instruments, such as forward currency contracts to hedge its foreign currency risks. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. The forward contracts that meet the definition of a derivative under Ind AS 109 are recognised in the Consolidated statement of profit and loss. Any gains or losses arising from changes in the fair value of derivatives are taken directly to Consolidated profit or loss.

t. Cash dividend and non cash distribution to equity holders

The Group recognises a liability to make cash and non cash distribution to equity holders when the distribution is authorised and the distribution is no longer at the discretion of the Group. As per the Corporate laws in India, a final dividend distribution is authorised when it is approved by the shareholders whereas for interim dividend when authorised by board. A corresponding amount is recognised directly in equity. Non cash distribution are measured at fair value of the assets distributed with fair value re-measurement recognised directly in equity.

u. Non-current assets held for sale

The Group classifies non-current assets and disposal Groups as held for sale/ distribution to owners if their carrying amounts will be recovered principally through a sale/ distribution rather than through continuing use. Actions required to complete the sale/ distribution should indicate that it is unlikely that significant changes to the sale/ distribution will be made or that the decision to sell/ distribute will be withdrawn. Management must be committed to the sale/ distribution expected within one year from the date of classification. For these purposes, sale transactions include exchanges of non-current assets for other non-current assets when the exchange has commercial substance. The criteria for held for sale/ distribution classification is regarded met only when the assets or disposal Group is available for immediate sale/ distribution in its present condition, subject only to terms that are usual and customary for sales/ distribution of such assets (or disposal Groups), its sale/ distribution is highly probable; and it will genuinely be sold, not abandoned. The Group treats sale/ distribution of the asset or disposal Group to be highly probable when:

- The appropriate level of management is committed to a plan to sell the asset (or disposal Group),

- An active programme to locate a buyer and complete the plan has been initiated (if applicable),

- The asset (or disposal Group) is being actively marketed for sale at a price that is reasonable in relation to its current fair value,

- The sale is expected to qualify for recognition as a completed sale within one year from the date of classification , and

- Actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.

Non-current assets held for sale are measured at the lower of their carrying amount and the fair value less cost to sell. Assets held for sale are presented separately in the balance sheet. Property Plant and Equipment and Intangible Assets once classified as held for sale are not depreciated or amortised.

v. Recent accounting pronouncements Standards issued but not yet effective & not early adopted by the Group: Ind AS 115, Revenue from Contracts with Customers

In March 2018, the Ministry of Corporate Affairs issued the Companies (Indian Accounting Standards) Amendment Rules, 2018, notifying Ind AS 115 'Revenue from Contracts with Customers' (New Revenue Standard), which replaces Ind AS 11 'Construction Contracts' and Ind AS 18 'Revenue'. This establishes a comprehensive framework for determining whether, how much and when revenue should be recognised. It replaces existing revenue recognition guidance, including Ind AS 18 Revenue, Ind AS 11 Construction Contracts and Guidance Note on Accounting for Real Estate Transactions. Ind AS 115 is effective for annual periods beginning on or after 01 April 2018 and will be applied accordingly.

The core principle of Ind AS 115 is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Specifically, the standard introduces a 5-step approach to revenue recognition.

Step 1: Identify the contract(s) with a customer

Step 2: Identify the performance obligation in contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation

for the year ended 31 March 2018

For the sale of goods, revenue is currently recognised when related risks and rewards of ownership are transferred. Revenue is recognised at this point provided that the revenue and costs can be measured reliably, the recovery of the consideration is probable and there is no continuing management involvement with the goods.

Under Ind AS 115, revenue will be recognised when a customer obtains control of the goods. For certain contracts that permit the customer to return an item, revenue is currently recognised when a reasonable estimate of the returns can be made, provided that all other criteria for revenue recognition are met. If a reasonable estimate cannot be made, then revenue recognition is deferred until the return period lapses or a reasonable estimate of returns can be made. Some of the key changes introduced by Ind AS 115 include additional guidance for measurement approaches for variable consideration.

Under Ind AS 115, revenue will be recognised for these contracts to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognised will not occur. As a consequence, for those contracts for which the Group is unable to make a reasonable estimate of return, revenue is expected to be recognised sooner than when the return period lapses or a reasonable estimate can be made. A refund liability and an asset for recovery will be recognised for these contracts and presented separately in the consolidated balance sheet. Significant additional disclosures in relation to revenue are also prescribed. The New Revenue Standard also provides two broad alternative transition options – Retrospective Method and Cumulative Effect Method – with certain practical expedients available under the Retrospective Method. The Group is in the process of evaluating the impact of the New Revenue Standard on the present and future arrangements and shall determine the appropriate transition option once the said evaluation has been completed.

Ind AS 21, The effect of changes in foreign exchange rates

The amendment clarifies on the accounting of transactions that include the receipt or payment of advance consideration in a foreign currency. The appendix explains that the date of the transaction, for the purpose of determining the exchange rate, is the date of initial recognition of the non-monetary prepayment asset or deferred income liability. If there are multiple payments or receipts in advance, a date of transaction is established for each payment or receipt. The Group is evaluating the impact of this amendment on its financial statements.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

	ľ
ţ	ľ
ΞŪ.	1
Σ	
Ξ.	
ð	
ш	
9	
A	
PROPERTY, PLANT AND EQUIPMEN	
Ā	
2	
3	
Ê	
<u>لنا</u>	
6	
Ř	
Δ.	
0	

(at cost) 158.3 $3.093.9$ 321.4 $8.83.1$ $23.763.0$ 701.9 114.2 273.5 <th></th> <th>Leasehold land</th> <th>Freehold land</th> <th>Leasehold buildings</th> <th>Freehold buildings</th> <th>Plant and equipment</th> <th>Furniture and fixtures</th> <th>Vehicles</th> <th>Office equipment</th> <th>Total</th>		Leasehold land	Freehold land	Leasehold buildings	Freehold buildings	Plant and equipment	Furniture and fixtures	Vehicles	Office equipment	Total
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Gross carrying value (at cost)									
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	As at 01 April 2016	158.3	3,093.9	321.4	8,833.1	23,763.0	701.9	114.2	273.5	37,259.3
(10) (10) (10) (10) (10) (10) (10) (10) (10) $(15,4)$ $(11,3)$ $(15,4)$ $(11,3)$ (12) (12) (10) $(15,4)$ $(11,3)$ $(15,4)$ $(11,3)$ (13) (22) (43) (10) 2.0 5.6 0.42 $2.006.8$ 7.0347 294.4 41.7 123.0 (10) $2.206.6$ 0.44 $6.6.8$ 380.5 $21.0.6$ 31.33 $21.0.6$ (10) $2.202.6$ 394.7 $15.66.1$ $38.776.3$ $12.74.6$ 26.4 471.3 (10) $2.202.6$ 394.7 $31.47.8$ $11.4.1$ 39.7 $21.74.6$ 26.4 471.3 (10) (10) (10) (10) $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $(11,3)$ $($	Additions	1	1,306.8	14.7	2,126.1	7,070.1	286.9	125.3	73.0	11,002.9
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Disposals / adjustments	ı		ı	0.2	76.5	1.2	10.8	10.9	9.66
(15.4) (15.4) (41.3) (80.1) (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 (4.3) 0.2 0	Additions on acquisition			,		1		1		1
v (19.3) (15.4) (41.3) (80.1) (4.3) 0.2 0.3 0.3 0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.2 <td>Other adjustments</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Other adjustments									
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	- Exchange differences		(19.3)	(15.4)	(41.3)	(80.1)	(4.3)	0.2	(4.3)	(164.5)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	As at 31 March 2017	158.3	4,381.4	320.7	10,917.7	30,676.5	983.3	228.9	331.3	47,998.1
1000 10000 10000 10000 10000 10000 10000 10000 10000 100000 10000 10000	Additions	2.0	5.6	44.2	4,006.8	7,704.7	294.4	41.7	123.0	12,222.4
n $=$ 290.4 $=$ 658.8 380.5 $=$	Disposals / adjustments		2,508.6	0.4		103.9	9.1	10.2	13.7	2,645.9
\circ 33.8 30.2 82.8 120.5 6.0 - 9.7 160.3 2,202.6 394.7 15,666.1 38,778.3 1,274.6 260.4 471.3 - 8.5 0.6 10.2 365.6 2,867.5 99.9 30.1 73.0 8.5 0.6 10.2 365.6 2,867.5 99.9 30.1 73.0 1.7 1.1 13.9 397.7 3,147.8 114,1 39.9 64.2 1.8 1.1 13.9 397.7 21.4 0.1 5.5 0.5 1.8 1.1 13.9 397.0 (1.9) $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$	Additions on acquisition		290.4	,	658.8	380.5		1	21.0	1,350.7
\circ 33.8 30.2 82.8 120.5 6.0 $-$ 9.7 160.3 2,202.6 39.7 15,666.1 38,778.3 1,274.6 260.4 471.3 $ 8.5$ 0.6 1.0 1.02 365.6 $2,867.5$ 99.9 30.1 73.0 8.5 0.6 1.0 1.02 365.6 $2,867.5$ 99.9 30.1 73.0 8.5 0.6 1.1 139 397.7 $3,147.8$ 114.1 39.9 64.2 67.7 471.3 10 $ 21.4$ 0.1 5.5 0.5 11 13.4 1.1 13.9 367.0 143.4 57.4 82.5 13.4 1.1 15.9 562.3 $3,807.0$ 143.4 57.4 82.5 0.5 13.4 1.1 15.9 562.3 $3,807.0$ 143.4 57.4 82.5 0.6 10 $ -$	Other adjustments									
160.3 2,202.6 394.7 15,666.1 38,778.3 1,274.6 260.4 471.3 8.5 0.6 10.2 365.6 2,867.5 99.9 30.1 73.0 8.5 0.6 1.0 13.9 397.7 3,147.8 114.1 39.9 64.2 1.1 13.9 397.7 3,147.8 114.1 39.9 64.2 1.1 1.3 1.7 23.2 75.3 (1.9) $ 1.4$ 1.7 23.2 758.0 $5,900.2$ 212.0 64.5 134.6 $1.3.4$ 1.7 23.2 758.0 $5,900.2$ 212.0 64.5 134.6 $1.3.4$ 1.7 23.2 758.0 $5,900.2$ 212.0 64.5 134.6 $1.3.4$ 1.7 23.2 $3,907.0$ 143.4 57.4 82.5 1.5 $ -$ <	- Exchange differences		33.8	30.2	82.8	120.5	6.0		9.7	283.0
8.5 0.6 10.2 365.6 $2,867.5$ 99.9 30.1 73.0 8.5 0.6 1.1 13.9 397.7 $3,147.8$ 114.1 39.9 64.2 1.1 $1.3.9$ 397.7 $3,147.8$ 114.1 39.9 64.2 1.1 1.2 2.3 2.14 0.1 5.5 0.5 1.1 1.2 2.3 $3,3.7$ (1.9) $ -$ <	As at 31 March 2018	160.3	2,202.6	394.7	15,666.1	38,778.3	1,274.6	260.4	471.3	59,208.3
8.5 0.6 10.2 365.6 $2,867.5$ 99.9 30.1 73.0 1.0 1.1 13.9 397.7 $3,147.8$ 114.1 39.9 64.2 1.0 $ 21.4$ 0.1 5.5 0.5 1.0 $ -$	Depreciation									
4.9 1.1 13.9 397.7 $3,147.8$ 114.1 39.9 64.2 10 - - - - 21.4 0.1 5.5 0.5 0.6 11 - - - 21.4 0.1 5.5 0.5 0.6 11 - - - - - $ -$	As at 01 April 2016	8.5	0.6	10.2	365.6	2,867.5	6.99	30.1	73.0	3,455.4
Is $ 21.4$ 0.1 5.5 0.5 n $ -$	Charge for the year	4.9	1.1	13.9	397.7	3,147.8	114.1	39.9	64.2	3,783.6
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Disposals / adjustments	I	I	I	I	21.4	0.1	5.5	0.5	27.5
s - (0.9) (5.3) (33.7) (1.9) - (2.1) 13.4 1.7 23.2 758.0 $5,960.2$ 212.0 64.5 134.6 4.9 1.1 15.9 562.3 $3,807.0$ 143.4 57.4 82.5 rs - 0.1 - 39.6 6.7 4.6 13.7 n - - 0.1 - - $ n$ - 0.1 - 39.6 6.7 4.6 13.7 n - $ -$	Additions on acquisition			T		1	1	1	1	1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Other adjustments									
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	- Exchange differences	I	I	(0.0)	(2.3)	(33.7)	(1.9)	I	(2.1)	(43.9)
4.9 1.1 15.9 562.3 3,807.0 143.4 57.4 82.5 13 - - 0.1 - 39.6 6.7 4.6 13.7 11 - - 0.1 - 39.6 6.7 4.6 13.7 12 - - - - - - - - 13 - - - - - - - - - - - 13 -	As at 31 March 2017	13.4	1.7	23.2	758.0	5,960.2	212.0	64.5	134.6	7,167.6
13 13.7 13.7 13.7 13.7 11 - - - 13.7 13.7 11 - - - - - - - 12 - - - - - - - - - - 13 - - 2.7 7.6 47.8 2.6 - 4.6 1.7 18.3 2.8 41.7 1,327.9 9,775.4 351.3 117.3 208.0 - 144.9 4,379.7 297.5 10,159.7 24,7716.3 771.3 164.4 196.7 - 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3 -	Charge for the year	4.9	1.1	15.9	562.3	3,807.0	143.4	57.4	82.5	4,674.5
n 2.7 7.6 47.8 2.6 - 4.6 s - 2.7 7.6 47.8 2.6 - 4.6 s - - 2.7 7.5 9,775.4 351.3 117.3 208.0 144.9 4,379.7 297.5 10,159.7 24,776.3 771.3 164.4 196.7 1 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3 1	Disposals / adjustments	I	I	0.1	I	39.6	6.7	4.6	13.7	64.7
3 2.7 7.6 47.8 2.6 - 4.6 18.3 2.8 41.7 1,327.9 9,775.4 351.3 117.3 208.0 144.9 4,379.7 297.5 10,159.7 24,716.3 771.3 164.4 196.7 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3	Additions on acquisition	I	I	I	I	1	1	I	I	1
3 2.7 7.6 47.8 2.6 - 4.6 18.3 2.8 41.7 1,327.9 9,775.4 351.3 117.3 208.0 14.9 4,379.7 297.5 10,159.7 24,776.3 771.3 164.4 196.7 1 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3 4	Other adjustments									
18.3 2.8 41.7 1,327.9 9,775.4 351.3 117.3 208.0 144.9 4,379.7 297.5 10,159.7 24,716.3 771.3 164.4 196.7 1 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3 1	- Exchange differences	I	I	2.7	7.6	47.8	2.6	I	4.6	65.3
144.9 4,379.7 297.5 10,159.7 24,716.3 771.3 164.4 196.7 142.0 2,199.8 353.0 14,338.2 29,002.9 923.3 143.1 263.3	As at 31 March 2018	18.3	2.8	41.7	1,327.9	9,775.4	351.3	117.3	208.0	11,842.7
144.9 4,379.7 297.5 10,159.7 24,716.3 771.3 164.4 196.7 1 142.0 2,199.8 353.0 14,38.2 29,002.9 923.3 143.1 263.3 1	Net carrying value									
142.0 2,199.8 353.0 14,338.2 29,002.9 923.3 143.1 263.3	As at 31 March 2017	144.9	4,379.7	297.5	10,159.7	24,716.3	771.3	164.4	196.7	40,830.5
	As at 31 March 2018	142.0	2,199.8	353.0	14,338.2	29,002.9	923.3	143.1	263.3	47,365.6

Capital work-in-progress ₹ 13,995.4 (31 March 2017: ₹12,373.6) (including expenditure during construction period) (refer Note 37)

Notes:

- The title deeds of land and buildings aggregating to ₹166.5 (31 March 2017: ₹166.5) are pending transfer to the Parent Company's name. Depreciation for the year include ₹3.1 (31 March, 2017: ₹4.6) taken as pre-operative capital expenditure on capital projects pending capitalisation.
 - Details of finance lease refer note 32(A). 0. 0. 4.
- Land of one of the subsidiaries to the extent of 100.44 acres amounting to ₹ 99.0 (31 March 2017 ₹ 99.0) has been attached by the Directorate of Enforcement during the financial year 2012-13 in a legal case pertaining to the Parent Company.

Company Overview

Statutory Reports

Financial Statements

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

4. GOODWILL

	Goodwill
Gross carrying value (at cost)	
As at 01 April 2016	4,063.0
Additions	
Disposals / Adjustments	-
Acquisition through business combination	-
Other adjustments	
- Exchange differences	
As at 31 March 2017	4,063.0
Additions	-
Disposals / Adjustments	-
Acquisition through business combination	3,740.9
Other adjustments	
- Exchange differences	361.6
As at 31 March 2018	8,165.5

5. INTANGIBLE ASSETS

	Brands	Product development cost	Licences and patents	Total
Gross carrying value (at cost)				
As at 01 April 2016	2,043.6	125.4	2,207.0	4,376.0
Additions	-	4.9	292.1	297.0
Disposals / Adjustments	-	2.6	131.6	134.2
Acquisition through business combination	-	-	-	-
Other adjustments				
- Exchange differences	(43.4)	(2.8)	(198.8)	(245.0)
As at 31 March 2017	2,000.2	124.9	2,168.7	4,293.8
Additions	2.2	22.3	2,430.0	2,454.5
Disposals / Adjustments	-	47.7	390.3	438.0
Acquisition through business combination*	3,149.5	-	1,403.0	4,552.5
Other adjustments				
- Exchange differences	314.5	3.4	393.3	711.2
As at 31 March 2018	5,466.4	102.9	6,004.7	11,574.0
Accumulated amortization				
As at 01 April 2016	210.7	29.9	205.4	446.0
Charge for the year	212.9	25.4	259.0	497.3
Disposals / Adjustments	-	2.7	45.6	48.3
Acquisition through business combination	-	-	-	-
Other adjustments				-
- Exchange differences	(11.2)	(1.8)	(32.5)	(45.5)
As at 31 March 2017	412.4	50.8	386.3	849.5
Charge for the year	212.3	31.0	665.0	908.3
Disposals / Adjustments	-	-	(37.1)	(37.1)
Acquisition through business combination	-	-	-	-
Other adjustments				
- Exchange differences	5.0	2.1	96.3	103.4
As at 31 March 2018	629.7	83.9	1,184.7	1,898.3
Net carrying value				
As at 31 March 2017	1,587.8	74.1	1,782.4	3,444.3
As at 31 March 2018	4,836.7	19.0	4,820.0	9,675.7

Intangible assets under development ₹ 1,835.0 (31 March 2017: ₹2,207.2)

* Excludes intangibles under development of ₹ 12.5 acquired through business combination.



for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

6. INVESTMENTS

(A)(i) Investments accounted for using the equity method

	Face	As at 31 Marc	h 2018	As at 31 Marc	h 2017
	value	Quantity	Amount	Quantity	Amount
Investments in unquoted equity shares (fully paid,					
carried at cost, unless stated otherwise)					
In joint ventures					
Novagen Pharma (Pty) Limited, South Africa	-	927,236	320.9	927,236	394.7
Eugia Pharma Specialities Limited, India	₹10	198,901,611	1,956.7	198,901,611	1,972.4
Tergene Biotech Private Limited, India	₹10	7,500,000	-	3,390,000	-
Raidugam Developers Limited, India (formerly	₹10	4,000,000	30.3	-	-
Aurobindo Antibiotics Limited, India)					
		Α	2,307.9		2,367.1
(ii) Non-current investments					
Investments in unquoted equity shares (fully paid,					
carried at cost, unless stated otherwise)					
In others (At fair value through profit and loss)					
Jeedimetla Effluent Treatment Limited, India	₹100	753	0.1	753	0.1
Patancheru Envirotech Limited, India	₹10	103,709	1.0	103,709	1.0
Progressive Effluent Treatment Limited, India	₹100	1,000	0.1	1,000	0.1
		B	1.2		1.2
Investments in unquoted preference shares (fully paid,					
carried at amortised cost, unless stated otherwise)					
In joint ventures					
Tergene Biotech Private Limited, India	₹ 100	950,000	95.0	900,000	90.0
(10.5% Cumulative Preference shares redeemable at					
par within five years from the date of issue)					
		C	95.0		90.0
Investments in unquoted optionally convertible					
debentures (fully paid, carried at cost, unless					
stated otherwise)					
In joint ventures					
	7 1000				
Raidurgam Developers Limited, India (formerly	₹ 1000	710,933	710.9		-
• • • •	₹ 1000	710,933	710.9		-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at	₹ 1000	710,933	710.9	-	-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at	₹ 1000	710,933	710.9		-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100	₹ 1000	710,933	710.9	-	-
Aurobindo Antibiotics Limited, India)	₹ 1000	710,933 D	710.9	-	-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year)	₹ 1000			-	-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year)	₹ 1000			-	-
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities	₹ 1000				- 0.2
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income	₹ 1000		710.9		0.2
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income	₹ 1000		710.9		- 0.2 0.2
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income	₹ 1000	D	0.2		
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income	₹ 1000	D	0.2		0.2
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments	₹ 1000	D	710.9 0.2 0.2 3,115.2		2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid,	₹ 1000	D	710.9 0.2 0.2 3,115.2		0.2 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments		D E A+B+C+D+E	710.9 0.2 0.2 3,115.2		0.2 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid,	₹ 1000	D	710.9 0.2 0.2 3,115.2		0.2 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid, carried at fair value through profit and loss)		D E A+B+C+D+E	710.9 0.2 0.2 3,115.2		0.2 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid, carried at fair value through profit and loss) Citadel Aurobindo Biotech Limited, India (Aggregate impairment of ₹7.0 (31 March 2017: ₹7.0) Investments in quoted equity shares (fully paid, carried at fair value through profit and loss)		D E A+B+C+D+E	710.9 0.2 0.2 3,115.2		0.2 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid, carried at fair value through profit and loss) Citadel Aurobindo Biotech Limited, India (Aggregate impairment of ₹7.0 (31 March 2017: ₹7.0) Investments in quoted equity shares (fully paid, carried at fair value through profit and loss)	₹ 100	D E A+B+C+D+E 70,000	710.9 0.2 0.2 3,115.2 3,115.2 -	70,000	0.2 2,458.5 2,458.5
Aurobindo Antibiotics Limited, India) (1.5% to 9.5% over a period of ten years redeemable at par within ten years from date of issue, convertible into 100 equity shares per debenture at any time after one year) Unquoted investment in government securities (Carried at fair value through profit and loss) National Savings Certificate (includes held by Income tax authorities ₹ 0.1 (31 March 2017: ₹0.1)) Aggregate value of unquoted investments (B) Current investments Investments in unquoted equity shares (fully paid, carried at fair value through profit and loss) Citadel Aurobindo Biotech Limited, India (Aggregate impairment of ₹7.0 (31 March 2017: ₹7.0) Investments in quoted equity shares (fully paid, carried at fair value through profit and loss)		D E A+B+C+D+E	710.9 0.2 0.2 3,115.2		0.2 2,458.5

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

	Face	As at 31 Marc	h 2018	As at 31 March	1 2017
	value	Quantity	Amount	Quantity	Amount
Aggregate value of unquoted investments			-	·	-
Aggregate value of quoted investments			0.2		0.2
Market value of quoted investments			0.2		0.2
Aggregate amount of impairment in value of			7.0		7.0
investments					

7. TRADE RECEIVABLES

(Unsecured, considered good unless stated otherwise)

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
Doubtful	175.7	175.7
Loss allowance for doubtful receivables	175.7	175.7
	-	-
(B) Current		
Considered good	30,843.6	27,653.3
Doubtful	777.0	1,059.9
	31,620.6	28,713.2
Loss allowance for doubtful receivables	777.0	1,059.9
	30,843.6	27,653.3

No trade receivable are due from directors or other officers of the Company either severally or jointly with any other person. Refer note 40 for dues from related parties.

Refer Note 46 for the Group's credit risk management process.

8. LOANS

(Unsecured, considered good)

	As at 31 March 2018	As at 31 March 2017
(A) Non current		
Loans to employees	54.4	57.0
	54.4	57.0
(B) Current		
Loans to employees	101.9	108.9
	101.9	108.9

No loans are due from directors or other officers of the Company either severally or jointly with any other person. Refer note 40 for dues from related parties.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

9. OTHER FINANCIAL ASSETS

(Unsecured, considered good unless stated otherwise)

		As at 31 March 2018	As at 31 March 2017
(A) Non current			
Security deposits			
Considered good *		854.7	690.9
Doubtful		0.4	0.4
		855.1	691.3
Provision for doubtful deposits		0.4	0.4
i de la companya de l		854.7	690.9
Other non-current bank balances (R	efer note 14(B)) **	19.9	60.8
· · · ·		874.6	751.7

* Non-current deposits includes restricted deposits pledged with Enforcement Directorate ₹ 131.6 (31 March 2017: ₹ 32.6)

^{**} Margin money deposits given against bank guarantees or performance guarantees

(B) Current		
Security deposit	31.1	59.2
Derivatives - foreign currency forward contracts	-	94.8
Interest accrued on deposits	33.4	34.0
Other Receivables- From bank*	7,877.5	7,388.5
	7,942.0	7,576.5

* During the previous year, a wholly owned subsidiary of the Group executed an agreement with bankers to establish an accounts receivable securitisation program. Under the program, the Company sells, on an ongoing basis and without recourse, eligible accounts receivables up to limited as agreed to the bankers, who is conveyed the right to the proceeds of subsequent collection from such customers. On sale of eligible receivables, the rights to collection are separate and distinct from those embodied in the Group's assets. These assets are unavailable to the Group or the Group's creditors in case of insolvency and all rights ensuing from the sale of securitised receivables, including the right to pledge or exchange the assets are with the bankers. These receivables which have been contractually sold but not yet funded by bankers has been fair valued and disclosed as other receivables in the financial statements. The same is subject to normal conditions, availability of proceeds and serve as collateral under the agreement.

10. DEFERRED TAX ASSETS AND LIABILITIES (net)

		As at 31 March 2018	As at 31 March 2017
(A)	Deferred tax assets (net)		
	Business loss and unabsorbed depreciation carried forward	96.8	101.6
	Provisions	1.2	0.7
	Unused tax credits	30.1	30.1
	Receivables, financial assets at amortised cost	-	-
	Property plant and equipment	(26.3)	(21.2)
	Inventories	1,486.2	1,566.4
	Others	-	-
		1,588.0	1,677.6
(B)	Deferred tax liabilities (net)		
	Property plant and equipment	4,796.3	3,792.8
	Business loss and unabsorbed depreciation carried forward	(2.1)	-
	Receivables, financial assets at amortised cost	(145.1)	(207.4)
	Provisions	(360.7)	(275.7)
	Unused tax credits	(3,269.5)	(2,836.3)
	Inventories	73.1	
	Others	1,260.8	19.6
		2,352.8	493.0

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Movement in deferred tax assets/deferred tax liabilities

	As at 1 April 2017	Recognised in statement of profit and loss	Recognised in OCI	Business Combination	Foreign Currency Translation	31 March 2018
Deferred tax asset						
Business loss and unabsorbed	101.6	(10.8)	-	-	6.0	96.8
depreciation carried forward						
Provisions	0.7	0.5	0.4	-	(0.4)	1.2
Unused tax credits	30.1	-	-	-	-	30.1
Receivables, financial assets	-	-	-	-	-	-
at amortised cost						
Property plant and equipment	(21.2)	(5.1)	-	-	-	(26.3)
Inventories	1,566.4	(80.2)	-	-	-	1,486.2
Others	-	-	-	-	-	-
	1,677.6	(95.6)	0.4		5.6	1,588.0
Deferred tax liability						
Property plant and equipment	3,792.8	997.4	-	-	6.1	4,796.3
Business loss and unabsorbed	-	(2.1)		-	-	(2.1)
depreciation carried forward		. ,				
Receivables, financial assets	(207.4)	62.3		-	-	(145.1)
at amortised cost						
Provisions	(275.7)	(72.3)	(12.7)	-	-	(360.7)
Unused tax credits	(2,836.3)	(433.2)	-	-	-	(3,269.5)
Inventories	-	72.2	-	-	0.9	73.1
Others	19.6	339.8	-	836.1	65.3	1,260.8
	493.0	964.1	(12.7)	836.1	72.3	2,352.8

(i) The Parent Company has unused tax credits (Minimum Alternate Tax (MAT)) credit of ₹3,269.5 as on 31 March 2018 (31 March 2017: ₹ 2,836.3). The Parent Company based on its business plan along with supporting convincing evidence including future projections of profit believes that the used tax credits would be utilized within the stipulated time period as per the Income-tax Act, 1961.

(ii) The Group's tax jurisdictions are in various countries, primarily in India, USA and Europe. Significant judgements are involved in determining the provision for current tax, including amounts expected to be paid / recovered for uncertain tax positions.

(iii) Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based on the likely timing and the level of future taxable profits together with the future tax planning strategies.

11. TAX ASSETS (net)

	As at 31 March 2018	As at 31 March 2017
Non current		
Advance income-tax (net of provision for taxation)	825.9	579.8
	825.9	579.8
Current		
Advance income-tax (net of provision for taxation)	645.5	175.1
	645.5	175.1
	Advance income-tax (net of provision for taxation) Current	Non current31 March 2018Advance income-tax (net of provision for taxation)825.9Current825.9Advance income-tax (net of provision for taxation)645.5

Refer note 31 for details of income tax expense.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

12. OTHER ASSETS

(Unsecured, considered good unless stated otherwise)

	As at	As at 31 March 2017
	31 March 2018	31 March 2017
(A) Non-current		
Export incentives receivable		
Considered good	566.9	463.3
Doubtful	19.6	44.8
	586.5	508.1
Provision for doubtful receivables	19.6	44.8
	566.9	463.3
Export rebate claims receivable	288.8	288.8
Capital advances		
Considered good	728.4	1,014.9
Doubtful	0.8	0.8
	729.2	1,015.7
Provision for doubtful advances	0.8	0.8
	728.4	1,014.9
Advances other than capital advances		· · · · · ·
Considered good	15.5	18.0
Doubtful	30.1	30.1
	45.6	48.1
Provision for doubtful advances	30.1	30.1
	15.5	18.0
Balances with government authorities		
Considered good	78.7	204.2
Doubtful	38.1	38.1
Doubtidi	116.8	242.3
Provision for doubtful receivables	38.1	38.1
	78.7	204.2
	1,678.3	1,989.2
(B) Current	1,070.3	1,303.2
Advances other than capital advances		
Considered good	2,720.7	2,719.9
Doubtful	10.2	2,7 19.9
Doubliui	2,730.9	2,728.6
Provision for doubtful advances	10.2	8.7
	2,720.7	2,719.9
Export rebate claims receivable	1,880.6	828.6
Insurance claim receivable	0.8	020.0
Assets held for sale	0.8	60.3
Export incentives receivable	2,440.9	2,441.0
Balances with government authorities	4,101.9	2,057.8
	11,144.9	8,107.6

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

13. INVENTORIES

(Valued at lower of cost and net realisable value)

	As at	As at
	31 March 2018	31 March 2017
Raw materials	22,071.4	15,201.0
Packing materials	2,805.1	1,991.5
Work-in-progress	10,794.7	8,626.7
Finished goods	6,300.2	3,186.8
Stock-in-trade	15,183.7	13,027.5
Stores, spares and consumables	1,429.0	1,271.9
	58,584.1	43,305.4
Details of material in transit included in inventories above		
Raw materials	888.3	665.9
Finished goods	1,359.7	80.6

14. CASH AND CASH EQUIVALENTS AND OTHER BANK BALANCES

(A) Cash and cash equivalents

	As at 31 March 2018	As at 31 March 2017
Balances with banks:		
in current accounts	11,314.5	4,611.9
in cash credit accounts	313.8	31.4
in unpaid dividend account	19.0	15.9
in deposit accounts - with orginal maturity of less than 3 months	316.5	229.4
Cash on hand	3.3	5.8
Cheques on hand	191.9	-
	12,159.0	4,894.4

(B) Other bank balances

	As at 31 March 2018	As at 31 March 2017
Balances with banks - deposits with maturity less than 12 months	457.2	240.4
Earmarked balances with banks:		
Margin money deposits - given against bank guarantees/performance guarantees	19.9	60.8
	477.1	301.2
Amount disclosed under non-current financial assets (refer note 9(A))	(19.9)	(60.8)
	457.2	240.4

(C) For the purpose of statement of cash flows, cash and cash equivalents comprise of following:

	As at 31 March 2018	As at 31 March 2017
Cash and cash equivalents as above	12,159.0	4,894.4
Less: Bank overdraft (refer note 17(B))	(40.6)	(1,698.1)
	12,118.4	3,196.3

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(D) Details of Specified Bank Notes (SBN) held and transacted during the period 8 November 2016 to 30 December 2016

	SBN*	Other denominations	Total
Closing cash on hand - 8 November 2016	2.7	4.1	6.8
Add: Permitted receipts	-	1.2	1.2
Add: Withdrawal from bank	-	0.9	0.9
Less: Permitted payments	-	2.3	2.3
Less: Amount deposited into bank	2.7	0.6	3.3
Closing cash on hand - 30 December 2016	-	3.3	3.3

* For the purposes of this clause, the term "Specified Bank Notes" shall have the same meaning provided in the notification of the Government of India, in the Ministry of Finance, Department of Economic Affairs number S.O.3407(E), dated the 8th November 2016.

15. EQUITY SHARE CAPITAL

	As at 31 March 2018	As at 31 March 2017
(a) Authorised Share Capital		
660,000,000 (31 March 2017: 660,000,000) equity shares of ₹1 each	660.0	660.0
1,000,000 (31 March 2017: 1,000,000) preference shares of ₹100 each	100.0	100.0
	760.0	760.0

b) Issued, subscribed and fully paid-up equity shares

	Equity Shares	
	Numbers	Value
As at 01 April 2016	585,169,586	585.2
Issued during the year under employee stock option plan (ESOP)	712,823	0.7
As at 31 March 2017	585,882,409	585.9
Issued during the year under employee stock option plan (ESOP)	25,200	0.0
As at 31 March 2018	585,907,609	585.9

c) Terms/rights attached to equity shares

The Parent Company has only one class of equity shares having a par values of ₹1 per share. Each holder of equity shares is entitled to one vote per share.

The Parent Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing Annual General Meeting, except in case of interim dividend. For the year ended 31 March 2018, the amount of dividend per share declared as distribution to equity shareholders was ₹ 2.50 (31 March 2017: ₹ 2.50). Refer note 16(c) for details of dividend declared/recognised in the consolidated financial statements.

In the event of liquidation of the Parent Company, the holders of equity shares will be entitled to receive remaining assets of the Parent Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

d) Details of shareholders holding more than 5% of total number of equity shares in the Parent Company:

	As at 31 Mar	As at 31 March 2017	
	Numbers	% holding	
RPR Sons Advisors Private Limited & Mrs.P.Suneela Rani (Joint Holders)	196,376,250	33.52%	
	As at 31 Mar	ch 2018	
	As at 31 Mar Numbers	ch 2018 % holding	

As per records of the Parent Company, including its register of shareholders/members and other declarations received from shareholders, the above shareholding represents legal ownerships of shares and the beneficial ownership is with RPR Enterprises, a partnership firm.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

e) Aggregate number of bonus shares issued, shares issued for consideration other than cash during the period of five years immediately preceeding the reporting date:

	Number
Equity shares allotted as fully paid bonus shares by capitalisation of securities premium	
Year ended 31 March 2018	-
Year ended 31 March 2017	-
Year ended 31 March 2016	291,982,275
Year ended 31 March 2015	-
Year ended 31 March 2014	-

f) For details of shares reserved for issue under Employee stock option plan (ESOP) of the Company, refer note 35.

16. OTHER EQUITY

	As at	As at
	31 March 2018	31 March 2017
Capital reserve	818.9	818.9
Capital redemption reserve	90.0	90.0
Employee stock options outstanding account	0.7	1.0
Securities premium account	4,175.8	4,173.1
General reserve	8,131.6	8,131.6
Retained earnings	102,117.6	80,530.3
Other Comprehensive Income (OCI)	883.7	(611.7)
	116,218.3	93,133.2

a) For details of stock options refer note 35.

b) The disaggregation of changes in reserves and surplus and OCI are disclosed in statement of changes in equity.

c) The details of distribution of dividend made and proposed are as under:

As at 31 March 2018	As at 31 March 2017
2,197.1	1,141.1
447.3	232.3
2,644.4	1,373.4
As at	As at
31 March 2018	31 March 2017
-	732.4
-	149.1
-	881.5
	31 March 2018 2,197.1 447.3 2,644.4 As at

* Under Ind AS dividend is recognised as a liability in the period in which it is declared by the Parent Company. Accordingly, the above dividend and dividend distribution tax has not been recognised in the consolidated financial statements for the year ended 31 March 2018 and 31 March 2017 respectively.

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

(a)	Capital Reserve :	Represents capital reserve balances of the acquired entities which are transferred to the Group upon mergers in the earlier years and those arising on acquisition.
(b)	Capital redemption reserve :	The Parent Company has recognised capital redemption reserve on redemption of non-convertible preference shares. The amount in Capital Redemption Reserve is equal to nominal amount of the non-convertible preference shares redemeed.
(C)	Employee stock options outstanding account :	The fair value of the equity-settled share based payment transactions with employees is recognised in consolidated statement of profit and loss with corresponding credit to employee stock options outstanding account.
(d)	Securities premium account :	The amount received in excess of face value of the equity shares is recognised in securities premium reserve. In case of equity-settled share based payment transactions, the difference between fair value on the grant date and nominal value of share is accounted as securities premium reserve.
(e)	General reserve :	The Parent Company has transferred a portion of its net profit before declaring dividend to general reserve pursuant to the earlier provisions of the Companies Act, 1956. Mandatory transfer to general reserve is not required under the Companies Act, 2013. This reserve also includes transferred cumulative translation differences arising from foreign operations forming part of foreign currency translation reserve which were deemed to be zero upon transition to Ind AS as at 01 April 2015.
(f)	Retained Earnings:	Retained earnings are the profits that the Group has earned till date, less any transfers to general reserve, dividends or other distribution to shareholders.
(g)	Other Comprehensive Income (OCI):	Other comprehensive income comprises of:
		(i) Re-measurement of defined employee benefit plans: Difference between the interest income on plan assets and the return actually achieved, any changes in the liabilities over the year due to changes in acturial assumptions or experience adjustments with in the plans, are recognised in other comprehensive income and subsequently not recalasified in to consolidated statement of profit and loss.
		(ii) Exchange differences on translation of financial statements of foreign operations: Represents exchange differences arising on account of conversion of foreign operations to Group's functional currency.
	Non-controlling interest	Net profit/(loss) attributable to minority shareholders.

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

17. BORROWINGS

As at	As at
31 March 2018	31 March 2017
-	1,775.9
-	1,775.9
269.6	-
269.6	-
4,242.4	38.1
4,512.0	1,814.0
	31 March 2018 - - 269.6 269.6 4,242.4

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

	As at 31 March 2018	As at 31 March 2017
(B) Current borrowings		
Term loans from Banks		
Current maturities of foreign currency term loans (Secured)	651.8	1,884.6
Current maturities of foreign currency term loans (Unsecured)	2,222.2	915.6
Loans repayable on demand from Banks - working capital loans		
- Cash credit facilities (secured)	40.6	1,698.1
- Buyers credit (secured)	78.7	-
- Working capital demand loan (Unsecured)	-	750.0
- Packing credit loans (secured)	3,151.2	347.1
- Packing credit loans (unsecured)	31,995.3	24,100.3
- Bill discounting facility (secured)	1,432.8	702.3
- Bill discounting facility (Unsecured)	18.8	18.6
- Short term loans from Banks (Unsecured)	3,596.0	1,410.8
	43,187.4	31,827.4
Amount disclosed under the head "Other financial liabilities" (refer note 20)	(2,874.0)	(2,800.2)
	40,313.4	29,027.2

(C) Details of secured and unsecured borrowings

	As at 31 March 2018	As at 31 March 2017
Secured borrowings	5,624.7	6,408.0
Unsecured borrowings	42,074.7	27,233.4
	47,699.4	33,641.4

(D) Terms of borrowings

- (i) Secured term loans in foreign currency carry interest in the range of LIBOR plus 1.2% to 1.5% (31 March 2017: LIBOR plus 1% to 1.5%). Out of these loans, loans amounting to ₹ Nil (31 March 2017: ₹ 1,080.9) are repayable in Nil (31 March 2017: two) equal annual installments and loan amounting to ₹ 651.8 (31 March 2017: ₹ 1,945.5) is repayable in equal half yearly installment of one (31 March 2017: three). Loans amounting to ₹ Nil (31 March 2017: ₹ 625.3, 1.5 and 7.3) are repayable in Nil (31 March 2017: monthly equal installments over a period of 6 years, 6 years and 3 years respectively) instalments.
- (ii) Unsecured foreign currency term loan amounting to ₹ 6,464.6 (31 March 2017: Nil) carrying interest rate of 0.91% (31 March 2017: Nil) and is payable in equal quarterly installments and the last installment is payable in March 2022. Unsecured foreign currency term loan amounting to Nil (31 March 2017: ₹ 953.7) carrying interest rate of LIBOR plus 1.05% is repayable in Nil (31 March 2017: equal quarterly installments upto December 2019).
- (iii) Unsecured foreign currency term loans amounting to ₹ Nil (31 March 2017: ₹ 953.7) carry interest rate of LIBOR plus 1.05%, repayable in equal quarterly installments.
- (iv) Term loans are secured by first pari passu charge on all the present and future property, plant and equipment, both movable and immoveable property of the Parent Company. Term loans amounting to ₹ 625.3 outstanding as of 31 March 2017 were secured by property, fixed assets, inventory and trade receivable of Aurolife Pharma LLC, Aurobindo Pharma USA Inc and Auromedics Pharma LLC. Term loans amounting to ₹ 8.8 outstanding as of 31 March 2017 were secured by equipments of Aurolife Pharma LLC, Aurobindo Pharma USA Inc and Auromedics Pharma LLC, Aurobindo Pharma USA Inc and Auromedics Pharma LLC, Aurobindo Pharma USA Inc and Auromedics Pharma LLC.
- (v) All secured loans payable on demand and secured short term loans from banks are secured by first pari passu charge by way of hypothecation of all the stocks, book debts and other current assets (both present and future).
- (vi) All secured packing credit foreign currency loans carry interest in the range of LIBOR plus 20 to 50 basis points. All unsecured packing credit foreign currency loans carry interest in the range of 1 month's LIBOR plus (20) to 50 basis points.
- (vii) Finance lease obligation is secured by the warehouse equipment of Aurobindo Pharma USA, Inc. acquired under finance lease. See note 32(A) for details.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

18. PROVISIONS

	As at	As at
	31 March 2018	31 March 2017
(A) Non-current		
For employee benefits		
Gratuity and other retirement benefits (refer note 36(b))	553.4	388.3
Compensated absences	5.2	3.0
	558.6	391.3
(B) Current		
For employee benefits		
Gratuity and other retirement benefits (refer note 36(b))	204.6	148.7
Compensated absences	660.1	555.0
Other provisions	1,144.6	1,645.3
	2,009.3	2,349.0

19. TRADE PAYABLES

	As at 31 March 2018	As at 31 March 2017
Trade payables for supplies and services	26,274.4	21,547.0
	26,274.4	21,547.0

(Refer note 46 for the Group's liquidity risk management process)

20. OTHER FINANCIAL LIABILITIES

	As at 31 March 2018	As at 31 March 2017
Current maturities of non-current borrowings (Refer note 17(B))	2,874.0	2,800.2
Capital creditors	2,170.9	1,854.2
Security deposits	1.5	1.5
Unclaimed dividend	19.0	15.9
Interest accrued but not due on borrowings	11.1	22.0
Derivatives - foreign currency forward contracts	23.3	-
Others	0.2	-
	5,100.0	4,693.8

21. OTHER LIABILITIES

	As at 31 March 2018	As at 31 March 2017
Advances from customers	671.7	390.0
Statutory liabilities	930.6	596.0
Employee payables	1,088.7	501.0
Other payables	9,987.0	6,687.4
	12,678.0	8,174.4

22. CURRENT TAX LIABILITIES

	As at 31 March 2018	As at 31 March 2017
Provision for income-tax (net of advance tax)	431.1	264.6

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

23. REVENUE FROM OPERATIONS

	For the year ended 31 March 2018	For the year ended 31 March 2017
Sale of products (including excise duty)*	162,008.7	147,916.6
Sale of services	320.0	531.3
Other operating revenue		
Scrap sales	133.6	87.6
Export incentives	2,536.0	2,363.1
	164,998.3	150,898.6

*The Company is liable to Goods and Services Tax (GST) with effect from 01 July 2017. The revenues for the year ended 31 March 2018 is net of such GST. However, the revenues for the period ended upto 30 June 2017 are inclusive of excise duty.

24. OTHER INCOME

	For the year ended 31 March 2018	For the year ended 31 March 2017
Interest income on financial assets (carried at amortised cost)		
Bank deposits	67.4	60.8
Other deposits and receivables	52.8	100.7
Provision no longer required on doubtful debts written back	95.9	-
Bad debts recovered from trade receivables (net)	-	70.8
Foreign exchange gain (net)	-	620.5
Commission income	57.9	67.1
Miscellaneous income	745.8	239.0
	1,019.8	1,158.9

25. COST OF MATERIALS CONSUMED

	For the year ended 31 March 2018	For the year ended 31 March 2017
Opening stock*	15,422.1	14,905.5
Add: Purchases	57,040.3	46,958.5
	72,462.4	61,864.0
Less: Closing stock	22,071.4	15,201.0
Cost of raw material consumed	50,391.0	46,663.0
Adjustment for fluctuation in exchange rates	29.1	(51.7)
Packing materials consumed	5,873.7	5,237.9
	56,293.8	51,849.2

*Includes inventories on acquisition of subsidiaries ₹ 221.1 (31 March 2017: ₹ Nil)

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

26. CHANGES IN INVENTORIES OF FINISHED GOODS, STOCK-IN-TRADE AND WORK-IN-PROGRESS

	For the year ended	For the year ended
	31 March 2018	31 March 2017
nventories at the beginning of the year		
Stock-in-trade*	13,662.6	5,895.8
Work-in-progress**	8,640.6	9,246.6
Finishedgoods***	3,550.8	7,817.2
	25,854.0	22,959.6
nventories at the end of the year		
Stock-in-trade	15,183.7	13,027.5
Work-in-progress	10,794.7	8,626.7
Finished goods	6,300.2	3,186.8
	32,278.6	24,841.0
	(6,424.6)	(1,881.4
On account of stock write off	109.4	221.2
Adjustment for fluctuation in exchange rates	(1,708.8)	989.4
-	(4,825.2)	(3,092.0

*Includes inventories on acquisition of subsidiaries ₹635.1 (31 March 2017: ₹ Nil) **Includes inventories on acquisition of subsidiaries ₹ 13.9 (31 March 2017: ₹ Nil)

***Includes inventories on acquisition of subsidiaries ₹ 364.0 (31 March 2017: ₹ Nil)

27. EMPLOYEE BENEFITS EXPENSE

	For the year ended 31 March 2018	For the year ended 31 March 2017
Salaries, wages and bonus	18,467.2	15,411.9
Contribution to provident and other funds (refer note 36(a))	881.5	692.8
Gratuity expense (refer note 36(b))	207.8	123.7
Leave encashment expense	207.1	192.9
Staff welfare expenses	1,544.7	1,256.1
Employee share-based payment expense - equity settled (refer note 35)	0.1	0.2
	21,308.4	17,677.6

28. FINANCE COSTS

	For the year ended 31 March 2018	For the year ended 31 March 2017
Interest on financial liabilities measured at amortised cost	628.9	545.1
Bank and other finance charges	146.8	122.1
Exchange differences regarded as an adjustment to borrowing costs	1.5	-
	777.2	667.2

29. DEPRECIATION AND AMMORTISATION EXPENSE

	For the year ended 31 March 2018	For the year ended 31 March 2017
Depreciation of property, plant and equipment (refer note 3)	4,671.4	3,779.0
Amortisation of intangible assets (refer note 5)	908.3	497.3
	5,579.7	4,276.3

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

193.6

193.6

_

30. OTHER EXPENSES

	For the year e		For the year ended
	31 March		31 March 2017
Conversion charges		51.3	342.5
Consumption of stores and spares	,	88.5	1,554.3
Chemicals consumed	,	13.6	1,893.8
Power and fuel	,	09.5	4,371.4
Carriage inward		42.8	642.5
Factory maintenance		74.8	349.2
Effluent treatment expenses		19.2	182.9
Excise duty on sales		68.0	1,803.2
Excise duty on changes in inventories	(;	31.4)	5.3
Repairs and maintenance			
i) Plant and machinery	,	02.9	995.6
ii) Buildings		50.5	506.1
iii) Others		63.3	155.7
Rent (Refer note 32(A))		05.4	773.1
Rates and taxes		45.3	612.7
Printing and stationery		86.6	155.2
Postage, telegrams and telephones	22	28.2	225.0
Insurance	38	89.6	415.7
Legal and professional charges	3,69	93.6	2,883.1
Directors sitting fees		3.5	1.9
Remuneration to auditors		13.6	15.6
Sales commission	1,10	68.9	820.1
Carriage outwards	5,2	24.3	4,405.5
Selling expenses	3,80	65.3	3,258.7
Delayed supply charges	2,1	93.6	2,548.8
Travelling and conveyance	5	84.1	563.8
Vehicle maintenance expenses	19	95.0	154.9
Analytical charges	1,2	76.6	915.2
Donations		2.3	9.4
Registration, license and filing charges	1,5	06.7	1,648.3
Foreign exchange loss (net)	1(67.6	-
Product development expenses	29	92.2	165.8
Product destruction expenses / Stock written off	1(09.4	221.2
Software license and implementation expenses	1;	31.9	130.0
Loss on sale/write-off of fixed assets (net)	1(63.5	62.7
Fair value of changes to current investments		0.1	-
Corporate Social Responsibility (CSR) expenditure (refer note below)	20	00.0	193.6
Miscellaneous expenses	2,34	44.7	1,552.8
	38,44	45.0	34,535.6
Details of CSR expenditure a) Gross amount required to be spent by the Parent Company during the year	4/	24.9	424.5
	cash Yet to be in	e paid I cash	Total
b) Amount spent during the year ending on 31 March 2018:			
i) Construction/acquisition of any asset	-	-	-
	00.0	-	200.0
c) Amount spent during the year ending on 31 March 2017:			
i) Construction/acquisition of any asset	-	-	-
ii) On purposes other than (i) above	23.6		102.6

On purposes other than (i) above

ii)

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

31. INCOME TAX

	For the year ended 31 March 2018	For the year ended 31 March 2017
The major components of income tax expense for the year ended 31 March 2018 and 31 March		
2017 are:		
Statement of profit and loss		-
Current income tax charge	7,123.0	6,917.0
Deferred tax and Tax credit - relating to origination and reversal of temporary differences	1,059.7	679.5
• • • •	8,182.7	7,596.5
Other comprehensive income		`
Deferred tax - net loss on remeasurements of defined benefit plans	13.1	29.7
· · · · · ·	13.1	29.7
Reconciliation of effective tax rate for the year ended 31 March 2018 and 31 March 2017:		
Profit before tax	32,411.8	30,608.4
Enacted tax rate in India	34.608%	34.608%
Tax at statutory tax rate	11,217.0	10,593.0
Other than temporary differences		
Tax holidays (Refer Note "a" below)	(2,132.1)	(1,313.4)
Weighted deduction allowed for research and development expenditure	(765.0)	(1,299.8)
Differences in tax rate	(715.6)	(39.7)
Unrecognised taxes	250.1	171.3
Others	328.3	(514.9)
Total	(3,034.3)	(2,996.5)
Income tax expense	8,182.7	7,596.5
Effective tax rate	25.246%	24.818%

Notes:

- (a) The Company benefits from the tax holiday available for units set up under the Special Economic Zone Act, 2005. These tax holidays are available for a period of fifteen years from the date of commencement of operations. Under the SEZ scheme, the unit which begins providing services on or after 01 April, 2005 will be eligible for deductions of 100% of profits or gains derived from export of services for the first five years, 50% of such profit or gains for a further period of five years and 50% of such profits or gains for the balance period of five years subject to fulfillment of certain conditions. From 01 April, 2011 units set up under SEZ scheme are subject to Minimum Alternate Tax (MAT).
- (b) During the year ended 31 March 2018 and 31 March 2017 the Company has paid dividend to shareholders, this has resulted in payment of dividend distribution tax to the taxation authorities. The Company believes that dividend distribution tax represents additional payment to tax authorities on behalf of shareholders. Hence, dividend distribution tax paid is charged to equity.
- (c) Deferred taxes have not been recognised on undistributed earnings of subsidiaries and joint ventures, where it is expected that the profits of its subsidiaries and joint ventures will not be distributed in the foreseeable future. The Group reinvests the profits of its subsidiaries and joint ventures, and accordingly, has not recorded any deferred taxes for the same. Significant judgements are involved in determining provision for current tax and deferred tax on deductible temporary differences. Deferred tax is not recognised on deductible temporary differences, where the Group believes that availability of taxable profits against which such temporary differences can be utilised, is not probable.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

32. COMMITMENTS AND CONTINGENCIES

A. Leases

i

a. Operating lease commitments - Group as lessee

The Group has operating leases agreements, which are mainly in the nature of lease of office premises for a period up to five years, with no restrictions and are renewable/ cancellable at the option of either of the parties except for details in (ii) below. These leases include a general clause to enable upward revision of the rental charge on an annual basis according to the prevailing market conditions. There is no other escalation clause in the lease agreement. There are no sub-leases. There are no restrictions imposed by lease arrangements. The aggregate amount of operating lease payments recognised in the consolidated statement of profit and loss is ₹ 1,105.4 (31 March 2017: ₹773.1). The Group has not recognised any contingent rent as expense in the consolidated statement of profit and loss.

ii) The Group has entered into non cancellable leases for office premises in current year and previous year. These leases have remaining non cancellable period of 6 months (31 March 2017: 5 months). The lease includes an escalation clause in the lease agreement. Future minimum lease rentals under non cancellable operating leases are as follows:

		31 March 2018	31 March 2017
a)	With in one year	6.0	21.1
b)	After one year and not more than three years	-	-
C)	After three years and not more than five years	-	_

b. Finance lease - Group as lessee

- i) Building includes factory buildings acquired on finance lease. The lease term is for major part of the economic life of the buildings and the agreement is silent on renewal terms and transfer of legal title at the end of lease term.
- ii) The lease agreement did not specify minimum lease payments over the future period.
- iii) The net carrying amount of the buildings obtained on finance lease as at 31 March 2018 is ₹ 353.0 (31 March 2017: ₹ 297.5).
- iv) The Group's property, plant and equipment include warehouse equipment acquired under finance lease arrangements. The future lease rents payable and other related information in respect of such assets are as follows:

	As at 31 March 2018	As at 31 March 2017
Net carrying amount	269.6	-
Future minimum lease payments	270.6	-
Less: Interest included in the above	20.3	-
Present value of future minimum lease payments	250.3	-

v) Future Minimum lease payments and their present value at the Balance Sheet date for each of the following periods.

	Minimum Leas	Minimum Lease payments		ue of future yments
	31 March 2018	31 March 2017	31 March 2018	31 March 2017
Not later than one year	58.0	-	56.6	-
Later than one year not later than 5 years	212.6	-	193.7	-
	270.6	-	250.3	-

Lease commitments - the Group as lessor

The Group has entered into agreements in the nature of non-cancellable leases for office premises. The Group has identified assets under operating and finance lease based on the factors indicated under Appendix C to Ind AS 17 and terms of the agreement, viz., economic life of the asset vs. lease term, ownership of the asset after the lease term.

Lease commitments - the Group as lessee

The Group has entered into leases for land and office premises. The Group has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a major part of the economic life of the land and office premises and the fair value of the asset, that it does not retain significant risks and rewards of ownership of the land and the office premises and accounts for the contracts as operating leases.



Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

B. Capital and other commitments

	As at 31 March 2018	As at 31 March 2017
Estimated amount of contracts (net of advances) remaining to be executed on capital	5,051.6	6,528.1
account and not provided for		

33. CONTINGENT LIABILITIES

	31 March 2018	31 March 2017
(A) Claims against the Group not acknowledged as debt		
Claims arising from disputes not acknowledged as debts - indirect taxes (excise duty and	339.3	342.0
service tax)*		
Claims arising from disputes not acknowledged as debts - direct taxes *	568.8	586.3
Claims against the Group not acknowledged as debts - other duties/ claims ^	150.3	150.3
(B) Guarantees		
Outstanding bank guarantees	1,059.5	891.1

* in respect of above matters, future cash outflows in respect of contingent liabilities are determinable only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Group. The Group is contesting these demands and the Management, including its advisors, believe that its position will likely be upheld in the appellate process. No expense has been accrued in the financial statements for the demands raised. The Management believes that the ultimate outcome of this proceeding will not have a material adverse effect on the Group's financial position and results of operations.

^ The Group is involved in disputes, claims, Governmental and/or regulatory inspection, inquires, including patents and commercial maters that arise from time to time in the ordinary course of business. The same are subject to uncertain future events not wholly within the control of the Group. The management does not expect the same to have materially adverse effect on its financial position, as it believes the likely hood of any loss is not probable.

34. EARNINGS PER SHARE

The following reflects the income and share data used in the basic and diluted EPS computations:

	For the year ended 31 March 2018	For the year ended 31 March 2017
Earnings		
Consolidated profit after taxation considered for calculation of basic and diluted earnings per share	24,231.7	23,016.6
Shares		
Weighted average number of Equity Shares considered for calculation of basic earnings per share (a)	585,882,685	585,213,641
Effect of dilution on account of Employee Stock Options granted (b)	5,039	9,782
Weighted average number of Equity Shares considered for calculation of diluted earnings per	585,887,724	585,223,423
share (a+b)		
Earnings per share of face value ₹1/-		
- Basic	41.36	39.33
- Diluted	41.36	39.33

35. SHARE BASED PAYMENTS

Employee Stock Option Plan "ESOP-2006"

The Parent Company instituted an Employee Stock Option Plan "ESOP-2006" for issue of shares to eligible employees of the Group as per the special resolution passed in the 19th Annual General Meeting held on 18 September 2006. The compensation committee of the Board of directors accordingly, granted 3,240,500 options under eight grants of 175,000, 25,000, 90,000, 1,205,000, 300,000, 500,000, 915,500 and 30,000 options to eligible employees on 30 October 2006, 31 July 2007, 31 October 2007, 16 December 2011, 19 June 2012, 09 January 2013, 28 January 2013 and 09 August 2013 respectively. The method of settlement under scheme is by issue of equity shares of the Parent Company and there are no cash settlement alternatives for the employees. Each option comprises of one underlying Equity Share of ₹1/- each. The said options vest on an annual basis at 10%,

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

15%, 25% and 50% over a period of four years and can be exercised over a period of six years from the date of grant of options. The options have been granted at the then prevailing market price of ₹ 120.70, ₹ 132.35, ₹ 114.50, ₹ 91.60, ₹ 106.05, ₹ 200.70, ₹ 187.40 and ₹ 161.30 per share respectively. The fair value of share options grants is estimated at the date of grant using Black-Scholes model, taking into account the terms and conditions upon which the share options were granted.

The details of ESOP 2006 Scheme are summarised below:

Grant	Grant date	Number of options granted*	Exercise price*	Weighted Average Fair value of option at grant date*
1st Grant	30 October 2006	175,000	60.35	73.10
2nd Grant	31 July 2007	25,000	66.18	78.82
3rd Grant	31 October 2007	90,000	57.25	68.18
4th Grant	16 December 2011	1,753,800	45.80	54.35
5th Grant	19 June 2012	300,000	53.03	57.42
6th Grant	09 January 2013	500,000	100.35	119.22
7th Grant	28 January 2013	1,483,170	93.70	111.32
8th Grant	09 August 2013	57,000	80.65	96.30

*Adjusted for bonus issue.

The details of activity under the Scheme ESOP 2006 are summarised below :

	31 March 2018	31 March 2017
Options outstanding at the beginning of the year	56,219	1,027,120
Granted during the year	-	-
Vested / exercisable during the year	56,219	638,932
Exercised during the year	25,200	712,823
Forfeited during the year subject to reissue	-	258,078
Options outstanding at end of the year	31,019	56,219
Exercisable at the end of the year	31,019	27,719
Weighted average exercise price for all the above options (₹)	80.66	88.76
Weighted average fair value of options at the date of grant (₹)	96.30	105.63

The details of share options outstanding are summarised below:

	Range of exercise prices	Number of options outstanding	Weighted average remaining contractual life of options (in years)
As at 31 March 2018	80 to 94	31,019	1.36
As at 31 March 2017	80 to 94	56,219	2.23

The following table lists the assumptions used for the plan:

	31 March 2018			
Grant	Dividend yield	Expected volatility	Risk-free interest rate	Expected life of options granted in years
7th Grant	0.80%	0.31%	8%	4
8th Grant	0.61%	0.31%	8%	4

The following table lists the assumptions used for the plan:

		31 Ma	rch 2017		
Grant	Dividend yield	Expected volatility	Risk-free interest rate	Expected life of options granted in years	
7th Grant	0.80%	0.31%	8%	4	
8th Grant	0.61%	0.31%	8%	4	

Company Overview Statutory Reports

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

36. EMPLOYEE BENEFITS

a) Disclosures related to defined contribution plan

In accordance with Indian law, all eligible employees of APL and its subsidiaries are entitled to receive benefits under the provident fund, a defined contribution plan in which both the employee and employer (at a determined rate) contribute monthly. APL and its subsidiaries in India contribute as specified under the law to the Provident Fund:

	31 March 2018	31 March 2017
Provident fund contribution recognised as expense in the consolidated statement of profit	322.1	274.7
and loss*		

* Includes ₹19.3 (31 March 2017: ₹14.3) transferred to capital work in progress

b) Disclosures related to defined benefit plan of the Parent Company

The Parent Company has a defined benefit gratuity plan governed by the Payment of Gratuity Act, 1972. Every employee who has completed five years or more of service is entitled to gratuity on departure at 15 days last drawn salary for each completed year of service or part thereof in excess of six months.

This defined benefit plan exposes the Parent Company to acturial risk, such as longevity risk, currency risk, interest rate risk and market (investment) risk.

The plan is funded with Life Insurance Corporation in the form of a qualifying insurance policy. The following tables summarise the components of net benefit expense recognised in the consolidated statement of profit and loss, the fund status and amounts recognised in the consolidated balance sheet:

Net employee benefit expense (included under employee benefit expenses)

	31 March 2018	31 March 2017
Current service cost	143.5	114.4
Past service cost	55.3	-
Interest on defined benefit liability	12.8	18.1
Net employee benefit expenses*	211.6	132.5

* Includes ₹ 8.2 (31 March 2017: ₹ 10.9) transferred to capital work in progress

Details of the employee benefits obligations and plan assets are as follows:

	31 March 2018	31 March 2017
Present value of funded obligation	1,054.5	818.3
Fair value of plan assets	628.5	544.6
Net defined benefit liability	426.0	273.7

Details of changes in present value of defined benefit obligation are as follows:

	31 March 2018	31 March 2017
Opening defined benefit obligation	818.3	618.1
Current service cost	143.5	114.4
Past service cost	55.3	-
Interest on defined benefit obligation	59.0	47.9
Benefits paid	(49.9)	(47.3)
Remeasurement due to:		
Actuarial loss arising from changes in experience	43.8	14.4
Actuarial loss arising from changes in demographic assumptions	6.3	-
Actuarial (gain)/loss arising from changes in financial assumptions	(21.8)	70.8
Closing defined benefit obligation	1,054.5	818.3

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Details of changes in fair value of plan assets are as follows:

	31 March 2018	31 March 2017
Opening fair value of plan assets	544.6	340.5
Interest on plan assets	46.1	29.8
Employer Contribution	93.9	222.2
Benefits paid	(49.9)	(47.3)
Remeasurement due to - actual return on plan assets less interest on plan assets	(6.2)	(0.6)
Closing fair value of plan assets	628.5	544.6

Sensitivity analysis

The sensitivity of over all plan obligations to changes in key assumptions are as follows:

	31 March 2018	31 March 2017
The sensitivity of over all plan obligations to changes in key assumptions are as follows:		
Defined benefit obligation without effect of projected salary growth rate	677.4	381.1
Add: effect of salary growth rate	377.1	437.2
Defined benefit obligation with effect of projected salary growth	1,054.5	818.3
Defined benefit obligation, using discount rate plus 50 basis points	1,019.8	769.2
Defined benefit obligation, using discount rate minus 50 basis points	1,091.3	871.9
Defined benefit obligation, using salary growth rate plus 50 basis points	1,089.9	864.4
Defined benefit obligation, using salary growth rate minus 50 basis points	1,020.8	774.8

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

	31 March 2018	31 March 2017
Funds managed by Insurers	100.00%	100.00%

The principal assumptions used in determining gratuity obligations for the Parent Company's plans are shown below: Financial assumptions

	31 March 2018	31 March 2017
Discount rate (p.a.)	7.70%	7.40%
Expected salary increase (p.a)		
Until 2 years	-	10.00%
Beyond 2 years	-	7.00%
Until 1 year	10.00%	
Beyond 1 year	7.00%	-
Demographic assumptions		
Mortality rate (% of IALM 06-08)	100%	100%

Attrition rate	2018	2018		2017	
	Age (years)	Rates (p.a)	Age (years)	Rates (p.a)	
	21 - 30	16%	21 - 30	8%	
	31 - 40	12%	31 - 40	4%	
	41 - 50	3%	41 - 57	1%	
	51 - 57	23%	-	-	

Discount rate : The discount rate is based on the prevailing market yields of Indian Government securities as at the balance sheet date for the estimated term of obligations.

Salary escalation rate : The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other related factors.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Maturity profile of the defined benefit obligation

	31 March 2018	31 March 2017
Weighted average duration of defined benefit obligation (in years)	6.77	12.53
Expected future cash flow of gratuity		
Within 12 months	143.2	43.0
Between 2 and 5 years	488.3	160.8
Between 5 and 10 years	399.6	223.5
Beyond 10 years	984.3	2,099.6

Notes:

- 1. The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.
- 2. The Parent Company expects to contribute ₹ 90.0 (31 March 2017: ₹65.0) during the year ending 31 March 2019 to the qualifying insurance policy.
- 3. The sensitivity analysis above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occuring at the end of the reporting period by varying one actuarial assumption, keeping all other actuarial assumptions constant.

37. CAPITAL WORK-IN-PROGRESS INCLUDES EXPENDITURE DURING CONSTRUCTION PERIOD PENDING CAPITALISATION:

	31 March 2018	31 March 2017
Balance brought forward	1,397.8	999.6
Add: Incurred during the year		
Salaries, wages and bonus	356.1	460.2
Consumption of material for testing	173.5	249.2
Consumption of stores and spares	95.1	208.3
Carriage inward	1.5	1.5
Power and fuel	122.9	270.2
Conversion charges	39.2	50.8
Rates and taxes	9.0	30.7
Printing and stationery	5.7	8.6
Postage, telegram and telephones	2.0	2.4
Insurance	1.9	(1.0)
Legal and professional charges	9.2	8.9
Travelling and conveyance	7.8	10.5
Depreciation	3.1	4.6
Factory maintenance	42.4	46.5
Miscellaneous expenses	37.8	74.6
	2,305.0	2,425.6
Less: Capitalised to property, plant and equipment during the year	623.3	1,027.8
Balance carried forward	1,681.7	1,397.8

38. ACQUISITION OF SUBSIDIARY

Effective 01 May 2017, the Parent Company through its step-down subsidiary, Agile Pharma B.V. acquired 100% equity of Generis Farmacêutica S.A. ("acquired entity" or "Generis") which in turn had the following wholly owned subsidiaries on the date of acquisition.

- (i). Mer Medicamentos, Lda
- (ii). Generis Phar, Unipessoal Lda
- (iii). Farma APS Promocao de Medicamentos, Unipessoal Lda.,
- (iv). Generis MZ, Lda.,

Generis Farmaceutica S.A., is engaged in the manufacture and sale of pharmaceutical products in Portugal. The acquisition includes the manufacturing facility in Amadora, Portugal.

Generis Farmacêutica S.A. is a generic pharmaceutical Company that focuses on both the retail and hospital segments apart from exports. Generis has a wide portfolio of products with share in the therapeutic areas of cardiovascular (CVS), Central Nervous

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

System (CNS), anti-infectives and genitourinary system ailments.

Synergies are expected from Parent Company's vertical integration and pipeline breadth, improvement in Amadora plant capacity utilization by servicing both local and European markets, and operational advantages.

The purchase price of the acquired entity on 01 May 2017 had been allocated based on estimated fair values at the acquisition date, for various assets and liabilities acquired/ assumed under a Sale and Purchase Agreement. The Company determined fair values based on its then estimates and third party technical evaluation for various tangible and intangible assets acquired.

As at 31 March 2018, the consolidated balance sheet reflects the purchase price allocated to the assets acquired and liabilities assumed based on revised estimated fair values. The excess of the purchase consideration over the fair value of the net assets acquired has been allocated to Goodwill. The following table summarizes the allocation of purchase price consideration, for the fair values of the assets acquired and liabilities assumed and the determination of Goodwill.

	Amount as on 01 May 2017
Purchase consideration	6,658.9
Net Debts taken over	3,103.8
Total implied consideration [A]	9,762.7
Liabilities assumed:	
Provisions	40.0
Trade payables	799.2
Current tax liabilities	15.7
Other financial liabilities	102.0
Other current liabilities	151.4
Deferred tax liabilities	811.5
Total liabilities assumed [B]	1,919.8
Fair value of assets acquired	
Property plant and equipment	1,358.2
Intangible assets	4,565.0
Inventories	1,261.4
Trade receivables	611.6
Cash and cash equivalents	1.3
Current tax assets	61.3
Other current assets	82.8
Total fair value of assets acquired [C]	7,941.6
Goodwill [A+B-C]	3,740.9

The valuation techniques used for measuring the fair value of assets acquired were as follows:

Assets acquired	Valuation technique
Property, plant and equipment	Market comparison technique and cost technique: The valuation model considers quoted market prices for similar items when they are available, and depreciated replacement cost reflects adjustments for physical deterioration as well as functional and economic obsolescence.
Intangible assets	Relief-from-Royalty method and multi-period excess earnings method. The relief from royalty method considers the discounted estimated royalty payments that are expected to be avoided as a result of the licenses and trademarks being owned. The multi-period excess earnings method considers the present value of net cash flows expected to be generated by customer relationships, by excluding any cashflows related to contributory assets.
Inventories	Comparative sales method and replacement cost method: The comparative sales method estimates fair value from the actual or expected selling prices of inventory in the normal course of business less the cost of disposal, the holding costs. The replacement cost approach follows the general methodology that raw materials should be valued at current replacement cost for a market participant.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

a. Summary of post acquisition loss of the acquired entities included in the consolidated statement of profit and loss for the year ended 31 March 2018

Particulars	31 March 2018
Revenue	4,776.8
Net loss considered in the consolidated statement of profit and loss	526.1

b. The consolidated revenue and consolidated net profit of the Group for the current reporting period had the acquisition taken place at the begining of the accounting period.

Particulars	31 March 2018
Consolidated revenue from operations	165,358.4
Consolidated profit for the year	24,199.3

c. For acquired receivables:

Particulars	31 March 2018
The gross contractual amounts receivable	622.9
The best estimate at the acquisition date of the contractual cash flows not expected to be collected	11.3
(provision)	
Net value	611.6

39. During the previous year, Auro Vaccines, LLC, a subsidiary of Aurobindo Pharma USA Inc., entered into an agreement to purchase certain assets of Great Elm for an initial consideration of ₹ 194.6. The acquisition is subject to certain conditions specified in the agreement which among others includes settlement of a legal dispute by the shareholders of Great Elm. Subject to the same, the assets received as a result of the acquisition have been recognised in the consolidated balance sheet as at 31 March 2017. There are no binding commitments to invest additional cash or consideration in connection with the acquisition. The details of assets acquired and included in the consolidated balance sheet are as under:

Particulars	
a) Property, Plant and Equipment - freehold building	97.3
b) Other current assets	97.3

40. RELATED PARTY DISCLOSURES

i) Names of related parties and description of relationship

a) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurobindo Pharma (Pty) Limited, South Africa)

Eugia Pharma Specialities Limited, India

Tergene Biotech Private Limited, India

Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics Limited, India)

(b) Enterprises over which key management personnel or their relatives exercise significant influence

Pravesha Industries Private Limited, India Sri Sai Packaging, India (Partnership firm) Trident Chemphar Limited, India Auropro Soft Systems Private Limited, India Axis Clinicals Limited, India Pranit Projects Private Limited, India SGD Pharma India Limited (formerly Cogent Glass Limited), India Orem Access Bio Inc, India Veritaz Healthcare Limited, India Alex Merchant PTE. LTD, Singapore Trident Petrochemicals DMCC, Dubai Axis Clinicals LLC, USA Alex Merchant DMCC, Dubai Crest Cellulose Private Limited, India

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

East Pharma Technologies, India (Partnership firm) Axis Clinicals Latina SA DE CV, Mexico Viwyn Pharma Private limited, India Gelcaps Industries, India

c) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director
Dr. M. Sivakumaran, Whole-time Director
Mr. M. Madan Mohan Reddy, Whole-time Director
Mr. P. Sarath Chandra Reddy, Whole-time Director (from 01 June 2016)
Mr. N. Govindarajan, Managing Director
Mr. Santhanam Subramanian, Chief Financial Officer
Mr. A. Mohan Rami Reddy, Company Secretary (upto 31 May 2016)
Mr. B. Adi Reddy, Company Secretary (ueto 31 May 2016)
Mr. K. Ragunathan, Independent Director
Mr. M. Sitarama Murty, Independent Director
Mr. D. Rajagopala Reddy, Independent Director
Mr. Rangaswamy Rathakrishnan Iyer, Independent Director (Upto 09 December 2017)
Mr. P.V.Ramprasad Reddy, Non Executive promoter director
Mrs. Savitha Mahajan, Independent Director (w.e.f. 16 December 2017)

d) Relatives to Key Managerial Personnel

Mr. Vishnu M Sriram (Son-in-law of Dr. M. Sivakumaran, Whole-time Director)

ii) Transactions with related parties

a. Transactions with joint ventures

ticulars	31 March 2018	31 March 2017
pans given and repayment thereof		-
Raidurgam Developers Limited		
Receipt/ converted into optionally convertible debentures against loan and interest	1,071.8	-
Interest accrued	8.3	-
Loan given	1,065.2	-
Balance receivable	1.8	-
Other transactions		
Sale of land	1,681.2	-
Reimbursement of expenses	152.1	-
Equity allotment	31.0	-
Investment in optionally convertible debentures	710.9	-
Novagen Pharma (Pty) Limited, South Africa		
Sale of goods	209.7	274.9
Eugia Pharma Specialities Ltd, India		
Sale of goods	10.2	0.5
Purchase of goods	0.5	
Reimbursement of Expenses Received	3.4	2.4
Tergene Biotech Pvt. Ltd, India		
Equity allotment	41.1	
Investment in 10.5% Cumulative Redeemable Preference shares	5.0	

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Transactions with enterprises over which key management personnel or their relatives exercise significant influence		
	31 March 2018	31 March 20
Pravesha Industries Private Limited, India		
Sale of goods	0.3	(
Purchase of goods	2,280.4	1,925
Rent and electricity charges received	-	(
Sri Sai Packaging, India		
Sale of goods	0.5	(
Purchase of goods	211.2	194
Axis Clinicals Limited, India		
Purchase of services	830.7	55
Axis Clinicals LLC, USA		
Purchase of services	76.0	42
Axis Clinicals Latina SA DE CV, Mexico		
Purchase of services	11.9	
Trident Chemphar Limited, India		
Sale of goods	-	2
Purchase of goods	761.4	77
Auropro Soft Systems Private Limited, India		
Purchase of services	0.2	
Pranit Packaging Private Limited, India		
Purchase of goods	199.1	16
Sale of goods	-	
Pranit Projects Private Limited, India	_	
Purchase of services (civil services)	-	
SGD Pharma India Limited (formerly Cogent Glass Limited), India		-
Purchase of goods	973.8	70
Orem Access Bio Inc, India		
Purchase of goods	201.1	20-
Veritaz Healthcare Limited, India		
Sale of goods	127.3	9
Rent received	0.3	
Alex Merchants DMCC, Dubai		
Purchase of goods	677.6	55
Crest Cellulose Private Limited, India		
Purchase of goods	255.9	5
Sale of Services	0.1	
East Pharma Technologies, India		
Purchase of goods	57.0	
Viwyn Pharma Private limited, India		
Purchase of services	58.1	
Reimbursement of expenses received	0.7	
Gelcaps Industries, India		
• *	130.0	

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Particulars	31 March 2018	31 March 2017
c. Transactions with key managerial personnel		
Mr. K Nityananda Reddy		
Managerial remuneration	15.1	15.0
Rent expense	2.4	2.4
Dr. M Sivakumaran		
Managerial remuneration	15.1	15.0
Mr. M Madan Mohan Reddy		
Managerial remuneration	26.7	26.5
Mr. P Sarath Chandra Reddy		
Managerial remuneration	8.3	6.9
Director sitting fees	-	0.1
Mr. Vishnu M Sriram		
Remuneration	5.4	4.8
Mr. N Govindarajan		
Managerial remuneration	146.3	124.3
Mr. Santhanam Subramanian		
Remuneration	14.3	10.9
Mr. A. Mohan Rami Reddy		
Remuneration	-	0.6
Mr. B. Adi Reddy		
Remuneration	3.3	2.5
Mr. P.V. Ramprasad Reddy		
Director sitting fees	0.2	0.2
Mr. K. Ragunathan, Independent Director		
Director sitting fees	1.0	0.4
Mr. M. Sitarama Murty, Independent Director		
Director sitting fees	1.1	0.5
Mr. D.Rajagopala Reddy, Independent Director (upto 09 February 2017)		
Director sitting fees	-	0.4
Dr.(Mrs.) Avnit Bimal Singh, Independent Director		
Director sitting fees	0.6	0.3
Mr.RangaswamyRathakrishnanlyer,IndependentDirector(from09February201	7)	
Director sitting fees	0.6	0.
Mrs. Savitha Mahajan, Independent Director		
Director sitting fees	0.1	

Note:

i) Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.

ii) All transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances for trade receivable, trade payable and other payables are unsecured, interest free and settlement occurs in cash. The Group has not recorded any impairment of balances relating to amounts owed by related parties during the year ended 31 March 2018 (31 March 2017). Provisions for bad and doubtful debts will be made on an aggregate basis i.e; not specific to party. The assessment is undertaken each financial year through evaluating the financial position of the related party and the market in which the related party operates.

for the year ended 31 March 2018

articulars	31 March 2018	31 March 201
Novagen Pharma (Pty) Limited, South Africa		
Balance receivable	59.9	74.
Raidurgam Developers Limited, India		/+.
Balance receivable	152.1	
Eugia Pharma Specialities Ltd, India	102.11	
Balance receivable	4.8	
		-
. Enterprises over which key management personnel or their relatives exerci	se significant influence	9
articulars	31 March 2018	31 March 20
Pravesha Industries Private Limited, India		
Balance receivable	-	0
Balance payable	486.0	77
Sri Sai Packaging, India		
Balance payable	15.6	0
Axis Clinicals Limited, India		
Balance payable	77.1	62
Trident Chemphar Limited, India		
Balance payable	155.4	204
Pranit Packaging Private Limited, India		
Balance receivable	0.8	
Balance payable	8.3	2
SGD Pharma India Limited (formerly Cogent Glass Limited), India		
Balance payable	305.9	132
Veritaz Healthcare Limited, India		
Balance receivable	36.5	53
Alex Merchants DMCC, Dubai		
Balance receivable	38.2	173
East Pharma Technologies, India		
Balance payable	6.8	2
Crest Cellulose Private Limited, India		
Balance receivable	0.1	
Balance payable	35.9	16
Orem Access Bio Inc, India		
Balance payable	39.6	
Viwyn Pharma Private limited		
Balance receivable	2.0	
Gelcaps Industries		
Balance receivable Balance Payable	<u> </u>	

c. Key managerial personnel Particulars Mr.N Govindarajan Balance payable 100.0

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

- **41.** Details of advances due from private companies in which Parent Company's director is a director. Pranit Packaging Private Limited, India ₹0.8 (31 March 2017: ₹Nil)
- 42. i) Details of trade receivables due from private companies in which Parent Company's director is a director.
 Pravesha Industries Private Limited, India ₹Nil (31 March 2017: ₹ 0.1)
 - ii) Details of trade receivables due from partnership firm in which Parent Company's director is a partner. Sri Sai Packaging, India ₹Nil (31 March 2017: ₹0.0)
- 43. The amount of research and development expenditure charged to consolidated statement of profit and loss is ₹ 6,664.6 (31 March 2017: ₹ 5,427.2)

44. INTEREST IN JOINT VENTURES

The Group has investment in two entities, Eugia Pharma Specialities Limited and Tergene Biotech Private Limited with a voting share of 67.82% and 76.84% respectively. As a result of a contractual arrangement with the third party partner, the Group has a majority representation on the entity's board of directors. However, the approval of directors represented by the third party partner are required for all major decisions with regard to operating and financing activities. As the Group does not control these entities and the other partners have significant participating rights, the Group's interest in these entities has been accounted under the equity method of accounting under Ind AS 111 - Joint Arrangements.

The group has investment in one entity, Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd) with a voting share of 40%. As a result of a contractual arrangement with the third party partner, the Group does not have majority/equal representation on the entity's Board of Directors. However, the approval of directors represented by both the Group and the third party partner are required for all major decisions with regard to operating and financing activities. As the Group jointly controls the entity with the third party partner, the Group's interest in this entity has been accounted under the equity method of accounting under Ind AS 111 - Joint Arrangements.

The Group has interest in the following joint ventures;

	31 March 2018	31 March 2017
Novagen Pharma Pty Ltd, South Africa	50.00%	50.00%
Eugia Pharma Specialities Limited, India	67.82%	67.82%
Tergene Biotech Private Limited, India	76.84%	60.00%
Raidurgam Developers Limited (formerly Aurobindo Antibiotics Limited), India *	40.00%	-

*Joint Venture w.e.f. 01 December 2017

These joint ventures are engaged in distribution of pharmaceuticals products except, Raidurgam Developers Limited, which is engaged in construction and infrastructure development. The Group's interest in these joint ventures is accounted using the equity method in the consolidated financial statements. Summarised financial information of the joint ventures, based on its Ind AS financial statements, and reconciliation with the carrying amount of the investment in consolidated financial statements are set out below:

(a) Novagen Pharma Pty Ltd, South Africa

(i). Summarised balance sheet

	31 March 2018	31 March 2017
Current Assets	587.3	642.9
Non - Current Assets	185.2	167.3
	772.5	810.2
Current liabilities	209.0	152.1
Equity	563.5	658.1
	772.5	810.2

(ii). Details of other financial information

	31 March 2018	31 March 2017
Cash and cash equivalents	111.7	110.1



for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(iii). Summarised statement of profit and loss

	31 March 2018	31 March 2017
Revenue	1,331.2	1,205.3
Interest income	10.7	2.9
Interest expenses	1.0	1.3
Depreciation	10.3	8.5
Profit before tax	209.7	136.8
Income tax expense	(59.1)	(38.4)
Profit for the year	150.6	98.5
Total comprehensive income for the year	150.6	98.5

The Group's Share of Dividend received

161.3

The Group's share of profits for the year ended 31 March 2018 and 31 March 2017 was ₹ 89.5 and ₹ 59.4 respectively. The carrying value of the Group's investment in equity shares in the joint venture as at 31 March 2018 and 31 March 2017 was ₹ 320.9 and ₹ 394.7 respectively.

(b) Eugia Pharma Specialities Limited, India

(i). Summarised balance sheet

	31 March 2018	31 March 2017
Current Assets	117.7	597.7
Non - Current Assets	5,174.3	3,541.4
	5,292.0	4,139.1
Current liabilities	270.5	166.1
Non - Current liabilities	2,122.4	1,064.8
Equity	2,899.1	2,908.2
	5.292.0	4,139,1

(ii). Details of other financial information

	31 March 2018	31 March 2017
Cash and cash equivalents	56.6	440.5
Non-current financial liabilities	2,118.3	1,062.3
Current financial liabilities	102.4	78.3
Capital Commitments (Group's Share)	443.2	67.1

(iii). Summarised statement of profit and loss

	31 March 2018	31 March 2017
Interest income	5.1	-
Profit before tax	(7.9)	(12.1)
Income tax expense	(1.3)	-
Profit for the year	(9.2)	(12.1)
Total comprehensive income for the year	(9.2)	(12.1)

The Group's Share of loss for the year ended 31 March 2018 and 31 March 2017 was ₹ 15.8 and ₹ 7.9 respectively. The carrying value of the Group's investment in equity shares in joint venture as at 31 March 2018 and 31 March 2017 was ₹ 1,956.7 and ₹ 1,972.4 respectively.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(c) Tergene Biotech Pvt.Ltd, India

(i). Summarised	balance sheet
-----------------	---------------

	31 March 2018	31 March 2017
Current Assets	7.3	2.2
Non - Current Assets	43.7	51.1
	51.0	53.3
Current liabilities	22.1	12.5
Non - Current liabilities	97.3	94.3
Equity	(68.4)	(53.5)
	51.0	53.3

(ii). Details of other financial information

	31 March 2018	31 March 2017
Cash and cash equivalents	2.2	0.4
Non-current financial liabilities	96.5	92.4
Current financial liabilities	17.9	9.0

(iii). Summarised statement of profit and loss

	31 March 2018	31 March 2017
Revenue	-	0.1
Interest income	-	-
Interest expenses	8.9	6.3
Depreciation	4.6	3.7
Profit before tax	(55.7)	(48.3)
Profit for the year	(55.7)	(48.3)
Total comprehensive income for the year	(56.1)	(49.4)

The Group's share of loss for the year ended 31 March 2018 and 31 March 2017 was ₹ 41.1 and ₹ 1.3 respectively. The carrying value of the Group's investment in equity shares in the joint venture as at 31 March 2018 and 31 March 2017 was ₹ Nil and ₹ Nil respectively and investment in Preference shares in the joint venture as at 31 March 2018 and 31 March 2017 was ₹ 95.0 and ₹ 90.0 respectively.

(d) Raidurgam Developers Limited (formerly Aurobindo Antibiotics Limited), India (i). Summarised balance sheet

	31 March 2018
Current Assets	49.6
Non - Current Assets	2,076.4
	2,126.0
Current liabilities	260.1
Non - Current liabilities	1,777.3
Equity	88.6
	2,126.0

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

(ii). Details of other financial information

	31 March 2018
Cash and cash equivalents	2.4
Non -current financial liabilities	1,777.3
Current financial liabilities	245.6

(iii). Summarised statement of profit and loss

	31 March 2018
Interest expenses	1.1
Profit before tax	(3.1)
Total comprehensive income for the period	(3.1)

The Group's share of loss for the year ended 31 March 2018 is ₹ 1.2. The carrying value of the Group's investment in equity shares in the joint venture as at 31 March 2018 is ₹ 30.3 and investment in optionally convertible debentures in the joint venture is ₹ 710.9.

45. HEDGING ACTIVITIES AND DERIVATIVES - DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS

The Group uses foreign currency denominated borrowings and foreign exchange forward contracts to manage some of its transaction exposures. The foreign exchange forward contracts are not designated as cash flow hedges and are entered into for periods consistent with foreign currency exposure of the underlying transactions, generally from one week to twelve months.

	Notes		Carrying amount	mount			Fair value		
Particulars		FVTPL	Other financial assets - Amortised cost	Other financial liabilities - Amortised cost	Total carrying amount	Level 1	Level 2	Level 3	Total
Financial assets measured at fair									
Non-current investments in others*	6(A)(ii)	1.2	1	1	1.2		1	1.2	1.2
Non-current investments in government securities*	6(A)(ii)	0.2	1		0.2		1	0.2	0.2
Current investments*	6(B)	0.2	1	1	0.2	0.2	1	1	0.2
Financial asset - Receivable from bank*^	9(B)	7,877.5	•	•	7,877.5	•	•	7,877.5	7,877.5
Derivative assets	9(B)	1	1	•	1	1	1	1	
		7,879.1	•	•	7,879.1	0.2	•	7,878.9	7,879.1
Financial assets not measured at fair value									
Non-current investments in preference	6(A)(ii)	•	95.0	•	95.0				
shares									
Trade receivables	7	'	30,843.6	1	30,843.6				
Loans	ω	'	156.3	1	156.3				
Cash and cash equivalents	14	1	12,616.2	1	12,616.2				
Other financial assets	ത	1	939.1	1	939.1				
		•	44,650.2	•	44,650.2				
Financial liabilities measured at fair value									
Derivative liabilities	20	23.3	1	1	23.3	1	23.3	1	23.3
		23.3	1		23.3		23.3		23.3

47,699.4 26,274.4 2,202.7 76,176.5

47,699.4 26,274.4 2,202.7 76,176.5

Borrowings Trade payables Other financial liabilities

NOTES TO STANDALONE FINANCIAL STATEMENTS

for the year ended 31 March 2018

S	
Ĕ	
ΞŪ	
7	
F	
TATE	
7	
F	
in	
IAL	
2	
Ζ	
4	
Ζ	
11	
ш	(
Z	
0	(
_	
◄	
Ζ	
4	(
H	1
ST	
Ο	
TO STANDALONE FINANC	
П С	
벁	
5	1
Y	
Z	4

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

A. Accounting classifications and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

31 March 2017

	Notes		Carrying amount	amount			Fair value	er	
Particulars	I	FVTPL	Other financial assets - Amortised cost	Other financial liabilities - Amortised cost	Total carrying amount	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value									
Non-current investments in others*	6(A)(ii)	1.2	1	1	1.2			1.2	1.2
Non-current investments in government securities*	6(A)(ii)	0.2			0.2	 1		0.2	0.2
Current investments*	6(B)	0.2	1	1	0.2	0.2		1	0.2
Financial asset - Receivable from bank*^	9(B)	7,388.5			7,388.5		.	7,388.5	7,388.5
Derivative assets	9(B)	94.8		·	94.8	.	94.8		94.8
		7,484.9	•	•	7,484.9	0.2	94.8	7,389.9	7484.9
Financial assets not measured at fair value									
Non-current investments in preference	6(A)(ii)	1	90.0		90.06				
shares									
Trade receivables	7	1	27,653.3	1	27,653.3				
Loans	ω		165.9	1	165.9				
Cash and cash equivalents	14	1	5,134.8	1	5,134.8				
Other financial assets	6	1	844.9	1	844.9				
		•	33,888.9	•	33,888.9				
Financial liabilities measured at fair value									
Derivative liabilities	20			1					1
		T		1	1	1	1	1	
Financial liabilities not measured at fair value									
Borrowings	17 & 20	1		33,641.4	33,641.4				
Trade payables	19	1		21,547.0	21,547.0				
Other financial liabilities	20	1		1,893.6	1,893.6				
			I	57,082.0	57,082.0				

payments to the bank and the underlying credit quality. As such, the requisite disclosures on assumptions (e.g. discount rates and anticipated credit losses) and other inputs *^ The Group values the accounts receivable subject to a securitization agreement (see note 9) that have been contractually sold but not yet funded by the bank as "Level and carrying values for such assets is not material as at 31 March 2018 and 31 March 2017 respectively given the short-term duration of the expected term of customer 3" within the fair value hierarchy, since the Group uses discounted cash flow models, which are considered unobservable inputs. The difference between the fair values "These are for operational purposes and the Group estimates that the fair value of these investments are not materially different as compared to their cost. are not considered significant.

Company Overview

Statutory Reports

Financial Statements

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

B. Measurement of fair values

i. Valuation techinque and significant unobservable inputs

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the consolidated balance sheet, as well as the significant unobservable inputs used:

Туре	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value
Derivative instruments	Forward pricing: The fair value is determined using quoted forward exchange rates at the reporting date and present value calculations based on high credit quality yield curves in the respective currency.	Not applicable	Not applicable

ii. Transfer between Level 1 and 2

There have been no transfers from Level 2 to Level 1 or vice-versa in 2017-18 and no transfers in either direction in 2016-17.

C. Risk management framework

The Parent Company's board of directors has overall responsibility for the establishment and oversight of the Parent Company's risk management framework. The board of directors has established the Risk Management Committee, which is responsible for developing and monitoring the Parent Company's risk management policies. The committee reports to the board of directors on its activities.

The Parent Company's risk management policies are estabilished to identify and analyse the risks being faced by the Parent Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the parent company's activities. The Parent Company, through its training and managment standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Parent Company's audit committee oversees how management monitors compliance with the Parent Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Parent company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the result of which are reported to the audit committee.

The Group is exposed primarily to credit risk, liquidity risk and market risk (including currency risk, interest rate risk and other price risk). The Group uses derivative financial instruments such as forwards to minimise any adverse effect on its financial performance.

i. Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk encompasses of both, the direct risk of default and the risk of deterioration of creditworthiness as well as concentration of risks. Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom the credit has been granted after obtaining necessary approvals for credit. Financial instruments that are subject to concentrations of credit risk principally consist of trade receivables, investments, derivative financial instruments, cash and cash equivalents, loans and other financial assets. The Group establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

Trade receivables

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, the Management also evaluates the factors that may influence the credit risk of its customer base, including the default risk and country in which the customers operate. The Management has established a credit policy under which each new customer is

Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

analysed individually for creditworthiness before the Group's standard payment and delivery terms and conditions are offered. The Group review includes external ratings, if available, financial statements, credit agency information, industry information and in some case bank references. Sales limits are established for each customer and reviewed quarterly.

The Group's receivables turnover is quick and historically, there was no significant default on account of trade and other receivables. An impairment analysis is performed at each reporting date on an individual basis for major clients. In addition, a large number of minor receivables are grouped into homogenous groups and assessed for impairment collectively. The Group assesses at each reporting date whether a financial asset or a group of financial assets is impaired. Expected credit losses are measured at an amount equal to the 12 months expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. The Group has used a practical expedient by computing the expected credit loss experience and is adjusted for forward looking information. The maximum exposure to credit risk at the reporting date is the carrying value of trade and other receivables. The Group does not hold collateral as security. The Group evaluates the concentration of risk with respect to trade receivables as low, as its customers are located in several jurisdictions and operate in largely independent markets.

Other financial assets

The Group maintains exposure in cash and cash equivalents, other receivables from bank and derivative instruments with financial institutions.

The Group's maximum exposure to credit risk as at 31 March 2018 and 31 March 2017 is the carrying value of each class of financial assets.

ii. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. The following are the remaining contractual maturities of financial liabilities at reporting date:

As at 31 March 2018	Carrying		Contractual	cash flows	
	amount	< 12 months	1 to 5 years	> 5 years	Total
Non-derivative financial liabilities					
Non-current borrowings	7,116.4	2,934.0	4,253.6	-	7,187.6
Current borrowings	40,313.4	40,510.9	-	-	40,510.9
Finance lease obligation	269.6	58.0	231.9	-	289.9
Trade payables	26,274.4	26,274.4	-	-	26,274.4
Other financial liabilities	2,202.7	2,202.7	-	-	2,202.7
Derivative financial liabilities					
Foreign exchange forward contracts	23.3	23.3	-	-	23.3

As at 31 March 2017	Carrying amount		Contractual ca	sh flows	
	-	< 12 months	1 to 5 years	> 5 years	Total
Non-derivative financial liabilities					
Non-current borrowings	4,614.2	2,845.4	1,817.5	-	4,662.9
Current borrowings	29,027.2	29,077.0	-	-	29,077.0
Finance lease obligation	-	-	-	-	-
Trade payables	21,547.0	21,547.0	-	-	21,547.0
Other financial liabilities	1,893.6	1,893.6	-	-	1,893.6
Derivative financial liabilities					
Foreign exchange forward contracts	-	-	-	-	-

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

iii. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Such changes in the values of financial instruments may result from changes in the foreign currency exchange rates, interest rates, credit, liquidity and other market changes. The Group's exposure to market risk is primarily on account of foreign currency exchange rate risk.

a) Foreign Currency risk:

The fluctuation in foreign currency exchange rates may have potential impact on the consolidated statement of profit or loss, where any transaction references more than one currency or where assets / liabilities are denominated in a currency other than the respective functional currency of each entity. The Group is subject to foreign exchange risk primarily due to its foreign currency revenues, expenses and borrowings. Considering the countries and economic environment in which the Company operates, its operations are subject to risks arising from fluctuations in exchange rates in those countries. The risks primarily relate to fluctuations in US Dollar, Euro and GBP against the functional currency of the Company. The Group, as per its risk management policy, uses derivative instruments primarily to hedge foreign exchange. The Group has a treasury team which evaluates the impact of foreign exchange rate fluctuations by assessing its exposure to exchange rate risks and advises the Management of any material adverse effect on the Group. It hedges a part of these risks by using derivative financial instruments in line with its risk management policies. The information on foreign exchange risk from derivative instruments and non derivative instruments is as follows:

The summary of quantitative data about the Group's exposure to currency risk (based on the notional amounts) as reported to the management is as follows:

Particulars	USD	Euro	GBP	Others	Total
Financial assets					
Trade receivables	10,282.6	837.5	-	119.2	11,239.3
Cash and cash equivalents	1,290.8	399.6	295.2	5.4	1,991.0
Loans	0.6	0.2	-	-	0.8
Other financial assets	1.3	-	-	-	1.3
Total	11,575.3	1,237.3	295.2	124.6	13,232.4
Less:					
Foreign exchange forward contracts	(2,038.3)	(767.7)	(645.9)	(288.8)	(3,740.7)
Net exposure in financial assets	9,537.0	469.6	(350.7)	(164.2)	9,491.7
Financial liabilities					
Borrowings	33,017.3	3,136.9	1,074.1	-	37,228.3
Interest accrued but not due	10.7	-	-	-	10.7
Trade payables (including capital	6,473.9	411.6	25.8	-	6,911.3
creditors)					
Total	39,501.9	3,548.5	1,099.9	-	44,150.3
Less:					
Foreign exchange forward contracts	(195.5)	(242.4)	(184.6)	-	(622.5)
Net exposure in financial liabilities	39,306.4	3,306.1	915.3	-	43,527.8
Net exposure in respect of	(29,769.4)	(2,836.5)	(1,266.0)	(164.2)	(34,036.1)
recognised assets/(liabilities)					

As at 31 March 2018

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

Net exposure in financial liabilities	25,593.6	5,616.7	673.2	21.5	32,553.6
Foreign exchange forward contracts	(324.3)	-	-	-	(324.3)
Less:					
Total	25,917.9	5,616.7	673.2	21.5	32,229.3
creditors)					
Trade payables (including capital	3,911.0	98.5	1.7	21.5	4,032.7
Interest accrued but not due	20.5	-	-		20.5
Borrowings	21,986.4	5,518.2	671.5	-	28,176.1
Financial liabilities	,				
Net exposure in financial assets	9,834.3	701.1	(602.0)	40.6	9,974.0
Foreign exchange forward contracts	(586.9)	(55.8)	(606.8)	-	(1,249.5
Less:					
Total	10,421.2	756.9	4.8	40.6	11,223.5
Other financial assets	3.4	0.2	-	-	3.6
Loans	-	0.2	-	-	0.2
Cash and cash equivalents	258.4	30.4	4.8	7.5	301.1
Trade receivables	10,159.4	726.1	-	33.1	10,918.6
Financial assets					
Particulars	USD	Euro	GBP	Others	Total

Sensitivity analysis:

A reasonably possible strengthening (weakening) of the Indian Rupee against US dollars at March 31 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

		Profit o	r (loss)	
Particulars	31 March	2018	31 March	2017
	Strengthening	Weakening	Strengthening	Weakening
USD (5% movement)	(1,488.5)	1,488.5	(788.0)	788.0
Euro (5% movement)	(141.8)	141.8	(245.8)	245.8
GBP (5% movement)	(63.3)	63.3	(63.8)	63.8
Others (5% movement)	(8.2)	8.2	1.0	(1.0)

b) interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rates. The Group's exposure to risk of change in market interest rates because it borrows funds at both fixed and floating interest rates. The Group manages its interest rate risk by having a balances portfolio of fixed and variable rate loans and borrowings. As the Group has no significant interest bearing assets, the income and operating cash flows are substantially independent of changes in market interest rates.

Particulars	31 March 2018	31 March 2017
Variable rate borrowings including current maturities	47,429.8	33,641.4
Total borrowings	47,429.8	33,641.4

Sensitivity analysis:

		Impact on pro	ofit and loss	
Particulars		31 March 2018		31 March 2017
	0.5% increase	0.5% decrease	0.5% increase	0.5% decrease
Variable rate instruments	(245.9)	245.9	(229.1)	229.1

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

c) commodity risk:

Exposure to market risk with respect to commodity prices primarily arises from the Group's purchase of active pharmaceutical ingredients and other raw material components for its products. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Group's raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Group's business are generally more volatile. Cost of raw materials forms the largest portion of the Group's cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of 31 March 2018, the Group had not entered into any derivative contracts to hedge exposure to fluctuations in commodity prices.

47. CAPITAL MANAGEMENT

For the purpose of the Group's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Group's capital management is to maximise the shareholder value.

48. ADDITIONAL STATUTORY INFORMATION IN RESPECT OF THE COMPONENTS OF APL AND ITS CONSOLIDATED ENTITIES

		31 Marc	h 2018			31 March	n 2017	
Name of the entity	Net Assets, i.e., t minus total li		Share in pro	it / (loss)	Net Assets, i.e., t minus total lia		Share in profi	t / (loss)
	As % of consolidated net assets	Amount	As % of consolidated profit / (loss)	Amount	As % of consolidated net assets	Amount	As % of consolidated profit / (loss)	Amount
Parent - Aurobindo Pharma Limited	85.45 %	99,825.8	74.81 %	18,127.7	90.00 %	84,361.8	74.15 %	17,067.6
Subsidiaries - Indian								
APL Research Centre Limited	0.10 %	119.5	-	-	0.13 %	119.6	0.00 %	0.0
APL Health Care Limited	1.09 %	1,277.5	(1.13)%	(273.4)	1.10 %	1,029.7	(0.92)%	(212.2)
Auronext Pharma Private Limited	0.33 %	388.3	(0.14)%	(33.8)	0.45 %	423.1	(0.58)%	(134.3)
Auro Peptides Limited	(0.21)%	(242.8)	(0.58)%	(139.9)	(0.11)%	(102.0)	(0.43)%	(99.0)
Aurobindo Antibiotics Limited	-	-	0.00 %	(0.3)	0.00 %	0.7	-	-
(converted into a joint venture,								
Raidurgam Developers Limited w.e.f.								
30 November 2017)								
Curepro Parenterals Limited	1.70 %	1,991.1	-	-	2.12 %	1,991.1	0.00 %	(0.4)
Hyacinths Pharma Private Limited	0.13 %	147.7	0.00 %	0.0	0.11 %	103.7	0.00 %	(0.1)
Silicon Life Sciences Private Limited	0.09 %	105.3	(0.02)%	(5.9)	0.12 %	110.8	(0.95)%	(218.8)
AuroZymes Limited	0.00 %	(0.4)	0.00 %	(0.1)	0.00 %	(0.3)	0.00 %	(0.2)
Auro Pharma India Private Limited	0.00 %	1.0	0.00 %	0.0	-	-	-	-
Subsidiaries - Foreign								
APL Pharma Thai Limited	0.14 %	162.5	0.00 %	0.4	0.16 %	146.3	(0.05)%	(11.8)
Aurobindo Pharma Industria	1.16 %	1,356.6	1.70 %	412.9	1.08 %	1,008.4	1.08 %	249.6
Farmaceutica Ltda								
Aurobindo Pharma Produtos	0.21 %	240.9	0.09 %	20.7	0.25 %	233.6	0.56 %	127.8
Farmaceuticos Ltda								
All Pharma (Shanghai) Trading	0.15 %	179.4	0.04 %	9.0	0.16 %	159.1	0.06 %	12.9
Company Limited								
Helix Healthcare B.V.	9.52 %	11,124.5	(0.77)%	(185.8)	9.77 %	9,166.3	(0.35)%	(80.9)
Agile Pharma B.V.	5.26 %	6,147.5	1.83 %	443.9	5.19 %	4,863.3	2.59 %	597.2
Auro Pharma Inc.	0.71 %	826.2	1.59 %	385.7	0.45 %	419.4	0.82 %	188.8
Aurobindo Pharma (Pty) Limited	0.68 %	799.1	0.80 %	193.2	0.54 %	506.2	0.24 %	55.9
Auro Healthcare (Nigeria) Limited	0.00 %	0.0	(0.01)%	(1.8)	0.00 %	2.1	0.00 %	0.3
Aurobindo Pharma Japan K.K.	0.11 %	123.5	(0.03)%	(6.3)	0.13 %	122.7	0.09 %	20.2
Laboratorios Aurobindo, S.L.	0.10 %	114.8	0.18 %	43.3	0.06 %	58.7	0.03 %	6.8
Aurobindo Pharma (Italia) S.r.I	0.08 %	89.7	(0.38)%	(92.1)	0.07 %	67.2	(0.77)%	(176.2)
Aurobindo Pharma (Portugal)	0.06 %	67.2	(0.02)%	(4.5)	0.07 %	61.8	(0.04)%	(9.2)
Unipessoal LDA			· · /	. ,			· · · ·	, ,
Aurobindo Pharma GmbH	0.38 %	449.3	0.35 %	84.9	0.33 %	307.2	0.14 %	32.3
Aurobindo ILAC Sanayi ve Ticaret	-	-	(0.26)%	(63.3)	0.07 %	62.2	(0.02)%	(4.5)
Limited Sirketi			(, / 0	()			(), 0	()
Aurobindo Pharma (Romania) s.r.l	0.12 %	143.6	(0.07)%	(17.7)	0.15 %	143.6	(0.38)%	(87.0)
Aurovida Farmaceutica S.A. de C.V.	0.35 %	411.4	0.00 %	0.8	0.43 %	398.7	(0.13)%	(30.6)
Aurobindo Pharma Colombia S.A.S.	0.12 %	144.6	0.34 %	81.3	0.06 %	53.9	0.11 %	25.0
Aurovitas, Unipessoal LDA	0.21 %	241.6	0.47 %	113.9	0.11 %	102.4	0.15 %	34.0
Pharmacin B.V. (formerly Aurex B.V.)	0.01 %	16.0	0.01 %	2.3	0.01 %	11.6	0.00 %	1.1

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

		31 Marc	h 2018			31 March	n 2017	
	Net Assets, i.e., minus total I		Share in prof	iit / (loss)	Net Assets, i.e., minus total li		Share in profi	t / (loss)
Name of the entity	As % of consolidated net assets	Amount	As % of consolidated profit / (loss)	Amount	As % of consolidated net assets	Amount	As % of consolidated profit / (loss)	Amount
Aurobindo Pharma USA Inc.	7.88 %	9,203.8	6.19 %	1,499.8	8.46 %	7,928.3	4.21 %	969.8
Aurolife Pharma LLC	8.76 %	10,228.0	4.60 %	1,115.4	9.56 %	8,966.8	8.03 %	1,847.3
Auromedics Pharma LLC	0.80 %	937.9	0.97 %	234.5	0.51 %	473.5	0.25 %	57.5
Auro Health LLC	(0.48)%	(561.7)	0.60 %	145.3	(0.75)%	(705.2)	(0.68)%	(156.9)
Natrol LLC	2.26 %	2,639.0	2.59 %	628.3	1.72 %	1,626.1	4.13 %	949.5
Auro AR LLC	0.01 %	6.5	-	-	0.01 %	6.5	-	-
Aurobindo Pharma USA LLC	-	-	-	-	-	-	-	-
Auro Vaccines LLC	0.02 %	26.2	(0.02)%	(4.2)	0.03 %	30.3	(0.01)%	(2.2)
AuroLogistics LLC	0.03 %	32.6	0.00 %	0.0	-	-	-	-
Acrotech Biopharma LLC	0.03 %	32.6	-	-	-	-	-	-
Aurex B.V. (formerly Pharmacin B.V.)	0.16 %	184.8	0.19 %	46.9	0.12 %	115.3	0.12 %	27.7
Milpharm Limited	0.96 %	1,119.1	0.81 %	196.5	0.85 %	795.0	0.38 %	87.3
Aurobindo Pharma (Malta) Limited	0.56 %	649.8	0.00 %	(1.1)	0.60 %	558.2	(0.01)%	(2.3)
APL Swift Services (Malta) Limited	0.31 %	359.7	0.29 %	70.7	0.26 %	243.4	0.26 %	60.0
Arrow Generiques SAS	2.74 %	3,198.0	4.33 %	1,048.9	1.90 %	1,777.7	0.25 %	56.7
1980 Puren Pharma GmbH (formerly	0.00 %	4.3	0.00 %	0.0	0.00 %	3.7	0.00 %	0.1
Actavis Management GmbH), Germany								
Puren Pharma GmbH (formerlyActavis	1.40 %	1,640.0	3.43 %	831.3	1.37 %	1,285.5	2.97 %	682.6
Deutschland GmbH & Co., KG,								
Germany)								
Aurovitas Spain SA	0.74 %	862.1	0.79 %	190.8	0.60 %	563.7	(0.27)%	(61.7)
Aurovitas Pharma Polska	0.10 %	113.3	0.01 %	1.8	0.02 %	16.4	-	-
Aurobindo Pharma B.V. (formerly Actavis B.V.)	0.34 %	393.7	0.58 %	140.3	0.22 %	208.6	0.74 %	171.1
Generis Farmaceutica S.A.	6.58 %	7,681.4	(2.17)%	(526.0)	-	-	-	
Mer Medicamentos, Lda	0.00 %	1.8	0.00 %	(0.1)	-		-	
Generis Phar, Unipessoal Lda	0.00 %	0.2	0.00 %	0.0				
Farma APS - Promocao de	0.00 %	0.2	0.00 /0	- 0.0				
Medicamentos, Unipessoal Lda.,	0.00 /0	0.4	-	-	_	_	_	_
Generis MZ, Lda.,			-	-	-	-		
Aurovitas Pharma Ceska	0.00 %	0.3	0.00 %	0.0	-	-	-	-
	0.00 %	0.5	0.00 %	0.0	-	-	-	-
Republica s.r.o Aurogen South Africa (PTY) Ltd	-				-	-	-	
Aurobindo Pharma Saudi Arabia	0.13 %	150.8	(0.09)%	(21.7)	-	-	-	-
	0.13 %	150.6	(0.09)%	(21.7)	-	-	-	-
Limited Company Aurovitas Pharma (Taizhou) Ltd	-			-		-	-	
· · · · · · · · · · · · · · · · · · ·	-	-	-	-	-	-	-	-
Joint Ventures								
Joint Ventures - Foreign	NIA	NIA	0.01.0/	75.0	NIA	NIA	0.01.0/	40.0
Novagen Pharma (Pty) Ltd	NA	NA	0.31 %	75.3	NA	NA NA	0.21 %	49.2
Joint Ventures - Indian Eugia Pharma Specialities Limited	NA	NA	(0.03)%	(6.2)	NA NA	NA NA	(0.04)%	(8.2)
Tergene Biotech Pvt Limited	NA NA	NA	(0.03)%	(39.3)	NA	NA	(0.04)%	(8.2) (29.6)
	NA NA	NA	0.00 %	,,	NA	NA	<u>(0.13)%</u> NA	(29.6) NA
Raidurgam Developers Limited	NA	NA	0.00 %	(1.2)	INA	INA	INA	INA
(formerly Aurobindo Antibiotics Limited)	0.00.0/	10.0	(0.01)0/	(0, 0)	0.00.0/	00.0	(0,00)0/	(1 7)
Minority Interests in all subsidiaries	0.02 %	18.2	(0.01)%	(2.6)	0.02 %	20.8	(0.02)%	(4.7)
Total	141.36%	1,65,137.8	102.03 %	24,723.7	138.470%	1,29,805.9	95.83 %	22,056.9
Consolidation adjustments Net amount	<u>(41.36)%</u> 100.00%	<u>(48,315.4)</u> 1,16,822.4	<u>(2.03)%</u> 100.00%	<u>(492.0)</u> 24,231.7	<u>(38.47)%</u> 100.00%	<u>(36,065.9)</u> 93,740.0	<u>4.17 %</u> 100.00%	<u>959.7</u> 23,016.6

* NA represents Not Applicable

Note :

1. The disclosure as above represents separate information for each of the consolidated entities before elimination of inter-company transactions. The net impacts on elimination of inter-company transactions / profits / Consolidation adjustments have been disclosed separately. Based on the group structure, the management is of the view that the above disclosure is appropriate under requirements of the Companies Act, 2013.

2. Percentages below 0.01% have been disclosed as 0.00%.

for the year ended 31 March 2018

(All amounts are in Indian Rupees in millions, except for share data and where otherwise stated)

49. SEGMENT INFORMATION

a) Identification of Reportable Segments:

Segments are identified in line with Indian Accounting Standard (Ind AS) 108 "Segment Reporting", taking into consideration the internal organisation and management structure as well as the differential risk and returns of the segment.

Based on the Group's / Consolidated entities business model of vertical integration, pharmaceuticals have been considered as the only reportable business segment and hence no separate financial disclosures provided in respect of its single business segment.

Operations of the Group / Consolidated entities are managed from independent locations, which are located in different geographical locations. However each of these operating locations are further aggregated based on the following factors: (a) similarity of economic and political conditions; (b) relationships between operations in different geographical areas; (c) proximity of operations; (d) special risks associated with operations in a particular area; (e) exchange control regulations; and (f) the underlying currency risk. Accordingly, the following have been identified as operating and reportable segments: (a) "India", (b) "USA" (c) "Europe" and (d) "Rest of the World".

The geographic information analyses the Group's revenues and non-current assets by the Company's country of domicile and other countries. In presenting geographic information, segment revenue has been based on the selling location in relation to sales to customers and segment assets are based on geographical location of assets.

a) Revenue from external customers

	31 March 2018	31 March 2017
India	19,802.8	20,134.9
USA	76,721.7	70,853.1
Europe	51,491.6	43,112.7
Rest of the world	16,982.2 16,79	16,797.9
	164,998.3	150,898.6

b) Non-current assets (other than financial instruments and deferred tax assets)

	31 March 2018	31 March 2017
India	50,819.0	46,067.8
USA	16,621.6	14,162.3
Europe	15,027.3	4,307.1
Rest of the world	1,073.5	950.4
	83,541.4	65,487.6

As per our Report of even date attached.

For **B S R & Associates LLP**

Chartered Accountants ICAI Firm Registration Number: 116231W/ W-100024

Amit Kumar Agarwal Partner Membership No.214198

Place: Hyderabad Date: 28 May 2018 for and on behalf of the Board of Directors of

Aurobindo Pharma Limited

N. Govindarajan Managing Director DIN-00050482

Santhanam Subramanian Chief Financial Officer Dr. M. Sivakumaran Director DIN-01284320

B. Adi Reddy Company Secretary Membership No.13709



Aurobindo Pharma Limited

(CIN - L24239TG1986PLC015190)

Regd.Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500 038 Tel No. +91 40 23736370, Fax No. +91 40 23747340 E-mail: info@aurobindo.com; Website: www.aurobindo.com

31ST ANNUAL GENERAL MEETING – THURSDAY, AUGUST 30, 2018 PROXY FORM

Nar	ne of the Member(s):		
Reg	istered address:		
E-m	ail Id:		
Foli	o No. / Client ID:	DP ID:	
I / V	/e, being the holder(s) of	Equity Shares of Aurobindo Pharma Limited, hereby appoint:	
1.	Name :		
	Address:		
	E-mail ID:	Signature:, or failing) him
2.	Name :		
	Address:		
	E-mail ID:	Signature:, or failing	ı him
З.			
	Address:		
	E-mail ID:	Signature:, or failing) him

as my/our proxy to attend and vote (on poll) for me/us, on my/our behalf at the Annual General Meeting of the Company to be held on Thursday, the 30th day of August, 2018 at 3.00 p.m. at Kaveri Ball Room, Hotel Trident, Hi-tech City, Near Cyber Towers, Madhapur, Hyderabad - 500 081 and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.	Resolution	For	Against
Ordinary Bus	siness		
1	To receive, consider and adopt the Standalone Balance Sheet as at March 31, 2018, Statement of Profit and Loss for the financial year ended on March 31, 2018, Cash Flow Statement for the financial year ended March 31, 2018 and reports of Directors and Auditors thereon		
2	To receive, consider and adopt the Consolidated Balance Sheet as at March 31, 2018, Statement of Profit and Loss for the financial year ended on March 31, 2018, Cash Flow Statement for the financial year ended March 31, 2018 and report of Auditors thereon.		
3	To confirm the first interim dividend of ₹1.50 and Second Interim Dividend of ₹1.00 in aggregate ₹2.50 per equity share of ₹1/- each, as dividend for the financial year 2017-18.		
4	To appoint a Director in place of Mr. K. Nithyananda Reddy who retires by rotation and being eligible, seeks re-appointment.		
5	To appoint a Director in place of Mr. M Madan Mohan Reddy who retires by rotation and being eligible, seeks re-appointment.		
Special Busi	ness		
6	To appoint Mrs. Savita Mahajan as an Independent Director of the Company		
7	To re-appoint Mr.K.Nithyananda Reddy as Whole-time Director of the Company.		
8	To re-appoint Mr.N.Govindarajan as Managing Director of the Company.		
9	To re-appoint Dr. M. Sivakumaran as Whole-time Director of the Company.		
10	To re-appoint Mr. M. Madan Mohan Reddy as Whole-time Director of the Company.		

Signed this _____ day of _____ 2018

Revenue Stamp

Signature of Member _____

Signature of Proxy

Notes: a. Proxy need not be a member of the Company.

- b. The proxy form duly filled in and signed by the Member(s) across the revenue stamp should reach the Company's Registered Office at Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038 at least 48 hours before the commencement of the meeting.
- c. Corporate Members intending to send their authorized representative(s) to attend the meeting are requested to send a certified copy of the Board resolution authorizing their representative(s) to attend and vote on their behalf at the meeting.



Aurobindo Pharma Limited

(CIN - L24239TG1986PLC015190)

Regd.Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500 038 Tel No. +91 40 23736370, Fax No. +91 40 23747340 E-mail: info@aurobindo.com; Website: www.aurobindo.com

31ST ANNUAL GENERAL MEETING - THURSDAY, AUGUST 30, 2018

ATTENDANCE SLIP

Folio No./Client Id:

No. of Shares:

DP Id:

Name and address of First/Sole Shareholder:

I, hereby record my presence at the Annual General Meeting of the Company to be held on Thursday, the 30th day of August, 2018 at 3.00 p.m at Kaveri Ball Room, Hotel Trident, Hi-tech City, Near Cyber Towers, Madhapur, Hyderabad 500 081.

Name of the Member/Proxy (In Block Letters)


Signature of the Member/Proxy

Notes: a. Only Member/Proxy can attend the meeting. No minors would be allowed at the meeting.

- b. Member/Proxy who wish to attend the meeting must bring this attendance slip to the meeting and hand over at the entrance duly filled in and signed.
- c) Member/Proxy should bring his/her copy of the Notice of Annual General Meeting and Annual Report for reference at the meeting.

AGM Venue - Route Map

Kaveri Ball Room, Hotel Trident, Hi-tech City, Near Cyber Towers, Madhapur, Hyderabad - 500 081



DISCLAIMER

This communication contains statements that constitute 'forward looking statements' including, without limitation, statements relating to the implementation of strategic initiatives and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgements and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance. Aurobindo undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances.



REGISTERED OFFICE

Plot No. 2, Maitri Vihar Ameerpet Hyderabad - 500 038 Telangana, India

www.aurobindo.com

CORPORATE OFFICE

Water Mark Building Plot No. 11, Survey No. 9 Kondapur, Hitech City Hyderabad - 500 084 Telangana, India